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Summary
This course of research examines ligand interactions with nuclear receptors and 
cross- talk between receptors and implications for human health by using a number of 
different scientific research tools. These include in silico molecular modelling using 
nuclear receptor crystal structures; in vitro assays and multivariate analytical techniques 
to derive robust models of receptor activation. The selection of ligands were based both 
on literature reviews, which constitutes Chapter 1, (Jacobs and Lewis, 2002) and Chapter 
2, an environmental pollutant case study of contaminants in the aquaculture food chain 
and dietary oil studies (Jacobs et al., 2002a; 2002b). The data from these studies informed 
likely relative dietary exposure of individual environmental contaminant congeners of 
European consumers of oily fish and oils (Jacobs et al., 2002a; 2002b; Jacobs et al., 2002 
c; Jacobs, 2002; Jacobs, 2003). While they were conducted in addition to the molecular 
work, as they contained information pertinent to my PhD project, and the studies were 
conducted at similar times, they have been included here as a legitimate and informative 
avenue of study. However they were not funded by my PhD funding through the BBSRC 
and GSK, University of Surrey facilities were not used, and they were conducted 
independently, in my own time, outside the time allocated for my PhD work. For support 
and collaboration with these studies I am extremely grateful to Joe Ferrario of the US 
Environmental Protection Agency, and Adrian Covaci, of the University of Antwerp, 
Belgium.
Chapter 3 presents the receptor models built and the relevant crystal structures 
used for the ERp, AhR, PXR, CAR, and PPAR models (Jacobs et al., 2003a). These 
models or the crystal structure if available later, are shown with ligands of interest 
docked in the ligand binding domains of the relevant receptors. Differences in the ligand 
binding domains and modes of binding were observed. These studies provided an 
additional basis for selection of experimental compounds to test in an in vitro nuclear 
receptor assay described in Chapter 4, and supported the receptor based Quantitative 
Structure Activity Relationships (QSARs) described in Chapter 5.
Chapter 4 describes how the biological data was generated experimentally 
utilising the in house GSK PXR transient transfection assay at the GSK site in Ware, UK. 
Additional biologically relevant data for PXR and E R a and AhR was obtained from 
GSK in house data sets, the literature and unpublished data was also kindly provided by 
Guosheng Chen from the University of Guelph, Canada (Jacobs et al. 2003b). These
16
data sets were utilised to generate the QSARs presented in Chapter 5. The QSARs 
presented were supported by further exploration of the modes of ligand binding in the 
crystal structures and/or homology models of the SHRs under study.
Chapter 6 discusses the applications of the studies documented in the preceding 
chapters and future avenues of related research with particular reference to the 
implications of the studies presented here for human health. Endocrine systems need to 
be allowed to maintain their equilibrium. Perturbing the endocrine system can result in ill 
health, reduced quality of life, and loss of self;
Tfyou skew the endocrine system, you lose the pathways to s e lf  
Hilary Mantel in Giving up the Ghost: A Memoir. Publ Fourth Estate 2003.
This thesis is a starting point for the development of scientific tools that add to 
and are alternatives to animal in vivo models of endocrine disruption, and tools that can 
suggest alternatives in the synthesis of new chemical entities, for better protecting human 
health and the wider global environment upon which we all depend.
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1. Abstract
Members of the nuclear steroid hormone receptor superfamily mediate essential 
physiological functions. Nuclear receptors (NRs) and steroid hormone receptors (SHRs) 
act directly upon DNA, regulate the synthesis of their target genes, and are usually 
activated by ligand binding. Both endogenous and exogenous compounds and their 
metabolites may act as activators of NRs and disruptors of endocrine, cellular and lipid 
homeostasis. The endogenous ligands are generally steroids such as l?P-oestradiol, 
androgens, progesterone and pregnenolone. The exogenous compounds are usually 
delivered through the diet and include non-steroidal ligands. Examples of such ligands 
include isoflavonoids or phytoestrogens and food contaminants such as exogenous 
oestrogens from hormone treated cattle, pesticides, polychlorinated biphenyls (PCBs) and 
plasticisers. Certain drugs are also ligands; so nuclear receptors are also important drug 
targets for intervention in disease processes.
This chapter summarises recent reports on ligand activated NRs that describe the 
selective regulation of a tightly controlled, cross-talking network involving exchange of 
ligands, and the control of major classes of cytochrome P450 (CYP) isoforms which 
metabolise many bioactive exogenous compounds. Many P450s have broad substrate 
activity and appear to be integrated into a co-ordinated metabolic pathway, such that 
whilst some receptors are ligand specific, other sensors may have a broader specificity 
and low ligand affinity to monitor aggregate levels of inducers. They can then trigger 
production of metabolising enzymes to defend against possible toxic nutrients and 
xenobiotic compounds. The influence of dietary intakes of nutrients and non nutrients 
upon the human oestrogen receptors (hERa and (3), the Aryl hydrocarbon Receptor 
(AhR) the Pregnane-X-Receptor (PXR), the Constitutive Androstane Receptor (CAR), 
and the Peroxisome Proliferator-Activated Receptors (PPARa and y), can be examined 
by utilising computer generated molecular models of the ligand-receptor interaction, 
based on information generated from crystallographic data and sequence homology. In
21
relation to experimental and observed data, molecular modelling can provide a 
scientifically sound perspective on the potential risk and benefits to human health from 
dietary exposure to hormone mimicking chemicals, providing a useful tool in a complex 
situation of considerable public concern.
1 .1 . Introduction
1.1.2. Endocrine disrupting chemicals
The endocrine system is complex, with many organs producing different 
hormones, contributing to a multifaceted feedback regulatory system that is deficient in 
the developing fetus and infant. Endocrine disrupting compounds (EDCs) are substances 
that can cause adverse effects by interfering in some way with the body’s hormones or 
chemical messengers that constitute the endocrine system. Under the control of the 
Central Nervous System (CNS), hormones are secreted by the endocrine glands and exert 
control on other cells of the body. Endocrine-disrupting chemicals are differentiated from 
classical toxicants such as carcinogens, neurotoxicants and heavy metals, because they 
can interfere with normal blood hormone levels or the subsequent action of those 
hormones, but do not have a classical toxic effect. The effects can influence and disrupt 
the hormonal regulation and hormonal imprinting (in the fetus) of normal cell 
differentiation growth, development, metabolism and reproduction throughout life. 
Endocrine disruption can occur at levels far lower than those of traditional concern to 
toxicologists. Sometimes high doses shut off effects that occur at low levels, and 
sometimes low and intermediate doses produce greater effects than those observed at 
high doses. Human populations are exposed to complex mixtures of environmental and 
endogenous agents, which may act together or modulate one another to produce 
biological effects. While exogenous endocrine modulators can involve any hormonal 
system and be affected by normal physiological states (such as menstruation and 
menopause in women, the andropause in men, and puberty, the somatopause and 
adrenopause in both sexes), diet, stress and other lifestyle factors, the principal focus and 
starting point of this Chapter is on sex-hormone, and especially oestrogen-mediated 
effects upon the steroid hormone and nuclear receptors in humans where the ligands are 
delivered through the diet. The intention is that this Chapter will provide a basis for 
understanding some of the critical issues involved in hormone receptor mediated toxicity, 
and the broad context involved.
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1.1.3. Hormone dynamics
Accurate assessment of a chemical’s potential to alter the endocrine system 
depends upon consideration of the entire hormone dynamic pathway together with 
changes in hormone activity. Figure 1.1 presents a simplistic model of hormone 
dynamics, following hormones from production to excretion.
After a hormone is produced, circulating and intracellular binding proteins 
regulate the hormones’ bioavailability. Then the hormone triggers action by binding to a 
specific cellular receptor. The hormone is then either excreted in the urine after 
conjugation reactions in the liver, or biotransformed into another hormone, which will 
begin the cycle of bioavailability, action, and excretion/biotransformation.
Hormones, and hormone mimicking chemicals, can potentially affect each point 
in the hormone dynamic cycle, and each point in the steroid hormone pathway, and the 
enzyme families associated with the pathway. Assessing the mode of action of an EDC is 
further complicated by many feed-back mechanisms within and between the different 
hormone systems, as well as interconnections with the nervous and immune systems. 
Current scientific knowledge of these systems is fragmentary but the emerging picture 
suggests an interlinked fabric of hormone dynamics where the delicately balanced 
compensatory systems are easily perturbed. Hormone dynamics have evolved over a long 
period of time to deal with hormone and dietary phytochemical exposure, but they are not 
a rapid response system able to deal effectively with the synthetic chemicals of the 
twentieth and twenty first centuries.
At the molecular level, receptors mediate alterations of hormone availability, 
action, excretion and biotransformation, in concert with the cytochrome P450 enzyme 
system. Many receptors have been identified and are awaiting the recognition of specific 
ligands and functions, and it is likely that more receptors will be discovered in the future. 
Each type of receptor has the potential to regulate a distinct endocrine signalling 
pathway, of which we only have a rudimentary knowledge.
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Figure 1.1. A simplified model of hormone dynamics (after Crain et al., 2000)
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1.1.4. Hormone mimicking chemicals and steroid hormone receptors
In recent years there have been many reports on the increasing incidence of 
breast cancer in women (Davis et al., 1993; B radio w et al., 1995; Bradlow et al., 1997; 
Davidson and Yager, 1997; Davis et al., 1997; DeBruin and Josephy, 2002; Green et al., 
2003) and decreased sperm counts and increasing incidence of testicular cancer in men 
(Sharpe and Skakkebaek, 1993; Sharpe, 2001; Auger et al., 1995; Adami et al., 1994), 
together with adverse wildlife effects that include birth defects, reproductive failures, and 
sexual abnormalities (Colburn et al., 1993; Guillette and McLachlan, 1996; Colburn et 
al., 1999; Hayes et al., 2002). These have stimulated research into both the chemical and 
molecular actions, and the clinical and epidemiological effects, of a large variety of 
natural and synthetic oestrogens present in the environment (Falck et al., 1992; Hunter 
and Kelsey, 1993; Wolff et al., 1993; Kreiger et al., 1994;Stevens et al., 1994; Ahlborg et 
al., 1995; Wolff and Toniolo, 1995; Gray Jr et al., 1997; Hunter et al., 1997; Safe, 1997a; 
Bernstein and Press, 1998; Petreas et al., 1998; Krstevska-Konstantinova et al., 2001). 
The growing body of evidence on the hormone-like effects of many synthetic chemicals 
and by-products in fish, wildlife and humans, has led to the instigation of endocrine 
disruption screening programmes relating to persistent organic pollutants (POPs), and the 
international POPs treaty signed in Stockholm, Sweden in May 2001.
1.1.5. The biological differences in hormones and hormone metabolism
In utero, our natural sex hormones are largely responsible for our development 
into females, or totally responsible for male development, as the default pathway for fetal 
development is phenotypically female. In the male fetus, androgens stabilise the Wolfian
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duct development in the fetus, and actively remove the Müllerian duct (the precursor to 
the female uterine system) (Sharpe 2001),
The most important factors guaranteeing the homeostasis of female and male 
sexual functions include differentiation and reproduction. Main target tissues include 
bone and skin, the cardiovascular system, the brain and central nervous and immune 
system. Many endocrine hormones are lipophilic (fat loving), moving easily through cell 
membranes to activate or suppress the nuclear receptors (i.e. receptors in the nucleus of 
the cell) that directly act upon DNA. In concert with each other they contribute to the 
control of broad aspects of growth, development and adult organ physiology. The NR and 
SHR family is extensive but currently the emphasis is on a sub-classification, the 
oestrogen receptors (ER) (Colburn et al., 1993; Soto et al., 1995; Guillette and 
McLachlan, 1996; Colburn et al., 1999) with most effects attributable to pubertal or adult 
levels of steroids. Other members of the SHR family and other nuclear receptors of 
unknown functions (not discussed here) also play key roles in endocrine disruption 
(Parker, 1993). For example, EDCs are known to affect the thyroid, adrenal glands and 
pancreas, a clear link between DDT and pancreatic cancer was recently reported (Porta 
et al., 1999), and the persistent DDT metabolite p, p  '-DDE has been shown to have anti- 
androgenic potential (Kelce et al., 1995). EDCs such as phthalic acid and nonylphenol are 
now known to activate PXR, both in vitro and in vivo, as observed in the ERs, while 
bisphenol A has been both reported to have no effect on PXR-mediated transcription 
(Masuyama et al., 2000), and later reported to be a ligand for PXR (Takeshita et al., 
2001) while also significantly enhancing ER-mediated transcription (Masuyama et al., 
2000).
1.2. Molecular mechanics of endocrine action
1.2.1. Receptor-based mechanisms
There are many different steroid hormones and therefore many different SHRs 
and NRs. These receptors are proteins which are synthesized by the cell in the same way 
as other proteins are synthesized, under genetic control. Thus all cells have the ability to 
synthesize all receptors, but variations in the extent of gene expression means that an 
individual cell or tissue probably does not synthesize receptors for more than three or 
four hormones (Gard, 2001). This is considered to be part of the selectivity of the 
hormone mechanism to produce effects on selected target tissues.
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The nuclear receptor family have structural features in common. These include a 
central highly conserved DNA binding domain (DBD) that targets the receptor to specific 
DNA sequences, termed hormone response elements (HREs). A carboxyterminal 
portion of this receptor includes the ligand binding domain (LED) that interacts directly 
with the hormone. Embedded within the LED is a hormone dependent transcriptional 
activation domain. The LED acts as a molecular switch that recruits coactivator proteins 
and activates the transcription of target genes when flipped into the active conformation 
by hormone binding. The currently accepted theory of steroid hormone binding suggests 
that in the absence of the hormone, each receptor is associated with certain ‘chaperone’ 
proteins (these are other proteins which protect and aid the receptor) (Weigel, 1996). 
Binding of the steroid hormone with the receptor protein causes a conformational change. 
This molecular switch results in the removal of the heat shock complex and allows the 
receptors to dimerise. Then DNA binding to a hormone response element (HRE) occurs, 
to produce a complex that can trigger or suppress the transcription of a selected set of 
genes, see figure 1.2 for a simple illustration of the mechanism of action of nuclear 
receptors (Weigel, 1996; Alberts et al., 1997).
Figure 1.2. Diagram showing the simplified mechanism of action of nuclear 
receptors
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1.2. 2. Receptors interacting with enzymes
The hormone receptors and chaperone cofactors also mediate hormonal 
homeostasis by the coordinated release and degradation of bioactive hormones. Steroid 
hormones, their metabolites, ingested plant and animal steroids and bioactive xenobiotic
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compounds are primarily metabolised by cytochrome P450 (P450s) enzymes reduction 
and oxidation in the liver. Many P450s have broad substrate activity and appear to be 
integrated into a coordinated metabolic pathway, such that whilst some receptors are 
ligand specific, other sensors may have a broader specificity and low ligand affinity. In 
this way they can monitor aggregate levels of inducers to trigger production of 
metabolizing enzymes, and thereby mount a defense against toxic compounds in the diet. 
This hypothesis is strongly supported by the expression of a receptor sensing system in 
the digestive tissue (Jones et al., 2000). P450 induction by EDCs and other xenobiotics 
may therefore lead to alterations of endogenous regulatory pathways, with associated 
physiological consequences harmful to health.
1.3. Most research is based on the oestrogen receptors (ER)
Due to the early identification of ER a and links between DDT and breast cancer, 
the ERs have received most EDC research attention. So far they are known to exist as 
two subtypes, each one encoded by a separate gene. These are ER a (Brzozowski et al., 
1997), see figure 1.3, and the recently discovered ER(3 (Kuiper et al., 1997; Kuiper et 
al., 1998) and its isoforms, of which a spliced isoform, ER|3/2 appears to be equally 
expressed in tissue density studies (Petersen et al., 1998).
Figure 1.3. 17(3 oestradiol docked in the LBD of the ERa crystal structure (using 
SYBYL biopolymer software from Tripos associates, St Louis Missouri) on a Silicon 
Graphics Indigo” IMPACT 10000 Unix workstation. (Jacobs, 1998) *
i
* The pink ribbon denotes the protein backbone of the receptor, key amino acid residues 
are shown in blue and red, 17 P oestradiol is shown in orange. Hydrogen bonding is 
indicated by the dotted pale blue lines.
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Figure 1.4. Schematic diagram showing differences in tissue distribution of the 
oestrogen receptors (Gustafsson, 1999; Warner et al., 1999)
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The classical ER a subtype and ERP receptors and isoforms apparently evolutionary 
diverged over 450 million years ago (Kelley and Thackray, 1999), suggesting that 
although they have evolved in parallel, this ancient duplication was to facilitate unique 
roles in vertebrate physiology and reproduction. The ERs differ in tissue distribution and 
relative ligand binding affinities (Kuiper et al., 1997; Petersen et al., 1998), which may 
help explain the selective action of oestrogens in different tissues (Gustafsson, 1999). 
Indeed there is evidence that ERp plays an important role in the organization and 
adhesion of epithelial cells in breast tissue and is therefore instrumental in the 
differentiation of tissue morphology, particularly if stimulated at an early age (Forster et 
al., 2002). This has important gender implications due to the differences in tissue 
physiology between women and men and important disease implications, as different 
spliced variants are observed in malignant as opposed to normal tissues that lead to poor 
patient prognosis related to oestrogen refractoriness (Fujimoto et al., 2000a; Fujimoto et 
al., 2000b; Omoto et al., 2002).
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1.3.1. Tissue differences in ER distribution in adults
Whilst women have E R a and ER(3 in breast, uterine and ovarian tissue, men have 
ERp in the prostate and E R a in the testes. Both women and men have E R a in the 
adrenals and kidneys, but ERp in the brain, thymus, lung, vascular system, bladder and 
bone and skin (Kuiper et al., 1997; Paech et al., 1997; Tetsuka et al., 1997; Thornton et 
al., 2003). E R a dominates specifically in the reproductive tissues, while ERp plays an 
important role in the physiology of several tissues, as indicated in figure 1.4. Female and 
male sex hormones can be understood to act as functional antagonists, such that an 
excess of oestrogenic hormones may depress male development or male functions. There 
are also situations in which male and female hormones may act synergistically (and, for 
example, show effects upon bone density or the promotion of liver tumours). This 
complexity is the consequence of the multiple targets of these hormones within 
mammals, including target tissue other than the sex organs, as the tissue distribution of 
the ERs in adults indicate.
1.3.2. Serum oestradiol levels in prepubertal children
Oestrogens are considered reversible cellular signals for adults, but when given 
to newborn mice, at least one gene under oestrogen control is persistently expressed, even 
in the absence of oestrogen (Nelson et al., 1991). While very little is known about the 
role of hormones in gene imprinting, potent oestrogens have been observed in vivo to 
contribute to DNA méthylation or déméthylation (McLachlan et al., 2001). Low doses of 
oestrogen have been observed to have a significant biological effect in girls with Turner 
syndrome. A dose of lOOng/kg/day ethinylestradiol administered orally for 5 weeks 
resulted in a significantly increased growth velocity (P<0.001), with no effects upon 
vaginal maturation or breast tissue. Higher doses did not increase the growth rate, 
indicating that oestrogen has a biphasic dose response relationship for epiphyseal growth. 
Similar effects have been reported in boys, but there are clear gender differences in serum 
oestradiol levels prepubertally, with girls having approximately eightfold higher 
oestradiol levels than boys (Klein et al., 1994). This may explain why girls mature faster 
than boys, but also, in a population exposed to excessive but low levels of oestrogen, one 
may expect to see a slightly younger age for pubertal onset (Andersson and Skakkebaek, 
1999; Krstevska-Konstantinova et al., 2001) and an increase in oestrogen related diseases 
and cancers (Newbold et al., 2001).
29
1.3.3. ERs and the brain: relationships with neurodegenerative conditions
The brain and the role of ERp in the brain is attracting increasing interest. The 
expression of ERs in the adult cortex and hippocampus, areas associated with learning 
and memory, have been observed experimentally to be responsive to neuronal injury, 
suggesting a link may exist between early onset of senile dementia or Alzheimer’s 
disease in post menopausal women with significantly reduced oestrogenic activity, 
compared with normal post menopausal levels (Shughrue and Merchenthaler, 2000; 
Wise et al., 2001). During fetal and postnatal development, peak neuronal cell 
proliferation occurs within specific brain regions, including the hippocampus and cortex. 
Unlike other organ systems, the brain and CNS development has a limited capacity to 
compensate for cell loss, and environmentally induced cell death can lead to a permanent 
reduction in cell number. Combined with higher relative cerebral blood flow and the 
immaturity of the blood brain barrier, this can give rise to increased exposure of the brain 
to potential neurotoxins and EDCs (Faustman et al., 2000; ten Tusscher and Koppe, 
2003). The involvement of E R a and ER(3 in the brain learning and memory centres 
suggest a logical mechanism of action of EDCs in the brain that could trigger learning 
difficulties, as reported in male ERP deficient mice. Whilst this is speculation, in vivo 
work on ER deficient and aromatase deficient mice (Simpson et al., 2000) should shed 
more light on the mechanism of the disruption of ERs and aromatase upon brain function.
1.4. Receptors and ‘cross-talk’
The receptors often have ligands in common (albeit with different binding 
affinities), and there is also a great deal of ‘cross-talk’ and ‘ligand promiscuity’. That is, 
the same chemical may be able to bind with different receptors, and if they do, the 
binding strength may differ greatly between different receptors. This can occur for 
endogenous hormones, exogenous hormones and environmental chemicals. For example, 
forms of the oestrogenic (oestradiol) and androgenic (androstanes) hormones are both 
ligands for ERp. Oestradiol is less potent in ERP than in ERa, whilst the natural 
ligands for ERP may actually be androgens: 5 a  androstane diol and 3p androstane diol 
(Gustaffson, 2000). The organochlorine pesticides trans-nonachlor and chlordane are 
known to activate both known ERs, and PXR, but with different affinities (Kuiper et al., 
1997; Barkhem et al., 1998; Waxman, 1999; Jones et al., 2000). As these receptors are 
present in different ratios in different cell types and tissues, the response on a cellular, 
tissue and systemic level may be quantitatively very different, and may vary over time.
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Receptor modulation has been seen with lactation, when a form of ERp has been 
observed to increase in the rat mammary glands (Gaido et al., 1999; Gustafsson, 2000) 
and in breast tissue hyperplasias, where a frequent mutation in the E R a gene shows 
increased sensitivity to oestrogen compared with wild type ERa, by affecting the border 
of the hinge and hormone binding domains (HBD) (Fuqua et al,, 2000).
EDCs may act on some but not all of the receptors and their isoforms in the 
tissues of these organs, or act to different affinities, as methoxychlor and its analogue 
DDT do in E R a and ERp. More specifically, ERp is dependent on pure agonists for the 
activation of transcription from its target promotors, while ER a can be activated by 
agonists, partial agonists (such as tamoxifen, which is used in the treatment of ER 
positive breast cancer) and ligand independent mechanisms. Appropriate test systems 
must be strategically designed to cover such multiple actions and interactions.
There is also evidence that isoforms of different receptors modulate each other at 
a functional level, attempting to retain a balance. The modulation is aided at low (Hall 
and McDonnell, 1999) and high hormone levels (Petersen et al., 1998) by different ERp 
isoforms, which may enable a tissue to govern its own responsiveness to oestradiol, 
oestradiol metabolites and related hormones such as progestins, and oestrogen mimics or 
EDCs. This speculation is supported by what appears to be an emerging pattern in 
nuclear receptor signalling, as similar balancing acts have been observed also in the a  
and p forms of the human glucocorticoid receptor (GR), the progesterone receptor (PR), 
and more recently between the pregnane X receptor (PXR) and the constitutive 
androstane receptor (CAR) (Honkakoski et al., 2003).
1.4.1. Differences in activation: How much inhibition, how much activation?
The proliferative role of E R a in breast cancer is well established, but there is 
increasing evidence that ERp is part of the disease picture, through antiproliferative 
activity, which has therapeutic implications. The distinct differences in activational 
mechanisms between the different ERs and their isoforms will have a direct effect upon 
possible disease scenarios, such as ER positive and ER negative breast cancers, testicular 
and prostate cancers, and perhaps also brain injury.
EDCs may act on some but not all of the receptors and their isoforms in the 
tissues of these organs, or act to different affinities, as many phytoestrogens (e.g. 
coumestrol and genistein), synthetic chemicals such as bisphenol A (Matthews et al..
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2001) and organochlorine pesticides (e.g. methoxychlor and its analogue DDT) do in 
E R a and ERp.
These differences between the two isoforms are of great importance with respect to the 
endocrine disrupting ability of a ligand. The ability of ERP to function both as an 
inhibitor or activator depending on the agonist concentration suggests that totally 
different patterns of gene expression may be observed at different hormone levels, and 
may be a mechanism by which cellular sensitivity to hormones is controlled.
In tissues where E R a and ERp co-localise, fluctuations in the bioavailability of 
receptor activating ligands may have a greater impact, so characterizing the interactions 
of EDCs with both E R a and ERp (see figure 1.4.). There can also be additional non- 
hormonal pathways influenced by specific compounds. A substance may act in a 
synergistic way on one target and in an antagonistic way on another one (Paech et al.,
1997). Such opposing effects may also occur at different dose levels of the same 
substance, or as combinations of, for example, phytoestrogens and PCBs (Jacobs and 
Lewis, 1999), and other EDCs (Payne et al., 2001) but experimentally there have been 
difficulties replicating these findings, and consequently one study has been retracted 
(Arnold et al., 1996; Arnold et al., 1997; McLachlan, 1997). The in vitro evidence of 
additive potency of combined EDC pesticides in E R a is far stronger (Ramamoorthy et 
al., 1997; Payne et al, 2001; Silva et al., 2002), and has been noted for other receptors 
also (Carpenter et al., 2002).
Phytoestrogens appear to have a greater affinity for ERP than E R a (Kuiper et 
al., 1997), but they have an E R a selective efficacy (Pike et al., 1999; Gustafsson, 2000), 
while EDCs such as the hydroxylated metabolites of methoxychlor appear to be an 
E R a specific agonist, and ERP antagonist (Gaido et al., 1999), but with about the same 
affinity for both isoforms (Kuiper et al., 1997).
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Table 1.1. Relative Binding Affinities of suspected endocrine disrupters for 
ER a and ERp, adapted from solid phase competition experiments (Kuiper et al., 
1997).
Compound RBA
ERa
RBA
ER(3
17(3 oestradiol 100 100
Isoflavones:
Coumestrol 20 140
Genistein 4 87
Daidzein 0.1 0.5
Pesticides:
o,p’-DDT 0.01 0.02
Chlordecone 0.06 0.1
Endosulphan <0.01 <0.01
Methoxychlor* <0.01 <0.01
RBA of each competitor was calculated as a ratio of concentrations of oestradiol and competitor 
required to reduce the specific radioligand binding by 50% (=ratio of IC50 values).
RBA value for oestradiol was arbitrarily set at 100.
*The metabolite of methoxychlor, 2,2-bis-(p-hydroxyphenyl)-l,l,l-trichloroethane (HPTE) is 
approximately 100-fold more active at ERa than methoxychlor (Gaido et al., 1999).
1.4.2. ERp and men
Perinatal exposure of the male fetus to potent oestrogens is known to increase 
the incidence of cryptochordism and hypospadias at birth, and small testes, reduced 
sperm counts, epididymal cysts, prostatic abnormalilites and testicular cancer in adult 
animals. ERP appears to be preferentially expressed at significant levels in 
spermatocytes at various developmental stages in the testes, specifically the gonocytes, 
spermatogonia and spermatocytes. This suggests that EDCs with an affinity for ERP 
may find their way into precursors of sperm and cause disturbances in their function, 
disrupting male reproductive functions (Giwercman et al., 1993; Hess et al., 1997; 
Sharpe, 1997; Sharpe et al., 1998; Shughrue and Merchenthaler, 2000; Sharpe, 2001; 
Richtoff et al., 2003).
Timing is all-important. During fetal testicular development, if one phase of 
development is out of phase with the following step ( such as Müllerian duct regression 
for instance), developmental problems ensue in the adult that may not become apparent 
until later developmental stages, such as puberty, have been completed. This is reflected 
particularly in the reports of falling sperm counts (Auger et al., 1995) the incidence of 
testicular cancer (Adami et al., 1994), and decreased in vitro fertilization rates in couples 
with paternal pesticide exposure (Tielemans et al., 1999). Coupled with the likelihood
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that the endogenous ligand for ERP is probably not oestradiol, but is an androgenic 
metabolite, investigation of the androgenic interactions with ERp is critical for the 
understanding the increasing adverse reproductive effects seen in men in relation to 
dietary exposure to hormonally active compounds.
ERp is also reported to play a central role in oestrogen signalling in normal and 
malignant prostate epithelial cells (Lau et al., 1999), while the roles played by oestrogens 
in the transformation from a healthy prostate cell to a cancerous one remain controversial, 
whereas the role of androgens in this transformation is clearer. However ERp, AR, 
androstane and CYP7B1 are known to regulate an endocrine pathway in the prostate 
(Weihua et al., 2002). Peroxisome proliferator-activated receptor a  (PPARa) also has a 
role, it is functionally present in human prostate, but is down regulated by androgens 
and over expressed in advanced prostate cancer (Collett et al., 2000).
1.4.3. The many biological roles of ERp
Data addressing the various biological roles of ERp are being generated from in 
vivo studies by developing mice with a deleted ERP gene (Gustafsson, 1999; Forster et 
al., 2002). These ERP knockout (BERKO) mice display significantly reduced fertility 
in the female, and show the essentiality of ERp for normal functioning ovaries. At the 
beginning of the estrus cycle in particular, ERP expression is high, but after the 
Luteinizing Hormone (LH) surge, ERp is rapidly downregulated. The ratio between E R a 
and ERp in the ovary is about 1: 9. Another phenotypic characteristic of BERKO animals 
of both sexes is that the bladder epithelium, the epithelium of the dorsal prostate, the 
coagulation glands and the urethra show signs of hyperproliferation, suggesting that the 
growth control of these tissues is impaired if ERp levels are compromised, and that ERP 
may have a protective role against hyperproliferation and carcinogenesis. For both male 
and female BERKO mice, reproductive behaviour appears normal, although the males 
appear to be more aggressive under certain conditions (compared to wild type mice). 
Kuiper, Gustafsson and coworkers are continuing to investigate the phenotypic 
characteristics of BERKO animals with particular reference to the cardiovascular system, 
bone, the immune system, sexually differentiated liver metabolism and reproductive and 
non-reproductive behaviour. Research into defects in ERp expression and activity should 
also yield useful data for disease syndromes involving excess androgens in women, 
particularly as seen in women with polycystic ovarian syndrome (PCN), with
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symptoms such as secondary male characteristics, menstrual disruption and difficulty 
conceiving (Franks et al., 1999; Abbott et al., 2002).
1.4.4. ERp and ovarian cancer
Steroid hormone expression in ovarian surface epithelial cells (the tissue of 
origin for over 90% of ovarian cancers) has been observed to be disrupted in ovarian 
cancer cells taken from postmenopausal women (Lau et al., 1999). In the cancerous cells, 
the normal healthy coexpression of E R a and ERp mRNA (along with other receptors) 
were disrupted with an ensuing loss of ERa, PR and AR mRNA, suggesting that these 
receptors may be responsible for the neoplastic transformation of this cell type, but not 
ERp, whose mRNA levels appear to be unaffected by this malignant state. The 
researchers also suggest that ERP action may depend upon functional E R a levels. Taken 
together, these findings implicate the regulation of normal ovarian cells by oestrogens 
(Britt and Finday, 2002), androgens and progestins. The emergence of sex hormone 
resistance, via down-regulation or mutational inactivation of receptors (including the 
receptors ER, AR, CAR and PXR described below) may be a key feature of ovarian 
epithelial transformation, which may lead to diseases such as endometriosis, some cases 
of sterility and uterine/ovarian cancers.
1.4.5. Dietary exposure: Synthetic oestrogens versus phytoestrogens
Phytoestrogens are found in the diet, and are widely available from plant foods, 
including nitrogen fixing plants and legumes such as clover, lentils and soya, grains such 
as rye, and lignans such as those found in linseed, and hops (Aldercreutz, 1998; Milligan 
et al., 1998; Milligan et al., 1999; Cassidy and Faughnan, 2000). They do not rapidly 
accumulate and are water soluble. They are readily excreted in urine (6-8 hours), and they 
are probably the source of greatest dietary exposure to environmentally derived oestrogen 
mimics. On one hand, they can be regarded as a defense mechanism for the plant to 
reproductively impair herbivore and omnivore endocrine systems and thus be an effective 
strategy to reduce local herbivore populations, as first noted in the 1950’s when 
Australian clover was found to be the feminising agent responsible for impairing sexual 
performance in rams with a consequent dramatic effect in lambing (Bradbury and White, 
1954). However, on the other hand scientific evidence indicates that counter defenses 
have evolved such that adult diets rich in phytoestrogens are associated with a reduced 
incidence of cardiovascular disease, breast cancer, prostate cancer and osteoporosis.
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Asian women and vegetarians have a lower than average breast cancer risk, together with 
a relatively higher excretion of urinary phytoestrogens (Cassidy, 1996; Aldercreutz, 
1998; Bingham et al., 1998; Cassidy and Milligan, 1998; Milligan et al., 1998; Milligan 
et al., 1999; Cassidy and Faughnan, 2000).
Some of the possible SHR mechanisms of action of EDCs and phytoestrogens 
such as genistein are structure specific (figure 1.5), but others combine with structurally 
diverse ligands, for example hydroxylated PCB 153 (figure 1.6), DDT (figure 1.7), and 
polybrominated diphenyl ether flame retardant (PBDE) 47 (2,2’4,4’PBDE) (figure 1.7).
When the structures of many phytoestrogen compounds are overlaid with the 
oestrogen structure, they are virtually superimposable, the distance between the hydroxyl 
groups at each end of the molecules are almost identical. These distances determine 
hydrogen bond interaction with the receptor. The more structurally diverse synthetic 
compounds have far greater flexibility, so they can move to, bind with, and activate a 
wider range of receptors. The less flexible phytoestrogens such as genistein, however, 
have sub-optimal interactions in the LBD of the ERs (figure 1.6), especially in ERp, 
giving a partial agonist activity compared to antagonists such as raloxifene (Pike et al., 
1999).
Synthetic hormone mimics, such as PCBs, dioxins, polybrominated flame 
retardants (PBDEs) and organochlorine pesticides, accumulate within the food chain and, 
due to their fat solubility and long half-lives, persist and bioaccumulate in adipose tissue 
and bone for many years, unlike phytoestrogens. DDT, for example, has a half-life of 10 
years. While dietary intakes of synthetic xenoestrogens are in far smaller doses compared 
to phytoestrogen intakes, they remain available as ligands to the SHR system for a far 
longer period of time, and the metabolised forms, particularly when hydroxylated have 
greater affinity for the ERs (Jacobs, 1998; Meerts et al., 2001). The ubiquitous EDCs 
represent potential risk factors for a number of human cancers and other detrimental 
health effects. They are present at detectable levels in food and water even those such as 
DDT, which have been banned in many countries. PCBs, DDT metabolites, dioxins and 
PBDEs are the predominant POPs contaminants of concern in fatty animal based foods 
such as oily fish, fish oils, meat and dairy products (Liem and Theelen, 1997; Liem et al., 
2000; Jacobs et al 2002a; 2002b; 2002c; Solomon and Weiss, 2002).
Phytoestrogens may influence carcinogenesis via their hormonal, antihormonal 
and antioxidant actions in a beneficial way, when administered throughout life. 
Substantial evidence indicates that diets high in plant-based foods may explain
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epidemiological variance of many hormone dependent diseases that are major causes of 
mortality and morbidity in Western populations. Phytoestrogens such genistein (from 
soya) have been shown to stimulate cell proliferation and bind to ERs at relatively low 
levels (i.e. a low affinity) both in vitro (Cassidy, 1996; Bingham et al., 1998;Cassidy and 
Milligan, 1998; Jacobs et al., 1999) and in vivo (Milligan et al., 1998), and have been 
reported to have a protective effect if given before puberty (Lamartinière et al., 1995) and 
an inhibitive effect upon the growth of cancerous prostate cells (Hillman et al., 2001), but 
a detrimental effect, with increased risk of uterine cancer, if given in infancy (Newbold et 
al., 2001).
EDC pesticides have a more flexible molecular structure compared with 
phytoestrogens and thus greater affinity with the cellular receptors. It is frequently argued 
in the literature that the EDC pesticides bind very weakly to the oestrogen receptor 
compared with natural oestrogens and some phytoestrogens (Safe, 1995; Safe, 1997; Safe 
et al., 1997). QSAR studies have revealed more fully the importance of understanding 
differences in ligand binding within the ER (Jacobs, 1998; Jacobs and Lewis, 1999), and 
these differences need to be related to differences in serum levels of hormones at all 
stages of human development. EDC pesticides binding affinity in the classical oestrogen 
receptor (ERa) differs markedly from those of ERp and other receptors (e.g. PXR), and 
there are additional modes of action taking place. For example, organochlorine pesticides 
such as o, p ’ DDT and alachlor have been reported to partially mimic oestradiol and 
function to suppress apoptosis (programmed cell death) in ER responsive cells. Apoptosis 
appears to play a critical role in the generation and progression of cancer, and is probably 
regulated by steroid hormones in hormone responsive tissues (Burow et al., 1999). p ,p ’~ 
DDT has been found to be capable of activating cellular signalling events in ER- 
negative breast cancer cells (Shen and Novak , 1997a; Shen and Novak, 1997b), so it is 
highly likely that some organochlorine pesticides may function through other signalling 
pathways.
Chronic exposure to large quantities of phytoestrogens in foods might have a 
direct binding effect upon the ER and other hormone receptors. Indeed, coumestrol, a 
very potent phytoestrogen, has uterotropic activity in the immature rat that is typical of 
the activity of the endogenous oestradiol (Ashby et al., 1999b). Newbold and co-workers 
(2001) report that in vivo genistein exposure in newborn mice, a time at which the 
developing organism would normally be using natural oestrogen signals to guide 
development, increase the risks of uterine cancer in adult life. The amount of genistein
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used by Newbold et al. was slightly higher than the amount consumed by infants, but was 
within one order of magnitude of the level of human exposure (approximately 27 mg of 
genistein per day for infants feeding on formula vs. 50 mg/day in the experiment). 
Outbred female CD-I mice were treated on days 1-5 with equivalent estrogenic doses of 
diethylstilbestrol (0.001 mg/kg/day) or genistein (50 mg/kg/day). At 18 months, the 
incidence of uterine adenocarcinoma was 35% for genistein and 31% for DES. These 
data suggest that genistein is carcinogenic if exposure occurs during critical periods of 
differentiation. Other impacts observed from genistein exposure included reductions in 
fertility during adulthood following exposure as newborn.
Inappropriate oestrogens can alter development by changing the intensity of the 
oestrogen signal whether they are from natural sources or synthetic sources. In the adult, 
such an intake may also have indirect modulating effects upon associated and related 
factors (e.g. chaperone heat shock proteins), such that even whilst acting as an oestrogen 
at certain doses, phytoestrogens such as genistein may be also be acting upon multiple 
sites having indirect anti-oestrogenic, and anti-cancer effects.
A significant but neglected dietary intake avenue of oestrogens occurs in 
hormone residues from meat treated with sex steroids for growth promotion (Andersson 
and Skakkebaek, 1999). While the Joint Food and Agriculture Organisation/World 
Health Organisation (FAO/WHO) expert committee on food additives (JECFA) and the 
US Food and Drug Administration (FDA) consider that the residues found in meat from 
treated animals are safe for consumers, they have not considered the sensitivity of 
healthy prepubertal children to low levels of oestradiol (Andersson and Skakkebaek 
1999) or oestrogen mimicking compounds (Howdeshell et al., 1999), and pre and post­
natal infants to gene imprinting (McLachlan et al., 2001) from this dietary source of 
oestrogens. Possible adverse effects on human health by consumption of meat from 
hormone-treated animals cannot be excluded.
1.5. Key nuclear receptors: a multifaceted communication system
Members of the same nuclear receptor family share a common 
heterodimerization partner, retinoid-X-receptor (RXR), and there is cross talk with other 
nuclear receptors and with a broad range of intracellular signalling pathways. There may 
be competition for RXR for the dimerization stage of receptor activation of DNA. There 
may even be a cascade effect, where metabolites produced through the activities of one
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receptor are specific signalling molecules (and ligands) to modulate the next receptor,
providing a link in the nuclear receptor intercommunication web of the body (figure 1.8).
Figure 1.5. a) Daidzein and b) Genistein docked in the LBD of the h E R a  crystal 
structu re  (Jacobs, 1998). The photos are oriented to show the respective ligands 
hydrogen bonding (dashed orange lines) with key amino acids (in blue and red). The 
ribbon denotes the protein backbone of the receptor.
Figure 1.6. a) Genistein (in green) and PCB 153 (in orange) docked in the LBD of 
the hE R a crystal structure and h) hydroxy PCB 153 docked in the LBD of the 
hE R a  crystal structure. (Jacobs, 1998)
Figure 1.7. a) DDT (space-filled) docked in the LBD of the h E R a  crystal structure  
and h) PBDE 47 docked in the LBD of the h E R a  crystal structure . (Jacobs, 1998)
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Figure 1.8. Schematic diagram showing gender differences in tissue distribution of 
steroid hormone receptors (collated from the literature).
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Activation of an NR may either increase or decrease the synthesis of that or 
another receptor. A given receptor population is not constant and may be influenced by 
the concentrations of circulating ligands and also the state of the receptor population.
To demonstrate how important it is to consider the spectrum of receptors when 
assessing the dietary input of endocrine disrupters, a brief description of selected 
receptors and their known interactions with ERs follows. The interactions are far more 
complex than the brief descriptions may imply.
1.5.1. Aryl hydrocarbon Receptor (AhR)
The AhR, a member of the PAS (Per-Arnt-Sim) family of nuclear regulatory 
basic helix-loop-helix proteins, has been detected in nearly all vertebrate groups 
examined (Hahn et al., 1998; Hahn, 2002a) and appears to have a fundamental role in 
cellular physiology, neurodevelopment and circadian rhythmicity (Poellinger, 2000). 
Predominantly found in hepatocytes, but also in breast cancer cells (Nguyen et al., 1999), 
and the lung (Song et al., 2002). The AhR regulates the expression of a number of genes, 
including cytochrome P450 1 A l, 1A2, IB l and glutathione S transferase M (GSTM) in a
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ligand dependent manner. AhR is also upregulated during cell division, and in patients 
with cardiomyopathy (Mehrabi et al., 2002). Exposure to 2,3,7,8-tetrachlorodibenzo-p- 
dioxin (TCDD), the most potent AhR ligand known, results in a wide variety of species- 
and tissue-specific toxic and biological responses. Animals treated with 2,3,7,8-TCDD 
have developed abnormalities in several organs including the thyroid, thymus, lung and 
liver, immune and endocrine function. Wasting, lethality and induction of gene 
expression by TCDD have also been shown to be AhR dependent (Abbott et al., 1999; 
Diliberto et al., 2000).
Within the cytosol of the cell, the AhR is associated with a heterodimeric 
transporter protein partner, termed the Aryl Hydrocarbon Receptor Nuclear Transporter 
protein (ARNT). The unliganded AhR may also act through other mechanisms by being 
phosphorylated to key regulatory proteins such as hsp90, which appears to be required for 
maintaining the receptor in a non- activated ligand binding conformation (Pongratz et al., 
1992, cited in Poellinger 2000), as with the ERs, and other proteins such as p37, AIP, 
XAP2, src, rel, and Rb (Bimbaum, 2000; Bimbaum and Tuomisto, 2000). AhR knock out 
mice display reduced fertility, reduced viability, and liver and immune deficits (Diliberto 
et al. 2000) in some independently generated line mice, but not others (for a review see 
Poellinger 2000).
The best characterised high affinity ligands for the AhR include a variety of 
ubiquitous man-made toxic and hydrophobic chemicals, including halogenated aromatic 
hydrocarbons (HAHs), such as the polychlorinated dibenzo-p-dioxins, dibenzofurans, and 
biphenyls, and polycyclic aromatic hydrocarbons (PAHs) such as benzo(a)pyrene, 3- 
methylcholanthrene, benzoflavones and other chemicals. Certain dietary indole 
derivatives, such as indolo[3,2-6]carbazole, appear to bind to the AhR with the same 
affinity to that of 2,3,7,8-TCDD (Gillner et al., 1993), but a physiological receptor ligand 
has not been identified yet. Weaker ligands include diaminotoluene, omeprazole, 
brevetoxin, indole carbinols (found in cruciferous vegetables), and endogenous weak 
ligands such as bilirubin (a hydrophobic heme degradation product metabolised in the 
liver), biliverdin (Sinai and Bend, 1997; Phelan et al., 1998), and water soluble 
metabolites of tryptophan, tryptamine and indole acetic acid (Heath-Pagliuso et al.,
1998), equol, a daidzein metabolite and compounds produced endogenously for 
prostaglandin pathways, including arachidonic acid, prostaglandins and lipoxin A4 
(Schaldach et al., 1999; Denison et al., 2002). More recently, a further endogenous 
ligand, with an indole thiazole structure, ITE (2 -(l’H- indole-3’carbonyl)-thiazole-4-
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carboxylic acid methyl ester) has been proposed, after isolation from porcine lung, it 
appears to have relatively high affinity with the AhR, with similar activity to BNF (Song 
et al., 2002). It is possible that this compound is not endogenous; it may have formed in a 
reaction with the extraction and purification acid treatment combination. Clearly there is 
a wide gamut of structural diversity of AhR ligands, many of which are ligands for other 
NRs.
Many of these ligands activate other receptors, dioxins for example have anti- 
oestrogenic activity in the ER, while equol is strongly oestrogenic. The endogenous 
ligands hint further at the developmental role of AhR, as persistent C Y PlA l and 
CYP1A2 gene expression has been observed in congenitally jaundiced Gunn rats 
(Lorenzen and Kennedy, 1993, cited in Phelan et al., 1998). Both enzymes play a role in 
the oxidative metabolism of bilirubin, decreasing its toxicity and enhancing its 
elimination, an important detoxication role in the newborn infant where jaundice 
commonly occurs due to less developed liver function and excretion. Increased AhR 
induction is observed with increased oxidative stress, and it is probable a route for 
antioxidant activity is through the AhR to down regulate oxidative signaling.
1.5.2. Pregnane X Receptor (PXR)
An important requirement for homeostasis is the detoxication and removal of 
endogenous hormones and xenobiotic compounds with biological activity. PXR 
(Lehmann et al., 1998a; Kliewer et al., 1998; Blumberg et al., 1998) is involved in 
activating the expression of several P450 detoxifying enzymes, including CYP3A4 in the 
adult and CYP3A7 in the fetus in response to xenobiotics and steroids (Pascussi et al.,
1999). CYP3A4 is the major human hepatic P450, and has been suggested as being 
involved in the metabolism of over 60% of drugs in clinical use (Maurel, 1996). Wide 
species differences exist in PXR activation due to differences in the LBD (Jones et al.,
2000).
The major site of PXR expression is in the liver cells and the gastrointestinal 
tissues, but they are also present in both normal and neoplastic breast tissue. Indeed a 
statistically inverse relationship between the level of PXR mRNA expression and ER 
status has been observed (P=0.04) (Dotzlaw et al., 1999). PXR can be activated by a 
variety of chemically distinct ligands, in a species dependent manner, including 
endogenous hormones such as oestrogen, pregnenolone (figure 1.7), and progesterone, 
their synthetic derivatives such as pregnenolone 16a carbonitrile (PCN), bile acids.
42
rifampicin, dexamethasone, corticosterone, spironolactone, phénobarbital, antiretroviral 
drugs, simvastatin (reviewed in Plant and Gibson, 2003), vitamin D3 (l,25-(OH)2-D3), 
and plant-sourced ligands such as hyperforin (Moore et al., 2000a), coumestrol and 
genistein (Chapter 4). Organochlorine pesticides and the synthetic food contaminants, 
phthalic acid and nonylphenol (Masuyama et al., 2000) with known ER activity (Harris et 
al., 1997) also activate PXR. Many of these compounds activate other receptors from 
liver receptors such as LXR and FXR, to the ERs, AhR and the vitamin D receptor. The 
percentage inhibition in competition binding assays for the pesticide trans-nonachlor is 
close to one hundred percent, with seven times greater activation than the activation by 
PCN in human PXR transfection assays (Jones et al., 2000). PXR is also essential in 
mediating transcriptional activation of CYP3A by environmental contaminants (Schuetz 
et al., 1998).
It appears that there is a specific regulatory pathway where the accumulation of 
steroidal PXR ligands, including xenobiotics, results in increased CYP3A transcription 
and steroid catabolism, possibly providing the route for excess steroids to be eliminated 
from the body. So not only is PXR a xenobiotic sensor, it is also a key player in the 
regulation of steroid homeostasis, steroid metabolism, by involvement in the expression 
of steroid hydroxylases and detoxication (Kliewer et al., 1999). By implication, EDCs 
affecting PXR may also have indirect effects upon the regulation of steroid homeostasis. 
Some NRs have quite different, unanticipated mechanisms of action which EDCs may 
also influence directly or indirectly, as with the constitutive androstane receptor.
1.5.3. The Constitutive Androstane Receptor (CAR)
Present in the liver and intestine, CAR belongs to the subfamily of NRs that 
includes the Vitamin D receptor (VDR), and PXR. CAR similarly heterodimerises with 
RXR (Baes et al., 1994; Choi et al., 1997; Honkakoski et al., 2003) and interacts with, 
and is inhibited by, two endogenous steroids, androstanol and androstenol, via a 
mechanism that involves a widely expressed nuclear receptor coactivator, SRC-1. Both 
PXR and CAR are involved in the expression of steroid hydroxylases, and consequently 
regulate key steps in steroid metabolism (Kliewer et al., 1999). However, unlike most 
NRs, including PXR and ER, CAR is constutively active in nature and is sequestered in 
the cytoplasm of non-exposed cells. Ligand activation of CAR inhibits receptor- 
dependent gene transcription. It does this through the ligand-independent recruitment of
43
transcriptional co-activators. CAR functions in a complex manner, a manner opposite to 
that of the conventional NR pathways.
The physiological relevance of CAR is unknown as yet, although evidence is 
accumulating that CAR is a drug-activated receptor integral to the elimination of drugs 
mediated by P450s.
There are significant sex differences in plasma androstane levels and CAR has 
been recently implicated as a transcriptional regulator of the gene governing the steroid 
hydroxylase CYP2B (Forman et al., 1998; Honkakoshi et al., 1998). The PB responsive 
DNA elements (PBREM) reporter gene has been shown to be activated by CAR 
(Honkakoshi et al., 1998). CAR is highly responsive to phénobarbital (PB) type 
compounds, including certain PCBs, pesticides, drugs, solvents and other xenobiotics, 
such that endogenous CYP2B is responsive to PB and other inducers only in the presence 
of suppressed CAR. At the systemic level, hormonal imbalances that affect androstanol 
and androstenol levels may impart a perturbation at the molecular level, preventing or 
inducing the inhibition of CAR and consequently the steroid hydroxylase CYP2B.
1.5.4. Human peroxisome proliferator activated receptor (hPPAR)
The Peroxisome Proliferator-Activated Receptors (PPARs) are a family of orphan 
receptors with fundamental roles in regulating energy balance (Johnson et al., 1997; 
Blumberg and Evans, 1998; Uauy et al., 2000; Willson et al., 2000; Bar-Tana, 2001). A 
number of prevalent metabolic disorders such as obesity, atherosclerosis and type 2 
diabetes are associated with a shift in this balance. The PPARs are activated by chemicals 
which elicit increases in the number and size of peroxisomes when administered to 
rodents (Kliewer et al., 1999).
Three closely related PPARs, a , (3/8 and y, are found in the liver, kidney, heart, 
haematopoietic and adipose tissue, but with different expression patterns. PPAR a  is 
found in liver, kidney, heart and muscle, PPAR (3/8 is expressed in nearly all tissues and 
PPAR y is expressed in fat cells, the large intestine, and monocyte lineage cells (Memon 
et al., 2000). They each play key roles in lipid metabolism and homeostasis; they are 
responsible for CYP4A induction, peroxisomal enzyme induction and hepatic peroxisome 
proliferation. PPA Ra has a central role in hepatogenesis, and PPARy a central regulatory 
role in adipogenesis (Willson et al., 2000). PPARa regulates key steps in lipid and fibrate 
metabolism and this receptor is the molecular target for naturally occurring plant fatty 
acids (pristinic acid and phytanic acid) present at physiological concentrations (Zomer et
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al., 2000), long chain polyunsaturated fatty acids (LCPUFA), eicosanoids (Uauy et al., 
1999), and peroxisome proliferators, which include drugs such as the fibrates (used 
widely to lower high triglyceride levels, a risk factor in coronary heart disease) and 
synthetic chemicals such as the phthalate ester plasticisers, and pesticides (Kliewer et al.
1999). PPARy ligands include fatty acids, prostaglandins and the antidiabetic 
thiazolidinedione (TZD) drugs (Memon et al., 2000; Willson et al., 2000). Pristinic acid 
and phytanic acid are branch-chained fatty acids obtained through the diet from the 
chlorophyll in plants. Present at micromolar concentrations in healthy individuals, they 
can accumulate in a variety of inherited disorders. Potent binding of pristinic acid and 
phytanic acid in the LBD of PPA Ra (Zomer et al., 2000) indicates a primary 
mechanism for metabolising these dietary fatty acids. The PPARs have a far larger ligand 
binding pocket than the receptors so far discussed, and there are differences in the shape 
of each PPAR ligand binding pocket, giving broad ligand specificity on a structural basis 
(see Chapter 3).
Another factor to be considered is modulation through cross-talk between PPAR 
and other nuclear receptors/signalling molecules. For example, thyroid hormone 
suppresses hepatic PP responses and exhibits inhibitory cross-talk with PPARa, due in 
part to competition between the thyroid receptor and PPAR for their common 
heterodimerization partner RXR (Miyamoto et al., 1997) (See figure 1.1.).
Rosiglitazone occupies a fraction of the available LBD space in PPARa, and even less 
than that in PPARy, particularly the rosiglitazone TZD head-group, and thus 
comparatively reduced selectivity is observed. This has also been observed for different 
ligands in the PPAR family, and is a clear descriptor for PPAR selectivity.
1.6. Co-modulators that enhance or suppress transcriptional activity
NRs interact with a group of novel nuclear proteins, including steroid hormone 
receptor coactivator-1 (SRC-1), Steroidogenic factor 1 (SF-1), and receptor interacting 
protein 140 (RIP 140) (Luo et al., 1999). RIP 140 has been shown to interact with the ER 
LBD in the presence of oestrogen, amplifying and potentiating ER dependent 
transcriptional activity (Sheeler et al., 2000). SF-1 is a key regulator of the tissue specific 
expression of the cytochrome P450 steroid hydroxylases, and is essential for the 
embryonic survival of the primary steroidogenic organs and the regulation of 
reproductive function at all three levels of the hypothalamic-pituitary-gonadal axis from
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the earliest stages of gonadogenesis (Luo et al., 1999). In vitro studies suggest that 
exposure to o,p -DDT (and other oestrogenic compounds) at sufficient concentrations or 
in the presence of an ER coactivator could have deleterious effect upon normal cell 
function due to the untimely activation of oestrogen regulated genes (Sheeler et al. 2000). 
Similarly, in a yeast two hybrid protein interaction assay, PXR has been observed to 
interact with SRCl and RIP 140 (Masuyama et al., 2000). Cellular efflux transporter 
proteins present in the intestine and liver, such as Organic Anion Transporting 
Polypeptides (e.g. OATP-C, OATP-1), P-glycoprotein (P-gp) and multidrug resistant 
proteins (e.g. M DRl, MDR2 ) can have major effects upon PXR ligand availability by 
interacting with PXR pathways. It has also been suggested that the differences in potency 
of phytoestrogen ligands in binding studies for ERs, especially ERp, compared with the 
lower potency detected in whole cell assays may be a consequence of interactions with 
binding proteins.
Perturbation of the endocrine system hormones can also affect certain transport 
proteins, many of which are gender specific. However as part of the complicated nature 
of hormonal interactions it is relevant to note that sex steroids are known to regulate 
certain excretory transport proteins, such as the mRNA levels of Oats in in vivo rat 
models, in a gender specific manner. Androgens have been reported to increase rat 
organic anion transporter 1 (Oatl) mRNA in kidney, while the female GH (growth 
hormone) secretion pattern increases a different Oat, Oat2, with both androgens and GH 
regulating Oat3 mRNA levels in the liver (Buist et al., 2003).
The implications of the interactions with transporting proteins, such as OATP, P- 
gp, M RDl and MRD2 are significant with respect to ligand availability and this is 
discussed further with particular reference to PXR in Chapter 4.
1.6.1. Cytochrome P450 enzymes: CYP17A1/19A1 (Aromatase)
Aromatase is a key P450 in the production of oestrogen, catalyzing the 
conversion of androgens, androstenedione and testosterone via three hydroxylation steps 
to estrone and estradiol (Martucci and Fishman, 1993; Brodie et al., 1999). Aromatase is 
expressed in many tissues, including the ovaries, the testis, the placenta, the brain, and 
adipose tissue of the breasts, abdomen, thighs, buttocks and bone osteoblasts. 
Phytoestrogens are potent inhibitors of aromatase (reviewed in Whitten and Patisaul,
2001).
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1.6.2. Aromatase, breast cancer and hormonal disruption in women
Adipose tissue is the major site of oestrogen biosynthesis in postmenopausal 
women, with the local production of oestrogen in breast adipose tissue implicated in the 
development of breast cancer. Inhibition of this pathway is one method that is exploited 
pharmacologically in ER positive breast cancer treatments to inhibit oestrogen 
production. Another approach is to inhibit oestrogen action by antioestrogens, which 
interact with the oestrogen receptor in the tumours. Adipose tissue is also the most 
significant storage site in the human body for environmental pollutants such as PCBs and 
DDT, compared to blood and the liver. lida et al. (1999) reports measured values for PCB 
118, for instance, as follows; blood: 59.2 pg/g tissue, liver: 1692 pg/g tissue, and fat: 
13,896 pg/g tissue.
Recently, rosiglitazone and troglitazone, compounds known to activate another 
receptor, PPARy (a key factor in adipocyte differentiation), used in the control of insulin 
-resistant diabetes, have also been found to inhibit aromatase expression in human breast 
adipose stromal cells (Simpson et al., 2000; Rubin et al., 2000). They have also been 
observed to stimulate breast cancer cell lines (Mueller et al., 1998). Developmental 
inhibition of the aromatase pathway can give rise to polycystic ovarian syndromes (PCN) 
(Franks et al., 1999). EDCs that may affect this pathway include those that have been 
observed to bind with the ER. Figure 1.7 indicates current knowledge of the gender 
differences in the distribution of steroid hormone receptors. It is likely that there are also 
polymorphisms to consider, as inter-individual variations in gene sequences (Masahiko 
and Honkakoski, 2000), suggest that individuals may vary in terms of amount and 
function of all the receptors discussed herein. The hierarchy of ligand activation differs 
between the receptors as well as for receptors isolated from different species, and in 
many instances molecules that were previously regarded as metabolic intermediates are 
in fact “intracrine” signalling molecules within tightly coupled metabolic pathways for 
altering gene expression.
1.7. Molecular modelling
Using computer generated molecular models of the ligand receptor interaction, 
one can examine the likely mechanisms of action of NRs. By modelling such interactions 
and evaluating the activity of potentially hormone mimicking materials by way of 
Quantitative Structure Activity Relationships (QSARs), it is possible to examine and
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estimate the potency differences within these compounds in human hormone receptor 
ligand-interactions. This thesis aims to improve the development of this area, examining 
the differences in affinity of NRs for a given ligand. In relation to experimental data, it 
can provide a useful tool in a complex situation of considerable public concern. Whilst 
used extensively by the pharmaceutical industry, QSARs are under-utilised by 
nutritionists, food scientists and environmental toxicologists. By using crystal structure 
co-ordinates it is possible to examine the mode of binding of selected chemicals and 
calculate the values for the ligand binding affinity, when compared to in vitro data. Thus, 
a measure can de derived of the potency and action of a chemical in a given receptor, 
compared with another chemical, at the molecular level. This information can be related 
to physiological and epidemiological health effects observed, providing an essential part 
of the whole picture of endocrine function and dysfunction.
Data from animal and in vitro studies provide convincing evidence for the 
potential of phytoestrogens in influencing hormone dependent states, although many in 
vivo studies can be confounded by the oestrogenic activity of components of the rodent 
diets (Boettger-Tong et al., 1998; Ashby, 2001), housing and species (Anon, 1999). 
While the clinical application of high phytoestrogen human diets is in its infancy, data 
from preliminary studies suggest beneficial effects of importance to women and men’s 
health.
Chapter 3 reports the generation by homology modelling of the three-dimensional (3-D) 
structures of the ligand-binding domain (LBD) of several interrelated human nuclear and 
steroid hormone receptors. These are the oestrogen receptor(3 (hER(3), the pregnane-x- 
receptor (PXR) (figure 1.7), the Ah receptor (AhR) and the constitutive androstane 
receptor (CAR). They were produced by homology modelling from the human oestrogen 
receptora (hERa) crystallographic coordinates ( figures 1.3 and 1.5) (Brzozowski et al., 
1997) as a template, together with the amino acid sequences for hERp (Mosselman et al., 
1996), PXR (Lehmann et al., 1998), AhR (Burbach et al., 1992) and CAR (Forman et 
al., 1998), respectively. The selective endogenous ligand was docked interactively within 
the putative ligand binding site using the position of oestradiol in hER a as a guide, and 
the total energy was calculated. In each receptor model a number of different ligands 
known to fit closely within the ligand binding site were interactively docked and binding 
interactions noted. Specific binding interactions included combinations of hydrogen 
bonding and hydrophobic contacts with key amino acid sidechains, which varied 
depending on the nature of the ligand and receptor concerned. With the AhR an
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important facet of the ligand binding process involves a n-n stacking interaction between 
benzene rings on selected PCB molecules and aromatic amino acid residues in the AhR 
ligand binding site. Differences in the binding affinities for the same ligands in E R a 
compared to ERP are under investigation, further to the report published by Pike et al. 
(1999).
We also produced PPARa by homology modelling using the human PPARy (hPPARy) 
LBD crystallographic coordinates reported by Nolte and co-workers (Nolte et al., 1998) 
as a template together with the amino acid sequence for hPPARa (Sher et al., 1993; 
Lewis and Lake, 1998). Models of selected ligands were docked interactively within 
the putative ligand binding site using the position of rosiglitazone as a guide, and the total 
energy was calculated. This work comprises Chapter 3, it was conducted prior to the 
publication of the PPARa crystal structure, and has been published (Jacobs and Lewis, 
2000; Jacobs et al., 2003a).
The models provide a useful tool in unravelling the complexity in the physiologic 
response to xenobiotics, by examining the ligand binding interactions, differences and 
cross talk between the steroid hormone receptors and activation or inactivation by their 
ligands. Nuclear receptors are important drug targets for intervention in disease 
processes. Exogenous compounds that target these receptors can therefore disrupt both 
normal and abnormal functioning of these key metabolic pathways. While environmental 
hormone mimics contribute to detrimental health effects by activating certain receptors 
and disturbing normal function, there are therapeutic uses from both dietary and 
pharmacological treatment for abnormal functioning of the hormone pathways and 
hormone dependent diseases.
The promiscuous ability of many cellular receptors to bind to ligands of different 
chemical structures is a major mechanism by which dietary ligands, including 
environmental chemicals, can enhance or inhibit receptor activation, as well as being the 
basis for the pharmaceutical development of receptor regulating drugs. However, 
endocrine effects are mediated through multiple sites of action, and EDCs are able to 
alter endogenous hormone pathways, as well as acting directly upon receptors. Fetal 
exposure to EDCs at critical time points will have harmful health effects that do not 
become evident until puberty and adulthood, and again there will be gender differences 
and not just age-related susceptibilities. Vulnerability to the adverse effects of EDC 
exposure and protective effects from phytoprotectants such as phytoestrogens escalates 
during dynamic periods of growth and development. Children may metabolize
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compounds faster, but they detoxify more slowly and have greater body burdens due to 
higher dietary intakes in relation to body size, compared to adults.
The effect of ligand binding to a steroid hormone receptor needs to be considered as a 
synthesis of the entire endocrine system, over time, according to gender and reproductive 
status and with due consideration for diurnal rhythms and environmental factors.
1.8. Conclusion
The nuclear receptors modelled display a spectrum of ligand specificities, 
ranging from the highly specific, as seen in CAR, which binds 5a-androstan-3a-ol 
(androstanol) but not 5 a-androstan-3p-ol, and in PPAR selectivity, to the highly non­
specific, such as hPXR, which is very flexible, and can bind with a large number of wide 
ranging molecules, from rifampicin to steroidal structures. They also display a spectrum 
of binding modes within the LED, from hydrogen bonding with different key amino acids 
(as observed in all the receptors) to n-n  stacking, as seen in the AhR and also binding 
outside the LED, as seen with antagonists such as tamoxifen in ERa.
The receptor models can be used to explore modes of binding of different ligands in the 
LED, and to generate Quantitative Structure Activity Relationships in conjunction with 
experimental ligand binding data from the literature.
The identification and in silico assessment of the different ligands both in 
isolation and within the receptor models will add to a better knowledge of their 
specificity and may help explain the selective action of oestrogens, phytoestrogens and 
EDCs in different tissues, and expand knowledge on the role of nutrition and 
pharmacology for therapeutic intervention in various endocrine, developmental and 
energy homeostasis functions that involve the ERs, AhR, CAR, PXR and the PPARs. 
Pervasive EDCs that target these receptors, disrupting normal functioning of key 
metabolic pathways, contribute to detrimental side effects in just the same way as 
observed pharmacologically, with the inadvertent activation of orphan receptors by 
certain drugs. Without considering the whole steroid hormone receptor super family, 
current EDC research can only be considered piecemeal, insufficient and ineffective for 
risk assessment and not representative of the hormonal effects of EDCs. The full range of 
effects of EDCs, whether of synthetic or plant origin, from exposure routes to health 
outcomes, upon women, men, and subsequent generations can only be unravelled with an 
integrated multidisciplinary approach.
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2.1 Introduction
A major route of exposure for compounds that are ligands for the NRs, as reviewed in 
chapter 1, is dietary. This chapter uses a case study format to examine the dietary routes of 
exposure to environmental contaminants that are also ligands for SHRs and are key 
suspected endocrine disrupters. The salmon aqauculture food chain is the subject of this case 
study. The POPs levels are determined in mainly farmed salmon, feed and fish oils. In recent 
years, the salmon industry has grown significantly in Europe, and salmon is becoming 
increasingly available to the consumer, so is a common dietary source for many European 
consumers. Until very recently, and at the time of this investigation was conducted and 
published, there were very little data available on contamination pathways in aquaculture 
systems, such as that for farmed salmon farmed fish, although there is extensive literature 
documenting the bioaccumulation of persistent organic pollutants in the marine environment.
Data are available on the concentrations of polychlorinated biphenyls (PCBs), and other 
organochlorine contaminants such as polychlorinated dibenzo-p-dioxins (PCDDs) and furans 
(PCDFs), in fish from wild stocks, where exposure is associated with chronic contamination 
due to leaching of these chemicals from treated or contaminated soils into surface waters and 
the global distribution and deposition by atmospheric transport (North Sea Task Force, 1993). 
With farmed fish, potential hazards associated with the ingredients and additives used in 
aquaculture feed were not considered significant until very recently (World Health 
Organisation, 1999; European Commission, 2000; Scientific Committee on Food, 2000a; 
Scientific Committee on Food, 2000b).
Fish oil is a by-product of the fish meal manufacturing industry and comes from many 
different parts of the world. As chlorinated compounds accumulate in the lipid compartment 
of the animal, oil extracted from fish caught in polluted waters may be contaminated with 
chlorinated hydrocarbons (Jacobs et al., 1997; Ministry of Agriculture Fisheries and Food, 
1997; Jacobs et al., 1998). Existing data on the levels of PCBs, PCDDs, PCDFs and 
organochlorine pesticides consumed in the UK have been mainly derived from total diet 
surveys and surveillance data for specific food types (Ministry of Agriculture Fisheries and 
Food, 1996; Food Standards Agency, 2000). These data indicate the presence of elevated 
organochlorine contamination of farmed fish. Salmon and trout samples tested in 1997 were
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found to contain residues of PCBs at concentrations between 23 and 620 ng/g lipid weight 
(Veterinary Medicines Directorate, 1998; Ministry of Agriculture Fisheries and Food / 
Department of Health, 1998). DDT and HCB were the predominant organochlorine 
pesticides detected in these samples.
The widely used flame retardants, polybrominated diphenyl ethers (PBDEs), are also 
persistent and ubiquitous organic pollutants (POPs) that biomagnify and may have endocrine 
disrupting effects (World Health Organisation, 1994; De Boer et al., 1998; Bergman, 2000; 
Damerud et al., 2001; Branchi et al., 2003). Concern with the risks to human health, 
particularly infants, is increasing due to observations of increasing PBDE concentrations in 
human breast milk (Branchi et al., 2003; Meironyté et al., 1999), although available data, 
including that reported here, suggest that current levels of PBDEs in the UK salmon industry 
are an order of magnitude lower than those of PCBs. While PBDEs are in extensive 
production and use, existing data on the levels of PBDEs consumed in the UK are very 
limited, although surveys to determine the distribution and fate of PBDEs in marine life in 
waters around the UK have been recently reported (Allchin et al., 2000; Boon et al., 2002).
The determination of these contaminants in fish and identification of the original sources 
of the contamination is, therefore, important for dietary exposure assessment and the 
protection of public health, particularly in view of the increasing availability to the consumer 
of farmed salmon. The farmed salmon industry is rapidly expanding; it has trebled in 
production from 1990 to 1998 (FAO Fishery Information, 1998). The three major producers 
are Norway, the United Kingdom and Chile, although other countries, notably the US, are 
also increasing the growth rate of their salmon farming industries. While the use of fish meal 
in aquaculture feeds for farmed fish and shrimp continues to increase (FAO Globefish, 2000), 
it should be noted that twice as much fish meal is used in poultry and pig feeds (FAO 
Globefish, 2000; FAO Fishery Information, 1998). However, the feed costs to produce 
farmed salmon appear to be significantly greater on a live weight basis (Naylor et al., 2000). 
The proportion of fish meal supplies used for farming fish rose from 10% in 1988 to 33% in 
1997 (FAO Globefish, 2000; Forster, 1999).
The use of fish meal and fish oil of European origin are considered to be of critical 
concern when used in diets for farmed fish and other food producing animals (Scientific 
Committee on Food, 2000a; Scientific Committee on Food, 2000b). The aquaculture sectors 
most dependent on the use of fish oil (commonly herring oil) as a source of dietary lipids are 
the salmon and marine finfish industries. Fish oil is now being strongly promoted by the 
aquaculture industry as an aquaculture additive in a ‘High Energy diet’ that encourages fast
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growth of fish whilst minimising protein utilisation as an energy source, and improves the 
nutritional value to humans through raised omega-3 fatty acid levels. Its use has increased 
significantly since 1995, from less than 30% to 33% and even 36.3% of the total diet for 
Salmon, in recent years (Royce, 1996; Bell, 1998; BOCM, 1998; Trouw Aquaculture., no 
date).
The change in use of fish oil is indicated in Table 2.1.
Table 2.1. Manufacturers prediction of UK consumption of fish oil (Barlow 1995).
Thousand tonnes
1995 2010
Hardening 1,050 500
Farming 350 750
Supplements/Industry 100 200
Refined oil 0 50
TOTAL 1,500 1,500
Section 2.2 presents the results of analysis of farmed Scottish salmon samples for 
PCDDs, PCDFs and selected coplanar PCBs. These values are compared with those obtained 
from salmon reported in other studies. The potential contribution of fish oils to the 
bioaccumulation of PCDDs and PCDFs and PCBs in farmed fish is discussed, together with 
suggestions on how to reduce these contaminant levels whilst also achieving nutritional and 
environmental benefits in an economically viable way for both industry and the consumer 
(Jacobs et al., 2000; Jacobs et al., 2002a).
To our knowledge, section 2.3 presents the first independently published assessment of 
levels of organohalogenated compounds in the farmed salmon food chain (Jacobs et al., 
2001a; 2001b; Jacobs et al., 2002b). Farmed European Salmon, feed and fish oil samples 
were analysed for a wide range of PCBs, organochlorine pesticides and PBDEs. This chapter 
builds on the initial study, presented in section 2.2, by including data on a further five salmon 
samples, eight aquaculture feed samples and five fish oils. These values are compared with 
those for fish and feed data reported in the literature, and the potential contribution to the 
bioaccumulation of PCBs, organochlorine pesticides and PBDEs in farmed salmon is
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discussed. Since publication, the findings of these studies have been confirmed through 
testing by the UK Food Standards Agency and extensive testing conducted by the aquaculture 
industry (Nutreco, 2003).
Section 2.4 is a case study examining the organhalogen contaminants in dietary omega- 
three rich supplements, which as with animal feeds is considered a major growth area by the 
fish oil industry (see Table 2.1). Multivariate analytical techniques are utilised to examine 
time trends in the contaminant loads between samples tested in 2002 compared to eight years 
previously (Jacobs et al., 1997).
Section 2.5 discusses the changing contaminant patterns observed and the issues, 
implications and further data needs and tools required to provide realistic dietary exposure 
estimations on POPs contaminants, and realistic cost-benefit scenarios.
55
2.2 Investigation of polychlorinated dibenzo-p-dioxins, dibenzofurans and selected 
coplanar biphenyls in Scottish farmed Atlantic Salmon (Salmo salar).
2.2.1. Abstract
This study determines the levels of PCDDs, PCDFs, and selected coplanar PCBs in 
Scottish farmed Atlantic salmon {Salmo salar). This study initiates an investigation of the 
changing dietary pathways of fish oil and fish meal, and bioaccumulation of organochlorines 
such as dioxins in fish tissue destined for human consumption, which is developed further in 
Chapter 2.2. where the same salmon samples and aquaculture feeds and oils are further 
analysed for a wider range of organhalogen pollutants.
Twelve farmed and wild Scottish Atlantic Salmon fish were obtained from retail 
suppliers, producers and Stirling University, in Scotland during January 1999 for 
determination of 17 PCDDs and PCDFs, and 7 non-ortho and mono-ortho PCBs. The study 
confirms previous reports of relatively high concentrations of PCDDs, PCDFs and, 
especially, PCBs in farmed Scottish Salmon. The results indicate that high consumption of 
salmon, particularly by children under 5 years, could lead to intakes above the tolerable daily 
intake (TDI) and temporary tolerable weekly intake (tTWI) for these chemicals, especially 
PCBs, in combination with mean or high level intakes from the UK diet.
These results suggest further investigation of farmed salmon and salmon feed, including feed 
fortified with fish oil and feed fortified with selected vegetable oils, are warranted.
2.2.2. Materials and methods 
2.2.2.1. Sites and sampling
Nine British salmon samples (of which seven samples were from individual fish, and two 
samples were composites of two fish each) and one Norwegian salmon {Salmo salar) sample 
that enter the European fish market were analysed. Salmon fish samples of variable age, both 
farm raised and wild, were obtained from eight different sites in January 1999, and were 
essentially samples of opportunity. The timing of the sample collection was in accord with 
the seasonal variation in the oiliness of fish fed diets containing greater than 28% lipid, as the 
exudation of free oil affects the ease of handling and preparation of the fish samples. The 
sampling times to avoid are September to mid November, and the month of April (Royce, 
1996; Bell et al. 1998). The fresh samples were obtained from commercial farms, supplying 
the local and national markets and national supermarket chains, and the Glasgow fish market. 
They were wrapped in polyethylene bags and packed in ice (for less than 3 hours) prior to
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being placed in a deep freeze. Frozen samples, originally sourced from a supermarket, 
Scottish salmon farms and Norway, were kindly provided by Dr S. George and Dr. G. Bell, of 
Stirling University, Scotland. Upon collection, each sample was given a unique laboratory 
reference number, and the sample details logged into a database. Laboratory reference 
numbers and GC-MS data file codes are included in the results tables. When all samples 
were collected (3 days), and frozen, they were packed in ice and transported directly by M. 
Jacobs to the laboratory where they were stored at -20°C. Random sampling was not 
possible, but unbiased representation of the situation of interest was achieved, by obtaining 
fish from the Northwest Scottish Highlands, the Western Scottish Highlands, the lowlands 
surrounding Stirling, plus a wild fish from the Scottish border with England, two samples for 
which no reliable information was available (but one may have been wild), and a Norwegian 
sample for which no information was available.
Whole body weights of the fish ranged from 400g to 5.2kg, the fish ranged in age from 1 
year to 3+ years. Table 1 gives sample details for the salmon and it is important to note that 
the ‘wild’ fish may not have been genuinely wild, but were probably farm escapees (S. 
George, personal communication).
Figure 2.1 indicates the spread of the sample sites in Scotland.
Sample identity numbers beginning 213 refer to the sample codes allocated by the US ERA 
analytical laboratory. The sample identity numbers in brackets beginning M refer to the 
relative duplicate sample analyzed in collaboration with Adrian Covaci at the University of 
Antwerp, reported in section 2.3.
L.Tain: 213-02; 213-04; 213-05 (M il,  M24, M25)
Fort William
L. Leven: 213-07 ( M l 2)
R.Devon:213-09 '
Stirling: 213-10; 213-11; 
213-12, (M14, M28, M31)
Allen: 213-06
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2 2 2 2 .  Sample preparation
The samples were thawed, filleted, skinned and the epaxial muscle homogenised before 
being subdivided into smaller replicate portions of approximately 100 grams. The portions 
were weighed, stored in tightly sealed polythene bags and frozen at -20°C.
Two samples consisted of homogenised samples of two fish each (from the same source and 
of the same age and size) to ensure similar sample quantities of tissue. One set of the frozen 
samples remained at the laboratory for subsequent analysis. The other set of samples were 
packed in dry ice and taken directly by courier to the US EPA/OPP laboratory the following 
day, where they were inspected, logged-in and stored at -60°C prior to analysis.
2.2.2. j .  Analytical Procedures
Many of the sample preparation procedures, analytical techniques, and quality control 
strategies described in this paper parallel those defined in U.S. EPA’s Method 1613 (Ferrario 
et al., 1996; Ferrario et al., 1997).
2.2.2.4. Sample preparation fo r  analysis
One hundred grams of homogenised muscle tissue were extracted using a mixture of 
hexane/methylene chloride/ 2-isopropanol to obtain the lipid and an aliquot representing a 7-8 
g subsample (when possible) taken for analysis. An aliquot was also removed to determine 
the percent lipid. The crude lipid extract was fortified with 13C labelled analogs of the 
various 2,3,7,8-CL substituted congeners and selected coplanar PCBs. The crude extract was 
cleaned up using acid/base-modified silica gel, alumina, and graphitized carbon column 
chromatography. The eluent was then concentrated, fortified with 13C labelled internal 
standards, and analysed by high-resolution gas chromatography/high-resolution mass 
spectrometry (HRGC/HRMS).
Though the methodology used in this study followed U.S. EPA Method 1613 closely, 
there were several significant changes, which should be noted:
(1) Standard solutions were prepared at lower concentrations than suggested in 1613. Method 
1613's lowest calibration standard contains 500 fg/pL TCDD and 100 pg/pL of 13C-labeled 
surrogates. This study's lowest calibration standard contained 50 fg/pL TCDD and 5 pg/pL of 
13 labelled surrogates. The samples in this study fortified with 13C-labeled surrogates to 
deliver 5 pg/pL, where Method 1613 delivers 100 pg/pL from the same 20-pL final volume. 
This lower 13C surrogate fortification level at 10 ppt allowed for a more realistic
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approximation of the actual recovery of native analytes at low part per trillion (ppt) levels and 
better approximates the behaviour of trace levels of natives during extraction, concentration, 
and chromatography.
(2) A DB-5MS column was used in place of the DB-5 specified by Method 1613. The DB- 
5MS has a superior separation of the 2,3,7,8-TCDD from the other tetra isomers and better 
resolves the 2,3,7,8 -Cl-substituted dioxins and furans. It should be noted that the elution 
order of the 1,2,3,7,8,9-HxCDF and the 2,3,4,6,7,8-HxCDF is reversed on the DB-5MS 
relative to the DB-5.
(3) Method 1613 uses an AX21 and Celite 545 mixture for the graphitized carbon column 
cleanup; this study used a mixture consisting of 9.5 g of BioSil A silica gel and 0.5 g of 
Amoco PX-21 carbon. The eluting solvents were also different: the column was conditioned 
with 10.0 mL of 50% dichloromethane/benzene solution, 10 mL of toluene, and 5 mL of 
hexane. The sample extract was then added plus two 0.5ml rinses of hexane. The column was 
then eluted with 4.5 ml of 25/75 methylene chloride (MeCl)/hexane (which is discarded) 
followed by 5.5 ml of MeCl and 12 ml of 75/25 MeCl/benzene solution which are collected 
to obtain the mono- and non-ortho PCBs. The column was inverted, and the dioxins/furans 
eluted with 12 mL of toluene. Two microliters of tetradecane was added, and the samples 
concentrated to <10 pL. The samples were then stored in a refrigerator until HRGC/HRMS 
analysis.
2.22.5. Instrumental Analysis
All analyses were performed on a Kratos Concept high-resolution mass spectrometer 
using isotope dilution. The HRMS was operated in the electron impact ionization mode using 
selected ion monitoring. Chromatographic separations were achieved using a Hewlett 
Packard 5890 Series II high-resolution gas chromatograph, utilizing a 60-m x 0.32-mm (0.25- 
pm film thickness) DB-5MS capillary column. The GC conditions were optimised to 
completely separate the various 2,3,7,8-Cl-substituted dioxins/furans: initial oven
temperature, 130°C; injector temperature, 270°C; interface temperature, 300°C; temperature 
programming, time 1: 1.0 min, rate 1: 5 °C/min, time 2: 15.0 min, rate 2: 6 °C/min, 
temperature 3: 295 °C; injector: splitless, 1.0 min, split flow: 30-40 mL/min; purge flow, 1-2 
mL/min; and temperature equilibrium time: 2 min. The mass spectrometer was tuned and 
calibrated prior to all analyses. It was tuned to a minimum resolution of 10 000 ppm (10% 
valley) using m/z = 330.9792 (or any suitable reference peak) at full accelerating voltage of 
8000 V. Pertinent MS parameters were as follows: cycle time for each congener group, -1 .0
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s; ESA sweep (analytes), 10 ppm; native ion dwell, -100 ms; 13C-labeled ion dwell, -35ms; 
lock mass sweep, 200 ppm; lock mass dwell, 50 ms; ionization voltage, -35 eV; source 
temperature, 250 °C; accelerating voltage, 8000 V; and trap current 500 pA.
2.22.6. Quality Control and Calibration
Between four and six calibration standards with native analyte concentrations bracketing 
the expected analyte concentrations were analysed prior to analysing samples. Dioxin/furan 
calibration solutions contained all 13C 2,3,7,8-Cl substituted recovery surrogates (5 pg/pL) 
and two internal standards (10 pg/pL) each. Native analyte concentrations varied depending 
on the calibration standard number. The native analyte concentrations in Calibration Standard 
1 were 100 fg/pL for the tetras (TCDD/TCDF); 500 fg/pL for the pentas (PeCDDs/PeCDFs), 
hexas (HxCDDs/HxCDFs), and heptas (HpCDDs/HpCDFs); and 1000 fg/pL for the octas 
(OCDD/OCDF). Native analyte quantities in other Calibration Standards were multiples of 
the calibration standard 1 as follows: 0.5x, 2x, 4x, 8x, and 16x. The analyses of these 
calibration standards permitted the response factors to be determined as a function of 
concentration using linear regression. The response factor (RF) for each native analyte at 
each concentration was calculated relative to its 13C-labeled analog. The relative standard 
deviation (RSD) for the average response factor for each of the native analytes had to be 
<20%. Similarly, the RF for each 13C recovery surrogate relative to the appropriate internal 
standard was also calculated. The RSD for the average RF for each labelled surrogate had to 
be <35%. The calibration curves were considered linear under these conditions, and the 
analytical system was considered calibrated when these conditions had been satisfied. If these 
conditions could be not satisfied, corrective actions were taken. The average RFs were used 
for subsequent quantitations. Prior to sample analysis, the linearity of the calibration curve 
was verified by analysing Calibration Solution 2 (200 fg of TCDD) and calculating the RF as 
described previously. The percent difference between the new RF and the average had to be 
<20% for the native analytes and <35% for the 13C recovery surrogates. The mass 
chromatogram was also examined to ensure that all the 2,3,7,8-Cl-substituted congeners 
were clearly separated. If the S/N values were =10, the ion abundance ratios were 15% of the 
theoretical, and the RF and isomer separations were within specified limits, then sample 
analyses proceeded. Corrective actions were initiated if specified control limits were 
exceeded. The concentrations of the various PCB congeners in pg/ul in Cal.Std. #3 were as 
follows: 77, 2.2; 118, 50.0; 105, 25.0; 126, 0.5; 156, 5.0; 157, 1.0 and 169, 0.5. C13 labelled 
recovery standards were present in all calibration standards at 5.0 pg/ul, and the two internal
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standards, PCB 111 and 128, were present at 10 pg/ul. All the native compounds in the 
remaining calibration standards were multiples of Cal. Std. #3 as follows: 0.25x, 0.5x, 2.5x, 
5.Ox, and lOx. The GC and Mass Spec acquisition parameters as well as the QA/QC 
conditions required prior to analyses for the PCBs were as described above. On the days that 
samples were analysed, 10 pL of the internal standard solution (20 pg/pL) was added to each 
sample, and the final volume was adjusted to 20 pL. Once all QA/QC parameters had been 
verified to be within specified limits, sample analyses proceeded. The mass spectrometer was 
operated in a mass drift correction mode using PFK to provide lock masses. The selected ion 
current profile (SICP) areas for the characteristic ions for each native and labelled analyte 
were measured. Native analyte concentrations were determined by isotope dilution. Peak 
areas from the characteristic ions for each native analyte and its 13C-labeled analog were 
used in conjunction with RFs from the internal calibration data to determine concentrations 
directly. Labelled surrogate concentrations (expressed as % recovery) were similarly 
calculated using an internal standard method. Samples were organised and analysed in sets: 
method blank, matrix blank, laboratory control spike (LCS), and the nine samples. Peak 
identification criteria were as follows: S/N > 3 .5 ; the isotope ratio of the two characteristic 
ions for each congener class within 15% of the theoretical value; the peak maxima for the 
molecular cluster ions coincide within 2 s; and native analytes elute within 3 s of their 
corresponding 13C-labeled analogs. Method blanks were examined for the presence of 
interfering background, which, if present, was subtracted from the sample amount prior to 
reporting. For furans, an ion for the appropriate chlorinated diphenyl ether was monitored and 
the ion chromatogram examined to ensure the absence of chlorinated diphenyl ether 
contamination. The amount of any native analyte detected was listed on the quantitation 
report, along with the recovery of its labelled analog. Recoveries of I3C-labeled analogs for 
the samples were between 25 and 150%. Sample sets were reviewed by the QA/QC officer to 
ensure compliance with QA/QC guidelines/criteria. Analyte concentrations were calculated 
on a pg/ul basis and, after background subtraction, were converted to ppt in both whole 
weight and lipid adjusted. Results were transcribed to an Excel spreadsheet for additional 
processing to derive TEQ values for each sample.
2.2.3. Results
The concentrations and Toxic Equivalent contributions (TEQ) from the analyses of the 
fish tissue for the 2,3,7,8-Cl-substituted dioxins and furans and selected coplanar PCBs are 
listed in Table 2.2 on a lipid adjusted basis together with summaries of the toxic equivalents
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(TEQ) results for each sample together with weight, age and lipid content data. All values 
were adjusted to the lipid content of the sample by dividing the whole weight concentration 
by the percent lipid in each sample. The percent lipid was determined according to Method 
1613. The rounded result for each congener was multiplied by the appropriate I-TEF 
(International toxic equivalent factor) (van den Berg et al., 1998) and summed (TEQ) for all 
seventeen congeners. In cases where congeners were reported as non detections, lower bound 
TEQs were calculated by treating the result as if zero and upper bound TEQs by treating the 
result as if present at half of the limit of detection (LOD). Quality control (QC) samples were 
included in batches of samples analysed. Data were rounded to three decimal places for all 
analytes and are reported on a lipid adjusted basis. The whole weight detection limits may be 
calculated by dividing the detection limit by the appropriate weight given in Table 2.2.
TEQs were also calculated for non-ortho and ortho-PCBs using internationally agreed 
TEE values by following the same procedures as above. All PCBs analysed for were detected. 
The summed concentration of selected PCBs is the sum of concentrations of the congeners 
measured and is an underestimate of the total PCB concentration as other isomers were 
present which were not measured.
The concentration of lipid found in the samples ranged from 3.43% to 14.7%. The 
immature fish are fed lower levels of oils, and tend to store lower levels of lipid in the flesh 
compared to mature fish and this is reflected in the lipid content of the samples, with one 
unusual exception (sample 213-10). Whether this fish had a similar dietary lipid intake to the 
other fish sampled is not known, but it has been observed that there can be marked variation 
in flesh lipid content within fish fed the same dietary oil level (the percentage of lipid in flesh 
of fish fed 28% oil varied from 3% to 17%,) such that certain individual fish utilise high- 
energy diets but deposit little lipid in their flesh while others tend toward greater adiposity 
(Bell, 1998).
Table 2.3 compares age specific mean lipid adjusted PCDD/F and selected coplanar 
PCBs TEFs with the means of all samples in this study and the MAFF 1999 report (Parsley 
et al. 1999).
The data was disaggregated by both age and whether the fish was farmed or wild. 
Significant differences were observed between the 2 year old + fish and 1 year olds, shown in 
Table 2.2, with no statistically significant difference between the 3 and 2 year old fish (not 
shown). There was also no statistically significant difference between the farmed and wild 
fish (or farm escapees).
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All fish contained detectable levels of PCDD/Fs and mono-ortho and non-ortho PCBs. 
Levels varied between samples, generally increasing with age, and showing a skewed 
distribution for the PCDD/Fs resulting from a minority of relatively high values. The main 
dioxins and furans detected were 2,3,7,8-TCDD, 1,2,3,7,8-PeCDD, 2,3,7,8-TCDF, 2,3,4,7,8- 
PeCDF and to a lesser extent 1,2,3,7,8-PeCDF. Apart from one fish (sourced via Stirling 
University, 213-10) which had been frozen a year previously, the highest levels of PCDDs, 
PCDFs and PCBs were observed in the oldest fish, 3 years +, as expected. The 2,3,7,8- 
TCDD concentrations ranged from 0.51 pg/g lipid adjusted in the post smolt fish, around a 
year old, (Sample 213-12) to 1.09 pg/g lipid adjusted in the most mature fish, between 4 to 5 
years old, (Sample 213-05), and 1.39 pg/g lipid adjusted in Sample 213-10. This is equivalent 
to 0.03 pg/g wet weight in the post smolt to 0.15 pg/g in the most mature fish, and 0.05 pg/g 
in Sample 213-10. This fish had the lowest lipid content of all the samples including the 
post smolts (See Table 2.2). 1,2,3,7,8-PeCDD concentrations ranged from 0.8 pg/g lipid 
adjusted to 4.16 pg/g lipid adjusted in the Sample 213-10 fish.
All the selected coplanar PCBs were detected, and they were quantitatively the dominant 
contaminants. The consistent congener patterns were markedly higher than one would expect 
from the range of sources of the samples, unless they were fed on similarly sourced feeds. 
The highest PCB concentration detected in all samples was PCB 118 with a highest lipid 
adjusted value of 31900 pg/g (1093 pg/g wet weight: Sample 213-10) and lowest lipid 
adjusted value of 14800 pg/g (1380 pg/g wet weight: Sample 213-07).
The highest total lipid adjusted PCB concentration was 45100 pg/g (Sample 213-10), but 
the lipid adjusted TEQ contribution for this fish was 24.0 pg/g, lower than the lipid adjusted 
TEQ contribution for one of the largest fish (Sample 213-05) with a value of 24.8 pg/g. On a 
wet weight basis the largest fish PCB TEQ remained high at 3.40 pg/g, whilst the wet weight 
PCB TEQ value for Sample 213-10 fell to 0.82 pg/g due to the lower lipid content in the fish 
tissue.
2.2.4. Discussion
The results from this study are comparable and of a similar order of magnitude to the 
values reported in the recent MAFF study (Parsley et al., 1999), see Table 2.3 and also data 
reported more recently by the Irish Food Safety Authority of Ireland (Food Safety Authority 
of Ireland, 2003). The results presented here indicate a contamination problem, especially in 
the case of the selected PCBs. Comparisons with background data from the MAFF study 
(using the pre 1998 TEF values, (Kutz et al., 1990) suggest that for wild species such as cod.
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the concentrations on a lipid adjusted basis are similar. However, due to the higher fat content 
of salmon, the concentrations reported here are comparatively higher on a whole weight 
basis. Species with a higher fat content in the body tissues, such as herring, are reported to 
have consistently higher concentrations both on a lipid adjusted (mean 83 pg/g WHO-TEQ 
lipid) and whole weight basis, but this is not seen in other fatty fish such as mackerel (mean 
17 pg/g WHO-TEQ lipid). Flat fish with a low fat content, such as plaice, approach the 
concentrations seen in herring on a lipid adjusted basis (mean 67 pg/g WHO-TEQ lipid). 
Interestingly, the TEQ levels reported for another UK farmed species, trout, are in very good 
agreement with the salmon concentrations on a lipid adjusted basis, again suggesting that the 
probable source of contamination lies in the aquaculture feed, although other environmental 
factors could not be ruled out at this stage. Recent, as yet unpublished, data from fish uptake 
and diet analytical studies, strongly indicate that diet is the primary source on PCB and 
pesticide contamination in young farmed salmon (Fernandez et al., unpublished data, in 
review 2003). Further research conducted by the regulatory bodies is required, and action to 
address the contaminant problem is now being taken by the aquaculture and aquaculture feed 
industry.
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2.2.4. Discussion (continued)
More detailed comparison with other existing data sets is confounded by the fact that 
many previous studies quote only means and ranges, or they use a different TEF system 
or the WHO-TEF system prior to 1998.
Thus, direct comparison with Norwegian data for Atlantic salmon was not possible as 
the TEQ values reported in the literature use the Nordic TEFs, and not the revised WHO- 
TEFs (Vuorinen et al., 1997). As the values for the individual congeners are not given, a 
corrected TEQ value cannot be recalculated, as undertaken in this report with the UK 
MAFF study. Table 2.4 provides comparative data for PCDD/Fs and coplanar PCBs in 
Salmon and Herring fish from studies where individual congener levels were reported. 
Both this study and the MAFF study report surprisingly high detections of PCB 
congeners. From the literature one might speculate that the source of contamination was 
from the herring and fish oil based aquaculture feed consumed by the salmon (Bergqvist 
et al., 1990). A fish oil study found relatively high levels of PCBs 52, 101, 118, 138, 149, 
153, 170, 180 in both the herring oil sample from Germany and salmon oil sample, e.g. 
PCB 118 detection of 60 pg/g Iwt in Salmon oil and 158 pg/g Iwt Herring oil (Jacobs et 
al., 1998). (The coplanar PCBs, TCDDs and TCDFs were not analysed in this fish oil 
study.) Preliminary data on the analyses of salmon aquaculture feeds and fish oil 
components of the feeds for organochlorine pesticides and selected PCBs indicate that 
this is a probable route of contamination (Jacobs et al., 2002b).
It is unlikely that the ash fraction could account for the high PCB detections, although 
it might also contribute to the contaminant profile in aquaculture feed as contaminated 
ball clay was found to contribute the PCDD and PCDF concentrations detected in 
samples of US farmed catfish and chickens (Ferrario et al., 1999; Ferrario and Byrne, 
2000). Both ash and ball clay are used as fillers and mineral sources in animal feeds, and 
can be expected to have a specific PCDD/F congener profile that can be used to identify 
the source of contamination when compared to biological matrices. However, the 
PCDD/F congener profile from the fish in this study did not match that found in the ball 
clay.
Previous reports have detected significant levels of PCDDs, PCDFs and PCBs in fatty 
fish such as herring and salmon, particularly from the Baltic Sea, see Table 4 (Rappe et 
al., 1989; Bergqvist et al., 1990; Svensson et al., 1991; De Boer et al., 1992; Vuorinen et 
al., 1997; Liem and Theelen, 1997; Atuma et al., 1998).
The potential contribution to the human diet of PCBs, PCDDs and PCDFs from 
Scottish salmon will vary according to the age of the fish, whether the individual fish had 
a predisposition to adiposity, or not, and the frequency of consumption, and portion size.
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cooking practises (it is more usual to retain the oils when cooking salmon, for their 
nutritional fatty acid benefits), and age of the consumer. The UK Ministry of Agriculture 
Fisheries and Food (Ministry of Agriculture Fisheries and Food, 1999), using pre 1998 
WHO TEF values, give an estimate of upper bound dietary intake for adults of PCDD/Fs 
and PCBs from salmon of 2.3 pg TEQ/kg bw/day. Upper bound adult dietary exposure for 
high level consumers is 5.6 pg TEQ/kg bw/day, the average consumer intake is estimated 
at 2.6 pg TEQ/kg bw/day. However, young children are particularly susceptible to higher 
intakes, as they have a more limited diet than older children and adults, together with a 
low body weight. This leads to higher consumptiombodyweight ratios than that of the of 
the average consumer. Currently the World Health Organisation recommends a Tolerable 
Daily Intake (TDI) of 1-4 pgTEQ/kg bw/day (van Leeuwen and Younes, 1998) and the 
European Commission Scientific Committee on Food recommend a temporary tolerable 
weekly intake (tTWI) of 7 pg WHO-TEQ/kg bw (Scientific Committee on Food, 2000a). 
The equivalent of this recommendation was adopted by the UK Committee on Toxicity 
of Chemicals in Food, Consumer Products and the Environment (COT) in 2001, reducing 
the TDI to 2pg/kg from 10 pg/kg bw/day for 2,3,7,8-TCDD, based on lifetime averages. 
The COT has acknowledged that ‘for people in the UK and many other countries, the 
daily intake of dioxins could be close to or even above the guideline value’ (UK 
Committee on Toxicity of Chemicals in Food, 2000). One gram of sample 213-05, the 
largest fish, would give a contribution of 4.98 pg of the congeners analysed, towards the 
total TEQ/day. The possible contribution to dietary intakes of organochlorines from 
farmed fish could be significant for high fish consumers, and may be congener specific, 
similar to the species being consumed, as observed in Finnish studies (Kiviranta et al., 
2000; Kiviranta et al., 2002), and also observed in the livers of Canadian salmon, 
compared to their feed (Dconoumu et al., 2003, paper in review).
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2.3. Investigation of selected persistent organic pollutants in farmed Atlantic Salmon 
{Salmo salar), Salmon aquaculture feed and fish oil components of the feed
2.3 .1 . Abstract
This study builds on the dioxin and dioxin-like PCB study of farmed salmon (Chapter
2.2.), taking a closer look at a more extensive range of contaminants detected in 
aquaculture feed and components of the feed, particularly fish oil, as introduced in section
2.1. This study reports on the determination of a wide range of polychlorinated biphenyls 
(PCBs), organochlorine pesticides and polybrominated diphenyl ethers (PBDEs) in 
farmed and wild European Atlantic salmon fish, aquaculture feeds and fish oils used to 
supplement the feeds. It confirms previous reports of relatively high concentrations of 
PCBs, and indicates moderate concentrations of organochlorine pesticides and PBDEs in 
farmed Scottish and European Salmon. Concentrations of the selected persistent organic 
pollutants varied among the samples: PCBs (salmon, 145-460 ng/g lipid; salmon feeds, 
76-1153 ng/g lipid; fish oils, 9-253 ng/g lipid), X DDTs (salmon, 5-250 ng/g lipid; salmon 
feeds, 34-52 ng/g lipid; fish oils, 11-218 ng/g lipid) and PBDEs (salmon, 1-85 ng/g lipid: 
salmon feeds, 8-24 ng/g lipid; fish oils, ND-13 ng/g lipid). Comparison of the samples for 
all groups of contaminants, except for HCHs, showed an increase in concentration in the 
order fish oil < feed < salmon. Homologue profiles were similar, with an increase in 
contribution of hepta- and octa-PCBs in the fish, and profiles of DDTs were similar in all 
three types of samples. With a constant contribution to the total PCB content, the ICES 7 
PCBs appear to be reliable predictors of the PCB contamination profile through all the 
samples. For PBDEs, BDE 47 dominated the profiles, with no significant difference in the 
PBDE profiles for the three matrices. Samples with higher PCB contents generally 
showed higher levels of the pesticide residues, but this was not the case with the PBDEs, 
indicating the existence of different pollution sources.
2.3.2. Materials and methods
2.3.2.1. Sites and sampling
Seven British salmon samples (of which six samples were from individual fish, and 
one sample was a composite of two fish from the same source and of the same age and 
size to ensure similar sample quantities of tissue), and one Norwegian salmon {Salmo 
salar) sample that enter the European fish market were analysed. The samples were of 
variable age, both farm raised and wild, and were obtained from five different Scottish
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sites, and were duplicates of the samples documented in Chapter 2.2 and shown in figure
2.1. Whole body weights of the fish ranged from 400g to 5.2kg. In addition five salmon 
samples, two originating from Ireland (one wild, one farmed) and three farmed samples 
for which no further information was available, purchased from the Belgian market, were 
analysed. The fresh and frozen samples were wrapped in polyethylene bags and frozen 
immediately at Eight salmon feeds were analysed (from four different Scottish
sources), five fish oils and one vegetable oil were analysed, (all but one of which were 
obtained from the same source, on the same date, but originally from widely varying 
sources). The fish oil and feed were not samples fed directly to the salmon collected as 
these were not available, but were collected from Scottish sites in January 1999. Table 2.5 
gives complete sample details.
23.2.2. Sample preparation
The samples were thawed, filleted, skinned and the epaxial muscle homogenized 
before being subdivided into smaller replicate portions of approximately 100 grams. The 
portions were weighed, stored in tightly sealed polythene bags and frozen at -20°C. The 
samples were sent packed in dry ice to the Toxicological Center, Antwerp, where they 
were logged-in and stored at -20°C prior to analysis.
All samples were analysed for HCH isomers, HCB, DDT and metabolites (six op- and 
/7/7-isomers) (Table 2.6) and for nine PBDE congeners (lUPAC no. 28, 47, 66, 71, 75, 99, 
100, 153 and 154). The samples obtained from Scotland were analysed for 59 PCB 
congeners (see Table 2.6), including mono-ortho PCBs with an assigned toxic equivalency 
value (TEF) (van den Berg et al., 1998). All dioxin-like PCB levels compared favourably 
with those found in duplicate salmon samples analyzed earlier by the US Environmental 
Protection Agency laboratory at the John C. Stennis Space Center, MS, USA , section 2.2 
(Jacobs et al., 2000; Jacobs et al, 2002a).
The samples obtained in Belgium were analysed for 23 PCB congeners. The 
procedures used to analyze the salmon samples were similar to those used to analyze 
organochlorine compounds in chicken and pork fat as described elsewhere (Schepens et 
al., 2001; Covaci et al., 2002).
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Table 2.5. Sam ple details for the salm on, feed  and fish oil.
Sample
codes
Sample type 
and collection
Information
%
lipid
Sample
Weight
(g)*
Lipid
Weight (g)
M il (f) 3+ yrs fresh 13.5 8.19 1.10
M12 (f) 2+ yrs fresh 14 8.13 1.14
M13 Norway frozen 13.7 8.39 1.15
M14 Salmon: (w) 2+yrs frozen 4.9 9.73 0.47
M24 Scotland (f) 3+ yrs fresh 19.9 9.69 1.93
M25 Jan 1999 (f) 3+ yrs fresh 19.1 9.04 1.73
M28 (w) 12.3 8.19 1.17
M31 (f) N=2, Smolt, 
fresh
9.3 8.13 0.85
M18 (f) sm Bio. 3.9 4.60 0.18
M19 Salmon: (0 Fresh Bio. 16.5 5.15 0.84
M20 Belgian Market (f) Fresh 11.0 5.48 0.60
M21 March 2001 (w) Ireland, sm. 11.6 4.51 0.52
M22 (f) Ireland, sm. 14.8 7.25 1.07
MCI Fry l-5g (A) 18.1 3.00 0.54
M02 1000-2200g (B) 30.1 3.00 0.90
M03 350-1000g (B) 31.0 3.03 0.94
M04 S. feed 1000-2200g (C) 35.9 3.07 1.10
M05 Jan 1999 Fry(C) 19.8 2.26 0.45
M15 500- 1300g (D) 28.1 2.00 0.56
M16 1300-2200g (D) 34.3 2.11 0.72
M17 500-1300g (D) 32.7 1.97 0.64
M06 Fish oil (C) 100 0.5
M07 Fish oil (C) 100 0.5
M08 Fish oils 
Jan 1999
Fish oil (C) 100 0.5
M09
MIG
Fish oil (C) 
Vegetable Oil (C)
100
100
0.5
0.5
MD Fish oil (E) March 100 0.5
EPA 01
*= Sample weight taken for analyses; ND= Non Detects (treated as V2 LOD for 
Xcalculations); (w)=wild; (f)=farmed; Sources A, B, C, D, E denoted in brackets; S. 
Feed=Scotland aquaculture salmon feed; Sm=smoked; Bio=bioculture
The methods used to analyze PBDEs are described in Covaci et al. 2002 (Covaci et 
al., 2002a). PCB 46, PCB 143, e-HCH and ^^C-BDE 47, 99 and 153 were used as internal 
standards, while 1,2,3,4-tetrachloronaphthalene (TCN) and bromobiphenyl (PBB 80) 
were used as recovery standards. All individual standards of PCBs and pesticides were 
obtained from Dr. Ehrenstorfer Laboratories (Augsburg, Germany). PBDE native and 
labelled standards were available from Wellington Laboratories (Guelph, Canada). 
Acetone, hexane, dichloromethane and iso-octane were of pesticide grade (Merck,
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Germany). Anhydrous sodium sulphate, basic aluminium oxide and silica gel (Merck) 
were used after heating overnight at 120°C. An accelerated Soxhlet extractor B-811 
(Buchi, Switzerland) was used for the extraction of target compounds from fish tissues 
and feed.
2.3.2.3. Fish tissue
The fish fillet was defrosted at room temperature and approximately lOg precisely 
weighed were ground with 20g anhydrous sodium sulphate, and placed into an extraction 
thimble. Internal standards (20ng of PCB 46, PCB 143, lOng of e-HCH and 1.5ng of a 
mixture of ^^C-BDE 47, 99 and 153) were added and the mixture was extracted for 2 h 
with 75 ml hexane: methylene chloride: acetone=3:l:l(v/v) into a hot Soxhlet manifold. 
After concentration and fat content determination, the extract was subjected to clean-up 
on 2 successive solid phase extraction (SPE) cartridges containing 5g acid silica and acid 
silica (5g): neutral silica (Ig): deactivated basic alumina (2g) (from top to bottom), 
respectively. Fifty (50) ml of hexane were used for complete elution of PCBs, pesticides 
and PBDEs in the same fraction. The final eluate was concentrated under nitrogen and 
recovery standards were added prior to GC analysis.
2.3.2.4. Fish oil
0.5g fish oil were precisely weighed, and solubilised in 3 ml hexane. Internal 
standards were added and the mixture equilibrated in an ultrasonic bath for 5 minutes, 
after which it was ready for application to the SPE cartridges.
2.3.2.5. Fish feed
Approximately 3g of fish feed were weighted accurately and placed into an extraction 
thimble. Internal standards were added and the feed was extracted for 2h with 60ml 
hexane: methylene chloride: acetone=3:l:l (v/v) into a hot Soxhlet manifold. After 
concentration and fat content determination, the extract was ready to be applied to the 
SPE cartridges
2.3.2.6. Fat content determination
The Soxhlet extract was concentrated and then transferred to a preweighed tube. The 
extract was completely dried under a gentle nitrogen stream and then kept at 60°C until 
constant mass. The measured weight represented the fat content of the sample.
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23.2.7. Organochlorine analysis
One \il was injected in pulsed splitless mode on a Hewlett Packard 6890 GC 
connected via direct interface with a HP 5973 mass spectrometer. A 50m x 0.22mm x 
0.25pm, HT-8 capillary column (SGE, Zulte, Belgium) was used with helium as carrier 
gas at a constant flow of 0.7 ml/min. Injector and interface temperatures were set at 270°C 
and 300°C, respectively. The oven temperature program began at 90°C, was kept for 1 
min, then with 15°C/min to 170°C, held 3 min, then with 4°C/min to 270°C, held 1 min 
and further with 10°C/min to 290°C, held 15 min. The mass spectrometer was operated in 
electron impact ionisation mode. Three most abundant ions were monitored for each level 
of chlorination for PCBs or for each pesticide. Method limits of detection (LOD) for 
individual PCB congeners ranged between 0.1-0.5 ng/g lipid. For HCHs and DDTs, the 
detection limit was 0.2 ng/g lipid for each isomer. Recoveries of target compounds ranged 
between 72 and 80%.
2.3.2.8. PBDE analysis
The analysis, previously described by Covaci and coworkers (Covaci et al., 2002a), 
was performed on a Hewlett Packard 6890 GC equipped with a 10m x 0.10mm x 0.10pm 
AT-5 (5% phenyl polydimethyl siloxane) capillary column (Alltech, Belgium) and 
connected via direct interface with a HP 5973 mass spectrometer. Helium was used as 
carrier gas at constant flow (0.4 ml/min). The low-resolution quadrupole mass 
spectrometer (El) was operated at 70 eV in the selected ion monitoring (SIM) mode. The 
ion source and quadrupole temperatures were 230 and 250°C, respectively. The electron 
multiplier voltage was set at 2300 V. Dwell times were set at 10 ms. Two most abundant 
ions (M^ and [M+2]"  ^ for the tri-, tetra-, and penta- congeners and [M-2Br]^ and [M- 
2Br+2]^ for the hexa-congeners) were monitored for each level of bromination for native 
and labeled PBDEs. Recoveries of internal standards, ^^C-labeled BDEs, ranged between 
81 and 103% (RSD < 21%). Method limits of detection (LOD) for individual PBDE 
congeners ranged between 0.1 and 0.4 ng/g lipid.
2.3.2.9. Quality Control and Quality Assurance
Retention times, ion chromatograms and intensity ratios of the monitored ions were 
used as identification criteria. A deviation of the ion intensity ratios within 20% of the 
mean values of the calibration standards was considered acceptable. The method 
performance was assessed through rigorous internal quality control, which included daily 
check of calibration curves and regular analysis of procedural blanks and certified 
material CRM 350 (PCBs in mackerel oil). The method was tested by participation in an
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interlaboratory test organized by the Institute for Reference Measurements and Materials 
(IRMM, Geel, Belgium). Seven PCB congeners (no. 28, 52, 101, 118, 138, 153 and 180) 
were determined in non-spiked, medium- and high-level spiked pork fat. The results of 
the individual PCB congeners deviated less than 10% from the target values. For PBDEs, 
the analysis of two samples of biota (eel and porpoise liver) used for the first 
interlaboratory test on PBDE (de Boer, 2000), showed a variation of less than 10 % from 
mean values obtained from eighteen participating laboratories.
2.3.3. Results
All samples examined contained detectable residues of organochlorine contaminants. 
Summary results are presented in Table 2.6, figure 2.2, with total sum (E) values given 
using a value equal to Vi LOD where there were no detections, as recommended by the 
EC Scientific Committee on Animal Nutrition in 2000 (Scientific Committee on Food, 
2000b). Detailed results of PCB congeners are presented in Table 2.7 and figure 2.3. All 
concentrations were adjusted to the lipid content of the sample. o,p' isomers of DDTs 
were not found in any sample. PBDEs were detected in all fish samples, all feed samples 
but only one of the fish oil samples (see Table 2.8). The total concentration of selected 
PBDEs is the sum of concentrations of the congeners measured and is an underestimate of 
the total BDE concentration as other isomers present were not measured.
2.3.3.1. Salmon samples
PCB concentrations in the farmed samples were between 145.1 and 459.9 ng/g lipid 
weight. Profiles and concentrations of PCBs were similar and of the same order of 
magnitude for all the farmed samples, but lower in a Norwegian sample (M l3) and a 
magnitude lower in a wild Irish sample (M21). In the sample M13, the PCB profile is 
dominated by the hexa- and hepta-PCB congeners, while in the other samples, the lower 
chlorinated congeners (tri-, tetra- and some penta-PCB congeners) had a higher 
contribution to the EPCBs. The mean of the 7 ICES marker PCBs was 129.5 ± 38.1 ng/g 
lipid and they constituted 41.1 ± 1.8 % of the total EPCB congeners for the Scottish 
salmon samples.
The mean for HCB for all the salmon samples (n=13) was 11.6 ± 11.9 ng/g lipid, but 
was much lower in sample M13 (under the detection limit of 0.2 ng/g lipid). The mean 
concentration for HCHs (Ea, p, y-HCH) was 13.8 ± 7.6 ng/g lipid for the samples 
obtained in Scotland and 8.5 ±9. 1 ng/g lipid for all the salmon samples (n=13). y-HCH 
was the predominant HCH isomer with a mean ratio y-HCH/EHCHs of 0.69 ± 0.01. The 
mean concentration of DDTs (E/7/7-DDE, /7/7-DDD and pp-DDT) was 69.6 ± 58.4 ng/g
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lipid for all the samples (n=13) and pp-DDE was the predominant contributor to the 
EDDTs. The ratio of /7/?-DDT/EDDTs ranged from 0.1 to 0.31 (mean 0.22). 
Concentration of DDTs in M13 was much lower (5.1 ng/g lipid).
The PCB, organochlorine pesticide and PBDE contaminant loading of the bioculture 
farmed salmon (n=2) appears to be of the same magnitude as that of the farmed salmon, 
however the sample size is too small to draw any firm conclusions. Bioculture salmon 
diets are similar to those of farmed salmon with regard to fishmeal content, but the 
maximum fish oil content is 28% of the total diet (Soil Association., 2000). All fish 
contained detectable levels of PBDEs, the sum of the BDEs (EBDEs) ranged from 1.1 to 
85.2 ng/g lipid for the thirteen salmon samples. The highest levels were found in a wild 
(or possible farm escapee) salmon sample. As expected, BDE 47 dominated the profiles, 
with a mean ratio BDE 47/sum BDEs was 0.53 ± 0.04. The levels of PBDEs found the 
salmon analysed in this study are comparable with those found in other cultured oily fish, 
particularly gray mullets and yellow tails, as reported recently in a Japanese study 
(Akutsu et al., 2001), and also wild fish (de Boer et al., 1998).
2.3.3.2. Aquaculture feed
Concentrations of PCBs in the eight feed samples ranged between 75.6 and 1153.2 
ng/g lipid (Table 2.6, 2.7 and figure 2.3.). Six feed samples presented the same profile of 
PCBs, with the penta- and hexa-PCB congeners representing up approximately 80% of 
the total PCB content. The 7 ICES marker PCBs constituted approximately 40% of the 
total EPCB congeners. As expected, the concentration of PCBs was high (147 ± 41  ng/g 
lipid), probably due to the high fish oil content of some samples (up to 35%). Two 
samples from the same manufacturer (M2 and M3) presented a totally different profile of 
PCB congeners when compared with the other six feed samples. Tri and tetra congeners 
(approximately 55 and 28%, respectively) dominated, and the profile was close to that of 
Aroclor 1242. This different profile correlated with the high PCB concentrations found 
for these two samples (the highest concentrations detected in all the samples) and could 
point to the existence of local PCB sources or illegal dumping of used Aroclor mixtures 
in the animal food chain (Schepens et al., 2001). The mean for HCB was 9.2 ± 2.9 ng/g 
lipid, while for HCHs, the mean was 23.7 ± 14.9 ng/g lipid, with y-HCH being the 
predominant HCH isomer (mean ratio y-HCH/EHCHs of 0.63 ± 0.16). The mean for the 
EDDTs was 42 ± 8 ng/g lipid, with pp-DDE the predominant contributor to the EDDTs 
(Table 2.6). The mean ratio pp-DDT/EDDTs was 0.13 ± 0.04. The levels of PBDEs 
ranged from 8.1 to 23.9 ng/g lipid for the eight feed samples (Table 2.8, figure 2.2). The
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fry feed samples, with a far lower fish oil content, had lower residue levels than the feeds 
designed for smolts and adult salmon with a fish oil content over 20%.
Figure 2.2: M edian concentrations of HCB, HCHs, DDTs, PBDEs and m arker PCBs
in salmon, feed and fish oil samples
H salmon (n=13) a fe ed  (n=8) □  fish oil (n=5)
HCB
% 100
op 80
2 60
H 40
HCHs D D T s PB D E s Marker PCBs
Figure 2.3: Profiles of individual PCB congeners in salmon, feed and fish oil samples
□  salmon a  feed □  fish oil
CDIO
Hci
PCB congener
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2.3.3.3. Fish oils
The fish oil samples showed varying PCB contents between 8.8 and 252.5 ng/g lipid 
(ND = Vi LOD). Hexa and penta-PCB congeners dominated the PCB profile for all 
samples. The same profile was found in fish oil used for diet supplement (sample 
MDEPA), which contained higher PCB amounts (450 ng/g lipid). However, the tri- and 
tetra-PCB congeners were higher contributors to the total sum in the fish oil M06 than in 
the fish oils M08 and MDEPA. Furthermore, the hepta- and octa- congeners were more 
important for the last two oils. The difference in profiles can be due to different species 
used for collection of the oil and to different processing procedures. During the oil 
processing (usually a steam distillation), some of the low chlorinated PCB congeners can 
be lost through their increased volatility.
Mean HCB concentrations were 2.5 ±1. 5  ng/g lipid, while mean HCHs levels were 
10 ± 7 ng/g lipid. y-HCH was the predominant HCH isomer with a mean ratio y- 
HCH/EHCHs of 0.50 ±0.21. Mean ZDDT concentrations were 66 ± 87 ng/g lipid and pp- 
DDE was the predominant contributor and the mean ratio pp-DDT/ZDDTs was 0.15 ± 
0.07. The levels and ratios of the HCB, HCHs and DDT are reflected in the aquaculture 
feed, and the DDT levels were less wide ranging in the feeds. PBDE concentrations 
ranged from ND to 12.7 ng/g lipid.
2.3.3.4. Comparison between the three types o f  samples
The three types of samples were compared using median values for all groups of 
compounds (Figure 2.2). Except for HCHs, all other groups of contaminants show an 
increase in concentration in the order fish oil < feed < salmon. Samples with 
concentrations close to the median value can be considered as representative for each type 
of sample: M06 for fish oil, M04 for feed and M24 for salmon.
For individual congeners (Figure 2.3), a higher contribution of PCB 18, 28, 31 (tri- 
PCBs), 66 (tetra-PCB), 101, 105 (penta-PCBs), 138 (hexa-PCBs) and all hepta and octa- 
PCB congeners was found for the salmon, together with a lower contribution of PCB 
47/48, 49, 52 (tetra-PCBs), 87, 110 (penta-PCBs), 132, 146 and 149 (hexa-PCBs). The 
profiles of homologues were similar, with an increase of contribution of hepta- and octa- 
PCBs in the fish. Profiles of DDTs were similar in all three types of samples. For HCHs, 
the a-HCH isomer had a higher contribution in the fish oil, while the y-HCH isomer had a 
lower contribution. With a constant contribution to the total PCB content, the ICES 7 
PCBs appear to be reliable predictors of the PCB contamination profile through all the 
samples. For PBDEs, BDE 47 dominated the profiles, as expected, ranging between 50 to 
100% of the XBDEs included in the analyses. There was no significant difference in the
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PBDE profiles for the three matrices. Samples with higher PCB contents generally 
showed higher levels of the pesticide residues, but this was not the case with the PBDEs, 
indicating the existence of different pollution sources.
2.3.4. Discussion
The PCB results from this study are in good agreement and of a similar order of 
magnitude to the values for salmon reported in recent studies (Parsley et al., 1999; 
Ministry of Agriculture Fisheries and Food, 1999) (see Table 2.9). The comparability of 
the PCB data suggests that both the data sets can be considered fairly representative of 
PCB concentrations in British farmed salmon. Previous reports have detected significant 
levels of PCBs and organochlorine pesticides in fatty fish such as herring and salmon 
(Table 2.3), (Parsley et al., 1999; Ministry of Agriculture Fisheries and Food, 1999; 
Vuorinen et al., 1997; Atuma et al., 1998; Becher et al., 1998). The 7 marker PCB 
concentrations in the farmed salmon samples from this study and a Dutch study (RIVO 
Fisheries Institute of Holland, 2000) were very similar. The Dutch study found PCB 
concentrations of 110 and 170 ng/g lipid in farmed salmon from Norway, while farmed 
salmon from Scotland contained 135 and 210 ng/g lipid, ranging from 61 to 183 ng/g 
lipid. The Dutch study also found farmed salmon from Norway or Scotland had relatively 
low TEQ values (< 4 pg TEQ/g whole weight). Assuming a mean value of 20% of the 
lipid content (RTVO Fisheries Institute of Holland, 2000), the TEQ value becomes 
approximately 20 pg TEQ/g lipid, similar with or somehow lower than values found in 
our study (see Table 2.3).
79
I
1
CQ
T J
ë
I
1
g .a
i
B
I
•43
C
CQ
%
8
a
t
I
I
I
1c
I
T 5§
CO
CO Æ
u CL
CL
Cm 0£
0
" o b
t r 3
1
1
s CO
3 3
% 9
VO
3
r i 3
C4 " a
Z
3
H * 0
II
" I
è i
wS
X
g
t" 0  P VO CO CO
00'
-  ^ 0C5 0C3 cd cd
0 Ov VO ov rv Ov
R in 0 00 OV 0 Z 5
VO Û VO VO O ' 00 VO
ov cd P i CO vd vd c d c s
T f
w  g
f3
w  y
o
W
H
W  • £
(D
II
o ^ > n v O ' —i voo\ >ni CS^CSCSCNfS 
0  0 0 0 0 C 5 0 0
^  ON 
» n  T f 
(N
o \  V ) T f vn 
\d 00 vi \d
T f  T f  T f  V I
VO ov CO ^ CO p p 04 p p p
0 00 ^  0^ 0 2h OV 2h
o
i n
GO O  \0 O  r-i
CO O '
i 2 CD 23
Q Q Q CD
z Z Z 04
%  z  %
00
vd  Ti"
p
i
oo
o l g
( S O\ —( c n o o ^ o i n oV/“| — | ' - | ' 0 / ^ _ I _ 1 ( S J Q
VO
VO VO 1—1 OS 1—1 CD
vd
O '
CO
8
CO S 0
O n
s 8CO s
00 CD 00 VO VO VO 00 VO
cd 04 cd cd T|- 04
VO T f CO p CD P O '
9 R00CO oSCO oSCO R
CO CS 04 VO p P 04
2h
0 vd
t~ ' S 04 CO S
VOf Sl O' ^ ' ^ ' OTf
2  ON i n  o  CT\ t-h’
c n  r o  
o  vd 
i n  Tj-
'-H 04 i n  p  ^
vd  T|- T f  o \  r dcn cn 04 cn
p p VO VO 04 04 p p
cd c d CD CD CD ov
CO CN
04 CO Tj- Ti­ VO 00
e s 04 (S COs s
uouijBS
o  >—I ov cn ov
04 c n  04 04 ^
C3 cd c> CD c 5
T f T f  O ' i n  i n
1—I O  00 
VO v£) i n  T t
i  i  i  i  i
04 00 04
O ' 04  VO 00 OV 
c n  c n  f o
i  i  i  i  i
i  i  i  i  i
i  i  i  i  z
i i g g g
p O ' VO VO Q l~'
vd 04 vd z vd Ov 23CO
§ g g 5
r t  p  p
g  o4 ^
VO
04 VO ^
VO Ov 04 O  O ' 
CD 04  T-i rH cd
p  p  p  p  p
vd  (D  vd  04 r d
04 "Tf" 04 I ^
04
O '
O
m
04
04 m  T f 00  i n  
o~ 0~ T f 04 v i
00  Ov CD ^  04 
§ §  § §  §
^ o 4 o 4 o 4 v o o 4 i n c n
04
C D C D O O O C D C D C D
p  p  p  p  p  p  CO
i n  00 i r i  00 c d  I—i 1—i
CO CO CO r o  CO i n  i n
04 oo  t J-Ov oo  O ' VO Ov
i n  0'  ^ o4  OV vd  23 —
p p p p - ^ p p p
O' TfTf-Ti - invdcsvd
p  p  p  T f  p  p  T t
CN i n  c d  ^  c d  i n  CD 
O4 04 04 04 O 4 C O C O C O
i n  VO O ' CO
I CS T f
00  O '
' - i  00
(N r—I T—I
i i i 2 g g g g
o
i n
p  p  p  04 OV
■^' 04 v d  i n  vd
p p p p p p p p
O 4 T | - T f v d ( D 0 ' O v 0 '
VO VO p VO O ' O '
00
VO CO a 5 3
p
t
00
R
c s
s
Th p
00
VO
vd 3
p
00
p
oS
VO
OS 04 i~'
p  p  p  p  Q  p  oo  Tj- 
c d o c d c d Z c d c d c d
O O P c D ^ O ' A r i ^
c ^ S o d ^ c d - ^ S
VO p O ' T^ 00 p O s VO T f 00 OV
8
T|-
23 3 9 K 00 8
04
l>
Ov
O '
00
VO
CD
CO
CD ov (S T f VO CD VO 00 CO
R
ov
t~ ' a t 3 a R CDVO oSVO 9 5
oo CO Th
T f VO
CN CO 
CD CD
lOv 00 00 Ov p Q 04
00 vd oS 04 ? 2304 CS CS
CO CD p 00 Ov CO 04
cd CS cd cd CD CD
T|- VO VO VO O ' VO t ' ' 00
CD CD CD CD CDs
P 99J
^  O  l / l  /-N o
^  1-^  y
CD o '  CD CD ^  O
p  T t  O  
CD vd  
CO I i n
OV
. o g |
00  P
o o  i n  VO O  .
c d  c d  vd  Z
o o  VO P  VO 
S  H  R  V i 2  o<
vd
I I
CO
vd ^
p  p  
c d  ^
04
04
i s
«> p  
T f 04
i i
S i
04 CN 
CD CD
CD O '
VO
5  =
3 :
1 Tf
P  p
Z  04
i s
p  Q
N  g
CO OV
i i
i i
O  z
no qsH
00
25
s i
00  p
04 CD 
. .. 00«3 I
l l
g  +
S 3
s q
I— I CO
,0 i n
i i
§ p-
82 
8 5 
S;2
II
T 3 ^
IS
i
CD
00
CL
CL
3
I
3'3
I
■§
3'C
a
I
l
3
§
U
*-Cc
3fi
3
î
3J3
-%
S©
I
?
%
8PL
ifi
•§g-
loU
04
ü
H
i i z i z z z i i i i i z i i i ê i i i i i i i i i ê i i i i z z
i i i i i i i i g g i g i i i i s i s i s s i s i s i i i i i s g
Q  Q  Q  Q  Q  Q  Q  P  en O'. «N Q  Q  o  -H en o i vq vo vq Z Z Z Z Z Z Z < o <n <n o - Z Z Z ' - ' - ' ( n o s - ' h Q Z 23 i o' Z ^
g g g s g g g g g g g g g g g g g g g g g s g s g s g g g g g s g
Q Q Û ' O S ' Q c ' v O ' O c < V ' ^ < r ) 0 \ Û S ' S ' O v Q r ' ' O f O i - i v o c n Q f O ' ^ a \ i o i r ) Q o v o  
Z Z Z d d Z d Tt o <N Z o o <N Z d c5 Tf d s-' Z >o d d d -■ Z t5 '-:
O Q Q o i o \ Q Q f < v r ' S - s - c s o \ ' H O 'Z Z Z - ^ ' d Z Z d ^ n ' c s i v d c M S - c v i o
Q Q Q o i o o û Q ' c v ' - ' 0 \ ' ' 0 \ T r o \ o \  
Z Z Z d Z Z s-' <N <N oC c4 WÔ <N d
Q Q O Q Q Q Q i > ' » - : o : p T Ç < N pZ Z Z Z Z Z Z T C ' H m \ O M V ) < N O
w v Q ( S f < ^ t ' - ' 5 \ o H Q ' i l o \ r ' o o o \ Q
c4 Z d —■ «ci 2 2 Z 2 o Z
p P S- S- o-vo 23 Z 2 o 'H o Z
o o Q- Hç v ) ç v i d \ o mQ^ .  oJ C' OOc np^ .  S"
d Z d d vd 2  d o\ Z S d 'h' o d Z 2 d
g g g § S g g S g g 3 g g i S S S i S S a S g 3 g 3 g 2 i 5 i S 2
Q P O p p P p p - ^ p p S ^ p p p p N pZ Z Z o o Z o c s c v i c N f ^ c M < n r v i d fd d d d vd 2 g g S - 2 S S g §
q <q (N <N p p (N Tf p 'H Tj. Tf ^ ^ ^ ov _
R ^ a 5 ; o : : Q ; A 5 2 8 5 ^ ^ : 2 d d T f d v d d v d 2 d 2 z 2 d d d d Z o <
T p S ^ O V O O V O V o Q p p
i r -wvovovovovvriwvooT v o o o r ' i n i n o o o v ' H V ° Q ° ® o r - - v o o v Q '5
o o « N o o ^ i d 2 Z 2 d d d d z 2
T f r - , . - H o o . - i q p q p r ' - ' q  p p  
d d fd (N d d d d d d d d cd
o - ' ' O Q < r i o o v o c c i o v o Q o r - - S ' v o o o Q ' o
d d d Z d d d rr d s-' Z d d d o d z  2
es en es 00
d d d
d d d
g S s
0 0 vo es
d d
ao r f  
rf d
d vd
d d
g g g
d d vd
d d d
p  p  'H p  p
d d d ■d d
o o VO vo vo 
d d d Ov Tf
g g g g g
p  cN vq en 00 
c4 '«t vd en
00 es 
en vd
in  -
CD t>
g g
d
Tf Ov C:
d d d d (D s- 2
g g
un o
vd <D\
cK
g s
Tt d
d d d
S S g
f-h' en o
3 :
00
Tf P
O 2
r t  vn 
d d
vo es ov 2  icv
p p Q
o< d 2  R o<
Q p p 
Z S-' d
vo P 
O 2
q s: p 
'H en o
d en d
00 00 \o  VI
1-H 1-d es en
es* vS o  vd es '  s :  d  a
d d
d :
es es 
es en
s- en 2 vop q p q q Q p q pen Z  es (S S 2 i
z z z z z z z z z z z z z z z z z z z z z z z
g s § s s g i 2 i i i i i i i i i s g s g i i
<—i i n ' 5 e s ' 5 Qt ' ' e n Qe s o v o o o v r ~ o o t ' ' e n v O ' ^ ' ~ l Qo O ' ^  
en 00 ^  vd ^  Z  d  2: d  d  d  cs‘ d  en d  es' o\  en 2  Z  d  d
Z Z d Z d Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z Z
o o e s o v v O ' ^ < n i O ' ' < Q i r i Q Q ' ^ Q i n Q c S e n e s v o Q Q Q
d  <N d  d  00 d  d  d  Z  d  Z  Z  d  Z  d  Z  d  d  d  d  Z  Z  Z
: = s % g s g g s g : g : s s 2 g g g
2 3 g 5 g 2  2 g g 2 g g S g : g S 2 S 3 g g g  
2 ; 2 s S s s 3 g S g g § g S g g 5 § 3 g g g  
s s s s g s s a g g g g g g g g g s i s g g g
2 “ a S § 2 § S g S g g § g 2 § g S 2 “ g g g
e n o r - i n ^ .  Q r ' O v Q Q Q Q Q Q r ' Q Q o o Q o Q Q Q
2 Z o s - Z Z Z Z Z Z o Z Z - Z e n Z Z Z
p p p Q q O Q p Q q Q Q e N Q p Q Q Qo o > o Z - ' Z Z o Z o Z Z c s Z e n Z Z Z
5 5 P w S 3 S 3 g S g g g g S g g S S S g g g
es
es un
"tes vo
en vo 
es vS
en 00
00 es 
O en
P  P  es vo
o
es ^  o\ ^  es o
d  00
S"
^  d  d
ov en 
d  d
es' d  d
es d
rf  d
OV es
en 00 
Ov es
es es 
d  es
<N es  2i 2  d
q  'H
es r-
vo Tf l/V
d  es d
q  p  Ov
d  es d
p  q  rf 
o  es o
d  o
y §
2  CN >n
S- 2  .H
q  p  p  p  p
es d  d  d  ci es
t '  o
d  es 00 d
es es 2 es d
g g
g g
g g
g g
g g
g g
g g
g g
g g
g g
g g
g g
p  Q
O Z
q  Q 
Z
p  Q
O Z
p  Q 
o  Z
ov Q 
o  Z
d  d
es Ov 
d  O
d  d
p  p  
00 es
ov f '  O >n
Tf d
S  én ^  <n
SI
g#
M ^ 8
p  q  ^  p
"S2 g
§ 1 1 .
H
5 i
m a
es <  <  <  <  <
d  z  z  z  z  z
en < ; ■ < < ; <  <1d z z z z z
es <  <  <  <  <
d  Z  Z  Z  Z  Z
m a
< ■ < < ! <  <! 
es Z  Z  Z  Z  Z
g g g
g g g
g g g
p  p
p  o  p  
3 d ; ;
CS
«n CS
fl
8 |
es Q
il
2 l
^  "o
lA Z
Table 2.8: Selected PBDEs in European Atlantic salmon, aquaculture feed and fish oils: 
lipid adjusted (ng/g, ppb)
Sample
codes
BDE
28
BDE
71
BDE
47
BDE
75
BDE
66
BDE
100
BDE
99
BDE
154
BDE
153
sum
BDEs
BDE
47
/sum
M 11 1.3 7.1 29.3 0.3 2.0 6.5 4.9 1.3 1.0 53.7 0.55
M12 0.9 4.4 14.7 ND ND 2.9 2.8 0.7 0.8 27.2 0.55
M13 ND ND 0.4 ND ND ND 0.7 ND ND 1.1 0.37
M 14 0.8 1.7 12.9 ND 0.9 2.4 5.9 ND ND 24.6 0.52
M24 1.5 7.1 28.9 0.2 2.2 6.4 5.0 1.6 ND 52.9 0.55
M25 1.5 7.1 28.0 0.4 1.8 6.1 4.4 1.0 ND 50.3 0.56
M28 2.0 7.9 43.0 0.3 3.2 9.9 14.0 3.6 1.3 852 0.50
M31 1.3 6.7 25.0 0.5 1.6 5.6 4.0 0.9 ND 45.6 0.55
M18 ND ND 3.1 ND ND ND ND ND ND 3.1 -
M 19 0.5 2.8 10.2 ND 0.8 2.8 1.6 0.2 ND 18.9 0.54
M20 0.5 2.4 9.4 ND 0.4 1.5 1.5 ND ND 15.7 0.60
M21 0.2 0.7 5.0 ND 0.1 1.1 1.3 ND ND 8.4 0.59
M 22 1.0 8.1 25.8 0.7 1.7 7.9 5.6 1.3 ND 52.1 0.49
MOl 0.3 1.4 7.0 ND ND ND ND ND ND 8.7 0.81
M02 0.5 3.1 8.2 0.2 0.5 1.5 1.7 ND ND 15.6 0.53
M03 0.5 3.1 8.2 ND 0.7 1.5 1.4 ND ND 15.4 0.54
M04 0.7 4.3 12.3 0.3 0.7 1.8 2.7 ND ND 228 0.54
M05 ND 1.4 5.1 ND ND 0.9 0.7 ND ND 8.1 0.63
M15 0.6 4.6 13.2 ND ND 2.3 23 ND ND 220 0.57
M 16 0.6 4.4 13.0 0.3 0.9 2.4 2.2 ND ND 23.9 0.54
M 17 0.5 3.0 9.5 ND ND 1.8 1.4 ND ND 16.2 0.59
M06
M07,
0.3 2.7 7.1 ND ND 1.4 1.2 ND ND 127 0.56
08, 09, 
10
ND ND ND ND ND ND ND ND ND ND
N D  =  not detected
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Table 2.9. Comparison of mean congener specific PCB (ng/g, ppb, lipid weight) with 
means of Salmon samples from this study (n=8) and Parsley et al. 1999 (n=12)
PCB
congener
Salmon 
Mean ± SD 
(ng/g lipid weight)
Herring 
Mean ± SD 
(ng/g lipid weight)
This study 
(n=8)
Parsley et al 
19 99 
(n=12)
Parsley et al 
19 99 
(n=10)
18 2.8 ± 1.8 1.3 ±0.6 1.2 ±0.5
28 7.4 ± 8.7 4.3 ± 1.3 8.0 ±3.6
31 4.0 ±1.6 2.7 ± 0.8 3.5 ±1.5
47 3.0* ± 1.0 2.1 ±0.6 4.4 ± 2.2
49 4.4 ±1.9 4.0 ±1.2 4.4 ±2.1
52 10.2 ± 3.7 10.2 ±3.4 17.8 ±8.7
99 10.2 ±4.2 9.6 ±2.9 29.8 ± 14.2
101 19.0 ±9.0 22.8 ± 6.8 55.7 ±25.9
105 5.5 ±1.8 6.3 ± 1.8 20.3 ± 10.5
114 0.8 ± 0.4 0.4 ±0.1 0.9 ± 0.5
118 18.3 ±6.5 19.0 ±5.8 60.3 ± 28.7
123 1.4 ±0.5 0.9 ± 0.3 2.4 ±1.2
128 2.7 ± 0.6 4.6 ± 1.4 14.7±7.2
138 25.8 ± 5.4 34.3 ± 10.0 110.5 ±46.8
153 37.0 ± 8.7 37.2 ±11.1 129.7 ± 70.0
156 1.9 ±0.4 1.8 ±0.6 5.3 ±3.1
167 1.0 ±0.3 1.1 ±0.3 2.5 ± 1.3
180 10.9 ± 2.7 11.6 ±4.5 40.7 ± 20.4
Lipid (%) 13.3 ±4.9 13.6 ±3.3 9.6 ± 2.9
*PCB 47/48
Wild salmon from polluted waters contain higher concentrations of PCBs. Up to 3500 
ng/g lipid for the sum of 6 PCB congeners are reported for Baltic salmon (Asplund et al., 
1999). In Lake Michigan Coho and Chinook salmon {Oncorhynchus kisutch and 
Oncorhynchus tshawytscha), mean concentrations of PCBs (78 congeners) were 39,870 
and 53,638 ng/g lipid (Jackson et al., 2001), much higher than in the farmed salmon 
analysed in this study.
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PCB profiles are more species dependent for fish and birds than for mammals, due to 
selective metabolism depending upon the degree of chlorination. Fish species can 
accumulate lower chlorinated PCB congeners (such as tetra- and penta-PCBs), some of 
which have the highest TEF values among dioxin-like PCBs (van den Berg et al., 1998). 
Indeed, levels of PCBs are higher in fish compared with other farm raised animals (such 
as chicken, beef or pork) intended for human consumption. The concentrations of 
organochlorine pesticides in salmon compare favourably with those reported for farmed 
salmon obtained during 1997 in the UK. XDDT concentrations ranged from 10 to 40 ng/g 
whole weight (n=14), y-HCH concentrations ranged from ND in 11 samples to 2 ng/g 
whole weight in 3 samples, and HCB ranged from 2-5 ng/g whole weight (n=14) 
(Ministry of Agriculture Fisheries and Food / Health and Safety Executive, 1998). The 
UK does not have statutory Maximum Residue Levels (MRLs) for these pesticides in 
fish, although they exist for other food products (Ministry of Agriculture Fisheries and 
Food / Health and Safety Executive, 1998).
The average concentration across all salmon samples of the XBDE congeners was 33.7 
ng/g lipid. The results from this study are an order of magnitude lower than the respective 
PBDE values for salmon reported in recent studies from polluted open waters. Previous 
reports have detected significant levels of PBDEs in fatty fish such as sprats, herring and 
salmon from the Atlantic and more polluted waters such as the Baltic (Bergman, 2000; 
Damerud et al., 2001), showing age related accumulation and biomagnification. The 
concentrations of PBDEs in the Atlantic salmon were markedly lower than Lake Michigan 
Coho and Chinook salmon (Manchester-Neesvig et al., 2001), (mean 2440 ng/g lipid, 
range 773 - 8120 ng/g lipid). Salmon from Lake Michigan tributaries in the US appear to 
have the highest PBDE concentrations so far reported worldwide, several orders of 
magnitude greater than the concentrations reported here, but with a similar congener 
distribution (Manchester-Neesvig et al., 2001).
PCB contamination of the farm-raised salmon comes via aquaculture feed, while for 
the wild salmon, sources are more diffuse, but clearly biomagnify through trophic levels 
(Jackson et al., 2001). One of the routes of food chain contamination may be partly as a 
consequence of ingestion of plastic resin pellets (Mato et al., 2001) by the marine wild 
fish used in the manufacture of fish meal. There is very little literature available for PCB 
and organochlorine pesticide comparison in fish feed. Data from the 1970’s exists for 
Aroclor 1254 in nine feed samples (range 0.05 -  0.23 pg/g whole weight) and p ,p ' DDE 
(range 0.05 - 0.34 pg/g whole weight) (Mac et al., 1979). Fish meal, a principal 
component of fish feed, shows a much higher degree of contamination with 
organochlorines if sourced from North Atlantic stocks than those from South Pacific
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(Scientific Committee on Food, 2000b). Thus, fish meal originating from Denmark and 
the Faroe Islands contained 120 and 250 ng/g lipid for the 7 marker PCBs, respectively, 
while fish meal from Peru had a concentration of 10 ng/g lipid (Schepens et al., 2001).
The PCB concentrations in fish oils from this study are consistent with the study 
reported by the UK Ministry of Agriculture, Fisheries and Food (now the Food Standards 
Agency) (Ministry of Agriculture Fisheries and Food, 1997), with surprisingly high levels 
of PCB congeners. A previous study (Jacobs et al., 1998) has found relatively high levels 
of PCBs 101, 118, 138, 149, 153, 170, 180 in both a herring oil sample from Germany 
and a salmon oil sample. For example, the concentration of PCB 118 was 158 ng/g lipid 
in the herring oil and 60 ng/g lipid in the salmon oil.
The average concentration of the EBDE congeners in the analysed feed samples was 
16.6 ng/g lipid. At the present time, comparative data are not available in the public 
domain, although since this work was published the aquaculture industry state that they 
monitor routinely, but results of PBDEs detected in samples are not reported (Nutreco 
2003). The target PBDEs were not detected in all but one of the oil samples, a fish oil 
from the Northern Hemisphere, with a sum PBDE concentration of 12.7 ng/g lipid. The 
data available in the literature concerning organohalogen contamination of fish oils vary 
widely, with higher contamination levels observed from more polluted Northern 
hemisphere waters (Scientific Committee on Food, 2000b; Jacobs et al., 1998; Falandysz 
et al., 1994; Nutreco, 2003).
Wild salmon from Lake Michigan have been shown to have a significant relationship 
with the congener concentrations in lower trophic levels of invertebrates. PCB congeners 
biomagnify 20-30 fold, with a more efficient transfer of penta- and hexa-PCBs through 
the pelagic food web (Jackson et al., 2001).
The risks of exposure to organochlorine contaminants from eating relatively 
contaminated fish have been known for many years, but how to quantify the risks to 
human health is frequently disputed. While PCBs and p,p'-DDE provide the bulk of 
organochlorine residues in human tissues (Longnecker et al., 1997), there is a lot of 
variability in regulations for PCB and pesticide concentrations in food worldwide. Many 
EU member states do not have national maximum limits for concentrations of PCBs in 
food (European Commission, 2000). However in Holland, the current norm for fish 
designated for human consumption is 620 ng/g lipid for the sum of the 7 marker PCBs 
(RIVO Fisheries Institute of Holland, 2000), a value lower than the concentrations 
observed in Baltic or Lake Michigan salmon. Due to comparatively lower toxicity, the 
risk assessments of non-dioxin-like PCBs have been given a lower priority than dioxin­
like PCBs, but with the proviso that the PCB risk assessment (IPCS, 1993) should be 
updated on a congener specific toxicological evaluation to provide an adequate risk
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assessment in the near future (Scientific Committee on Food, 2000b). In terms of risk 
assessment, the potential contribution to the human diet of PCBs, organochlorine 
pesticides and PBDEs from farmed European Salmon will vary according to the diet and 
age of the fish, the frequency of consumption, portion size, cooking practices and the age 
of the consumer. The possible contribution to dietary intakes of organohalogen 
compounds from farmed salmon could clearly be significant for high consumers, 
particularly if pregnant or breast feeding. As the PCB data are corroborated (Parsley et 
al. 1999), table 2.9., national extrapolations could be suggested on the basis of this study, 
but not for the other target contaminants, due to the relatively small sample size, and lack 
of available comparative data.
This study recommends that further investigation of farmed salmon and salmon feed, 
including feed fortified with fish oil and feed fortified with selected vegetable oils, is 
warranted, together with consistent regular vigilance by health authorities for PCBs, 
organochlorine pesticides and PBDEs, to monitor and reduce current human dietary 
exposure. While PCBs and many organochlorine pesticides have been banned in most of 
the world, they are still being delivered in the diet and European farmed salmon can be a 
significant source. In addition, in some cases there are suggestions of recent usage, 
particularly of DDT.
Whilst diets based on marine fish oils are currently favoured by the aquaculture 
industry, it is likely that these oils are contributing greatly to the contamination of farmed 
salmon by POPs. The degree of variations in levels of contaminants for the feed and fish 
oil data indicate the significance of changes in feedstock and variations in oil sources and 
processing procedures that can result in batch-to-batch differences in contaminant levels 
even in the final product from a single manufacturer. The generation of additional data is 
needed to further assess the importance of batch variation in animal feeds, this being 
conducted now by the aquaculture industry (Nutreco, pers comm.) in accordance with EU 
requests. The aquaculture industry are also conducting analysis to detect PBDEs, but the 
data are not easily accessible, and are not provided in the Nutreco Social and Economic 
report published in May 2003 (Nutreco 2003).
There is experimental evidence that suggests aquaculture diets utilizing vegetable oils 
(with both n-3 and n-6 fatty acids), and having fatty acid compositions which resemble 
those of invertebrates that comprise the natural diet of salmon, could be more beneficial 
in accommodating successful sea water adaptation than diets based on marine fish oils 
(Bell, 1998). Vegetable oil based diets could also facilitate the requirement for high- 
energy aquaculture feeds on an economically competitive basis, whilst reducing the 
problems of organochlorine contamination. This would reduce the reliance on fish meal 
and oils from non-sustainable natural resources. Contamination problems do exist with
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vegetable oils but to a far lesser degree than fish oils and this is examined further in 
chapter 2.4 (Jacobs et al., 1998; Jacobs et al., 2002c; Jacobs, 2003).
2.4 Investigation of selected PCBs, PBDEs and organochlorine pesticides in 
omega -3 fatty acid rich dietary fish oil and vegetable oil supplements
2.4.1. Introduction
Fish oil is a by-product of the fish meal manufacturing industry and comes from 
many different parts of the world. Fish oils are sold for dietary purposes due to the 
presence of long chain omega-3 (n-3) fatty acids which have certain health benefits 
and are essential to the human diet. Specific vegetable oils and foods are sources of 
the short chain form that is the precursor to the long chain form utilised in human 
metabolism. Essential fatty acids are needed for growth and repair of nervous tissue 
and for the maintenance of its structure. The consumption of long chain omega-3 
essential oils from fatty fish or concentrated sources such as fish oil supplements are 
thought to have associated benefits in reducing mortality from heart disease and 
improving symptoms of a number of diseases including multiple sclerosis, 
rheumatoid arthritis and osteoporosis.
However, oily fish and extracted fish oils are a major source of lipophilic 
contaminants entering the human food chain (MAFF., 1997; Jacobs et al., 1997). 
Chlorinated compounds accumulate in the lipid compartment of the animal, and oil 
extracted from fish caught in polluted waters may be contaminated with chlorinated 
hydrocarbons. UK government officials have met with the fish oil industry to discuss 
how dioxins and polychlorinated biphenyls (PCBs) can be reduced in dietary 
supplements and medicinal products containing fish oil (MAFF 1997). The market for 
fish oil as a supplement to large sections of the population has been noted in the UK 
(Hamilton and Rice, 1995; Gregory et al., 1990); see table 2.10 for manufacturers 
predictions. The Diet and Nutritional Survey of British Adults 1990 found that 17% of 
the women respondents took dietary supplements, commonly fish oil (Gregory et al., 
1990). Fish oils have also been traditionally given to children to protect against 
Vitamin D deficiency and rickets. As quantities consumed can vary enormously, it is 
important that close monitoring is undertaken to ensure contaminant levels are greatly 
reduced.
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There is an extensive and growing body of data on the presence of persistent 
organic pollutants (POPs), including polybrominated diphenyl ethers (PBDEs), in the 
aquatic environment, biota (de Boer and Allchin, 2001; Jackson et al., 2001; 
Manchester-Neesvig et al., 2001; Jacobs et al., 2002) and fish oils designated for 
aquaculture feed (Jacobs et al., 2002). However, there are few data available in the 
public domain, for PBDEs in fish oils, and other essential fatty acid containing dietary 
oils.
This study reports the levels of selected PCBs, organochlorine (OC) pesticides 
and PBDEs, in 21 omega-3 rich dietary fish and vegetable oil supplements obtained 
through retail and company outlets in London, UK. The sources and brands of the 
dietary fish oil supplements were the same as those previously reported (Jacobs et al., 
1998).
2.4.2. Materials and Methods
2.4.2.1. Sites and sampling
21 dietary supplements rich in omega-3 fatty aeids (7 cod liver oil supplements, 
7 whole body fish oil based supplements, 3 vegetable and fish oil combination 
supplements and 4 vegetable oils) were obtained from retail and practitioner suppliers 
of the UK market in December 2001 and January 2002 (Sample descriptions are given 
in Table 2.10). Samples were chosen to cover the products available to the UK 
consumer, including a neighbourhood pharmacy, a national high street chain 
pharmacy, whole food retailers and dietary supplement companies selling direct to 
nutritional therapists. While the samples cover the leading brands available on the 
London/UK market, this was not a comprehensive survey of all brands available.
2.4.2.2. Sample preparation
The samples were logged and prepared in duplicate pre-washed glass vials. 
They were kept at room temperature in the dark. All samples were analysed for 28 
PCB congeners n°: 18, 28, 31, 52, 74, 95, 99, 101, 105, 110, 118, 128, 132, 138, 149, 
153, 156, 163, 167, 170, 174, 177, 180, 183, 187, 194, 196, 199. All samples were
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also analysed for HCHs (3 isomers), HCB, DDT and metabolites (5 op- and pp- 
isomers) and 7 PBDEs congeners (n°: 28 ,47 ,99 ,100 ,153 ,154 ,183).
2.4.2.3. Sample analysis
0.5-0.7 g of the sample oils were solubilised in 3 ml hexane, internal standards 
(10 ng of PCB 46 and 143, 5 ng of e-HCH and 1 ng of BB 80, BB 103 and BB 155) 
were added and the mixture equilibrated in an ultrasonic bath for 5 min. The extract 
was applied to a hexane pre-washed SPE cartridge filled with 5 g acidified silica and 
eluted with 15 ml of hexane and 10 ml of dichloromethane. The final eluate was 
concentrated with a rotary evaporator and under nitrogen to approximately 100 pi 
(ready for GC analysis).
2.4.2.4. PCB and OCP determination
One pi of extract was injected in pulsed splitless mode into a GC-pECD 
equipped with a 50m x 0.22mm x 0.25pm, HT-8 capillary column. For confirmation, 
one pi was injeeted in pulsed splitless mode into a GC/MS equipped with a 25m x 
0.22mm x 0.25pm, HT-8 capillary column. The MS was operated in electron impact 
ionisation and SIM mode. Two most abundant ions were monitored for each level of 
chlorination for PCBs or for each pesticide. Method limits of determination ranged for 
individual compounds ranged between 0.1- 0.2 ng/g oil. Recoveries of internal 
standards ranged between 75 and 85%.
2.4.2.5. PBDE determination
One pi of extract was injected in cold splitless mode into a GC/NCI-MS 
equipped with a 10m x 0.10 x 0.10pm, HT-8 capillary column. The MS was operated 
in the negative chemical ionisation in SIM mode (ions: 79 and 81). Method limit of 
determination ranged between 0.05 and 0.1 ng/g oil for individual PBDE congeners.
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2A.2.6. Quality Control
All samples were analysed with GC-pECD and GC-MS systems. The lowest 
result for each compound obtained in both systems was considered for further 
calculations. The procedure was validated through regular analysis of procedural 
blanks, certified material CRM 350 (PCBs and organochlorine pesticides in mackerel 
oil) and through successful participation to Quasimeme interlaboratory studies (PCB 
determination in sediment and fish).
2.4.2.7. Oil density
Densities of oils were determined gravimetrically and were found to lie between 
0.87 and 0.90 g/ml. Thus, direct comparisons given in pg/1 with those given in pg/kg 
or ng/g (ppb) should allow for an approximate 10% underestimate of concentrations 
expressed on a volumetric basis.
2.4.3. Results and Discussion
All fish oil samples contained detectable residues of organochlorine 
contaminants, with cod liver oil (Samples 1-7) having similar levels as previously 
reported (MAFF, 1997; Jacobs et al., 1997; 1998) and the greatest levels of POPs 
contaminants compared to the other supplement groups in this study. Fish and 
vegetable oil mixtures (Samples 14-17) had lower levels than the whole fish body oils, 
while no PCBs were detected in the vegetable oils (Samples 18-21). On the whole, the 
fish oils showed less contamination compared with past reports (MAFF, 1997; Jacobs 
et al., 1998; Falandysz et al., 1994; Falandysz, 1994), suggesting that improved 
sourcing, developments in processing such as deodorisation and nutritional profile 
development in creating specific ‘optimum’ essential fatty acid balances (Samples 8, 
14-17, 21), are improving the quality of such supplements for the consumer.
With most of the samples, the predominant pesticide isomers were p,p'-DDE  
and y-HCH. Summary results are presented in Table 2.10, with total sum (X) values 
given using the LOD equal to zero where there were no detections. Table 2.11 gives 
full congener specific data for each sample. In comparison with the samples purchased
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eight years ago (Jacobs et al., 1997, 1998), there is an evident reduction of 
contaminant loadings. Most fish oil samples showed evidence of steam distillation, 
and this probably contributed to the reduction in contaminant levels. HCHs and HCB 
levels were very low, only the a -  and y-HCH isomers were detected. DDTs were 
present in all but one sample (Sample 21, a vegetable oil mix from Canada), while 
concentrations of PCBs were under the detection limit for some samples. The oils with 
higher concentrations of PCBs had low concentrations of volatile compounds, an 
indication of thermal processing. The PCB profile was dominated by hexa and penta 
congeners followed by hepta, with some variation in percentages of different PCB 
congeners depending upon the type of fish oil and sample formulation. In the fish oils, 
higher levels of DDTs were correlated with higher PCB concentrations (r^= 0.78), 
Figure 2.4. PCB concentrations in the fish oil samples were between ND and 90.9 
ng/g lipid. These concentrations are generally of the same order of magnitude, but are 
not as high, as previously reported based on ICES 7 PCBs (Jacobs et al. 1998). This is 
probably a consequence of the reduction of OC contaminants during refining (Hilbert 
et al., 1998), as requested by UK government departments (MAFF, 1997). 
Comparisons with unrefined fish oils would indicate whether a real reduction in the 
steady state of PCBs has occurred (Falandysz et al., 1994; Falandysz, 1994). The 
ICES 7 PCBs consistently constituted over 50% of the sum of PCB congeners in all 
cod liver oil and fish oil samples where PCBs were detected.
The PBDE levels in cod liver oils ranged from 14.6 to 34.2 ng/g and were 
greater than those reported in samples collected three years previously, as shown in 
sections 2.3 and 2.4 (Jacobs et al., 2002). The fish and fish/vegetable formulations 
showed PBDEs levels which were an order of magnitude lower than the cod liver oils 
and all but one fish/vegetable oil sample (Sample 17) had detectable levels of PBDEs. 
No PBDEs were detected in the pure vegetable oils. The most abundant PBDE (BDE 
47) was detected at concentrations comparable to PCB 118. PBDEs showed the same 
trend as PCBs (r^= 0.94), Figure 2.5. These results are in good agreement with the 
levels of PCB and OC pesticides previously reported for fish oil supplements (Jacobs 
et al., 1998; Fromberg, 2001), and for congener specific PCBs reported by the UK
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Food Standards Agency and the Irish Food Safety Authority for fish liver oils 
(Fernandes et al., 2002; Food Safety Authority of Ireland, 2002), but with higher 
levels of PBDEs than those recently reported (Jacobs et. al., 2002). A more detailed 
comparison with other studies is hampered by the lack of congener specific data (e.g. 
Fromberg 2001), or because different contaminants, such as dioxins and dioxin-like 
PCBs, were analysed and reported in other relevant and recent studies (Fernandes et 
al., 2002; Food Safety Authority of Ireland, 2002). More detailed time trend 
comparisons are made in the next chapter, 2.5.
Although fish are a significant source of POPs in the diet, fish and fish oil 
consumption are associated with numerous health benefits due to the long chain 
omega-3 essential fatty acids. There are alternative sources of omega-3 fatty acids (n-3 
PUFA) with evident lower contamination levels, a-linolenic acid (ALNA), abundant 
in rapeseed and flax (linseed) oil, is the short chain natural precursor found in the 
vegetable oil based nutritional supplements used in this study. These sources offer an 
abundant and accessible source of dietary n-3 PUFA that can be further elongated and 
unsaturated in vivo, to contribute to the health benefits associated with a reduction in 
the n-6:n-3 ratio, which is currently considered to be too high for most of the UK 
population (de Longeril et al., 1999; Hu et al., 1999). There is growing but still limited 
evidence of nutritional benefits of dietary ALNA, raising questions about the extent 
and efficiency of its long chain conversion, especially its conversion to DHA. A 
number of human clinical studies have demonstrated good conversion of a-linolenic 
acid to the metabolically active eicosapentaenoic acid (EPA) in infants and adults, but 
decosahexaenoic acid (DHA) synthesis is reported to be much lower (Emken et al., 
1994; Sauerwald et al., 1996; Wilkinson et al., 1999; Uauy et al., 2000; Pawlosky et 
al., 2001; Emken et al., 2001; Millward and Griffin, 2002). ALNA long chain 
conversion rate is known to vary with the dietary ALNA intake and dietary LA 
inhibits the conversion. ALNA can be converted to EPA and increase phospholipid 
EPA levels. Indeed, stable isotope studies show that ALNA can serve as a significant 
source of EPA, with a very approximate equivalence of 10:1 with dietary EPA, in 
subjects where the conversion is optimised by a low n6:n3 ratio (Millward and Griffin
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2002). This observation is also reflected in the dosages recommended by the 
manufacturers and producers of the omega 3 rich supplements, as can be seen in 
Appendix 1, Tables i and ii. Millward and Griffin, 2002, observed extensive and rapid 
conversion of ALNA to EPA and in contrast to the compositional data which showed 
no detectable increase in phospholipid DHA, the isotopic results showed that some 
DHA formation did occur in all subjects, albeit at a very low rate. In the study 
reported by Millward and Griffin, ALNA was given orally to a small cohort of 
normal, healthy male subjects. The subjects received either a diet enriched with 
flaxseed-oil (high ALNA, n=6) or a diet enriched with sunflower oil (high n-6 diet, 
n=5) and the conversion to EPA and DHA was measured over a two week period from 
their enrichments in phosphatidylcholine fractions isolated from plasma and 
erythrocytes. There was substantial conversion of ALNA into EPA with very much 
less further conversion to DP A or DHA, although significant enrichment was 
observed at 24 hrs in plasma DHA on both diets and after 7 days in red blood cell 
DHA in all subjects. The 14 day mean total distribution between ALNA, EPA, 
DP A and DHA, was 28%, 52%, 16% and 4%, respectively, with no differences 
between the two diets. Millward and Griffin, 2002, report an interesting observation, 
with respect to conversion efficiency, in one subject studied after a fish oil diet 
conversion was very much reduced. Such stable isotope studies are limited due to the 
high cost involved, but are generating very useful data for public health purposes. In 
the last ten years there has been clear shift in accepted wisdom, from the traditional 
position that humans do not synthesise long chain fatty acids efficiently, to the current 
situation, where robust scientific evidence suggests that efficient conversion to EPA 
can and does occur.
At the bottom of the food chain, DHA is originally synthesised by 
phytoplankton and krill {Euphausiapacified) (Saito et al., 2002). Species further along 
the food chain preferentially accumulate DHA, but appear to be unable to synthesise it 
effectively. DHA is of nutritional importance in fetal development, so nutritional 
sources of DHA are often promoted for pregnant and breast feeding women. However, 
dietary DHA is not necessarily essential throughout life, it appears that DHA turns
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over very slowly, much more slowly than EPA, which is consistent with its low rate of 
conversion to eicosanoids. DHA synthesis may be regulated through additional 
pathways or independently from EPA. Metabolic demands for DHA appear to be very 
low, especially once tissue pools are sufficient. Indeed, existing metabolic levels of 
DHA probably represent what is appropriate for normal healthy metabolism, with 
levels rising where metabolic demands for DHA may be increased such as infection 
and pregnancy. A well designed ethical study of pregnant women, particularly at 
term, when the cord blood could be sampled, would be needed to confirm such a 
hypothesis.
DHA has been shown to be toxic in vivo in advanced age. Supplementation with 
DHA resulted in oxidative DNA damage in the bone marrow of aged rats (Gress et al., 
2002). Taken together these studies suggest that if DHA is not found to be 
synthesized to any significant degree in the studies conducted so far, perhaps this is 
because it is not required in significant amounts for the general population’s healthy 
metabolism, and is only produced when required.
In terms of risk assessment, the potential contribution to the human diet of POPs 
from omega-3 fatty acids food sources increases if sourced from fish, particularly cod 
liver. The vegetable oils studied here presented little or no POP contamination, but 
approximately ten times the quantity needs to be consumed to provide comparative 
levels of EPA, and this increase in quantity needs to be accounted for when 
calculating comparative dietary intakes of POPs contaminants from these dietary 
sources. Furthermore, supplementation with fish oils may impair a person’s 
subsequent metabolic ability to convert EPA from vegetable sources of ALNA ( as 
observed for one of the subjects observed in the Millward and Griffin study). 
Although this is probably a transient effect, for a complete risk benefit analysis of the 
health benefits of fish oils versus the pollutants contained within the fish oils, this 
would need to be taken into account when reviewing the literature.
The possible contribution to dietary intakes of POPs from cod liver oils 
currently available in UK and international markets could clearly be significant for 
high consumers, as has been shown previously (Jacobs et al., 1997; 1998; MAFF,
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1997). Although preliminary, this investigation strongly supports the need for 
monitoring POPs, including the newer POPs, in fish oils designated both as nutritional 
supplements for consumers and as animal feed ingredients.
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Table 2.11: Congener specific PCBs and PBDEs in fish and vegetable oils rich in omega -3  fatty 
acids: lipid adjusted (ng/g, ppb)
oxlliAerdls fishoils Miand\^daHeoils \ŒtaHecils
i^'glipid sm S02 SOB SM SK SQ5 S07 SOB S09 SIO SU S12 S13 S14 S15 S16 S17 SI8 S19 sao S21 VIKBN
PCB 18 ND ND 02 0.6 15 0.7 02 ND ND ND ND 02 02 ND ND ND ND ND ND ND ND 3.3
PCB28 ND M) 0.8 0.9 1.1 0.8 ND ND ND ND ND ND ND ND 1 ND ND ND ND ND ND 12
PCB31 ND ND 1.8 1.4 5.7 5.4 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND 166
sumtri 0 0 28 29 83 69 02 0 0 0 0 02 02 0 1 0 0 0 0 0 0 319
PCB52 1.6 ND 28 27 1.9 1 24 ND 1.8 ND ND ND 3 ND 25 ND ND ND ND ND ND 47.9
PCB74 05 0.7 21 4 23 3.3 13 ND 0.3 ND ND ND 0.8 ND ND ND ND ND ND ND ND 31.3
sutntetra 22 07 49 67 42 43 38 0 21 0 0 0 3S 0 25 0 0 0 0 0 0 792
PCB95 35 3.6 11.3 10.7 9.7 102 4.1 ND 4.4 ND 0.3 0.6 4.6 ND 42 ND ND ND ND ND ND 91.8
PCB99 5 4.8 7.4 15.7 9.4 82 66 ND 3 3.7 12 1 3.9 ND 15 4.9 ND ND ND ND ND 75.6
PCB 101 67 7 128 226 14 152 9.3 ND 4.6 63 1.6 1.9 7.1 ND 28 4 ND ND ND ND ND 144.6
PCB 105 5.4 4.3 85 14 84 102 7.4 ND 4.1 5.3 25 45 5 ND 15 2 ND ND ND ND ND 43.9
PCB 110 45 5.7 10 183 10.3 11.7 7.3 ND 4 5.9 1.7 2 55 ND 21 1.6 ND ND ND ND ND 118
PCB 118 13.9 115 19.6 39.6 21.3 229 19.4 ND 86 11.8 61 7 125 ND 35 11 ND ND ND ND ND 1583
sunpEita 39 369 695 1209 "ai 784 5 t l 0 286 329 B 4 17.1 385 0 154 136 0 0 0 0 0 6323
PCB128^ m 5.8 63 5.3 122 7.1 65 86 ND 21 26 2 29 32 ND 22 02 ND ND ND ND ND 53.8
PCB 132 32 3.6 4.1 6 4.4 4.8 42 ND 2 1.3 2 23 3 ND 21 3 ND ND ND ND ND 60.9
PCB 138 272 31.1 21.8 568 287 272 39.3 ND 10.6 7.6 5.9 7.6 10.4 ND 7.6 7.1 ND ND ND ND ND 2229
PCB 149 63 7.8 10.6 167 112 13 9.8 ND 4.1 2 25 26 5.4 ND 3L7 1.4 ND ND ND ND ND 1587
PCB 153 31.6 355 21.6 621 31.9 31.1 45 ND 11.8 86 11.3 10.9 13.9 ND 9.6 65 ND ND ND ND ND 329.3
PCB 156 3.7 32 23 62 35 3.8 4.6 ND 25 12 25 3.9 22 ND 12 1.6 ND ND ND ND ND 186
PCB 163 10.3 111 9.3 183 6 5.7 63 ND 1.3 ND 21 1.6 2 ND 15 ND ND ND ND ND ND 925
PCB 167 22 4.1 11 5.3 1 1.3 28 ND ND 15 02 0.6 0.3 ND 1 02 ND ND ND ND ND 11.3
sunhraa 903 1027 79 1837 969 933 1205 0 344 248 286 325 404 0 288 20 0 0 0 0 0 948
PCB 17) 4.6 55 21 81 3.9 39 7.8 ND 05 0.3 12 1.8 1 ND 05 ND ND ND ND ND ND 34
PCB 177 ND 0.7 23 0.9 3.1 26 12 ND 38 ND 0.3 0.6 ND ND ND ND ND ND ND ND ND 41.3
PCB 180 11 11.6 52 17.1 89 9 18 ND 1.3 0.8 3 45 22 ND 3 ND ND ND ND ND ND 61.9
PCB 183 3.3 3.6 ND 4.9 28 26 4.6 ND 1 0.3 1.8 ND 1.3 ND ND ND ND ND ND ND ND 238
PCB 187 87 10 9 126 84 82 126 ND 3.3 1 1.8 11 35 ND ND 0.7 ND ND ND ND ND 715
sunhE{Éa 27.6 314 186 436 27.1 264 44 0 99 25 81 81 8 0 3S 07 0 0 0 0 0 2254
PCB 191 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
PCB 196 ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND ND
PCB 199 1.6 2 05 24 0.8 1.1 25 ND ND ND ND ND ND ND ND ND ND ND ND ND ND 27
sunoda 16 2 05 24 08 Ll 25 0 0 0 0 0 0 0 0 0 0 0 0 0 0 27
sumFCBs 1607 1717 1754 3601 2104 2103 2251 0 75 603 501 579 909 0 512 3M 0 0 0 0 0 1919.6
EŒ28 0.3 0.3 05 1.3 05 0.4 0.4 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0,0
H:E47 10.9 127 9.7 263 127 9.9 14.8 0.8 0.8 12 1.9 1.3 1.9 0.3 1.4 0.9 0.0 0.0 0.0 0.0 0.0
BŒ100 1.9 27 15 4.1 28 21 29 0.0 0.0 0.0 0.3 0.3 0.3 0.0 02 0.0 0.0 0.0 0.0 0.0 0.0
h:e 99 0.7 28 22 12 3.4 24 25 0.0 0.0 02 0.4 02 05 0.0 0.3 02 0.0 0.0 0.0 0.0 0.0
HE 151 1.0 12 0.4 1.3 0.6 05 1.4 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
HE 153 0.0 0.4 02 0.0 0.4 0.3 0.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
EŒ183 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
suttiBCE 149 200 146 342 203 156 223 08 08 14 26 19 27 03 19 11 oo 00 00 00 00
HB 0.0 0.0 9.1 29 7.3 4.9 0.0 0.0 3.4 02 0.0 0.0 0.8 0.0 42 0.0 0.0 0.0 0.0 0.0 0.0
a-KH 0.0 0.0 4.0 0.9 42 1.9 0.0 0.0 05 0.0 0.0 0.0 05 0.0 1.0 0.4 1.0 0.0 0.0 0.0 0.0
&KH 0.0 0.0 5.1 0.9 12 1.3 0.0 0.0 0.0 0.0 0.0 0.0 0.3 0.2 0.7 0.0 15 5.9 1.3 0.6 0.3
simHCK 00 00 9.0 18 54 3l2 00 00 05 00 00 00 08 02 17 04 25 59 13 06 03
pp-ETE 564 567 44.9 1063 620 505 75.3 1.6 145 105 10.3 63 20.8 123 14.4 486 05 0.7 05 0.3 0.0
o,p^ DCD 82 84 67 85 7.1 83 9.6 0.0 0.0 5.0 4.7 0.0 55 4.3 5.8 1.3 0.0 0.0 0.0 0.0 0.0
pp-EDT 64 9.7 3.1 72 29 0.0 9.1 0.0 0.0 0.0 7.1 0.0 0.0 0.0 1.8 5.1 0.0 1.3 0.7 0.0 0.0
ppCCD 44.1 55.1 329 73.7 368 387 652 1.3 10.2 11.4 7.6 1.9 127 27 11.7 102 0.6 0.8 05 0.7 0.0
pp-DDT 227 260 120 283 7.9 7.4 342 1.9 5.6 45 63 7.1 81 22 62 77.8 0.0 5.4 23 0.0 0.0
sunEDTs 137.7 1S&9 99.6 m i 1167 1019 isa3 48 303 314 359 154 47.1 214 m 1429 11 82 39 10 00
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Figure 2.4 Correlation between concentrations of PCBs versus DDT in omega-3 rich dietary 
fish oil and vegetable oil supplem ents
PCB vs DDT
250.0 y = 0.6122X+ 10.977 
R2 = 0.7799^^
200.0
150.0
DDT
100.0
50.0
0.0
50.0 100.0 150.0 200.0 250.0 300.0 350.0 400.0
PCBs
0.0
Figure 2.5 Correlation between concentrations of PBDEs versus PCBs in omega-3 rich dietary 
fish oil and vegetable oil supplem ents
PBDE vs PCB
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Figure 2.6 PCB profiles in omega-3 rich dietary fish oil supplem ents, ng/g lipid
Sample
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PCB congener
□  PCB 18
□  PCB 28
□  PCB 31
□  PCB 52 
a  PCB 74
□  PCB 95
□  PCB 99
□  PCB 101 
a  PCB 105 
a P C B IIO
□  PCB118
□  PCB 128/174
□  PCB 132
■  PCB 138
□  PCB 149
■  PCB 153
□  PCB 156
□  PCB 163
□  PCB 167
□  PCB 170
□  PCB 177
□  PCB 180
□  PCB 183
□  PCB 187 
a  PCB 194
□  PCB 196
□  PCB 199
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Figure 2.7. OC pesticides in omega-3 rich dietary oils
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Figure 2.8 PBDE congeners in omega-3 rich dietary oils
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2.5. Principal Components Time Trend Analysis Of Organochlorine 
Contaminants Detected In Omega- 3 Rich Fish And Vegetable Oil Dietary 
Supplements from UK outlets
2.5.1. Abstract
To examine contaminant variability over time, the fish oil and vegetable oil 
dietary supplement data obtained in the preceding chapter 2.4, were compared on a 
congener specific basis with similar or the same brands as those analysed in a study 
conducted eight years ago. The majority of samples were obtained from the same 
outlets and suppliers in late 1994/early 1995 (Jacobs et al., 1997; 1998) and also in 
late 2001/early 2002 (Jacobs et al., 2002c). The eight year time trend differences in 
selected organochlorine contaminant level data sets and patterns for these dietary 
supplements are examined using principal component analysis (PCA) (SIMCA-P v. 
10.0), as the datasets are multivariate (n=22:old samples; n=21 recent samples; 13 
measured PCBs and organochlorine contaminants) and there is a large variation 
within some of the variables.
OC contaminant data for omega-3 rich dietary oils, reported in Jacobs et al. 
(1997, 2002), were as follows: polychlorinated biphenyls (PCBs) 52, 101, 118, 138, 
149, 153, 170, 180, HCB, alpha-HCH, gamma-HCH, p,pD D E and p,pT>DT. Sample 
descriptions are provided in Chapter 2.4., and while the samples cover the leading 
brands available on the London/UK market, both studies were not comprehensive 
surveys of all brands available. The data were converted to ng/g where necessary.
A 3 component PCA model was constructed (R^X=0.76, Q^=0.44). While the recent 
oil samples (S1-S21), particularly the fish oils (S8-S13), showed less contamination 
compared with past reports (oldl-old21), the cod liver oils (S1-S7) had the greatest 
levels of contaminants compared to the other supplement groups. Fish and vegetable 
oil mixtures had lower levels (S14-S17) than the whole fish body oils (S8-S13), 
while no PCBs were detected in the vegetable oils (S18-S21) as observed previously 
(old22), but HCHs were detected. With most PCBs detected, a clear reduction in 
PCB contaminants were observed, but still at similar magnitudes, except for PCB 52 
(a high detection limit of 18pg/l for the old samples) and the pesticides HCHs, and 
DDT, which were dissimilar in pattern. A part explanation for the comparative 
increase in DDT in the recent samples may be the poor recoveries for DDT for the
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old samples (Jacobs et al., 1997). The difference in the HCH patterns may be partly 
due to the greater proportion of vegetable oils analysed in the recent study, which 
were not subjected to the same treatment processes as observed in the fish oils. In 
terms of risk assessment, the potential contribution to the human diet of OC 
contaminants from omega-3 fatty acid dietary supplements still increases if sourced 
from fish, particularly cod liver, and further investigation of contaminants such as 
DDT is needed.
2.5.2. Introduction
Fish oil is a by-product of the global fish meal manufacturing industry. It is rich 
in the long chain omega-3 fatty acids eicosapentaenoic acid (EPA) and 
decosahexaenoic acid (DHA). Omega-3 fatty acids are essential to the human diet, 
and are sold for dietary purposes due to their health benefits. The National Diet and 
Nutritional Surveys (UK) report that 17% of the women respondents took dietary 
supplements, commonly fish oil (Gregory et al., 1990), and 20% of the children and 
teenage respondents took dietary supplements (Gregory et al., 2000). Specific 
vegetable oils are good sources of the short chain form a-linolenic acid (ALNA), the 
precursor to long chain form utilised in human metabolism as discussed in the 
previous chapter (2.4).
2.5.3. Methods
2.53.1. Sample Sources
Samples were purchased from retail and practitioner suppliers of the UK market 
in late 1994/early 1995 and late 2001/early 2002. Samples were chosen to cover the 
products available to the UK consumer, including neighbourhood pharmacy; national 
high street chain pharmacy; whole food retailers and dietary supplement companies. 
The samples cover the leading brands available on the London/UK market, and 
where not a comprehensive survey of all brands available.
2.5.S.2. Multivariate Analytical Procedures
Two data sets were combined. The old samples data set consisted of 22 dietary 
supplements rich in omega-3 fatty acids, including nine cod liver oil supplements, 
ten whole body fish oil based supplements, two probable cod liver oils and one 
vegetable oil (Jacobs et al., 1997; 1998).
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The recent samples data set was as for the previous chapter (2.4): 21 dietary 
supplements rich in omega-3 fatty acids, seven cod liver oil supplements, six whole 
body fish oil based supplements, four vegetable and fish oil combination supplements 
and four vegetable oils. See Table 2.12 for the types of oils and respective codes, and 
Table 2.13 for the raw data.
Principal components analysis (PCA) is a projection method that helps turn data 
into information by giving an overview of similarity, dissimilarity and outliers, by 
characterising the groups graphically, displaying the multidimensional data plotted 
in K-dimensions, thereby reducing it to a highly visual 2D plane. The software 
programme used was Umetrics SIMCA (v.lO).
2.5.4. Results
Generally, the recent oil samples (S1-S21), particularly the fish oils (S8-S13), 
showed less contamination compared with past reports (oldl-old21) See Figures 2,8, 
2.9, and 2.10. The fish liver oils had the greatest levels of contaminants compared to 
the other supplement groups, see Figures 2.9 and 2.10, and sub-plot Figure 2.11 (cod 
liver oil shown).
Fish and vegetable oil combinations (S14-S17) had lower contaminant levels 
than the whole fish body oils, see Figures 2.9, and 2.12 (recent samples S9-S13 
shown), while no PCBs were detected in the vegetable oils (S18-821), as observed 
previously (old22), but HCHs were detected. See Figures 2.9, 2.10 and 2.13.With 
most PCBs detected, a clear reduction in PCB contaminants were observed, but still 
at similar magnitudes (Figure 2.8), except for PCB 52 (which had a high detection 
limit of 18mg/l for the old samples) and the pesticides HCHs, and DDT, which were 
dissimilar in pattern, see Figures 2.8, 2.9 and 2.10.
Sample 01d9, a salmon oil and one of the most contaminated supplements, is 
clustered with the most contaminated fish oil supplements (top right -  figure 2.10), 
but the present day equivalent from the same manufacturer, S8, is clustered with the 
least contaminated supplements (left centre of ellipse -  figure 2.10), sub-plot figure 
2.14. The comparative increase in DDT in the recent samples may be due to the poor 
recoveries for DDT for the old samples (Jacobs et al., 1997). The difference in the 
HCH patterns may be partly due to the greater proportion of vegetable oils analysed 
in the recent study, which were not subjected to the same treatment processes as
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observed in the fish oils, indeed many of the recent fish oil supplements showed 
evidence of thermal processing.
The primary variables (Table 2.13, Figure 2.8), loadings (Figure 2.9), scores (Figure 
2.10) and score sub-plots (Figure 2.11-2.14) are shown below.
Table 2.12. Abbreviations of omega-3 rich oils analysed
FO Fish oil
CL
SO
Cod liver oil
MLC Marine lipid concentrate
HL [a lib i, ver oi'
CFO Fish oil concentrate
UK Unknown fish oil
RF Redfish oil (CL)
SE S andeel oi
LO Linseed oil
FBO Fish body oil
FBC Fish body concentrate
EPO/TFO Evening primrose lil/ti fisii oil
EPO/MFO Evening primrose oil/marine fish oil
FOplus
FSO
Fish oil + garlic/lecithin/vitamins/ minerals
CPLO Cold pressed linseed oil
FSOplus Flax seed oil + sunflower seed oil/sesame seed oil/ 
medium chain triglycerides/rice bran & rice germ oils 
/oat bran &oat germ oils
Table 2 .13 . Variable data for Principle Component Analysis of OC contaminants in 
omega-3 ricb dietary supplements sampled in 1994 and 2002
Primary ID Type PCB52,_._ PCBJ01 PCB.118. RCB12&. ;B138 PC# 1 4 9 . PCB 153 PCB 170 PC B :18Q HCB a-HCH.. g-HCH.....p.p’-DDE . p.p'DDT. :
old1 FO 0 16.5 26.4 9.9 83.6 17.6 57.2 6.6 24.2 0 0 0 49.5 81.4
old 2 FO 0 11 15.4 6.6 53.9 0 40.7 11 13.2 0 0 0 33 15.4
old 3 CL 0 0 0 0 6.6 0 0 0 0 0 0 0 2.2 0
old 4 FO 0 0 0 0 26.4 11 26.4 0 23.1 2.2 6.6 0 68.2 36.3
old 5 FO 0 0 0 0 0 0 0 0 0 0 0 0 2.2 0
old 6 CL 0 0 5.5 0 31.9 0 35.2 3.3 7.7 19.8 102.3 0 64.9 0
old 7 CL 0 0 0 0 29.7 0 26.4 15.4 12.1 2.2 0 0 24.2 13.2
old 8 CL 0 31.9 130.9 12.1 121 19.8 77 13.2 14.3 23.1 9.9 3.3 61.6 20.9
old 9 SO 0 171.6 66 0 67.1 56.1 0 12.1 48.4 50.6 8.8 9.9 95.7 0
old 10 CL 0 0 41.8 18.7 47.3 0 62.7 11 34.1 0 0 0 30.8 7.7
old 11 MLC 0 0 9.9 0 0 0 0 0 0 0 0 0 4.4 0
old 12 HL 0 28.6 128.7 11 134.2 0 86.9 14.3 31.9 0 0 0 3.3 0
old 13 CL 0 0 0 0 13.2 0 0 0 0 11 13.2 0 66 34.1
old 14 CL 0 0 0 0 0 0 0 0 6.6 0 0 0 0 0
old 15 CL 0 24.2 127.6 8.8 66 19.8 82.5 15.4 18.7 0 0 0 38.5 0
o ld ie MLC 0 0 0 0 0 0 0 0 0 15.4 39.6 3.3 12.1 7.7
old 17 CFO 0 20.9 33 0 67.1 57.2 77 12.1 14.3 23.1 36.3 22 61.6 33
o ld ie FO 0 0 39.6 0 17.6 0 0 14.3 0 26.4 19.8 0 36.3 31.9
old 19 UK 0 56.1 83.6 0 71.5 48.4 88 23.1 15.4 8.8 15.4 12.1 15.4 0
old 20 RF 0 19.8 86.9 0 35.2 28.6 0 34.1 12.1 11 28.6 0 9.9 0
old 21 SE 0 23.1 33 0 48.4 45.1 61.6 0 13.2 0 0 14.3 0 0
old22 LO 0 0 0 0 0 0 0 0 0 0 0 13 0 0
SI CL 1.6 6.7 13.9 5.8 27.2 6.3 31.6 4.6 11 0 0 0 56.4 22.7
82 CL 0.0 7.0 11.5 6.3 31.1 7.8 35.5 5.5 11.6 0 0 0 56.7 26
S3 CL 2.8 12.8 19.6 5.3 21.8 10.6 24.6 2.1 5.2 9.1 4 5.1 44.9 12
S4 CL 2.7 22.6 39.6 12.2 56.8 16.7 62.1 8.1 17.1 2.9 0.9 0.9 106.3 28.3
S5 CL 1.9 14.0 21.3 7.1 28.7 11.2 34.9 3.9 8.9 7.3 4.2 1.2 62 7.9
S6 CL 1.0 15.2 22.9 6.5 27.2 13.0 31.1 3.9 9.0 4.9 1.9 1.3 50.5 7.4
S7 CL 2.4 9.3 19.4 8.6 39.3 9.8 45.0 7.8 18.0 0 0 0 75.3 34.2
S8 SO 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0 0 1.6 1.9
S9 MLC 1.8 4.6 8.6 2.1 10.6 4.1 11.8 0.5 1.3 3.4 0.5 0 14.5 5.6
S10 FBO 0.0 6.3 11.8 2.6 7.6 2.0 8.6 0.3 0.8 0.2 0 0 10.5 4.5
S11 FBO 0.0 1.6 6.1 2.0 5.9 2.5 11.3 1.2 3.0 0 0 0 10.3 6.3
SI 2 FBC 0.0 1.9 7.0 2.9 7.6 2.6 10.9 1.8 4.5 0 0 0 6.3 7.1
SI 3 FO 3.0 7.1 12.5 3.2 10.4 5.4 13.9 1.0 2.2 0.8 0.5 0.3 20.8 8.1
SI 4 EPO/TFO 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0 0 0.2 12.3 2.2
SI 5 EPO/MFO 2.5 2.8 3.5 2.2 7.6 3.7 9.6 0.5 3.0 4.2 1 0.7 14.4 6.2
SI 6 FOplus 0.0 4.0 1.1 0.2 7.1 1.4 6.5 0 0 0 0.4 0 48.6 77.8
SI 7 EPO/MFO 0 0 0 0 0 0 0 0 0 0 1 1.5 0.5 0
SI 8 LO 0 0 0 0 0 0 0 0 0 0 0 5.9 0.7 5.4
SI 9 FSO 0 0 0 0 0 0 0 0 0 0 0 1.3 0.5 2.3
S20 CPLO 0 0 0 0 0 0 0 0 0 0 0 0.6 0.3 0
S21 FSOplus 0 0 0 0 0 0 0 0 0 0 0 0.3 0 0
UJ6
Figure 2.8 P rim ary variables plot: Principal component analysis of selected 
OC contam inants in omega 3 rich supplem ents
Ellipse rings indicate poorly predicted contaminants, and are discussed in section 2.5.4.
H2=estimate ot goodness of tit 
02= estimate of goodness of prediction
H  R2V)^3](cum) 
Q2V)^3](cum)
Var D (Primary)
Figure 2.9 Loadings scatter plot, 2 components: Principal component analysis of selected OC 
contam inants in omega 3 rich supplem ents p[Component 1 ]/p[Component 2]
The clustering and positions of the specific OC contaminants in the plot space indicate the closeness of 
association between the contaminants and are examined in relation to the scores scatter plot ( Figure 2.10 
below) to identify the dominant contaminants detected in the study samples. For greater clarity score scatter 
sub-plots for supplements of interest are given in Figures 2.11-2.14.
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Figure 2.13
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2.5.5. Discussion.
The results in good agreement with the levels of PCBs recently reported for 
fish oil supplements (Fernandes et ah, 2002; Fromberg, 2001; Food Safety Authority 
of Ireland, 2002), and PCB data are highly comparable on a brand sample specific 
basis, and are in the same order of magnitude (same brand, different lot no.s) 
(Fernandes et al., 2002).
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e.g. SI =92.1 ng/g, 81.7 ng/g DEFRA2002
84 = 201.9 ng/g, 196.4 ng/g DEFRA2002 
(ICES 7 Marker PCB’s: 28, 52, 101,118,138,153, 180)
National extrapolations for levels and time trends of PCB contaminants in 
fish oils available in the UK market could be suggested on the basis of these studies 
in addition to other recent reports (e.g. Fernandes et al., 2002; Fromberg, 2001; Food 
Safety Authority of Ireland, 2002) but not for the other target contaminants, due to 
the small sample size and lack of available comparative data. On the whole, the 
recent fish oil samples showed a trend for slightly lower OC POPs contamination 
compared with the old samples and past reports, but this may just be due to dilution. 
Both this study and the UK FSA (Fernandes, et al., 2002) found that the fish oils 
available to the consumer were often diluted (usually with vegetable oils) compared 
with the pre-2000 fish oils analyses in the public domain. While new contaminants, 
such as polybrominated diphenyl ethers, PBDEs, were detected, improved sourcing, 
processing (e.g. deodorisation) and nutritional profile development of ‘optimum’ 
essential fatty acid balances (S. 8, 14-17, 21) could be improving supplement quality 
for the consumer.
2.5.6. Risk assessment
Fish and fish oil consumption are associated with numerous health benefits due 
to the long chain omega-3 essential fatty acids, but the potential contribution to the 
human diet of POPs from omega-3 fatty acids food sources increases if sourced from 
fish, particularly cod liver. The possible contribution to dietary intakes of POPs from 
cod liver oils currently available in UK and international markets could clearly still 
be significant for high consumers. The vegetable oils studied here presented little or 
no POP contamination, whilst still being good sources of omega 3 fatty acids, but 
according to current nutritional knowledge, do not provide an effective metabolic 
source of DHA for the average consumer, as discussed in section 2.4.
Although preliminary, this analysis strongly supports the need for ongoing 
monitoring of POPs and further investigation of DDT isomer levels and ratios, in fish 
oils designated both as nutritional supplements for consumers and as animal feed 
ingredients. This analysis also illustrates the value of multivariate analytical 
techniques for assessing contamination patterns and trends.
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Further, in the public interest, newer POPs such as PBDEs need to be included in 
national and international POPs contaminant monitoring programmes. An adequate 
risk benefit analysis of fish and especially cod liver oil supplements would need to 
consider all nutritional sources and currently available supplement formulations of 
short and long chain omega 3 fatty acids, together with reliable information on 
human variability in synthesis, metabolism and utilisation of the long chain forms, at 
different times of life, and in relation to other dietary fat intake as well as knowledge 
of critical windows of developmental exposure to POPs, and critical moments of 
nutritional requirement of the foetus of DHA particularly for brain and retinal 
development.
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Chapter 3.
Homology Modelling of the Nuclear Receptors
3.1. Abstract
This chapter describes how the three-dimensional structures of the ligand-binding 
domain (LED) of several interrelated human nuclear (NRs) and steroid hormone 
receptors (SHRs) were generated by homology modelling.
The receptors modelled are the oestrogen receptor p (hERP), the pregnane-X- 
receptor (PXR), the Ah receptor (AhR) and the constitutive androstane receptor (CAR). 
They were produced by homology modelling from the human oestrogen receptor a  
(hERa) crystallographic coordinates (Brzozowski et al., 1997) as a template together 
with the amino acid sequences for hERp (Mosselman et al., 1996), PXR (Lehmann et al., 
1998), AhR (Burbach et al., 1992) and CAR (Forman et al., 1998; Baes et al., 1994) 
respectively. The selective endogenous ligand, in each case, was docked interactively 
within the putative ligand binding site using the position of oestradiol in hER a as a 
guide, and the total energy was calculated. In each receptor model a number of different 
ligands known to fit closely within the ligand binding site were interactively docked and 
binding interactions noted. Specific binding interactions included combinations of 
hydrogen bonding and hydrophobic contacts with key amino acid sidechains, which 
varied depending on the nature of the ligand and receptor concerned. A homology model 
of the human peroxisome proliferator activated receptor a  (PPARa) was also produced 
using the human PPARy (hPPARy) LED crystallographic coordinates summarised in 
Lewis and Lake, 1998, as a template, together with the amino acid sequence for hPPA Ra 
(Lewis and Lake, 1998; Nolte et al., 1998).
It is intended that the models will provide a useful tool in unravelling the 
complexity in the physiologic response to xenobiotics by examining the ligand binding 
interactions and differences between the nuclear and steroid hormone receptors activation 
or inactivation by their ligands. This work supports the QSARs presented in chapter 5.
3.2. Introduction
As reviewed in chapter 1, nuclear receptors are a large protein superfamily that is 
involved in a wide range of physiological functions including development, reproduction, 
differentiation and homeostasis. They are important drug targets for intervention in
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disease processes. Exogenous compounds that target these receptors can therefore disrupt 
both normal and abnormal functioning of these key metabolic pathways. While 
environmental hormone mimics contribute to detrimental health effects by activating 
certain receptors and disturbing normal function, there are therapeutic uses from both 
dietary and pharmacological treatment for abnormal functioning of the hormone 
pathways and hormone dependent diseases.
NRs and SHRs are regulated by hormones and chemicals that can mimic 
hormones (Honkakoshi and Negishi, 2000). After a hormone is produced, circulating and 
intracellular binding proteins regulate the hormone’s bioavailability. Then the hormone 
triggers action by binding to a specific cellular receptor by docking into a ligand binding 
domain (LED) which is a hydrophobic pocket, and binding with specific amino acids 
(Weigel, 1996).
An important requirement for homeostasis is the detoxicifation and removal of 
endogenous hormones and xenobiotic compounds with biological activity. This crucial 
metabolic role is conducted by the cytochrome P450 (CYP) enzyme superfamily. The 
induction of specific CYPs via the adaptive increase of CYP gene expression commonly 
utilises the nuclear receptor pathway, where exposure to xenobiotics and drugs activates 
specific members of the nuclear receptor superfamily which in turn bind to their cognate 
DNA elements and stimulate the CYP target gene transcription (Denison and Whitlock, 
1995; Kliewer et al., 1999; Negishi and Honakoski, 2000; Xie and Evans, 2001). 
Knowledge of nuclear hormone-receptor activation and action upon the regulation of 
gene expression can aid the understanding of the progression of certain diseases, and 
facilitate the design of drugs with improved efficacy and fewer side effects. The super 
family is broadly divisible into three subclasses: the type I receptors for steroid 
hormones, including progestins (PR), estrogens (ER), androgens (AR), glucocrticoids 
(GR) and mineralocorticoids (MR); the type II receptors for thyroid hormone (TR), 
vitamin D (VDR), 9-cis retinoic acid (RXRs), dX\-trans retinoic acid (RARs), PPAR and 
finally the orphan class, for which cognate ligands have not yet been characterised, such 
as the PXR, CAR, COUP-TFs, HNF4, Rev Erb (McKenna et al., 1999; Nuclear 
Receptors Nomenclature Committee, 1999; Neve and Ingelman-Sundberg, 2000; 
Cottone et al., 2001; Willson et al., 2003).
As described in Chapter 1, the currently accepted theory of steroid hormone 
binding suggests that in the absence of the hormone, each receptor is associated with 
certain ‘chaperone’ proteins (Weigel, 1996). Binding of the steroid hormone with the
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receptor protein causes a conformational change. This molecular switch results in the 
removal of the heat shock complex and allows the receptors to dimerise. Then binding to 
a hormone response element (HRE) on DNA occurs, to produce a complex that can 
trigger or suppress the transcription of a selected set of genes (Weigel, 1996; Alberts et 
al., 1997) See Figure 1.1.
So far, 48 nuclear receptors have been identified in the human genome (Willson 
and Kliewer, 2000), but most of these are ‘orphan receptors’, in that they are awaiting 
the recognition of specific ligands and functions, and it is likely that more receptors will 
be discovered in the future. Each type of receptor has the potential to regulate a distinct 
endocrine signalling pathway, of which we only have a rudimentary knowledge. 
Members of this receptor family are related to each other in terms of their amino acid 
sequence and their function within cells. They therefore have structural features in 
common. These include a central highly conserved DNA binding domain (DBD) that 
targets the receptor to specific DNA sequences, termed hormone response elements 
(HREs). This domain contains 8 cysteines, which form a pair of tetra coordinate binding 
sites for zinc atoms. When the zinc atoms allow folding of the protein, an a-helix is 
placed into the major groove of the DNA double helix. The amino acids on this a-helix 
enable the receptor to recognise the DNA in a sequence specific fashion. A terminal 
portion of this receptor (COOH) includes the ligand binding domain (LBD), which 
interacts directly with the hormone. This part of the receptor is larger and more complex 
than the DNA-binding domain. It is composed of three layers of a-helices forming a 
pocket. Embedded within this pocket is a hormone dependent transcriptional activation 
domain, and this is where ligands are transported prior to binding (Weigel, 1996).
In essence the LBD acts as a molecular switch that recruits co-activator proteins 
and activates the transcription of target genes when flipped into the active conformation 
by hormone binding. From a refinement of the characterisation of the role of the 
3’untranslated region (3’UTR) of hER a mRNA, the existence of another level in the 
control of the expression of the ligand-activated transcription factor hER in addition to 
transcriptional regulation has been determined (Kenealy et al., 2000). Due to the general 
similarities in the structure and function of members of the steroid hormone family, it is 
likely that elements that influence the stability of mRNAs of other steroid hormones 
receptors should also be found in their 3’UTR (Kenealy et al., 2000). The members of 
this family also have dimérisation receptor partners in common, particularly with the 
ubiquitous 9-cis-TQtmoic acid receptor (RXR) (Kliewer et al., 1999).
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The ligand activated nuclear receptors CAR, PXR, and PPAR bind to their 
cognate DNA elements as heterodimers with RXR and thus activate the transcription of 
their CYP2B, CYP3A, and CYP4A genes (Figure 3.1). This process of gene activation 
then leads to enhanced metabolism of the compound of exposure (Kliewer et al., 1999; 
Willson and Kliewer, 2000; Xie and Evans, 2001).
Figure 3.1. P450 Transcription factors and examples of classes of known activation 
compounds
P450 Transcription Factors
f Steroids, Xenobiotics CYP1A 
Xenobiotic metabolism
Steroids, Xenobiotics
Steroids, Xenobiotics
CYP2B
Xenobiotic, Steroid metabolism
CYP3A
Xenobiotic, Steroid metabolism
Fatty acids, FIbrates CYP4A 
Fatty acid metabolism
However, there are further complications as there may be competition between 
the receptors for RXR, as well as reduced RXR availability and activation in response to 
stress-signaling, triggered from a variety of environmental stimuli (Lee et al., 2000a). As 
RXR is a cofactor that is essential to transcriptional activity, this suggests that stress- 
signaling will also indirectly affect all the receptors that dimerise with RXR, disabling 
gene activation even though ligand binding has occurred. Several receptors may be 
affected by the lack of availability of the dimérisation partner, including the ERs, PXR, 
CAR, the PPARs and other receptors. This will affect their ability to trigger or suppress 
gene transcription.
NRs are subject to cross talk interactions with other nuclear receptors, nuclear 
proteins, drug metabolizing enzymes, such as UGTs (Sugatani et al., 2001), the 
transporter P-glycoprotein, P-gp (Synold et al., 2001) and with a broad range of other
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intracellular signaling pathways (Kliewer et a l, 1999). There may even be a cascade 
effect, where metabolites produced through the activities of one receptor are specific 
signaling molecules (and ligands) to modulate the next receptor, along the chain of a 
nuclear receptor intercommunication web.
Dependency upon interactions with other nuclear proteins or cofactors that are 
important tissue/cell specific mediators of nuclear receptor function introduces further 
regulation of the members of the NR family. These may differ between receptors, or 
receptors may hold certain proteins or receptors in common with each other, such that 
part of the mechanism of action may be ascribable to competition between the receptor 
signalling pathways from the co activators or co repressors. This has been reported for 
the ER and AhR, for example (Nguyen et al., 1999). Table 3.1 presents the activation 
compounds and ligands for the selected receptors under study, further ligands for PXR 
are described in Chapter 4.
3.2.1. The human oestrogen receptor a  (hERa) and oestrogen receptor^ (hER/3)
The oestrogen receptors are known to exist as two subtypes, each one encoded by 
a separate gene. These are E R a (Brzozowski et al., 1997), and the recently discovered 
ER(3 (Mosselman et al., 1996) and its isoforms, of which a spliced isoform, ER|3/2 
appears to be equally expressed in animal model tissue density studies (Petersen et al.,
1998). The classical E R a subtype and ERp receptors and isoforms apparently 
evolutionarily diverged over 450 million years ago, suggesting that although they have 
evolved in parallel, this ancient duplication was to facilitate unique roles in vertebrate 
physiology and reproduction (Kelley and Thackray, 1999). The ERs differ in tissue 
distribution and relative ligand binding affinities for both endogenous and exogenous 
ligands (Table 1.1, figure 1.4) (Kuiper et al., 1997; 1998), which may help explain the 
selective action of oestrogens and androgens in different tissues (Figure 1.7) (Hall and 
McDonnell, 1999; Fuqua et al., 2000).
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Table 3.1. Selected receptors and their ligands, as reported in the literature
Receptor Activation compounds References
ERp
PXR
CAR
AhR
PPARy
PPARa
5a androstane did and 3P androstane diol,
17 P oestradiol, coumestrol, genistein, daidzein, 
trans-nonachlor, endosulphan, o,p’ DDT
Rifampicin, RU 486, SR 12813, androstanol, 
coumestrol, PB, TCPOBOP, pregnenolone 16a- 
carbonitrile (PCN), hyperforin (active constituent 
of St Johns Wort), 17 P oestradiol, P pregnane- 
3,20,dione, vitamin E, kava kava, bisphenol A, 
paclitaxel, guggulsterone, trans nonachlor, 
triclosan, DDE (in rPXR), enterolactone
Androstenol, androstanol, clotrimazole, 
TCPOBOP (in mCAR), DDE (in rCAR) PB, 5p 
pregnane-3,20,dione, PCN
Halogenated aromatic hydrocarbons (HAHs), e.g. 
polychlorinated dibenzo-p-dioxins (dioxins), 
dibenzofurans, and biphenyls (PCBs), polycyclic 
aromatic hydrocarbons (PAHs) e.g. 
benzo(a)pyrene, 3-methylcholanthrene, P- 
naphthaflavone, benzoflavones, carbaryl 
diaminotoluene, omeprazole, brevetoxin, indole 
carbinols (found in cruciferous vegetables) 
endogenous ligands e.g. bilirubin, biliverdin, 
water soluble metabolites of tryptophan, 
tryptamine, indole acetic acid, 2-(l’H-indole- 
3’carbonyl)-thiazole-4-carboxylic acid methyl 
ester, retinoids, antioxidants, Lipoxin A4, 
arachidonic acid, prostaglandins, 
indirubin, indigo
Fatty acids, eicosanoids, prostaglandins, 
metabolites of arachidonic acid and linoleic acid, 
antidiabetic thiazolidinedione (TZD) drugs 
including NSAIDs
Long chain polyunsaturated fatty acids 
(LCPUFA), eicosanoids, fibrates, phthalate ester 
plasticisers, pristinic acid, phytanic acid
Kuiper et al., 1997; 1998; 
Gaido, 1999; Gustafsson, 
2000
Lehmann et al., 1998; Moore 
et al., 2000a; 2000b;
Takeshita et al., 2001; Landes 
et al., 2003; Nallani et al., 
2003; Owsley and Chiang, 
2003; Raucy, 2003;Wyde et 
al., 2003, and Chapter 4.
Moore et al., 2000b; Maglich 
et al., 2002; Honkakoshi et 
al., 2003; Wyde et al., 2003
Gillner et a l.,, 1993; Denison 
and Whitlock, 1995; Sinai 
and Bend, 1997; Sinai and 
Bend, 1997; Denison et al., 
1998; Heath-Pagliuso et al., 
1998; Phelan et al., 1998; 
Schaldach et al., 1999;
Adachi et al., 2001; Denison 
et al., 2002; Gambone et al., 
2002; Song et al., 2002
Johnson et al., 1997; Memon 
et al., 2000; Bar-Tana, 2001; 
Chawla et al., 2001; Nixon et 
al., 2003; Willson et al., 2003
Memon et al., 2000; Zomer et 
al., 2000; Bar-Tana, 2001; 
Cronet et al., 2003; Willson 
et al., 2003; Xu et al., 2003
3.2.2. The Pregnane-X-receptor (PXR)
The Pregnane X Receptor (PXR), recently isolated and it’s sequence published 
by Kliewer and co-workers (Lehmann et al., 1998; Kliewer et al., 1998), and later 
Blumberg and co-workers (Blumberg et al., 1998) is involved in activating the expression 
of several P450 detoxifying enzymes, including CYP3A4 in the adult and CYP3A7 in the 
foetus, in response to xenobiotics and steroids (Pascussi et al., 1999). CYP3A4 is the
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major human hepatic P450, and is involved in the metabolism of over 60% of drugs in 
clinical use (Maurel, 1996). PXR is highly divergent between species, with great 
differences in PXR activation profiles due to differences in the LBD (Jones et al., 2000b). 
Variation in ligand binding domain is consistent with in vivo species differences in 
response to inducers, see figure 3.2.
Figure 3.2. PXR class similarities with different species and human CAR
(after Moore et al., 2000b)
N R l /  Subfam ily
human PXR
rhesus PXR 
pig PXR 
dog PXR 
rabbit PXR 
mouse PXR 
rat PXR 
frog BXRa 
frog BXRP 
fish PXR 
chicken CXR 
human CAR
The major site of PXR expression is in the liver hepatocytes and the 
gastrointestinal tissues, but it is also expressed in both normal and neoplastic breast 
tissue. Indeed a statistically inverse relationship between the level of PXR mRNA 
expression and ER status has been observed by ligand binding analysis (Dotzlaw et al., 
1999). PXR can be activated by a variety of chemically distinct ligands (Table 3.1), in a 
species dependent manner (Jones et al., 2000b; Moore et al., 2000b). Ligands include 
endogenous hormones such as pregnenolone, and progesterone and their synthetic 
derivatives such as pregnenolone 16a-carbonitrile (PCN), trans-nonachlor, rifampicin, 
dexamethasone, corticosterone, spironolactone, phénobarbital, and hyperforin (the active 
constituent of St John’s wort) (Moore et al., 2000a).
The mechanism of action is described further in Chapter 4.
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3.2.3. The Constitutive Androstane Receptor {CAR)
The Constitutive Androstane Receptor (CAR) is a member of the same nuclear 
receptor subfamily as PXR, sharing around 40% amino acid identity in their LBDs, as 
shown in figure 3.2, with 70% similarity between hCAR and rodent CAR LBD regions, 
although marked differences in ligand binding, (based upon in vitro radioligand binding 
studies) between PXR and CAR have been reported (Moore et al., 2000b), as shown in 
Figure 3.3.
In a pattern similar to that of the ERs, based upon phylogenetic analyses, it has 
been suggested that PXR and CAR are closely related to each other (Moore et al., 2000b). 
CAR is also present largely in the liver (it has also been detected by one group in the 
intestine, kidneys, lungs, heart, and muscle) (Baes et al., 1994), but not by Negishi’s 
group (Negishi et al., 2003) (Figure 1.7). It interacts with and is inhibited by two 
endogenous testosterone metabolites, androstanol and androstenol, via a mechanism that 
involves a widely expressed nuclear receptor coactivator, SRC-1 (Forman et al., 1998). 
The hierarchy of ligand activation differs between the receptors as well as for receptors 
isolated from different species, and in many instances, as identified in CAR, molecules 
that were previously regarded as metabolic intermediates are in fact “intracrine” 
signalling molecules within tightly coupled metabolic pathways for altering gene 
expression.
Unlike most nuclear receptors, including PXR and ER, the steroidal ligand for 
CAR inhibits receptor-dependent gene transcription by way of a ligand-independent 
recruitment of transcriptional co-activators (Forman et al., 1998). CAR functions in a 
manner opposite to that of the conventional nuclear receptor pathways and can be 
considered a 'repressed ' nuclear receptor in the presence of androstane metabolites 
(Tzameli and Moore, 2001). In cell based reporter gene assays, exogenously expressed 
CAR enters the nucleus and regulates the expression of target genes (Baes et al., 1994; 
Forman et al., 1998), it is not present in the nucleus but is sequestered in the cytoplasm, 
unlike the other receptors modelled and discussed here. There are significant sex 
differences in plasma androstane levels and it has been recently implicated as a 
transcriptional regulator of the gene governing the steroid hydroxylase CYP2B after 
binding with its cognate DNA response elements as a heterodimer with RXR (Forman et 
al., 1998). There appear to be additional mechanisms for the regulation of CAR activity, 
including phosphorylation by phénobarbital (PB). The effects of PB on CYP2B 
expression are blocked by the phosphatase inhibitor okadaic acid (Kawamoto et al., 1999)
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suggesting that déphosphorylation of CAR, rather than direct ligand binding, is involved 
in its translocation into the nucleus. Bilirubin also activates CAR, but does via binding in 
the CAR LBD (Honkakoshi et al., 2003).
This receptor is a coordinate regulator of hepatic gene expression in defense 
against chemical toxicity, and it also suggests a new area of androgen physiology whose 
significance is unknown as yet (Blumberg and Evans, 1998). Negishi has presented a 
model of CAR where a cytoplasmic CAR retention protein (CCRP) bound with hsp90 (a 
cofactor held in common with the ERs, chapter 1, and AhR, figure 3.3 and chapter 6), 
folds over to enclose the CAR. It appears that potent drugs can trigger translocation of 
CAR from this protein bundle, but they are not necessarily direct activators (Negishi et 
al., 2003).
A model of CAR can aid in the design of synthetic ligands that can help 
investigate the relevance of CAR to human metabolism and health.
Figure 3.3. Comparison of selected radioligand binding in CAR and PXR
(after Moore et al. 2000b)
Oh PXR
□  hCAR
□
3.2.4. The Aryl hydrocarbon Receptor (AhR)
The Ah receptor is a member of the Per-Arnt-Sim family of nuclear regulatory 
basic helix-loop-helix proteins (Swanson and Bradfield, 1993), and has been detected in
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nearly all vertebrate groups examined (Hahn, 1998). The Ah receptor binds to 2,3,7,8 
TCDD and other structurally similar PAHs to activate the cognate xenobiotic response 
element of the CYP lA  and IB l genes (Swanson and Bradfield, 1993; Denison and 
Whitlock, 1995; Hahn, 1998).
However, the AhR is the only member of that regulatory family known to bind to 
a ligand prior to heterodimerisation and bind to DNA in upstream regulatory regions of 
target genes. Predominantly found in hepatocytes, but also in breast cancer cells (Nguyen 
et al., 1999), the AhR regulates the expression of a number of genes, including 
cytochrome P450 lA l, 1A2, IB l, glutathione S transferase M (GSTM), DT-diaphorase, 
UGT and aldehyde dehydrogenase in a ligand-dependent manner (Nebert et al., 1981). 
AhR is also up regulated during cell division and is expressed in a specific spatial and 
temporal pattern in the developing foetus in vivo (Abbott et al., 1999). The best- 
characterised high affinity AhR ligands include a variety of ubiquitous lipophilic 
environmental contaminants in the polyhalogenated aromatic hydrocarbon family 
including dioxins, furans, coplanar biphenyls and polycyclic aromatic hydrocarbons 
(Denison and Whitlock, 1995). Other lower affinity ligands can be found endogenously, 
e.g. biliverdin (Sinai and Bend, 1997; Phelan et al., 1998), and in the diet (Gillner et al., 
1993; Heath-Pagliuso et al., 1998). Synthetic retinoids and pesticides have also been 
reported to activate the AhR pathway (Denison et al., 1998; Gambone et al., 2002). 
Exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), the most potent AhR ligand 
known, results in a wide variety of species- and tissue-specific toxic and biological 
responses (van den Berg et al., 1998). They are associated with the disruption of almost 
every hormone system that has been examined and responses to activation include 
developmental and reproductive toxicity. Animals treated with 2,3,7,8 TCDD have 
developed abnormalities in several organs, including the thyroid, thymus, lung and liver, 
immune and endocrine function. Wasting, lethality and induction of gene expression 
have also been shown to be AhR dependent (Femandez-Salugero et al., 1995; Schmidt et 
al., 1996; Femadez-Salugero et al., 1997; Abbott et al., 1999; Diliberto et al., 2003). 
Figure 3.3 illustrates the cellular events of AhR activation.
Within the cytosol of the cell, the AhR is associated with a heterodimeric 
transporter protein partner, termed the Aryl Hydrocarbon Receptor Nuclear Transporter 
protein (ARNT). Recently Yao and Bradfield (2003) have proposed an expanded model 
of AhR signalling, suggesting that receptor folding involves hsp90 co-chaperones Stilp, 
Cpr7p, and that trans-activation requires several complex subunits. From their
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observations, Bradfield’s group also report that the toxicity of dioxin must be due to a 
battery of gene changes, not just those for CYP lA l and 1A2, and that most novel dioxin 
responsive genes are down regulated in AhR null mice. The unliganded AhR may also 
act through other mechanisms by being phosphorylated to key regulatory proteins such as 
HSP90, p37, AIP, XAP2, src, rel, and Rb (Bimbaum, 2000). AhR levels have been 
reported to rise with increased oxidative stress activity. Many antioxidants are weak AhR 
ligands (Table 3.1.), which via the AhR down regulate oxidation by specific oxidative 
signalling (Yao and Bradfield, 2003).
Figure 3.3. TCDD (dioxin) molecules and Ah receptors: cellular events (After Wæm,
1995)
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3.2.5. The human peroxisome proliferator activated receptors (PPAR)
The Peroxisome Proliferator-Activated Receptors are a family of orphan 
receptors with fundamental roles in regulating energy balance (Johnson et al., 1997; 
Memon et al., 2000; Uauy et al., 2000; Xie and Evans, 2001). A number of prevalent
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metabolic disorders such as obesity, atherosclerosis and type 2 diabetes are associated 
with a shift in this balance. The Peroxisome Proliferator Activated Receptors are 
activated by xenobiotics, which elicit increases in the number and size of peroxisomes 
when administered to rodents (Kliewer et ah, 1999), and also induce hepatocellular 
carcinoma development by a non-genotoxic mechanism (Waxman, 1999).
There are three known closely related receptors: PPARa (3/6 and y, found in the 
liver, kidney, heart, haematopoietic and adipose tissue, but having different expression 
patterns. PPARa is found in liver, kidney, heart and muscle, PPAR6 is expressed in 
nearly all tissues and PPARy is expressed in fat cells, the large intestine, and monocyte 
lineage cells (Johnson et al., 1997). They each play key roles in lipid metabolism and 
homeostasis; PPARa is responsible for CYP4A induction; peroxisomal enzyme induction 
and hepatic peroxisome proliferation. PPARa has a central role in hepatogenesis, and 
PPARy, a central regulatory role in adipogenesis (Waxman, 1999; Memon et al., 2000; 
Chawla et al., 2001; Willson et al., 2003).
Figure 3.4. The mechanism for transcriptional regulation of the PPAR system
(adapted from Uauy et al., 2000)
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PPAR function may be affected by the nuclear availability of RXR, as it is involved 
in heterodimers with other receptors, notably the oestrogen receptors and thyroid 
receptor.
PPARa regulates key steps in lipid and fibrate metabolism. It is the molecular target 
for naturally occurring plant fatty acids (pristinic acid and phytanic acid) present at 
physiological concentrations (Zomer et al., 2000), long chain polyunsaturated fatty acids 
(LCPUFA), eicosanoids (Uauy et al., 2000; Chawla et al., 2001), and peroxisome 
proliferators, which include drugs such as the fibrates, (used widely to lower high 
triglyceride levels, a risk factor in coronary heart disease), and synthetic chemicals such 
as the phthalate ester plasticisers, and pesticides (Waxman, 1999). PPARy ligands include 
fatty acids, prostaglandins and the antidiabetic thiazolidinedione (TZD) drugs (Willson et 
al., 2003; Memon et al., 2000). Pristinic acid and phytanic acid are branch chained fatty 
acids obtained through the diet from the chlorophyll in plants. Present at micromolar 
concentrations in healthy individuals, they can accumulate in a variety of inherited 
disorders. Potent binding of pristinic acid and phytanic acid in the LED of PPARa 
(Zomer et al., 2000) indicates a primary mechanism for metabolising these dietary fatty 
acids.
The LED consists of 13 a-helices and a small 4-stranded p sheet forming a 
hydrophobic ligand binding pocket with a volume at least twice that of other receptors 
(Cronet et al., 2003). The PPARs have a far larger ligand-binding pocket than the 
receptors so far discussed, as indicated in Table 3.2, (Watkins et al., 2001), and there are 
differences in the shape of each PPAR ligand-binding pocket (Cronet et al., 2003; Xu et 
al., 2003), giving broad ligand specificity on a structural basis. Rosiglitazone occupied a 
fraction of the available LED space in PPARa, and less than that in PPARy, particularly 
the rosiglitazone TZD head group, and thus comparatively reduced selectivity was 
observed. This has been observed for different ligands in the PPAR family, and is a clear 
descriptor for PPAR selectivity.
There may be expression of a dominant-negative inhibitory human PPA Ra 
variant found in some individuals (Roberts et al., 1998) and human polymorphisms. It is 
possible that PPARy and PPARô, which is highly expressed in multiple human tissues, 
may be transactivated and consequently perturbed by a subset of peroxisome proliferating 
compounds, affecting the PPAR metabolic pathways, to elicit a pathophysiological 
response.
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Another factor to be considered is modulation through cross talk between PPAR 
and other nuclear receptors/signalling molecules. For example, thyroid hormone 
suppresses hepatic peroxisome proliferation responses and exhibits inhibitory cross-talk 
with PPARa, due in part to competition between the thyroid receptor and PPAR for their 
common heterodimerization partner RXR (Miyamoto et al., 2003). Indeed, all the 
receptors discussed here are interlinked, not least by their requirement for RXR as the 
heterodimerisation partner (See figure 3.1), except AhR (see figure 3.2).
3.3. Molecular modelling methods
3.3.1. Introduction
The steroid hormone receptor super family shares a conserved primary sequence 
and it is likely that their three-dimensional (3-D) stmctures are similar, so it is possible 
to model one member of the family from another.
In order to understand the role of ligand in receptor activation, homology 
molecular models of the ERp, hPXR, AhR and hCAR LBDs have been generated from 
the determinants of a ligand-bound hERa 3-D X-ray crystallographic structure 
(Brzozowski et al., 1997). Similarly, for the investigation of the role of ligand in 
hPPARa activation, a molecular model of the hPPARa ligand-bound hormone-binding 
domain (HBD) has been generated from a ligand bound hPPARy crystal structure (Nolte 
et al., 1998; Lewis and Lake, 1998b).
Knowledge of molecular mechanisms action for key proteins is built upon 
scientific models, and X-ray crystal structures are considered to represent the most 
reliable model for describing the 3-D conformation of a protein in a solid state (Lewis,
1996). While crystal structures are reliable starting points for investigations of the 
molecular mechanisms of receptors, as with other proteins, they are not necessarily the 
physiologically relevant shape that occurs in reality. The crystal structure reveals a 
composite X ray image of the receptor, in the solid state, usually containing water 
molecules, at a single moment in time, not in a dynamic situation. However, when 
examined in conjunction with experimentally derived data which is dynamic (in vitro 
and in vivo biological data) mechanistic models of activation can be refined and made 
more relevant to the human situation. Homology modelling can facilitate deeper insights 
into substrate selectivity and improve our understanding of receptor mediated 
metabolism.
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Using natural and synthetic ligands as chemical tools, the nature of receptor 
activation can be examined by assessing the structural mechanisms computationally, 
indicating highly probable modes and mechanisms of binding, together with the key 
amino acids involved. This can aid in the discovery of new hormone signalling pathways 
and cross-talk, and provide receptor specific insight into various disease scenarios, which 
in the case of hPPARa for example, would include the regulation and perturbation of 
lipid and TZD drug metabolism. It can also improve the prediction of the metabolic fate 
of new chemicals.
3.3.2 Materials and methods
3.3.2.1.Receptor alignments
The alignment was determined based upon previous alignments in the literature 
(Brzozowski et al., 1997). Domains of human ERa, retinoic acid receptor (RARa) and 
retinoid X receptor (RXRa), show conserved residues, these were used as the basis for 
modelling the HBD of hERp, hPXR, AhR and CAR. The respective sequences were 
adjusted in relationship to the other proteins in order to match theoretical helices of the 
receptors to known helices of hER a (figure 3.5). Similarly, domains of human PPAR and 
retinoid X receptor (RXRa) show conserved residues, and these were used as the basis 
for modelling the hormone-binding domain (HBD) of the hPPARa. The sequence was 
adjusted in relationship to the other proteins in order to match theoretical helices of 
hPPARa to known helices of hPPARy. The ligand binding domain sequences are shown 
in figure 3.6.
3.3.2.2. Building in silico models
The homology models of hERp (figure 3.7), hPXR (figure 3.8), and the hPXR 
crystal structure (figure 3.9) for comparison, CAR (figure 3.10), and AhR (figures 3.11 
and 3.12) were generated from the existing hER a structure (figure 3.2) using SYBYL 
biopolymer software (Tripos associates, St Louis, Missouri) implemented on a Silicon 
Graphics Indigo^ IMPACT 10000 Unix workstation. Loops were chosen from the 
Brookhaven Protein Databank to incur minimum interference with the core model. After 
energy minimisation with the Tripos force field, the endogenous moiety was docked into 
the structure. Some adjustment was needed in order for hydrogen bonding to occur 
between ligand and receptor. Finally, the structures were energy minimised again to
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achieve self-consistency. Similarly, the alignment and helices shown in figure 3.6 were 
used to generate the homology model of hPPARa from the existing hPPARy structure, 
shown in figure 3.13.
3.3.2.3. Range o f ligand probes
A number of compounds, with known receptor specific high, medium and low activation 
were individually docked in each receptor. For ERp these included the hormones 17 P 
oestradiol, androstanes, phytoestrogens and synthetic chemicals such as triclosan. For 
hPXR these included pregnenolone, coumestrol, PCN (a low affinity hPXR ligand, but 
high affinity rPXR ligand), progesterone, corticosterone, rifampicin, enterolactone, 
PCB118 , PCB 153, and triclosan. For the AhR these included 2,3,7,8 TCDD, and PCB 
126. With the AhR, little adjustment was needed in order for hydrogen bonding to occur. 
For the hCAR these included the testosterone metabolites androstenol and androstanol, 
and clotrimazole and TCPOBOP (both high affinity mouse CAR ligands).For both 
PPARa and PPARy these included fatty acids, thiazolidinediones (TZDs) and other 
drugs, and lipophilic chemicals.
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Figure 3.5. Alignment Between Steroid Hormone and Retinoic Acid Receptors LBDs
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T G L L S A IC L I C .G ................... DRMDLEEPEK VDKLQEPLLE ALRLYARRR.
4 9 6  5 4 5
LTLQQQHQRL A Q L L L IL S H I RHMSNKGMEH LYSMKCKNVV PLYDLLLEML 
..G Y F IH A A D  IIL H C A E S H I R .M IK T G .E . . SGMTVFRLL AKHSRVJRWVQ 
LTLQQQHRRL A Q L L L IL S H I RHMSNKGMEH LYNMKCKNVV PLYDLLLEML 
ISSQQQSMRL ANLLMLLSH*/ RHASNKGMEH LLNMKCKNVV PVYDLLLEML 
R PY PA H RFLFLK IM A V L.TELRSIN A Q Q TQ Q LLRIQD SH PFA .TPLM Q ELFSST 
QRRPRDRFLYAKLLGLL. A ELRSINEAYGYQIQHIQG. LSAM . M PL L Q E IC S. .
. . YPEQPGRF AKLLLRLPAL RSIG LKCLEH  LFFFK L IG D T  PIDTFLMEML 
..R P S Q P Y M F  PRMLMKITDL RGISAKGAER A IT LK M E IPG  PM PPLIREM L 
5 4 6  5 9 7
DAHRLHAPTS RGGASVEETD QSHLATAGST SSHSLQKYYI TG.EAEGFPATV 
SRWRWVQ
DAHRLHAPAS RMGVPPEEPS QTQLATTSST SAHSLQTYYI P P .E A E G F P N T I
N A H V L R G ..C  K S S IT G S E C S  PAEDSKSKEG SQNP
DGCAR
EAPHQMT................................................................................................................................................
ENPEMFEDDS SQPGPHPNAS . SEDEVPGGQ GKGGLKSPA........................................
CDAKGQLILG YTEVELCTRG 
F V C L K S IIL L  NSGVYTFLSS
345
LIGAND
B IN D IN G
DOMAIN
LIGAND
B IN D IN G
DOMAIN
hera=human oestrogen receptor alpha;ahr=aryl hydrocarbon receptor; mer=mouse 
oestrogen receptor alpha; cer=chicken oestrogen receptor alpha; herb=human 
oestrogen receptor beta; hpxr=human pregnane X receptor; car=constitutive 
androstane receptor; rxr=retinoid X receptor; rar=retinoic acid receptor. 
A=alanine; C=cysteine; D=aspartate; E=glutamate; F=phenylalanine; G=glycine; 
H=histidine; I=isoleucine; K=lysine; L=leucine; M=methionine; N=asparagine; 
P=proline; Q=glutamine; S=serine; T=threonine; V=valine; W=tryptophan; Y=tyrosine. 
The colouring system shown here for illustrative purposes gives the following 
chemical information:
Green = cyclic; ; cyan = aliphatic hydrophobic; red =
acidic; blue = basic; magenta = amides
The numbering system refers to the human ERa crystal structure (Brzozowski et al., 
1 9 9 7 ) .
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Figure 3.6. A section of the multiple sequence alignment of PPAR and RXR 
sequences from human, rat and mouse.
101
hrxr
mppar
rppar
hppar
hpparg
hppard
hrxr
mppar
rppar
hppar
hpparg
hppard
VSSSEDIKPP
ASTDESPGSA
TSTDESPGNA
GSVDESPSGA
KPHEEPSNSL
MGCDGASCGS
151
SCEGCKGFFK
ACEGCKGFFR
ACEGCKGFFR
ACEGCKGFFR
ACEGCKGFFR
ACEGCKGFFR
LGLNGVLKVP AHPSGNMASF TKHICAICGD
LNIE...................... CRICGD
LNIE...................... CRICGD
LNIE...................... CRICGD
MAIE...................... CRVCGD
LNME...................... CRVCGD
RTVRKDLTYT.CRDNKDCLID KRQRNRCQYC 
RTIRLKLVYDKC.D .RSCKIQ KKNRNKCQYC 
RTIRLKLAYDKC.D .RSCKIQ KKNRNKCQYC 
RTIRLKLVYDKC.D .RSCKIQ KKNRNKCQYC 
RTIRLKLIYDRC.D .LNCRIH KKSRNKCQYC 
RTIRMKLEYEKC.E .RSCKIQ KKNRNKCQYC
150
RSSGKHYGVY
KASGYHYGVH
KASGYHYGVH
KASGYHYGVH
KASGFHYGVH
KASGFHYGVH
200
RYQKCLAMGM
RFHKCLSVGM
RFHKCLSVGM
RFHKCLSVGM
RFQKCLAVGM
RFQKCLALGM
DNA
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hrxr
mppar
rppar
hppar
hpparg
hppard
201
KREAVQEERQ
SHNAIRFGRM
SHNAIRFGRM
SHNAIRFGRM
SHNAIRFGRI
SHNAIRFGRM
RGK.DR.... 
P .RSEKAKLK 
P .RSEKAKLK 
P .RSEKAKLK 
A .QAEKEKLL 
P .EAEKRKLV
AEILTCEHDL
AEILTCEHDL
AEILTCEHDI
AEISSDIDQL
AGLTANEGSQ
KDSETADLKS
KDSETADLKS
EDSETADLKS
.NPESADLRA
YNPQVADLKA
LGKRIHEAYL
LAKRIHEAYL
LAKRIYEAYL
LAKHLYDSYI
FSKHIYNAYL
220
hrxr ...NENEVE. 
mppar KNFNMNKVKA 
rppar KNFNMNKVKA 
hppar KNFNMNKVKA 
hpparg KSFPLTKAKV 
hppard KNFNMTKKKA
I < helix 1 > <helix2>
.STSSANE.D MPVERILEAE .LAV.EPKTETYVEANMGL.N 
RVILAGKTSN NPPFVIHDME TLCMAE.KTLVAKMVANGV.E 
RVILAGKTSN NPPFVIHDME TLCMAE.KTLVAKMVANGV.E 
RVILSGKASN NPPFVIHDME TLCMAE.KTLVAKLVANGI.Q 
RAILTGKTTD KSPFVIYDMN SLMMGE.DKIKFKHITPLQEQ 
RSILTGKASH TAPFVIHDIE TLWQAE.KGLVWKQLVNGP.P
LIGAND
hrxr
mppar
rppar
hppar
hpparg
hppard
260 < 
PSSPNDPVTN 
DKEAEVRFFH 
NKEAEVRFFH 
NKEVEVRIFH 
SKEVAIRIFQ 
YKEISVHVFY
helix 3 
ICQAADKQLF 
CCQCMSVETV 
CCQCMSVETV 
CCQCTSVETV 
GCQFRSVEAV 
RCQCTTVETV
T .LVEWAKRI 
TELTEFAKAI 
TELTEFAKAI 
TELTEFAKAI 
QEITEYAKSI 
RELTEFAKSI
290 <
PHFSELPLDD 
PGFANLDLND 
PGFANLDLND 
PAFANLDLND 
PGFVNLDLND 
PSFSSLFLND
helix4 X
QVILLRAGWN
QVTLLKYGVY
QVTLLKYGVY
QVTLLKYGVY
QVTLLKYGVH
QVTLLKYGVH
BINDING
DOMAIN
The amino acid designations as the same as indicated in Figure 3.5.
The numbering system refers to the human PPARy crystal structure (Nolte et al., 1998)
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Table 3.2.
Comparison of the volumes of nuclear receptor LBD cavities of known structure, 
(Adapted from Watkins et al., 2001 and Williams et al., 2003 indicated by *)
Receptor Ligand binding cavity 
volume
(A" )
ERa 476
LXRp* 830
PXR 1,150
PPARy 1,619
Progesterone receptor 557
Vit D receptor 871
3.4. Results and Discussion
Table 3.3 shows the results of the modelling of the receptors, including the energy before 
and after ligand binding, and indicates the main amino acid contacts between the ligands 
and receptors.
Figures 3.2 to 3.8 show the LBDs of the in silico homology receptor models.
Table 3.3.
Results for homology models of selected receptors with known ligand interactions
Receptor Energy before 
binding 
Kcal/mol 
(200 iterations)
Ligand Energy after 
binding 
Kcal/mol 
(200 iterations)
Main contacts between ligand 
and receptor 
(ERa alignment)
ERP -567.195 n p  oestradiol 
coumestrol
-611.802
-626.966
H bonding‘s with: Histidine, 
Arginine, Glutamate
PXR -558.873 pregnenalone
dexemethasone
-605.979
-602.867"
H bonding with: Glutamines 
Glutamate, Serine, Histidine
CAR -542.440 androstane 3P 
l ip  diol-17 -one
-603.932 H bonding with: Arginine, 
Aspartate, Gutamine, Histidine. 
Tyrosine may bond with longer 
structures or if androstane is 
moved further into the LBD 
Hydrophoblic contacts: Leucine, 
Valine, Cysteine, Methionine
AhR
PPARa
-334.982
-792.255
2,3,7,8 TCDD 
PCB 126
arachidonic acid 
bezafibrate
-364.120
-368.301
-848.050
-836.033
H bonding with: Arginines 
7Ü-7Ü stacking between 
Phenylalanines 
Ion bonding with: Histidine, 
Lysine, Cysteines 
H bonding with: Serine
400 iterations
H bonding: Hydrogen bonding 
Note: The values given in this table are relative and not absolute. They are included to demonstrate the 
stable low energy conformations of the proteins.
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3.4.1. Promiscuity of ligands; cross talk of receptors
Xenobiotics may act on some but not all of the receptors and their isoforms in the 
tissues of these organs, or act to different affinities, as methoxychlor and its analogue DDT 
do in E R a and ERp (Gao et al., 1999). Taking the ERs as a specific example, ERP is 
dependent on pure agonists for the activation of transcription from its target promoters, 
while E R a can be activated by agonists, partial agonists (such as tamoxifen, which is used 
in the treatment of ER+ breast cancer) and ligand independent mechanisms.
3.4.2. Evidence of ‘cross-talk’
Not only do receptors often have ligands in common (although with different binding 
affinities), there is also a great deal of ‘cross-talk’ and ‘ligand promiscuity’. For example, 
forms of the endogenous oestrogenic (oestradiol) and androgenic (androstanes) hormones 
are both ligands for ERp. Oestradiol is less potent in ERP than in ERa, whilst the natural 
ligands for ERp may actually be androgens: 5 a  androstane diol and Sp androstane diol 
(Gustafsson, 2000). The organochlorine pesticides trans-nonachlor and chlordane are 
known to activate both known oestrogen receptors (ER), and the pregnane X receptor 
(PXR), but with different affinities (Kuiper et al., 1997; Barkhem et al., 1998; Waxman, 
1999; Jones et al., 2000; Brady et al., 2002). As these receptors are present in different 
ratios in different cell types and tissues, the response on a cellular, tissue and systemic level 
may be quantitatively very different, and may vary over time. Receptor modulation has 
been seen with lactation, when a form of ERp has been observed to increase in the rat 
mammary glands (Gaido et al., 1999; Gustafsson, 2000), and in breast tissue hyperplasias, 
where a frequent mutation in the E R a gene shows increased sensitivity to oestrogen 
compared with wild type ERa, by affecting the border of the hinge and hormone binding 
domains (HBD) (Fuqua, et al., 2000).
There is evidence that isoforms of different receptors modulate each other at a 
functional level, attempting to retain a balance. The modulation is aided at low (Hall and 
McDonnell, 1999), and high hormone levels (Petersen et al., 1998) by different ERP 
isoforms - this may enable a tissue to govern its own responsiveness to oestradiol, 
oestradiol metabolites and related hormones such as progestins, and oestrogen mimics or 
endocrine disrupting compounds (EDCs). This speculation is supported by what appears to 
be an emerging pattern in nuclear receptor signaling, as similar balancing acts have been 
observed in the a  and P forms of the human glucocorticoid receptor, the progesterone
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receptor, and now also between PXR and CAR (Watkins et al., 2001; Xie and Evans, 2001; 
Maglich et al., 2002; Honkakoshi et al., 2003).
Phytoestrogens appear to have a greater affinity for ERp than ER a (Kuiper et al.,
1997), but they have an ER a selective efficacy, while the hydroxylated metabolites of 
methoxychlor appear to be an ER a specific agonist, and ERp antagonist (Gaido et al.,
1999), but with about the same affinity for both isoforms (Kuiper et al., 1997).
Figure 3.7. Homology model of human oestrogen receptorP (left) next to human 
oestrogen receptora crystal structure (right), hoth with oestradiol docked in the LBD
I
17 P oestradiol in the respective LBDs of ER a and ERp. The pink ribbon denotes the 
protein backbone of the receptors, and all the amino acids for both the model and the 
crystal structure are illustrated in this figure.
3.4.3. The Pregnane-X-Receptor (PXR)
Examples of hydrogen bonding and hydrophobic contacts with key amino acid 
sidechains for pregnenolone, coumestrol and PCN were Gin 521, Gin 524 and Glu 404. 
The steroids, progesterone and corticosterone, displayed hydrogen bonding with the 
same amino acids, plus Ser 350. His 388 may well have a significant role to play with 
certain ligands such as tamoxifen, as it can both accept and donate hydrogen bonds, as 
well as change orientation to facilitate binding.
Thus five key polar residues, including glutamine, glutamate, serine and 
histidine, are important for ligand binding in this hPXR model, although not necessarily 
all of them for every ligand. The hPXR crystal structure was published recently, both
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alone and complexed with the high affinity ligand SR 12813, and here the five key polar 
residues critical for establishing the activation of PXR in the LBD were Ser 208, Ser 247, 
His 407, Arg 410 and Gin 285. The ligand-binding pocket is highly flexible and may be 
able to expand the number of possible hydrophobic contacts by enlarging via a pore 
(Watkins et al., 2001). Two of these amino acids. Gin 285 and His 407, have been 
shown by Ostberg et al, 2002, to be essential for the species specific activation of PXR 
in mouse/human PXR receptor studies. Mutating the Glutamine residue altered the 
activation of the receptor from rifampicin, the positive control for human PXR ,to PCN, 
the positive control used for rodent PXR species. The Histidine residue, on the other 
hand, appears to be important for the basal level of activation of PXR (Ostberg et al., 
2002).
Comparisons between the homology model presented herein, and the recently 
published crystal structure of PXR (Watkins et al., 2001) and pharmacophore (Ekins and 
Erickson, 2002) compare favourably (figure 3.3 and 3.4), indicating that the use of 
homology modelling for receptors, as with enzymes, is a useful tool when crystal 
structure data are not available.
Figure 3.8. Molecular homology model of PXR with pregnenolone docked in the 
LBD plotted from the crystal structure coordinates of ERa.
Figure 3.9. Crystal structure of hPXR with pregnenolone docked in the LBD.
m
Figure 3.10. a) Molecular homology model of CAR with androstanol docked in the 
LBD, plotted from the crystal structure coordinates of hERa, left and b), close up 
photograph of the CAR LBD model, right.
For all figures the ribbon denotes the protein backbone of the respective receptor, and 
hydrogen bonding of the ligands with key amino acids is indicated by the dashed blue 
lines.
m
c) PB docked in the LBD and d) methoxychlor, plotted from the crystal structure 
coordinates of hERa
I
e) TCPOBOP docked in the LBD, plotted from the crystal structure coordinates of 
hERa, compared with f) TCPOBOP in the LBD of the PXR crystal structure
À
»
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3.4.4. The Constitutive Androstane Receptor (CAR)
Figures 3.10a shows the molecular homology model of CAR plotted from the 
crystal structure coordinates of ERa. Close-up pictures of the following compounds 
docked in the homology model of the CAR LBD, include 3.10b) androstanol; 3.10c) 
phénobarbital (PB), which probably acts through a phosphorylation mechanism; 3.10d) 
the agonist methoxychlor, and 3.10e) TCPOBOP compared with 3.10f) TCPOBOP in the 
LBD of the PXR crystal structure.
This model was built before the PXR crystal structure coordinates were made 
available, and subsequently a homology model of CAR based upon the PXR crystal 
structure has been built and published also (Maglich et al., 2003). The CAR LBD 
appears to be far less promiscuous, and thus less accommodating for ligands than the 
PXR LBD. CAR has chaperone proteins in common with the ERs, so models of CAR 
based upon the crystal structure of E R a and PXR may be able to indicate different 
aspects in the puzzle of CAR activation.
There is clear evidence of cross talk between PXR and CAR and marked 
pharmacological differences for the same ligands in the different receptors, as is being 
observed between the ERs. Thus clotrimazole, for example, is a PXR activator, but a 
potent deactivator in CAR (Moore et al., 2000). CAR has also been observed to be 
transactivated through the CYP3A4 xenobiotic response element that serves as the 
PXR/RXR binding site (Sueyoshi et al., 1999) and has been observed to be sequestered in 
the intact liver, in the absence of activators (Kawamoto et al., 1999). A ligand that affects 
androstanol and androstenol levels will also affect CAR and possibly the steroid 
hydroxylase CYP2B. CAR also has PB like PCB ligands in common with AhR. Both 
CAR and PXR m RNAs are also markedly reduced by the cytokine interleukin-6 (IL-6), 
but this has not been observed for the AhR or glucocorticoid receptor (GR) (Pascussi et 
al., 2000b).
3.4.5. The Ah Receptor (AhR)
2,3,7,8 TCDD (figure 3.11) and 3,3’,4,4’,5 PCB (lUPAC 126) (figure 3.12), both 
high affinity ligands, were docked in the LBD. Differences in binding were observed. 
The HOMO energy appears to describe an important facet of the ligand binding process, 
which could involve a n-n  stacking interaction (see figure 3.11) between benzene rings 
on the PCB molecule and one or more aromatic amino acid residues (eg. phenylalanine)
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in the AhR ligand binding site itself. The ligand-binding site preferentially accepts 
relatively planar aromatic molecules within a specific rectangular envelope. Hydrogen 
bonding does not appear to be as significant as it is with 2,3,7,8 TCDD.
For AhR ligands, QSAR studies indicate the HOMO energy to be an important 
descriptor with molecular planarity, together with the overall rectangularity as measured 
by the length/width ratio, planarity, length and energy of the highest occupied MO 
(Lewis and Jacobs, 1999). These descriptors have also been described for synthetic 
retinoids, with structural similarities to 2,3,7,8 TCDD and the coplanar PCBs, for the 
retinoic acid receptor (RAR) and the AhR/ARNT pathway (Gambone et al., 2002). 
Figures 3.11 and 3.12 illustrate the good steric complementarity for TCDD and closely 
related compounds such as PCB 126. The LBD of the AhR appears to also be able to 
accommodate many other recently identified dietary ligands, suggesting a dynamic 
plasticity in the LBD that may be similar to PXR, in vitro and in vivo.
Another AhR homology model has been published recently, a theoretical model 
for the mouse AhR based on available crystal structures of homologous PAS family 
members (Procopio et al., 2002). This model is based on three PAS proteins (bacterial 
photoactive yellow protein, PYP, human potassium channel, HERG, and the heme 
binding domain of bacterial FixL protein) with very different activation and function as 
well as low sequence similarity, although there are some highly conserved structural 
characteristics to that of the AhR. These proteins do not appear to have cross talk 
interactions with SHRs (and chaperone proteins) to the same degree that the AhR does. 
Hsp90 for example regulates AhR activity in vivo, and Ah responsiveness is partly 
dependent upon cellular ER content through a mechanism that involves Hsp90 (Caruso et 
al., 1999; Petrulis and Perdew, 2002). RIP40 also interacts with both receptors (Kumar et 
al., 1999).
At the time the AhR model based upon the ER a crystal structure was built 
(Jacobs and Lewis, 2000a) it provided an explanation of the likely reason for the high 
affinity binding of TCDD in the LBD, and continues to provide information on likely 
binding parameters in the LBD, which can be utilised further in molecular in vitro 
mutagenesis studies and ligand binding studies, in support QSAR analyses.
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Figure 3.11. Molecular homology model of AhR with 2,3,7,8 TCDD docked in the 
LBD (hydrogen bonding indicated by the yellow dashed lines), plotted from the 
crystal structure coordinates of ERa.
Figure 3.12. Molecular homology model of AhR with PCB 126 docked in the LBD 
(showing 7 1 -7 1  stacking), plotted from the crystal structure coordinates of ERa.
3.4.6. The Human Peroxisome Proliferator Activated Receptor (PPAR)
Rosiglitazone, a potent ligand in PPARy but not PPARa, occupied a fraction of 
the available LBD space in PPARa, less than that in PPARy, particularly the 
rosiglitazone TZD head group. Headgroup interactions in PPARa are different to those in 
PPARy because of a His to Tyr mutation. Thus comparatively reduced selectivity was
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observed in silico as reported experimentally for different ligands in the PPAR family, 
and is a clear descriptor for PPAR selectivity.
Figure 3 .13 . a) Homology model of human PPARa with rosiglitazone docked in the 
LBD, and b) A closer view of rosiglitazone docked in the ligand binding pocket of 
hPPARa showing binding with key amino acid residues
a) b)
%
3.5. Conclusion
The nuclear receptors modelled display a spectrum of ligand specificities, 
ranging from the highly specific, as seen in CAR which binds 5a-androstan-3a-ol 
(androstanol) but not 5a-androstan-3(3-ol (Moore et al., 2000b) and seen in PPAR 
selectivity, to the highly non-specific, such as hPXR, which is very flexible, and can bind 
with a large number of wide ranging molecules, from rifampicin to steroidal structures. 
They also display a spectrum of binding modes within the LBD, from hydrogen bonding 
with variable key amino acids (as observed in all the receptors) to tt-tc stacking, as seen in 
the AhR, and also binding outside the LBD, as seen with antagonists such as tamoxifen in 
ERa.
It is also likely that other amino acids play key roles in ligand binding, but do not 
bind directly, and this is an area that could be usefully explored by using the crystal 
structures and models further. For instance, with ERa, where key ligand binding occurs 
with His524, Arg 394 and Glu353 (Figure 1.3), it appears that mutation of L536 alters the 
coupling between ligand binding, transcription activation, and receptor conformation 
(Zhao et al., 2003).
The receptor models can be used to explore modes of binding of different ligands 
in the LBD, and conduct Quantitative Structure Activity Relationships in conjunction
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with experimental ligand binding data from both the literature and in house in vitro 
systems.
The identification and in silico assessment of the different ligands both in isolation and 
within the receptor models may add to a better knowledge of their specificity and may 
help explain the selective action of steroids and xenobiotics in different tissues. This 
information can be used to explore novel development compounds for therapeutic 
intervention in various functions that involve the PPARs, ERs, AhR, CAR and PXR, and 
their associated GYP enzymes, together with other chemicals of interest, such as 
industrial chemicals and dietary compounds. Since this work was conducted, the crystal 
structures of human ER(3 (Pike et al., 1999), PXR (Watkins et al., 2001), and PPARa 
(Cronet et al., 2001; Xu et al., 2002) have become available, and they compare 
favourably with the models described herein, as illustrated in figure 3.8 and 3.9, 
supporting the value of homology receptor protein models where crystal structures have 
not yet been determined. The models and crystal structure described here are utilised 
further in chapter 5.
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In Vitro Biological Parameter Estimation 
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Chapter 4 
Experimental Case Study 
Activation of PXR by Dietary Ligands: In Vitro Transient Transfection
Assays
4.1. Introduction: PXR activation
The nuclear receptors are a family of ligand-activated transcription factors that 
includes the steroid, retinoid, and thyroid hormone receptors. In 1998, a new member of 
this family was reported that is activated by nearly all of the structurally diverse 
compounds that induce CYP3A gene expression (Kliewer et al., 1998; Lehmann et al., 
1998; Bertilsson et al., 1998; Blumberg et al., 1998). Based on its activation by natural 
and synthetic C21 steroids, the new receptor was named the pregnane X receptor by 
Kliewer and co-workers (Kliewer et al., 1998) or Steroid X Receptor (SXR) by Evans 
and colleagues (Blumberg et al., 1998). PXR binds as a heterodimer with the 9-cis 
retinoid X receptor a  (RXRa) to DNA response elements composed of two copies of the 
consensus sequence AGTTCA organized as either a direct repeat with a three nucleotide 
spacer (DR3) or an everted repeat with a six nucleotide spacer (ER6). DR3 and ER6 
response elements have been identified in the regulatory regions of rat, rabbit, and human 
CYP3A genes.
The binding of ligands to PXR causes a conformational change in the receptor’s 
ligand binding domain (LBD) and results in the transcriptional activation of CYP3A4 and 
other PXR target genes (Kliewer et al., 1998; Lehmann et al., 1998; Bertilsson et al., 
1998; Blumberg et al., 1998). Mutation of four key residues in the LBD that contact the 
ligand, and are divergent among species, can shift the ligand specifity from mouse to 
human PXR (Watkins et al., 2001). That very few key residues in NR LBDs may need to 
be mutated to affect the mechanism of activation has been observed for other receptors 
also, e.g. such as the AR (Rabenoelina et al., 2002) and E R a (Zhao et al., 2003). The 
sequence differences in the LBD of PXR account for most of the variation in CYP3A 
induction across species. Compounds that are known to differentially induce CYP3A 
expression in rat or rabbit or human activate only the corresponding PXR (Jones et al., 
2000b; Xie et al., 2000).
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As discussed in Chapter 1, PXR upregulates the body’s main chemical defense 
system in response to challenge primarily by inducing CYP3A4, an enzyme that is 
involved in the metabolism of >60% of all marketed drugs, including chemicals as 
diverse as macrolide antibiotics, imidazole antimycotics, benzodiazepines, and steroids 
(Maurel, 1996; Waxman, 1999; Moore et al., 2000b). Notably, transcription of the 
CYP3A4 gene is increased in response to an extensive array of drugs and other 
xenobiotics, see figure 4.1.
The inducibility of CYP3A4 expression, coupled with the broad substrate 
specificity of this enzyme, represents the basis for an important class of drug-drug, 
phytochemical-drug-contaminant interactions. Humans are exposed to many ligands. In 
the pharmaceutical industry, until recently, it has been very difficult to accurately predict 
the clinical induction potential of drug candidate molecules because of the tremendous 
species differences seen in the induction of CYP3A enzymes. Thus, induction studies 
have generally been performed in primary human hepatocytes, which are difficult to 
obtain and vary considerably in quality. PXR transient transfection assays are utilised by 
the pharmaceutical industry for the prediction of the CYP3A induction potential of drug 
candidates. These assays also have applications for the analysis of dietary and endocrine 
disrupting compounds. There is increasing evidence that potent inducers of CYP3A can 
be present in the human diet, from food constituents, food contaminants and over-the- 
counter herbal remedies and vitamin supplements. These can be as potent as 
pharmaceutical compounds, as demonstrated by the effect of hyperforin (St John's Wort), 
which is ten-fold more potent than the prototypical PXR ligand, rifampicin (Moore et al., 
2000b).
Favourable comparisons of PXR activation have been reported between human 
hepatocytes and PXR transient transfection assays (Luo et al., 2002). Thus the recent 
development of high capacity assays to predict the CYP3A4 induction potential of drug 
candidates gives an early indication of the need for interaction studies and is considered 
to be a cost effective decision making tool to expedite the drug discovery process, 
particularly in the in-licensing arena where limited or incomplete pharmacology and 
toxicology information is available (Nolan et al., 2003). The PXR transient transfection 
assay is a tool that can result in safer medicines, particularly with the current prevalence 
of polypharmacy, but can also be part of a tier testing approach to assess endocrine 
disruption and dietary compound interactions mediated through PXR and CYP 3 A4.
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Here, the cell-based reporter assay is described and the results are discussed. The 
data generated from this assay were used to construct and test a PXR QSAR model 
(Chapter 5).
Figure 4.1. PXR: Mode of action
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4.2. Materials and Methods: 
4.2.1. Selection of chemicals
Chemicals were selected to be representative of likely dietary and drug exposure 
as well as including some experimental NCEs, to yield a good spread of activity, by 
reviewing the literature (please see the previous chapters) and searching directories of 
commercial and phytochemical dictionaries (Merck 1996; Harboume et al., 1999) 
together with in-house GSK data libraries displaying chemical structures. The 
compounds finally tested were a representative selection of ligands showing weak to high 
affinity for binding with PXR, many of these compounds are also ligands for other NRs. 
Ideally a larger data set would be generated, given a longer timescale and sufficient 
funding.
4.2.2. Ceil Based Transfection Assay
This assay profiles compounds for their efficacy and potency on PXR in a 
cellular context, and is considered a straightforward format for studying PXR activation 
in different species. The cell-based transfection assay developed at GlaxoWellcome, now 
GSK, to measure PXR activity is performed in two host cell lines, HuH7, human 
hepatoma, and CV-1, African Green monkey kidney cells. The assay has been validated 
in two species, rat and human. The HuH7 cell assay uses transient over expression of the
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full-length receptor and a corresponding reporter plasmid, which contains a PXR 
CYP3A4 responsive element in front of the minimal thymidine kinase (tk) promoter. The 
CV-1 cells use a truncated version of the receptor and plasmid. Both cell lines were 
utilised in this project, both for training and comparative purposes. The transfection 
method varied in terms of transfection reagent, cell type, reporter gene constructs and 
drug, as described below, but a standard scheme was followed, as established at GSK for 
the prediction of CYP3A4 induction potential in humans. All cell work was carried out in 
a Class II biological safety cabinet under aseptic conditions in a dedicated cell culture 
laboratory at GSK, Ware.
Cells were seeded onto 96 well plates at a density of 20,000 cells per well. After 
24 hours the cells were transfected with full length hPXR (PSG5-PXR) for HuH7 cells, 
or the chimera (UAStkSPAP) for CV-1 cells, the reporter gene construct 
(CYP3AtkSPAP) and pCH llO  containing p-galatosidase to correct for transfection 
efficiency. The following day the cells were dosed with test compound at lOuM to 
O.OluM. After 24 hours the culture medium was assayed for SPAP activity and the cell 
lysate assayed for Pgal activity. Activation of PXR by a compound was expressed as a 
percentage of that achieved with lOuM positive control, rifampicin (Rif) (EC 50 ca luM). 
When a full dose response curve was achieved, the EC 50 value and thus potency can be 
calculated. If a full dose response is not achieved, the EC 50 value is reported as ‘>10uM’. 
Table 4.1. In terp reta tion  of PXR transient transfection assay results
% M ax EC50 uM In terpreta tion
0 % >10 No response
<30% >10 Weak response
30-70% >10 Moderate response
>70% >10 PXR activation at high
concentrations only
>70% <10 PXR activation with
some potency
4.2.2.1 Preparation o f  nuclear receptor constructs
The PXR chimeric constructs required for the CV-1 cell transfections were 
prepared and supplied in advance by Linda Moore, Systems Research, GSK, RTP 
(Kliewer et al., 1998; Moore et al., 2000b). Briefly, the GAL4-chimera expression 
constructs (pSGSStratagene) were made to contain the translation initiation sequence 
(Kozak sequence) and amino acids 1-76 of the glucocorticoid receptor fused to amino
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acids 1-147 of the yeast transcription factor GAL4 DNA binding domain. The cDNA’s 
encoding LBD s of the nuclear receptors were amplified by polymerase chain reaction 
(PGR) and inserted C-terminal to the GAL4 DNA binding domain to generate the final 
chimeric nuclear receptor plasmids. The cDNA was transformed into competent cells 
(DH5a) using DNA prepared in Qiagen Maxi-Prep kits.
Preparation o f pSG5 human PXR:pSG5-fl hPXR-ATG The HuH7 cells were transfected 
with the full-length coding region of human PXR with a modified start codon, obtained 
using hybridisation technology and provided ready prepared. The expression plasmid 
pSG5-hPXR-ATG was generated by PGR amplification of cDNA encoding amino acids 
1-434 of hPXR and inserted into the pSG5 expression vector (Stratagene).
Preparation o f  reporter plasmid : Five copies of a GAL4 DNA binding element were 
inserted N-terminal to the minimal thymidine kinase promotor from the herpes simplex 
virus, followed by SPAP in the pGI12 expression vector, using Qiagen Maxi-Prep kits 
and provided ready prepared.
Preparation o f internal control plasmid: P-galactosidase (pGHllO from Pharmacia) was 
also prepared using Qiagen Maxi-Prep kits and provided as above.
Preparation o f pBluescript plasmid: pBluescript (Stratagene) was also prepared using 
Qiagen Maxi-Prep kits.
Preparation o f  coactivator: The human SRG-1 p i40 was cloned into the pSG5 vector at 
the B g lll-B g lll site with a kozak sequence just before the ATG and was also prepared 
using Qiagen Maxi-Prep kits and provided as above.
4.2.2.2. PXR Species differences: Rat versus Human
This transient cotransfection assay has a number of other uses. By transfecting 
different species specific PXR plasmids, species specific PXR and GYP 3A induction 
liabilities may be determined. Therefore, in GSK, rat PXR is routinely used as an assay 
for testing the induction potential of experimental drug compounds to predict GYP3A23 
induction, and a variety of other species have been tested, these show divergent responses 
compared to induction in cell lines transfected with human PXR.
Pregnenolone 16a carbonitrile (PGN) is used as the positive control (EG50 ca luM ), at a 
top dose of lOuM in rat studies.
146
4.2.3. Materials
4.2.3.1. Chemicals and supplies
Hyperforin, genistein, and coumestrol were purchased from Apin Chemicals 
(Abingdon, Oxon, UK). GW compounds and other phytochemicals were kindly donated 
by GSK. Lovastatin, lithocholic acid and 7 dehydrocholesterol (Vitamin D3) were 
originally purchased from Sigma (Sigma-Aldrich Company Ltd. Poole, Dorset, UK), 
and subsequently were kindly donated by GSK. Triclosan (5-chloro-2-2(2,4- 
dichlorophenoxy)phenol), trans-nonachlor, PCB 118 and PCB 153 were purchased from 
LGC Promochem (Hatfield, Herts, UK).
4.2.3.2. Cotransfection assays
4.2.3.2.1.Cell maintenance reagents
DME High Glucose HEPES Medium (Invitrogen), Foetal Bovine Serum 
(Hyclone), 6mL aliquot of 2mM L-Glutamine (Gibco), 6mL aliquot of Penicillin- 
Streptomycin (Gibco), DMEM/F-12 Medium without phenol red (Gibco), Foetal bovine 
serum Dextran Treated/Charcoal Stripped (Hyclone), HuH 7 Cells, CV-1 cells, 225cm^ 
cell culture flasks (Costar), 96 well plates for cells (Falcon), Phosphate Buffered Saline,
0.25% Trypsin EDTA. Trypan Blue Dye.
4.2.3.2.2. Cell media
Maintenance Medium, Experimental Medium, 2X Recovery Medium, IX 
Drugging Medium, SPAP Substrate buffer, B-Gal Substrate buffer.
4.2.3.2.3. Nuclear receptor constructs fo r  transfection
Nuclear receptor constructs were very kindly provided by Linda Moore from GSK, RTP 
as per section 4.2.2.1.
Additional reagents required included Lipofectamine Plus, Opti-MEM-1 reduced Serum 
Medium, 96 well deep-well blocks (Beckman), Triton X-100, Diethanolamine, NaCl, 
MgCLbHiO, pNPP (Sigma), ONPG (Sigma), Na2HP04, NaH2P04.
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4.2.4. Methods for media preparation
1. Maintenance Medium
DME High Glucose HEPES medium, fetal bovine serum, one aliquot of 2mM L- 
glutamine and one aliquot of penicillin-streptomycin were warmed to 37°C. Each item 
was sprayed with 70% ethanol and placed in a Class II cabinet.
500mL DME High Glucose HEPES medium, 50 mL fetal bovine serum, 5 mL of 2mM 
L-glutamine and 5 mL of penicillin-streptomycin were then filtered through a 0.22pm 
filter system and gently mixed by swirling, to produce a medium ready for use. The 
medium shelf-life was 10 days when stored at +2°C to 8°C.
2. Experim ental M edium
DMEM/F12, Dextran treated/Charcoal Stripped foetal bovine serum, one aliquot of 2mM 
L-glutamine were warmed to 37°C. Each item was sprayed with 70% ethanol and placed 
in a Class II cabinet.
500mL DME High Glucose HEPES medium, 50 mL fetal bovine serum, 2 mL of 2mM 
L-glutamine were then filtered through a 0.22pm filter system and gently mixed by 
swirling, to produce a medium ready for use. The medium shelf-life was 10 days when 
stored at +2°C to 8°C.
3 .2X Recovery M edium  
DME High Glucose HEPES medium, delipidated heat inactivated foetal bovine serum 
and two aliquots of 2mM L-glutamine. Each item was sprayed with 70% ethanol and 
placed in a Class II cabinet.
500mL DME High Glucose HEPES medium, lOOmL delipidated fetal bovine serum, 
lOmL of 2mM L-glutamine were then filtered through a 0.22pm filter system and gently 
mixed by swirling, to produce a medium ready for use. The medium shelf life was 10 
days when stored at +2°C to 8°C.
4. IX  Drugging M edium  
DME High Glucose HEPES medium, delipidated heat inactivated foetal bovine serum, 
one aliquot of 2mM L-glutamine and one aliquot of penicillin-streptomycin were 
warmed to 37°C. Each item was sprayed with 70% ethanol and placed in a Class II 
cabinet.
500mL DME High Glucose HEPES medium, 50 mL delipidated fetal bovine serum, 5 
mL of 2mM L-glutamine, 5 mL of penicillin-streptomycin were then filtered through a 
0.22pm filter system and gently mixed by swirling, to produce a medium ready for use. 
The medium shelf life was 10 days when stored at +2°C to 8°C.
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5. SPAP Substrate buffer
The SPAP Substrate buffer was made as follows:
16.36g NaCl and 0.102g MgCl26H20 were dissolved in 800mL MilliQ water, then 105.5 
mL Diethanolamine was added. The pH was adjusted to 9.85 using concentrated 
hydrochloric acid, and the final volume adjusted to lOOOmL with MilliQ water.
The buffer stock was kept for up to two months at room temperature.
6. B-Gal Substrate buffer
The B-Gal Substrate buffer was made as follows:
68.4mL IM Na2HP04 and 31.6 mL IM NaH2P04 were added to 900 mL MilliQ water. 
The buffer stock was kept for up to two months at room temperature.
4.2.5. Cell culture and maintenance
Both cell types were stored frozen in maintenance medium or 90% foetal bovine 
serum (FBS) plus 10% dimethylsulfoxide (DMSO), at a density of 10  ^cells/mL, in liquid 
nitrogen. To begin culturing the cells, a ImL vial of cells was thawed by gently agitating 
at 37°C before transferring the cell suspension to a 75cm^ vented flask (Nunclon™, 
Nunc brand products), followed by the gradual addition of 25mL of maintenance 
medium. Sudden dilution of DMSO can cause osmotic shock and greatly reduce cell 
viability. The flask was incubated at 37°C in an atmosphere of 5%C02 at >95% humidity 
for 6-24 hours to allow the cells to adhere firmly to the flask base. The following day, 
the medium was aspirated to limit exposure to residual DMSO from the freezing medium, 
and replaced with 25mL fresh maintenance medium. The cells were examined under a 
light microscope to establish percent confluence of the culture and were routinely split at 
70-90% confluence and grown in 225 cm^ vented flasks (Nunclon™, Nunc brand 
products). A typical split ratio was 1:10 every Monday and Friday in maintenance 
medium for passaging and a ratio of 1:5 in experimental medium, three days prior to the 
start of an investigation. Figure 4.2 shows the morphology of the CV-1 cells, while figure 
4.3 shows the morphology of the HuH7 cells.
To passage the cells, the existing media was aspirated and the cells washed with 
5ml of phosphate buffered saline (PBS, Dulbecco’s) to remove serum containing 
medium.
The PBS was aspirated and 2 ml of warmed trypsin-EDTA was added and 
tilted gently to keep it flowing over the cells. The flask was also tapped to facilitate cell 
detachment. Once detached, 8 ml of warmed Maintenance media was added (See Figure
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4.4) and mixed thoroughly to ensure all the cells were washed off from the base to 
achieve an overall trypsin neutralised single cell suspension. The trypsin inhibitor in the 
fetal bovine serum terminated the proteolytic activity of the trypsin. An aliquot of 
0.5/1ml of cells was pipetted in a new sterile flask and 50ml of Maintenance media was 
added. The date, passage number and the flask split ratio was recorded on the new flask. 
The flask was returned to the incubator, first spraying with 70% ethanol to prevent 
contamination. The cells in the new flask would be ready to passage again in 3-5 days, 
depending on the split ratio and cell line. A higher ratio was used for HuH7 cells of 2-2.5, 
compared to 1 in CV-1 cells. The flasks were placed in the incubator and kept at 37°C 
with 5% C 02 in air atmosphere in DME high glucose HEPES medium supplemented 
with 10% fetal bovine serum and 2 mM L-glutamine (Maintenance Medium), until the 
cells were -75%  confluent. See figures 4.2 and 4.3 for CV-1 and HuH7 cell morphology, 
respectively, in maintenance media.
Three days prior to plating for transfection, experimental cells were harvested 
with phenol red-free 0.25% trypsin/2 mM EDTA and collect in phenol red-free DMEM- 
F12/15 mM HEPES medium (Invitrogen) supplemented with 10% charcoal/dextran 
treated FBS (HyClone, Logan, Utah) and 2 mM L-glutamine (Experimental Medium). 
Figure 4.2. The morphology of CV-1 ceils in maintenance culture
'0 i
Figure 4.3. The morphology of HuH7 cells in maintenance culture
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Figure 4.4. The morphology of trypsinised HuH7 cells
Figure 4.5. The morphology of HuH7 cells in a well (96 well plate) ready for 
transfection
,  ' A  <
v ? P :|
•:  ^ ■ i:..
Figure 4.6. The morphology of transfected HuH7 cells
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4.2.6. Methods: Daily Experimental procedure
4.2.6.1. Day One- Cell plating
After aspirating the experimental media, the cells were washed with 5ml of PBS,
which was then aspirated and 2ml of warmed trypsin was added to detach the cells into a
single cell suspension. 8ml of experimental media was added and mixed well.
-Cell number
A clean dry heamocytometer was used for cell counting, lOul of cell suspension 
was applied to one end, and the cells in each quadrant were examined under a light 
microscope, (XIO Phase contrast), and then counted using a grid system under increased 
magnification.
The four numbers were averaged and multiplied by 10,000 to ascertain the number of 
cells in 1 ml of suspension. As 20,000 cells were required for each well, this number was 
further divided by 200,000 to derive the dilution factor. This multiple was used to deliver 
the final volume and ascertain the appropriate volume of experimental media to be added. 
lOOul of the cell suspension was pipetted into each well of a 96 well plate (Nunclon™, 
Nunc brand products), which were set up in triplicate for each experiment.
Example calculation: Quadrant 1 -9 3  cells
Quadrant 2 - 8 5  cells 
Quadrant 3 - 1 0 4  cells 
Quadrant 4 - 9 4  cells 
Average = 94 cells 
X 10,000 = 940,000 cells/ml 
Dilution factor to seed at 200,000 cells per ml = 4.7 
Therefore, take 1ml cells and add 3.7 mis media 
Therefore, take 20ml cells and add 74 mis media.
The plates were then incubated for 24 hours at 37^C/5%C02 in humidified chambers to 
prevent evaporation affecting the small volumes in the plates.
Figure 4.5 shows a well in a 96 well plate, plated HuH7 cells ready for transfection.
If more than one flask was used, all flasks were pooled prior to counting cells to 
ensure consistency.
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42.6.2. Day Two -  Transfection
All transfection calculations were performed using an Excel template, according to the 
transfection mixes required for the respective cell lines shown in tables 4.2 and 4.3, and 
according to the number of plates being set up per weekly experiment.
Table 4.2. hPXR transien t transfection assay: transfection mix for CV-1 cells
M i x l A m ount per well
Nuclear receptor chimera 2ng*
UAS5tkSPAP 8ng
pCHllO 25ng
SRC-1 p.l40 7ng
pBluescript Add until total DNA /well=80ng
OptiMEM-1 lOul
M ix 2
Lipofectamine 0.7ul
OptiMEM-1 lOul
^amount depends on the receptor’s basal activity but is normally 2ng/well 
Table 4.3. hPXR transient transfection assay: transfection mix for HuH7 cells
M i x l Am ount per well
PXR DNA 5ng
CYP3AtkSPAP 12ng
pCHllO 25ng
pBluescript Add until total DNA /well=65ng
OptiMEM-1 lOul
Lipofectamine Plus 0.7ul
M ix 2
Lipofectamine 0.5ul
OptiMEM-1 lOul
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Lipofectamine Plus™ Transfection method for HuH 7 cells.
Invitrogen’s Lipofectamine™ reagent (Life Technologies, Inc.) is a cationic lipid 
reagent that allows DNA introduction into the cells by forming complexes with the 
negatively charged DNA.
For HuH7 cells only. Plus™ reagent is used in conjunction with Lipofectamine™ 
reagent to enhance transfection in adherent cell lines. The protocol suggested by the 
manufacturers was followed. On one occasion when there was insufficient Plus™ 
reagent available, the transfection was not facilitated and the experiment was 
unsuccessful.
For HuH7 cells, the first transfection mix was mixed well and incubated for 
15 minutes at room temperature, before dispensing the appropriate amount of mix 2 into 
mix 1, again mixing well and incubating at room temperature for a further 15 minutes. 
The media was aspirated from the cells, and replaced with lOOul of transfection mix 
before incubating for 3 hours. Figure 4.6 shows the morphology of transfected HuH7 
cells.
CV-1 transfection methods
CV-1 cell transfection mixes were prepared according to Table 4.2, and the first mix 
mixed gently and incubated at room temperature for 30 minutes then combined with the 
DNA mixture. The cells were meanwhile aspirated and washed once with 100|il of Opti­
MEM-1 prior to the addition of lOOpl ml of diluted transfection mix to each well.
Treatment of cells post transfection
After transfection treatment, the cells were then returned to the incubator for 3 hours 
(HuH7 cells ) or for 6 to 18 hours (CV-1 Cells), after which the transfection process was 
halted by aspirating the transfection mix, and replacing it with lOOul Opti-MEM. The 
test compounds were prepared as for HuH7 cells and applied to the cells after removal of 
the Opti-MEM.
Washing CV-1 cells at the appropriate stages with Opti-MEM was a key element for 
successful transfection of the cells, HuH7 cells did not require these steps.
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4.2.63. Day Three- Compound treatment o f  transfected cells 
Drug Delivery Protocol.
Drug dilutions at 1:1000, were prepared under appropriate conditions, from 
lOmM drug stocks (in DMSO) in IX Drugging medium. Many of the phytochemicals 
tested, particularly hyperforin, are sensitive to light, therefore the preparation and dilution 
of these compounds was conducted in reduced light, and the compound stocks were 
stored at -20°C, in darkness. The dilutions of experimental compound stocks and vehicle 
were prepared in the Drugging media. 1:2 serial dilutions were carried out in drugging 
medium containing 0.1% DMSO, such that the concetrations ranged from lOuM to 
O.OluM. Rifampicin was included as the positive control compound for all plates. 
Triplicate plates were used for each experiment.
The test compounds were serially diluted across the 96 deep well block (Figure 
4.3). After aspirating the transfection mix from the wells, 100 [ll of diluted drug was 
dispensed to each well. For standards. Drugging medium containing 0.1% DMSO was 
added to wells A12-D12 as the vehicle control and lOuM rifampicin to wells E12-H12 as 
the positive control. The plates were incubated for a further 18-24 hours prior to the 
determination of reporter activity.
4.2.6.4. Day Four- Alkaline phosphatase (SPAP) assay
After overnight incubation in the presence of test compounds, the supernatant 
was sampled and assayed for alkaline phosphatase activity as follows: 50 pi of medium 
from each well of treated plates was transferred to daughter plates to assay for SPAP as 
an internal control for transfection efficiency. The transfer was conducted using a biohit 
multichannel pipettor when first learning the techniques, but later a Platemate or Zymark 
Rapidplate robot was utilised for this step. Occasionally problems with the robots were 
encountered with release into the daughter plates, particularly when they were first 
installed. This affected the reliability of the results, and the data were not used.
A 50ul sample of media used for drug dilution was used as a blank. Then p- 
nitrophenyl phosphate (186mg/100mL) was prepared in SPAP buffer (1 M 
diethanolamine/0.28 M sodium chloride/0.5 mM magnesium chloride at pH 9.85). 200 
pi of the substrate was added to each well of the daughter plates and the blank, the plates 
incubated at room temperature for approximately 30 minutes until a yellow colour 
developed, when the absorbance could be read at 405 nM using a UV plate reader.
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0.125% Triton X-100 and ONPG (1 lO/lOOmL) were dissolved in p-galactosidase 
buffer to lyse the cells in the mother plates. 200uI7well was dispensed to each mother 
plate and P-galactosidase blank plate using a hand pipettor or later, a multidrop. The 
plates were incubated at 37°C for up to an hour until a yellow colour developed. Basal 
values for the substrate buffers SPAP and B-Gal were determined from the blank plates. 
All the plates were read at 405 nM in 2 matching files, one for SPAP plates and one for 
B-Gal plates.
The results were considered acceptable when the B-Gal values were consistently 
0.4 across the plate and the SPAP positive control rifampicins were 0.8 or above, with the 
rest of the plate showing a dose response.
The quality of the data improved with greater operator experience in cell aspiration, 
repair of tools (e.g. the biohit multihit pipettor) use of viable plasmids, fresh reagent and 
drugs, and carrying out the drug dosing in darkened conditions,- this was particularly 
important for most of the Phytochemicals tested.
The experimental procedure and plate layout is summarised in figure 4.7, and figure 4.8 
illustrates the PXR transfection assay diagrammatically
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Figure 4.7. A diagrammatic summary of the hPXR transfection experimental
procedure (Adapted from diagrams by Charlotte Ashby)
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Figure 4.8. D iagram  illustrating an overview of the hPXR Transfection Assay
4.2.7. Data Analysis
Measurements were read using a UV plate reader (SpectraM ax). Data were 
copied from the SoftMax Pro files into Excel, and then analysed using ORPH.xla and 
RoboSage. ORPH.xla is a data reduction programme developed in house by M ark Lutz 
(GW RTP). Curves were fitted from these data and visually displayed using Robosage. 
Data were manipulated as triplicate values and expressed as percent of maximum or fold 
activation, by the following formulas
Where Y = % Max = (fold activation of unknown/positive control fold activation 
average) x 100
And, fold activation = ((SPAP-SPAP substrate blank average)/B-Gal-B-Gal substrate 
blank average))-(DMSO vehicle average)/DM SO vehicle average.
And, Y2 = an adjustment factor.
Using the robosage package, the equation used is a modified version of M ichaelis - 
Menton:
Y = ((Vmax*x)/(K+x))-Y2
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The plate layout also included quadruplicate wells for determination of basal activity 
from the vehicle itself, and quadruplicate wells for determination of the positive standard 
control, Rifampicin.
Where ECso’s for agonists could be plotted (if there was a clear plateau in the dose 
response curve), the formula was 
Response = (%max*[S]ECso + [S] )
To correct for transfection efficiencies, SPAP activity was normalised. The 
normalised SPAP activity was expressed as a percentage of maximum induction by the 
positive control (rifampicin) and dose-response curves were plotted. By plotting fold 
activation vs. log [compound concentration] and using non-linear least squares curve 
fitting, curves with Vmax values (and EC50 where possible) were generated using 
Robosage.
The data were normalised to 100% rifampicin, and in all experiments the overall 
trend of the data was unchanged by the normalisation procedure. The results were 
acceptable when the overall fold activation across all plates was above 4.0 for HuH7 cells 
(fold activation for CV-1 cells was always above 4.0), and when the Rifampicin curve 
reached a plateau and had a % Max induction of between 80-120%. This was to ensure 
results were standardised between operators, with a 20% margin from the standard value 
being acceptable. The EC50 value could only be quoted if a clear plateau was observed. In 
most cases a curve was generated, but not EC50 values, as this involved many more 
repetitions of the assays with incremental increases in the doses of drugs, and this 
became impractical given cell toxicity and solubility issues that can occur at higher 
concentrations, as well as time and financial constraints.
4.3. Com pounds tested
The full range of compounds tested in both cell lines can be found in Appendix 1. 
Initially, compounds were selected to include both a broad range of likely dietary ligands, 
drugs and experimental compounds, and drugs of known activation, to learn the operator 
procedure in the laboratory. Selection was based upon structural features (See selected 
structures in Table 4.4 and figures in Chapters 1, 3 and 5) and a literature review (Chapter 
1 and Chapter 3, table 3.1). Proprietary GSK compounds were also tested, to explore the 
binding properties of specific structural series, such as those seen with SR compounds. 
However, while PXR is of strong pharmaceutical interest, because it has evolved to deal
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principally with phytochemicals and other dietary compounds, testing with dietary 
compounds is a reasonable approach to examine hPXR activation in humans. To develop 
a better picture of cross talk, many of the compounds selected were ligands to differing 
degrees with associated receptors, particularly the ER (e.g. endogenous hormones and 
synthetic hormones: progesterone, pregnenolone 16a carbonitrile (PCN), 5(3pregnane 
3,20 dione, 17a ethinyl oestradiol, 17(3 oestradiol, experimental/drug hormones: ICI 
182780, tamoxifen and its metabolite, hydroxylated tamoxifen, SRI 2813 and in house 
GSK analogues, clotrimazole and dexamethasone, phytoestrogens: flavonoids, genistein, 
daidzein, coumestrol, quercetin and resveratrol; parent lignan: secoisolariciresinol and the 
metabolite enterolactone, equol, a daidzein product; organochlorines: PCB 118, PCB153, 
trans-nonachlor), the VDR (vitamin D 3  and the metabolite hydroxy vitamin D 3 ), LXR 
(the bile acid lithocholic acid), PPAR ( rosiglitazone and troglitazone).
Other compounds were selected on the basis of possible self-medication, such as 
hyperforin, a known PXR inducer (Moore et al., 2000b), herbal hepatoprotectants such as 
silybin, also a selective ER(3 agonist (Seidlova-Wuttke et al., 2002). Many other 
compounds originating from the diet have been shown to be induce CYP 3A4 and/or 
SHR ligands, so the test set is limited, and does not present a spectrum of dietary ligand 
activity for PXR. Additional dietary ligands of interest include bergamottin in grapefruit 
juice, which inhibits CYP3A4 induction, (He et al., 1998; loannides, 2002; Plant and 
Gibson, 2003), glycyrrhizin, found in licorice, which is also a ligand for GR (Zhou et al., 
2003; Paolini et al., 1999), kava kava (Raucy, 2003), vitamin E (a-tocopherol) and also 
dietary borne POPs not included here that are also of health concerns such as dioxins, 
DDT, DDE and PBDEs (Chapter 2). This is a realistic approach to examining drug- 
chemical interactions for drug development and, in total; this information can add a 
useful assessment component to a comprehensive risk assessment, for suspected EDCs 
(see Chapter 1).
Table 4.4 gives the selected chemical structures of the following classes of 
ligands, which were of particular interest:
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Table 4.4 Selected chemical structures of compounds tested in the PXR transient 
transfection assay and included in the PXR QSAR, (Chapter 5.4)
Endogenous hormones 
and experimental 
hormones
Drugs Phytochemicals POPs and additional 
phytochemicals
OH
OH
PCB118
(2,3',4,4'pentachloro
hiphenyl)
5Ppregnane3,20-dione Genistein
Positive control: 
Rifampicin
HC OH PCB153
(2,2'4,4',53'hexachloro
hiphenyl)
Cl Cl
.OH
H , C
H,C-
SR12813 HO IDaidzeinHO17a ethinyl oestradiol
OH Bacteriocide: Triclosan
.OH
CH, OH
HO'
OH
Clotrimazole OH
Progesterone Quercetin
Bile acid: 
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4.3.1 Flavonoids
Flavonoids are a diverse group of phytochemicals, sharing a common structural 
diphenylpyran skeleton, with two benzene rings linked through a heterocyclic pyran or 
pyrone ring (Hertog and Hollman, 1996). They are produced by various plants, including 
medicinal herbs, legumes, seeds and grains. They generally have high biological activity, 
and are considered to be beneficial, due to their antioxidant properties and ability to 
modulate several enzyme and receptor pathways. In some cases, however certain 
flavonoids have been shown to have mutagenic activity or interfere with essential 
biochemical pathways (as reviewed in Zhou et al., 2003), particularly if consumed in very 
large quantities. The isoflavones genistein and daizein, coumestrol are reviewed in 
chapter 1, so are not included here.
Q uercetin, is a flavonoid that is very common in onions (28.4-48.6 mg/lOOg 
fresh weight), and widely available in the diet from many other vegetables and fruits but 
to a lesser degree, e.g. apples (2.1-7.2 mg/lOOg fresh weight), red wine (0.4-1.6 mg/lOOg 
fresh weight), lettuce (0.3-3.0 mg/lOOg fresh weight) and black tea (1.7-2.5 mg/lOOg 
fresh weight), (Hertog and Hollman, 1996). Quercetin is believed to have a potent 
inhibitory effect upon estrogen sulphotransferase (EST), which determines free oestrogen 
levels in normal breast epithelial cells (Otake et al., 2000). It was found to suppress 
COX-2 promoter activity in colon cancer cells (Mutoh et al., 2000), and did not induce 
C Y PlA l in Hep G2 cells (Allen et al., 2001).
Equol, is an endogenous metabolite of daidzein, produced by around 36% of 
human subjects in a study reported by Rowlands et al., 2000 (in Pietinen et al., 2001), 
and is known to be a potent phytoestrogen activating the ER.
4.3.2. Herbs
H yperforin, the active ingredient of St Johns W ort {Hypericum perforatum), 
is one of the most commonly used self medicated herbal medicines for mild depression in 
the US and Europe (Diirr et al., 2000; Moore 2000b). However, because hyperforin is a 
potent inducer of CYP 3A4 and various other CYP enzymes, and the efflux transporter 
P-gp, there has been concern about the interactions with clinically important drugs. 
Serious and even fatal drug interactions have been reported.
Silym arin, the active ingredient of M ilk Thistle (Silybum marianum), is a 
flavonoid blend believed to have potent free radical scavenging activity, with prevention 
of glutathione oxidation and depletion, together with membrane stabilizing effects and
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inhibition of arachidonic acid (AA) metabolism (Saliou et al., 1998). The main 
constituent of silymarin, the isomer silybinin, has been reported to inhibit the formation 
of leukotrienes via the 5-lipoxygenase pathway at clinical doses and so have 
cytoprotective qualities. Leukotrienes have deleterious effects by promoting 
inflammatory reactions (Dehmlow et al., 1996). Other effects include increased protein 
synthesis by activation of mRNA polymerase and the selective inhibition of NF-kB, a 
key regulator in inflammatory and immune reactions (Saliou et al., 1998). Further, it is 
reported to be an antiproliferative agent (Scambia et al., 1996), and be a potent skin 
cancer preventive agent (Zi and Agarwal, 1999).
4.3.3. Lignans and polyphenols
The plant lignans matairesinol, secoisolariciresinol, pinoresinol and lariciresinol 
are present in foods such as rye, tea, linseed (flax), also a rich source of a-linolenic acid 
(see chapter 2, Tou and Thompson, 1999; Liggins et al., 2000; Xia et al., 2001), 
vegetables and berries. They are metabolized to enterolactone (Heinonen et al., 2001) and 
enterodiol, by intestinal bacteria, and matairesinol is the precursor to an important 
antiviral and anticancer agent, podophillotoxin (Xia et al., 2001).
Enterolactone is the colonically fermented metabolite of lignans such as 
secoisolariciresinol and maitaresinol (Adlercreutz and Mazur, 1997; Heinonen et al., 
2001; Adlercreutz, 2003) and is clinically important as high circulating serum and urinary 
enterolactone levels are associated with a significantly reduced risk of breast cancer in 
Finland (Pietinen et al. 2001) and a reduction in prostate cancer (Xia et al., 2001), 
Intestinal microflora patterns differ regionally, depending upon the dietary intake, and 
gut exposure in utero and whilst being breast fed.
Resveratrol (3,5,4’-trihydroxystilbene) is a polyphenol manufactured by 
grapevines in response to pest attack (Jeandet et al., 1995) (much the same as glyceollin 
production in stressed soya; Jacobs 1998). It is of medicinal interest particularly because 
it appears to be a major component of the ‘French Paradox’ where moderate red wine 
consumption has cardioprotective activities, and because it has chemopreventative 
potential via cell signaling (Hsieh and Wu, 1999; Nielsen et al., 2000). It is also reported 
to be a strong ER agonist in ER transfected MCF-7 cells, and a weak and partial ER 
agonist in a rat uterotrophic assay and a yeast hERa transcription assay (Ashby et al., 
1999a). It has also been reported to have ER antagonist activity in the presence of 
oestrogen in vitro, in MCF-7 cells (Damianaki et al., 2000; Basly et al., 2000), and in vivo
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(Henry and Witt, 2002), and has been observed to modulate constitutive CYP IB l in 
MCF-7 cells (Chang et al., 2000) and C Y PlA l in Hep G2 cells (Allen et al., 2001), and 
suppress COX-2 promoter activity in colon cancer cells as part of a chemopreventive 
action (Mutoh et al,, 2000). As with other flavonoids, resveratrol also modulates the AA 
metabolic cascade and is reported to affect prostaglandin synthesis (Moreno, 2003).
The active metabolite is probably a glucuronide conjugate (Kuhnle et al., 2000), and in 
further experimentation, it would be interesting and physiologically relevant to use this 
form as a test compound, as metabolites frequently behave differently to the parent 
compounds (Nolan et al., 2003).
4.3.4 Persistent Organic Pollutants (POPs)
Polychlorinated biphenyls (PCB 118 and PCB 153)
The persistent organic pollutant nature of PCBs has already been introduced in previous 
chapters. PCBs 118 (2,3’,4,4’,5-Pentachlorobiphenyl) and PCB 153 (2,2’,4,4’,5,5’- 
Hexachlorobiphenyl) were selected as test compounds, because they consistently feature 
highly in food contamination studies (see Chapter 2), whilst also being detected in human 
body compartments such as maternal serum and fetal cord blood (Covaci et al., 2002b), 
and liver and adipose tissue for example (lida, Hirakawa, Matsueda, Nagayama, and 
Nagata, 1999; Maruyama et al., 2003; Covaci, 2002) at the greatest magnitudes, 
compared to many other PCBs and PCB metabolites (Chu et al., 2003). They are both 
known to be weakly oestrogenic in hydroxylated forms, and certain hydroxylated PCBs 
have recently been shown to mimic binding in the crystal structure of human oestrogen 
sulphotransferase (hEST) (Shevtsov et al., 2003). PCB 118 is a non-ortho PCB, PCB 153 
is phénobarbital like (ten Tusscher and Koppe, 2003), and one of the ICEs 7 marker 
PCBs.
Trans nonachlor is an organo-chlorine pesticide that has been previously shown 
to induce PXR (Lehmann et al., 1998), and was therefore included in the test set for both 
structural information for the QSAR and as a QA measure, to ascertain that the data 
produced was also reproduced by another laboratory.
Triclosan ( also known under the registered trademark of Trgasan DP 300’) is an 
extensively used broad spectrum antimicrobial (Hanioka et al., 1996; Heath et al., 1999; 
Latch et al., 2003) present in cosmetics, soaps, shampoos and cleaning materials, food 
packaging materials, oral healthcare products such as toothpastes as well as shoes, carpets 
and fabrics, for example. It acts by inhibiting bacterial fatty acid synthesis (Heath et al.
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1999). Triclosan is not banned or restricted in use as with the other OCs in the test sets, as 
the traditional toxicity tests indicate a low toxic effect, with an acute oral LD50 of 
approximately 4000mg/kg in rat and mouse (Lyman and Furia, 1969; Jinno et al., 1997), 
and it is considered safe (Bhargava and Leonard, 1996; Jones et al., 2000). However, 
very little is known about enzyme and receptor induction by triclosan. In an in vivo rat 
study, triclosan has been shown to induce CYP2B1/2 together with a slight increase in 
CYP3A, suggesting that triclosan is a Phenobarbital-type inducer. Whilst its chemical 
structure closely resembles known non-steroidal oestrogens (e.g. DES, bisphenol A) and 
anti-oestrogens (e.g. TCDD), an in vivo fish study has suggested that triclosan is 
potentially weakly androgenic (Foran et al., 2000).
Triclosan is being increasingly viewed as an environmental pollutant. It is frequently 
detected as a contaminant of rivers and lakes, and appears to be responsible for 
producing a dioxin compound (2,8-dichlorodibenzo-p-dioxin) by an intramolecular 
photochemical substitution reaction (Latch et al., 2003), and a methylated form 
(Lindstrom et al., 2002; Erikson, 2002).
4.3.5. Essential Nutrients: Vitamins
Vitamins that are hormonal in structure are known to be SHR ligands, for 
instance vitamin E is weakly oestrogenic, and has been reported to be a PXR ligand 
(Landes et al., 2003), Retinioids, such as Vitamin A, are the natural ligands for RAR and 
RXR and Vitamin D 3 , particularly the hydroxylated form, is the endogenous ligand for 
the closely related VDR. l a ,  25-dihydroxy vitamin D 3  (OH Vit D3 ) is the hydroxylated 
form that Vitamin D3 is metabolized to in vivo. OH Vit D3 has been shown to induce 
CYP3A4 in human intestinal Caco-2 cells, but not via PXR, as Caco-2 cells reportedly 
do not express PXR (Thummel et al., 2001). OH Vit D3 has also been reported to induce 
P-gP and NADPH cytochrome P450 reductase (Schmiedlin-Ren et al., 1997), and to have 
antiproliferative activity in the same cell line (Scaglione-Sewell et al., 2000). Taken 
together, it is suggested by Thummel et al (2001) that OH Vit D3 and VDR induce 
intestinal CYP3A expression by binding of the activated VDR-RXR heterodimer to the 
CYP3A PXR response element and promoting gene transcription. This hypothetical 
model may not be appropriate for liver CYP3A induction and PXR expression, as 
investigated by the hPXR transient transfection assay in HuH7 and CV-1 cells.
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4.4. Results
Data for a diverse set of over 33 compounds and metabolites, many selected on 
the basis of likely dietary exposure, together with compounds of pharmacological 
interest, to ensure a broad spectrum of activity, were derived experimentally. Raw data 
are shown in Appendix 2, the selected structures of the test compounds are shown in table
4.4.
Many of the compounds were first tested in CV-1 cells, both for training 
purposes and for comparison with HuH-7 cells. On the whole, both HuH7 and CV-1 cells 
showed similar results with the known inducers, however HuH7 cells were ultimately the 
cell line of choice, and only the data generated by using HuH7 cells were used for QSAR 
purposes, for two reasons. First, the HuH7 cells are human (while the CV-1 cell line 
originates from a monkey kidney cell line), they contained the full length PXR and may 
contain endogenous human transporters (i.e. P-gp), so are more biologically relevant to 
humans than CV-1 cells. Second, a substantial amount of in-house data on % max 
induction for hPXR was available for the HuH7 cells, but this was not the case for CV- 
I ’s. These data bases were useful both for comparative purposes and for expanding the 
model, testing it for predictive qualities.
Inducers were considered in three potency groups, low (<30%), medium (30- 
70%) and high (>70%), see table 4.1. A good distribution of induction data was necessary 
for building an adaptive, robust model of PXR induction (Chapter 5). When testing a 
compound, only the induction of CYP3A via PXR is reported from this assay. Further 
induction studies would be required to eliminate other pathways such as CAR inducing 
CYP2B, AhR inducing CYPIA, cross-talk with these receptors and others such as HNF- 
4, COUP-TF, GR, LXR, and FXR, for example.
4.4.1. The test compounds
The test compounds included drugs with potent activity such as rifampicin, the 
positive control, (figure 4.9), experimental antioestrogens such as ICI 182780 and SR 
12813, (figure 4.10), and phytochemicals with high activity such as hyperforin, (figure 
4.11).
Phytochemicals with low activity (trans resveratrol, quercetin and silybin) are 
shown in figures 4.12, 4.13, 4.14, plant lignans (secoisolariciresinol), and mammalian 
lignan metabolites (enterolactone>equol) with low to medium activity are shown in 
figure 4.15. Phytoestrogens compared with the endogenous oestrogen, 17(3 oestradiol.
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with low to medium activity (coumestrol>daidzein>genistein) are shown in figure 4.16. 
Organochlorine contaminants including a pesticide, a pollutant and a bacteriocide, (trans 
nonachlor<PCB118< triclosan), were low to medium activators at lOuM top dose, as 
indicated in figure 4.17. Unlike the other compounds tested at greater concentrations, 
triclosan demonstrated an incremental increase from 10 to 20uM, in both CV-1 cells and 
HuH7 cells, from medium to high to very high, as indicated in figure 4.5. Differences 
were observed between hydroxylated compounds and the parent compounds where 
tested, and two different examples are shown in figure 4.18; the E R a positive breast 
cancer drug, tamoxifen and hydroxylated tamoxifen, (both ER a antagonists), and also 
vitamin D 3  and hydroxy vitamin D 3 , a potent ligand for the vitamin D receptor (VDR) 
and the glucocorticoid receptor (GR). Other compounds tested included a bile acid 
(lithocholic acid), hormones (progesterone), SR analogues, and various drugs as shown in 
the data table provided in Appendix 3, Table ii.
The degree of PXR activation ranged from 1.3 % (lOuM trans resveratrol) to 152 
% (lOuM ICI 182780) and 184% (GSK SR analogue) when compared to lOuM 
rifampicin (examples of typical experiments are shown in figures 4.9 to 4,18) in the 
HuH7 cell line. Some of the compounds tested were the same as those used in house as 
validation sets and those already published (Lehmann et al., 2000; Moore et al., 2000a; 
2000b). There was therefore a lot of comparative data for PCN, dexamethasone, 17(3 
oestradiol, pregnanes, lovastatin, clotrimazole, rifampicin, which was in accord with the 
data derived and presented here, all falling within the expected range reported in-house 
and in the literature (Lehmann et al., 1998; Moore et al., 2000a; 2000b). Where few 
experiments were run, only data that were supported by that of other operators are 
presented here. Initially, a number of in-house SR analogues and experimental GW 
compounds were run in the CV-1 cells, the resultant data originally to be utilized for 
QSAR purposes. However, due to confidentiality issues and ongoing in-house testing by 
GW/GSK operators, this route of investigation was altered to facilitate later peer 
presentation of the experimental work presented here. These data was collected for the 
construction of the PXR QSAR described in Chapter 5.
Figures 4.9 to 4.18 show representative % max induction plots for individual 
compounds tested. Data points represent the mean of representative assays performed in 
triplicate. Curves shown are representative of three or more experiments that met the 
acceptance criteria, unless otherwise stated. % max figures are indicated in red. Raw data 
for both cell lines are available in Appendix 2, Table i.
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Figure 4.9 shows standard curves for the positive control rifampicin in both a ) CV-1 and b) 
HuH7 cell lines
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Figure 4.10 shows representative curves for potent experimental antioestrogens tested at a 
top concentration of lOuM
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Figure 4.11 shows representative curves for hyperforin at top concentrations of
a) luM, b) 3uM and c) 5uM in CV-1 cells. Hyperforin is cytotoxic at lOuM concentrations
(NB. As the top dose here is not lOuM, the x axis giving the concentration [Ml is incorrect and 
should instead be interpreted as the respective serial dilutions of the top dose as given in the 
respective titles.)
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Figure 4.12 shows representative curves for trans resveratrol at top concentrations of 
a)10uM, b) 20uM in CV-1 cells
(NB. As for fig 4,11, the top dose here is not lOuM, the x axis giving the concentration [M] is 
incorrect and should instead be interpreted as the respective serial dilutions of the top dose given 
in the title).
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Figure 4.13 shows representative curves for the phytochemical silybin at a top concentration 
of lOuiVI, in a) CV-1 and b) HuH7 cells
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Figure 4.14 shows representative curves for phytochemicals and metabolites at top 
concentrations of lOuM
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The plant lignans (secoisolariciresinol), and mammalian lignan metabolites 
(enterolactone>equol) with medium to low activity.
Figure 4.15 shows representative curves for the phytoestrogens tested, compared to the 
endogenous oestrogen 1?P oestradiol all tested at top concentrations of lOuM
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Figure 4.16 shows representative curves for the organochlorines PCB 118, trans nonachlor 
and triclosan at top concentrations of lOuM, in HuH7 cells
Medium to low activators at lOuM top dose (trans nonachlor<PCBl 18< triclosan).
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Figure 4.17 shows representative incremental increases in the curves for triclosan at top 
concentrations of a) 10 and b) 20uM, in HuH7 cells and c) 30uM in CV-1 cells
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(NB. As for fig 4.11 and 4.12, where the top dose is not lOuM, the x axis giving the 
concentration [M] is incorrect and should instead be interpreted as the respective serial dilutions 
of the top dose.)
Figure 4.18 shows representative curves for hydroxylated compounds compared to their 
unhydroxylated parent compounds
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4 .5 . Discussion
Several points of interest arose from these studies, as follows;
4.5.1 Lignan potency
Lignans present in the human diets can be metabolised to weak-moderate affinity 
ligands for PXR as seen with the secoisolariciresinol metabolite enterolactone, as shown 
in figure 4,14. Common food sources such as rye, whole grains, flaxseed (Tou and 
Thompson, 1999) and berries provide the parent lignans from which enterolactone is 
fermented by colonic bacteria. Populations who consume large amounts of rye, such as 
Scandinavian and Eastern Europeans, may be stimulating moderate induction of PXR, in 
addition to the chemoprotective effects documented in the literature (Tou and 
Thompson, 1999; Pool-Zobel et al., 2000).
4.5.2 Potency of OH compounds: tamoxifen, vitamin D
Hydroxylated Vitamin D3 was significantly more potent than non-hydroxylated 
vitamin D 3 . (Figure 4.18).
This has not been observed for PXR activation in the human colon adenocarcinoma cell 
line (CaCo-2) (Schmiedlin-Ren et al., 2001), but has been observed in other human cell 
lines, and as suggested by the results of the AhR QSAR in chapter 5, CaCo-2 cells may 
not be as appropriate models for ligand activation or ligand binding studies as Human 
liver cell lines such as HuH7 and Hep G2.
A trend was also observed for the hydroxylated versus non hydroxylated tamoxifen. (See 
Figure 4.18). The fact that hydroxylated compounds tested were more potent than the non 
hydroxylated parent compounds implies that this is likely for other hydroxylated 
compounds, and this is explored further in chapter 5.
The implications that hydroxylated forms are more potent than the parent compounds 
could be significant when considering synthetic endocrine disrupting chemicals in food. 
For instance, the PCBs delivered in the diet are metabolized to hydroxy forms which are 
also known to be more potent in ER screening assays than parent PCBs.
4.5.3. Persistent organic pollutants
Polychlorinated biphenyls 118 and 153 are weak ligands, (Figure 4.12). However when 
metabolized into the hydroxylated forms, they are likely to have greater affinity.
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The pesticide trans-nonachlor is a medium affinity ligand, (Figure 4.16), as is triclosan, 
(Figure 4.17), a commonly used bactericide.
4.5.4. Differential effects of increasing dosage between compounds
The following compounds were tested above the lOuM top dose, and showed a 
subsequent increase in % max induction: triclosan (figure 4.17, top dose range 10-30uM), 
trans-resveratrol (Fig. 4.12, top dose range 10-20uM), trans nonachlor (figure 4.16, top 
dose range 10-20uM). This was not the case with other compounds, such as hyperforin 
which was tested at different ranges before reaching cytotoxicity (figure 4.11), and 
similar induction profiles were observed, not incremental increases.
The effect of the host cell is the variability in this assay, and this may help 
explain why, for many compounds, increasing the dosage did not affect the % max 
induction. Taking hyperforin as an example, the % max induction remained similar at 
luM, 3uM and 5uM concentrations and there does not appear to be an increase in 
potency with increase in dosage below that which is cytotoxic (lOuM), (figure 4.11). 
This is a pattern that was seen with other phytochemicals and drugs, both in this study 
and other GSK studies, both at RTP and Ware (unpublished data, Gail Nolan, Linda 
Moore). The explanation for this effect is not known, but similar effects have been 
observed in other receptor assays. In one report using the Yeast Oestrogen Screen (YES), 
a yeast reporter gene assay which assesses oestrogenic activity via the human E R a 
(Andersen et al., 1999; Miller et al., 2001), the reduced aqueous solubility of certain 
compounds (in this instance o,p’-DDT) was found to be a limiting factor for the 
compound to get into the cell from the plate (Rajapakse et al., 2001), which when not 
controlled for, may give misleading results. Using DMSO to dissolve the compound, as 
for the studies presented here, overcame this effect. It is unlikely that lack of dissolution 
of the test compounds in the vehicle (DMSO) is responsible for the effects seen with 
varied doses of hyperforin. It is more likely that that the involvement of relevant 
transporters and cofactors (such as other key transporters) play a role, so the transporters 
for specific compounds may become saturated, preventing further PXR activation, as the 
compounds can no longer reach the receptor. One could speculate that this is the case for 
the test compounds hyperforin, trans resveratrol, trans nonachlor, but not for triclosan, 
where PXR activation was observed in a concentration-dependent manner. That 
transporter proteins, such as P-gp, MDR, OATP play significant roles in PXR activation 
is well documented in the literature and briefly reviewed below.
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4.5.5. The role of transporters and other cofactors
There are many types of cofactors that have a role to play in removing 
xenobiotics from cells. These are cell surface transporters, transcriptions factors and other 
ancilliary proteins. The following examples of transporters are of therapeutic and 
metabolic interest, with significant and variable effects upon xenobiotic and drug 
metabolism.
4.5.5.I. Transporters: P-Glycoprotein (P-gp)
Discovered over twenty five years ago, P-gp is a surface phosphoglycoprotein 
encoded by the human multi-drug resistant genes (MDRl and MDR3). Regulated with 
CYP3A4, by PXR, it is an ATP-binding cassette (ABC) energy dependent membrane 
bound transporter involved in the extracellular efflux of many endogenous and xenobiotic 
compounds (and phospholipids), so functioning as a biological barrier (Kim, 2002; Lin 
and Yamazaki, 2003). It is found on the luminal membrane of the small intestine and 
blood brain barrier, in the apical membranes of excretory organs such as liver and kidney 
and in the brush border membrane of placental trophoblasts that form the matemo-foetal 
barrier. As a consequence of this expression pattern, P-gp plays a key role in both 
limiting intestinal absorption and CNS penetration, during initial digestive exposure to 
xenobiotics and excreting drugs and other xenobiotics for elimination, as well as 
preventing them from being reabsorbed from the intestine following bile secretion into 
the intestine for excretion.
P-gp can be modulated by genetic polymorphism (Xie et al., 2001; Fischer, 2002; Lin and 
Yamazaki, 2003), gene induction, or drug-drug interactions, with consequent effects upon 
the pharmacokinetics and target organ specificity of P-gp substrates. P-gp is also 
associated with the development of inflammatory bowel disease (Fischer, 2002).
The sister of P-gp (SP-gp) is the major hepatic bile salt export pump (BSEP), and bile 
acid ligands have been shown to induce BSEP in human hepatocyte cultures, in parallel 
with the bile acid /famysyl receptor FXR (Schuetz et al., 2001), and MRP2 is similarly up 
regulated by FXR and PXR (Takikawa, 2002).
As many drug interactions involve CYP3A4 and P-gp, the relative contribution of P-gp 
and CYP3A4 to overall drug interactions needs to be quantitatively estimated, to 
understand the underlying mechanism of drug interactions, or when using in vitro 
PXR/CYP3A4 screening assays. It is not as yet possible to do this with current PXR
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transient transfection assays, and consequently this is an ongoing area of pharmaceutical 
research. P-gp may therefore be a confounder of the PXR transient transfection assay 
assessment/screening procedure for many compounds.
M ulti-drug resistance associated protein (M R Pl and  M RP2) are also excretory 
proteins. Like P-gp, they are members of the ATP transporter superfamily. M RPl is a 
transporter of organic anions in normal cells, and confers resistance to anti cancer agents 
in tumor cells (Leslie et al., 2003). It is upregulated by a PXR ligand, dexamethasone, in 
rat hepatocytes (Courtois et al., 1999). MRP2 is a drug efflux pump that mediates the 
transport of several conjugated compounds across the apical membrane of the hepatocyte 
into the bile caniculi (Takikawa, 2002), and is governed by three receptors: PXR, CAR 
and FXR, as part of its multivariate signaling pathway (Takikawa, 2002). All three 
receptors converge upon a common response element in the 5’-flanking region of this 
gene (Kast et al., 2002). Many flavonoids induce M RPl (Leslie et al., 2003), and it is 
thus possible that this transporter may have been induced by the selected flavonoids run 
in the PXR HuH7 host transient transfection assay.
O rganic anion transporting protein (C A T?) belong to another large family of
transport proteins. They are principally involved in the hepatocellular uptake of
endogenous compounds as well as a variety of structurally divergent drugs (Kim, 2002), 
but can be found in brain (OATP-A, OATP-1,2), liver (OATP-B. OATP-C, OATP-8, 
OATP-1,2,3,4), kidney (OATP-B, OATP-1), small intestine (OATP-3), lung (OATP-B). 
They are capable of mediating rifampicin transport into the hepatocyte, and may 
modulate PXR function (Tirona et al., 2003), indeed they have many substrates in
common with PXR ligands, and other NRs such as bile acids, thyroid hormones,
ostradiol, eicosanoids and estrone-3-sulphate (Kim, 2002).
4.S.5.2. Receptor complements in cell lines
TaqMan® studies conducted at GSK by K Swales for HepG2 cells (Swales, 2002) 
and C Ashby for CV-1 cells (Ashby, 2002) have characterized major receptors involved 
in induction for both cell lines, identifying the relative receptor abundance in cells, 
differences between the cell lines, as well as the potential cross talk facilitation and 
modulation. For the human liver derived cell line, HepG2, characterization of the 
receptor compliment has been identified by measuring mRNA levels using human 
probes and primers in TaqMan® analysis. Swales reports that TaqMan® data suggest that 
in human GYP 3A regulation, the relative abundance of PXR heterodimerization partners
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were more important than the absolute level of PXR. In terms of absolute mRNA 
changes, the ratios of RXRa, RXRp and COUP-TF were the major factors influencing 
variability in response to xenobiotics. For the primate CV-1 cell line, the receptors 
shown to increase after transfection were; hPXR, CAR, GR, RXRa, RXRp, COUP-TF 
and P-Actin, and to decrease after transfection were; RXRy, HNF-4, and the 
housekeeping gene GADPH (involved in glycolysis, suggesting the cells were down 
regulating the glycolysis cycle). In the presence of test compounds, the receptor 
compliments altered in different ways in the transfected cells. Dexamethasone treatment 
stimulates some co-regulation between CAR and RX Ra and RXRp, with PCN 
coordinated regulation was seen for CAR and hPXR, and PB induced COUP-TF. Ashby 
also reports a competition effect between COUP-TF and hPXR with rifampicin treatment 
(the positive control). The CYP3A and associated proteins phenotype of HuH7 cells, in 
comparison with human adult and fetal livers, has been reported recently (Phillips et al., 
2003). The key receptor variables with respect to regulatory pathways were the ratios of 
COUP-TFl and RX Ra to PXR. As with the other cell lines discussed above, CAR is 
probably also key in the receptor cross talk in response to xenobiotics for this cell line 
also, a strong correlation between CAR and PXR (and CYP2B6) expression has been 
reported for human liver (Chang et al., 2003).
Transiently transfected HepG2 cells have been compared with human 
hepatocytes, with similar inductive properties of CYP3A4 mRNA observed for 
prototypical drug inducers, lOuM rifampicin (699±307% of control levels), lOOuM 
phenytoin (707 ±188% of control levels), ImM PB (536±207 % of control levels) and 
lOOuM omeprazole ( 404±8% of control levels), and the phytochemical kava kava 
(386±185 % of control levels) but not flavonoids sueh as quercetin, resveratrol and 
curcumin, or phytochemieals such as grapeseed extract, ginseng and silymarin. Quercetin 
was observed to produce some CYP3A4 mRNA accumulation, but in the HepG2 
reporter gene assay, this flavonoid produced neglible to low CYP3A4, here suggesting 
that CYP3A4 is induced by mechanisms that may not involve PXR (Raucy, 2003), unlike 
the prototypical inducers and kava kava.. The low degree of activation reported by 
Raucy, 2003 supports the low activation of PXR data by lOuM quercetin reported here, 
fig. 4.10, although it is reasonable that many phytochemieals will induce PXR, 
considering the evolutionary long term exposure of the intestine and liver to 
phytochemieals via the diet.
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Another important consideration to consider physiologically is the cyclical variability of 
CYP3A4 and CYP3A7 in women, probably reflecting the physiological requirement to 
eliminate the localized increased endogenous steroid exposure (Sarkar et al., 2003), 
activating NRs such as PXR to induce CYP3A, as well as the ERs and PR, as part of the 
menstrual cycle.
4.5.S.3. Example of other factors, Albumin
The main serum protein, albumin, binds a wide variety of lipophilic chemicals, 
but with low affinity. In a high capacity but low affinity binding capacity, it maintains 
osmotic homeostasis. Ligands include steroids, phytochemieals and xenobiotics that bind 
to the NRs. As a major carrier, albumin is a regulator of the access of these compounds to 
receptors. Albumin also functions as a sink for xenobiotics by reducing the binding of 
xenobiotics to NRs and other proteins (Baker, 2002).
4.6. Conclusions
The data presented here extend the range of published PXR ligands to include 
phytochemieals and phytochemical metabolites such as lignans, PCBs, and the common 
bactericide triclosan.
With respect to drug metabolism and pharmacological implications for drug-drug 
interactions, in addition to the interactions already reported to be of concern as, for 
example, seen with hyperforin, the contraceptive pill, idinavir and cylosporin (Moore et 
al., 2000a), for the first time to my knowledge, triclosan is also of similar concern. 
Particularly as it is used so widely with a high likelihood of oral ingestion from food 
contact materials and toothpaste directly and cleaning materials indirectly.
It has been reported recently that Vitamin E activates gene expression via PXR at 
the same concentrations as rifampicin, and the authors suggest clinical trials are needed 
to identify the dosages necessary for analogous effects to hyperforin to be observed 
(Landes et al., 2003). A further consideration, the hydroxylated forms of vitamins and 
drugs are likely to be more potent than the parent compound, and so these should be 
assessed in future PXR screening, in addition to the parent compounds. This also applies 
to PCBs, the hydroxylated forms of which are known to be more potent ER ligands (for 
the oestrogenic PCBs).
Finally it must also be remembered that using a single receptor test in vitro 
system does not necessarily reflect the in vivo situation, and should not be taken as such.
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Large discrepancies noted for oestrogenicity in ER assays have been discussed in the 
literature (Ashby, 1999a; Miller et al., 2001). However, this does not appear to be the 
case for the PXR transient transfection assay, which has been found to correlate well 
with CYP3A4 expression in human hepatocytes (Luo et al., 2002). Cell lines for assays 
need to be closely evaluated with each other, to obtain the cell line that and assay that is 
the closest approximation to the human in vivo state. Multivariate tools can be used to 
discriminate between the cell lines and systems, for ascertaining the most reliable and 
complementary method to assess the PXR induction potential of drugs and other 
xenobiotics, for example the QSAR presented in chapter 5.4.
From a clinical perspective, the data also illustrate the value of testing plant 
chemicals present in the diets of different populations, as diets rich in lignans, as with 
Scandinavian diets, or diets rich in phytoestrogens, as with Asian diets, may induce 
greater intestinal levels of PXR compared with UK diets. This also applies to 
contaminants, high consumers of Baltic herring, for example with have concomitantly 
higher levels of PCBs which as well as a broad range of health implications, may also 
increase PXR levels and CYP3A4 induetion to promote xenobiotic metabolism. This is 
likely therefore for other dietary contaminants such as organochlorine pesticides (and 
PCBs), as well as contact contaminants such as the widely used bacteriocide triclosan.
With the latter in mind, these results suggest it may be possible to identify and 
develop safer analogues that retain bacteriocide activity, but that do not activate PXR and 
induce CYP3A4, or have other undesirable qualities such as environmental persistence 
and pollution.
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Quantitative Structure Activity Relationships (QSARs) of Nuclear
Receptors
5. Abstract
A variety of quantitative structural activity relationships (QSARs) for the 
xenobiotic and steroid hormone receptors human PXR, AhR and ER a using multivariate 
techniques, specific descriptors, and biological data sets are generated and compared. 
These QSARs have utilized in-house and experimentally generated data sets, 
collaborative (unpublished) and literature sourced data sets in a variety of ways, ranging 
from both chemical class specific and broad data sets (drugs, pollutants, phytochemieals, 
hormones) in hPXR and hER a to the flame retardant polybrominated diphenyl ethers 
(PBDEs) biological data derived from a range of different species specific cell lines in 
the AhR. VolSurf descriptors were generated for each of the compound structures for 
which biological data were available and subsequently used to develop PLS regression 
based models;
With the ER a model: (n=30), the Root Mean Sqaure Error of Estimation 
(RMSEE) =1.3 for Log relative binding affinity (RBA), and R" = 0.62. Two subsequent 
validation sets with a similar range of compounds demonstrated the applicability of the 
model (n=30, n=60. Root mean Sqaure Error of Prediction, RMSEP = 1.6).
With the hPXR model: (n=33, RMSEE = 22.37, R^ = 0.83) for % maximum 
induction relative to rifampicin. This model was successfully internally validated using 
the randomization test
With the AhR model: (n=12, RMSEE = 15.71), 2,3,7,8 TCDD was an outlier 
compared to the PBDEs, and major differences were apparent between the different cell 
line EC50s (n=7) reflecting PBDE ligand potencies and cell line EROD values (n=7) 
reflecting P450 induction.
These QSARs are supported by utilizing the crystal structures of hERa, hPXR 
and a homology model of AhR (based on the E R a crystal structure), to examine the 
mode of binding of representative compounds in the ligand binding domain (LBD) of
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the receptor crystal structures and model. Key commonalities and differences between 
the receptors LBDs and between the ligands have been observed. Analyses of the 
Volsurf variable contributions together with observed in silico modes of ligand binding in 
the respective receptors allow additional insights into receptor activation on a compound 
specific basis as well as ligand promiscuity and ligand-receptor crosstalk. This is of 
relevance to drug design in, for example, the treatment of E R a breast cancers, 
consideration of drug-xenobiotic interactions, and for a better understanding of the 
mechanisms of pollutant toxicity and endocrine disruption.
5.1. Introduction
This chapter reports the QSARs for three NRs, the ERa, PXR and AhR and 
shows how a particular type of multivariate analysis, namely principal component 
analysis (PCA), and partial least squares regression (PLS), were used to model the data 
sets, and how these methods can be adapted to suit the available data and could be used 
for conducting comparative work with more NRs, to uncover the crosstalk signaling 
pathways between NRs and SHRs.
For this chapter, it was originally intended to utilize the NR models and crystal 
structures, as described in chapter 4, for interactive docking studies with selected ligands, 
and to then use the measurements taken of the ligand specific distances for binding to 
occur in the LBD, as part of the descriptor data. It was intended to be used with the 
biological data generated in chapter 3 for the three-dimensional (3-D) Quantitative 
Structure Activity Relationships (QSARs) receptor studies part of this project. However, 
I did not have access to the work station to conduct this work, for a prolonged period of 
time, due to both hardware and software problems. This gave insufficient time to dock all 
the compounds of interest in the NR data sets, but a reasonable spread of activity data 
was available from the studies conducted in Chapter 4 to establish relationships between 
the biological data (x’s) and the chemical descriptors (y’s), in a PXR QSAR model, that 
could be tested further for predictive purposes. Many other forms of computational 
descriptors were available in-house at GSK, so these were generated from the chemical 
structures. Two additional QSARs were also generated, one concerned with E R a ligand 
binding, and thus oestrogenicity, and the other with brominated flame retardant 
aetivation of the AhR and P450 induction. The in silico models and crystal structures 
were again utilised to examine selected ligands of interest in the LBDs of the NRs, when 
the work station later became available for use.
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The methodology for the QSAR for PXR ligands was originally intended to be 
the classical regression technique, multiple linear regression (MLR) (Jacobs, 1998). 
However this was subsequently changed to take advantage of the latest chemometric 
resources available within the GSK Biomet department. Multivariate statistical 
computational approaches, including the chemical structure descriptors, have been 
developed recently to deal with scientific and technological data sets. Whilst PLS was 
originally developed as part of chemometric toolsets in chemistry and engineering, it is 
now increasingly applied in the field of drug discovery for an early optimization of 
ADME (absorption, distribution, metabolism and excretion) properties. PLS regression 
utilizes the two block predictive model to model the structural relationship between two 
matrices, X and Y, and so provides further information than that of traditional regression 
techniques. In situations where the X-matrix contains less objects than variables, MLR is 
not appropriate, as it is designed to deal with situations in which the number of objects 
(N) is at least three times larger than the number of variables (K). Whilst this can be 
overcome by using stepwise MLR (Jacobs, 1998; Lewis and Jacobs, 1999), there is still a 
high probability to obtain relationships just by chance (Eriksson et al., 1995; Eriksson et 
al., 1997). Further, MLR assumes that the X-variables are "independent" and not 
correlated, but even at the outset, relationships between the variables for all the studies in 
this chapter are known, as for example with structural classes between flavonoids, PCBs, 
PBDEs, PB-like compounds and so on.
PLS models the structure of X and Y, giving richer results than the traditional 
MLR. PLS can examine strongly correlated data, many X variables and model several 
response variables simultaneously (Wold et al., 2001). These approaches are just as 
useful for examining compounds in other contexts, such as environmental pollutants and 
dietary composition, and are useful for elucidating descriptor-based relationships of 
ligands and receptors.
Chapter 2 used PCA techniques to compare data sets, in this chapter PCA and 
PLS are utilised to interpret and model NR and SHR activation. These receptor models 
can help understand the molecular mechanisms of ligand binding activation, and in doing 
so, improve prediction and identification of potential ligands. For these studies, the 
biological data was correlated to the 3-D molecular interaction fields of the molecular 
structures of the compounds and transformed into descriptors using Volsurf and 
theoretical physicochemical packages. Molecular descriptors were correlated to the 
biological data by a discriminant and PLS procedure. The NR activation QSAR models
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produced can be used for exploring molecular receptor-mediated signaling pathways, for 
improved understanding and prediction purposes, for example in the design of lead 
optimization libraries, in examining xenobiotic and drug metabolism, and examining drug 
interactions and efflux substrates (e.g, with CYP3A4 or P-gp, see chapter 4). These 
models can aid both the prioritization of metabolically stable compounds in medicinal 
chemistry and drug development, and be used in public health risk assessment for 
predicting whether the compounds are likely to be endocrine disrupters.
Several receptor QSARs were run in a variety of ways governed by the shape the 
data took. As a first step, a literature based QSAR study of utilizing in vitro ER alpha 
ligand binding data provided a training ground for using multivariate tools and a variety 
of different descriptors including Volsurf descriptors. Volsurf descriptors were used for 
the next QSAR study of hPXR, and then for a study of a suspected environmental 
pollutant class of AhR ligands, the brominated flame retardants (PBDEs), tested in a 
variety of different cell lines.
By using the same computational descriptors for each QSAR process, the 
differences and similarities between specific descriptors significant to each QSAR model 
could be identified. Collectively, this information gives an added dimension to the 
understanding of NR mechanisms of ligand binding.
5.2. Methods
5.2.1. Collection of data for QSAR analyses
Apart from the QSAR for PXR ligands, using experimental data generated 
myself, the other QSAR studies presented here were essentially QSARs of ‘opportunity’, 
in that the biological data sets utilised were governed by availability in the literature, 
GSK in-house data sets and from collaboration with another researcher. Biological data 
for a large and diverse set of oestrogenic compounds were obtained from the literature 
for a E R a QSAR (section 5.3), from the literature and from Dr Guosheng Chen 
(University of Guelph, Canada) for the AhR PBDE QSAR (section 5.5).
5.2.2. Generation of Smiles
As the descriptor programmes were written to read molecular structures as 
SMILES strings, all the chemical structures of the compounds used to build the models 
were first transformed into SMILES line notation code, in-house at GSK, using the 
Daylight toolkit. This was done in ISIS, by utilising Iris, accessed through the Mantis
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GSK intranet site, and sending the structure to ISIS as a sketch file. Using a GSK 
networked personal Pentium computer, the structures were built individually, then 
transferred, and the SMILES notation strings were retrieved and cut and pasted into the 
raw datasets built for PLS analyses.
5.2.3 Descriptors
Descriptors for QSARs vary according to the model being produced, and the 
purposes for which it has been designed. Historically, basic physico-chemical descriptors 
were first developed, and are still utilised, both in chemometrics (Olsson and Oprea, 
2001), environmental modelling (Calmari, 2002), and computational biology or 
bioinformatics (Fielden et al., 2002). A classie example is the octanol-air/water 
coefficient utilised extensively in environmental toxicology, such as surface/air 
partitioning and marine food web modelling for example (Escher and Hermens, 2002; 
Chen et al., 2002). This first approach and other similar parameters have been applied as 
empirical correlations between bioconcentration or solubility factors such as log Kow, in 
environmental QSARs, or lipophilicity, such as Log P, in pharmacokinetic QSARs (Van 
de Waterbeemd et al., 2001), or other properties or descriptors, particularly hydrogen 
bonding (Raevsky et al., 2002) for protein-ligand interactions (Eldridge et al., 1997).
Theoretical descriptors range from simple atom counts and geometric atom pair 
descriptors (Sheridan et al., 1996) to complex quantum mechanical calculations (Olsson 
and Oprea, 2001; Soffer et al., 2001). In drug discovery and development, several models 
based on different physicochemical descriptors have been proposed for building 
predictive pharmacokinetic models. These are generally based around molecular weight 
(MW), lipophilicity, the number of hydrogen bond donor/acceptors and groups of 
compounds (Lipinski et al., 1997; Raevsky et al., 2002; Lewis and Dickins, 2003). 
Lipinski’s ‘rule of 5’ method (Lipinski et al., 1997) is commonly used for screening 
drugs and NCEs for solubility and permeability. The rule states that if a compound 
satisfies any two of the following rules, it will probably be poorly absorbed in the gastro­
intestinal tract (GIT), the exception being if it is also a substrate for biological 
transporters: 1. MW is greater than 500, 2. Number of hydrogen bond donors is greater 
than 5 (expressed as the sum of OHs and NHs), 3. Number of hydrogen acceptors are 
more than 10 (expressed as the sum of Os and Ns), and 4. Clog P is over 5.0 (or Mlog P 
>4.15) (Lipinski et al., 1997). While a compound needs to be absorbed to activate the 
NRs studied here; it is the activation of the receptors that is the parameter of interest here.
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Lipinski’s ‘rule of 5’ does not apply to several compound classes, ineluding some 
antibiotics, vitamins, antiseptics/fungals, (and cardiac glycosides). As many of the 
compounds in the data sets used for the QSARS in this chapter include antibiotics, 
vitamins and an antifungal, and a better estimate of H-bond strength is required for 
quantitative predictions, a more appropriate choice and range of descriptors were used.
The descriptors selected here included the basic physicochemical descriptors, 
Abraham descriptors, GSK in-house descriptors produced from GSK in-house models 
(Modi, S, unpublished models and descriptors) and VolSurf descriptors. Selected 
examples of the calculated descriptor data sets are given in Appendix 3.
The logarithm of the octanol-water partition coefficient (ClogP) was calculated 
with the use of ClogP for Windows software (Biobyte version 4.7.1. Claremont, CA, 
USA). The experimental octanol-water coefficient was also obtained from the Biobyte 
program data base.
5.2.3.1 Abraham descriptors
The ‘chemically intuitive’ Abraham descriptors are designed to correlate solute 
properties such as solubility, partitioning, blood-brain distribution, cell permeability and 
intestinal absorption with a set of five molecular descriptors, based on a solvation 
equation that correlates these properties. These parameters can also be useful for 
examining ligand-receptor H bonding interactions. Based on a theoretical cavity model of 
solute-solvent interactions, the descriptors are:
A- solute H bond aeidity, B- solute H bond basicity, E- excess molar refraction 
(this models dispersion force interactions arising from the increased polarisability of 7C- 
and n- electrons, S- solute polarity/polarisability, V- McGowan characteristic molar 
volume (Abraham et al., 1994; Abraham et al., 2002).
5.2.3.2 GSK in-house descriptors
A number of useful descriptors have been produced within GSK by Sandeep 
Modi, such as structural alerts that signal likelihood to be metabolized by transporters, 
such as Pgp. As these descriptors are proprietary, further specific information cannot be 
given in this thesis, only the general findings.
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S.2.3.3 Volsurf descriptors
VolSurf is a computational procedure to produce and explore the 
physicochemical property space of a molecule starting from 3-dimensional (3-D) 
interaction energy grid maps. The information present in 3-D grid maps is compressed 
into a few quantitative 2-D numerical descriptors using image analysis software. Each 3- 
D map is considered as 3-D image, but the image compression process is made by adding 
chemical knowledge.
The pharmacokinetic properties of a compound depend on a variety of 3-D 
physicochemical parameters, mediated by surface properties such as shape, van der 
Waals forces, electrostatics, hydrogen bonding and hydrophobicity. They therefore 
require a multivariate description. VolSurf descriptors quantitatively charaeterize size, 
shape, polarity, hydrophobicity and the balance between them. VolSurf descriptors are 
both fast to calculate and are independent of alignment of molecules (Cruciani et al., 
2000a; 2000b). Volsurf was developed for structure-property relationships, but is also 
useful for structure-activity relationships and molecular diversity based on surface 
properties. VolSurf builds on the descriptors that are routinely used in medicinal 
chemistry (MW, number of hydrogen bond donors/acceptors and lipophilicity), by using 
the GRID forcefield (Goodford, 1985; Bobbyer et al., 1989; Kastenholz et al., 2000; 
Molecular Discovery Ltd), which is able to calculate energetically favourable interaction 
sites around a molecule to produce 3-D molecular interaction fields (MIF) onto a 3-D 
grid. It uses a potential based on the total energy of interaction including dispersion 
forces (the sum of Lennard-Jones, H bonding and electrostatic terms) between a target 
molecule and a probe which can be either an atom or a group. By moving probes (such as 
a water molecule) over the surface of the target molecule, GRID generates a property 
distribution of attractive and repulsive forces between the probe and the target compound. 
Thus, the information on the characterisation of the putative polar and hydrophobic 
interaction sites around target molecules, contained within 3-D molecular fields, is 
related to the interacting molecular partners, which here are the key amino acids for 
binding in the LBD of the NR’s studied. Such information is more specific and more 
appropriate than that generated by single or 2-D computed molecular descriptors. The 
water probe simulates the solvation-desolvation processes, while the hydrophobic probe 
(termed ‘dry’) and H bonding carbonyl probe (termed ‘O ’) are used to simulate 
interactions between polar headgroups and the dry hydrophobic core of biological 
membranes. The overall energy of the hydrophobic probe is computed at each grid point
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as Eentropy + £" u  ~ ^HB, whcrc e^ntropy IS the ideal eiitropic component of the hydrophobic 
effect in an aqueous environment, E u  measures the induction and dispersion 
interactions occurring between any pair of molecules and Em  measures the H-bonding 
interactions between water molecules and polar groups on the target surface. Although 3- 
D-QSAR models can be obtained from these 3-D maps (CoMFA (Cramer et al., 1998) or 
GOLPE (Baroni et al., 1993) procedures), they are hard to interpret. Further difficulties 
arise for alignment and molecular flexibility, although programmes are becoming 
available that have improved flexibility (Hindle et al., 2002). Using image analysis 
software, VolSurf is a specialised tool designed to automatically convert these 3-D 
molecular fields into physico-chemieally relevant molecular descriptors and to link 
experimental observations with molecular structures, thereby only extracting the relevant 
information for the investigation in question (Cruciani et al., 2000a; 2000b).
Volsurf generates 28 descriptors from the ‘water’ probe and 16 descriptors from 
the ‘dry’ probe. The first four parameters describe the size and the shape of the molecule, 
descriptors 5-12 indicate polar interaction sites at 8 different energy levels and 
descriptors 21-28 calculate the coneentration of polar interactions on the molecular 
surface. The "integy moment" (13-20) describes the distance of the centre of mass to the 
barycentre of polar interaction sites, at a given energy level. If the integy moment is high, 
there is a clear separation between polar and hydrophobic interaction sites. If the integy 
moment is small, the polar moieties are either close to the centre of mass or they are at 
opposite ends of the molecule and the resulting barycentre is close to the centre of the 
molecule. Descriptors 29-36 indicate interactions with the hydrophobic probe at 8 
different energy levels, which have been adapted to the energy range of the DRY probe. 
Descriptors 37-44 "hydrophobic integy moment" describe the distance of the molecular 
centre of mass and the barycentre of hydrophobic interaction regions.
In summary, the 3-D molecular structure is translated into physicochemically 
meaningful descriptors for the test compounds, without the need for alignment data from 
docking studies in the LBDs of the NR crystal structures or homology models (Chapter 
3). Size, shape, hydrogen-bonding and hydrophobicity are quantitatively differentiated 
within a series of molecules and the resulting collinearity of descriptors is analysed using 
suitable multivariate statistics, such as PCA and PLS, as described in the next section.
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5.2.4. Statistical tools
The statistical tools used were PCA, the multivariate analysis technique that 
deals with the X-variables only and PLS regression, a statistical technique that explains 
one or more dependent variables (Y’s) in terms of a number of explanatory variables 
(predictors, X ’s). PCA and PLS are well documented in the literature, the following 
overview is taken from the literature, Umetrics training manuals and GSK in-house 
modelling guidelines (Eriksson et al., 2001a; Luscombe, 2003). PCA and PLS were 
implemented in the SIMCA-P v.10.0 software (Umetrics AB, Umea, Sweden).
5.2.4.I. Principal Component Analysis (PCA)
PCA summarizes the information contained within initial data into a form that 
may be more easily overviewed and used. It is useful for understanding the distribution of 
the objects, and exploring similarity, dissimilarity and why there are differences. PCA 
can highlight the variables that contain similar information, or the variables that contain 
completely independent information. PCA is utilised in this thesis in section 2.4 (where 
the contaminants in the oils sampled at two time points seven to eight years apart) and 
with the PBDE/AhR study using a number of species specific cell lines, as presented in 
this chapter, section 5.4. In PCA, the original multidimensional space defined by the 
chemical descriptors is contracted into a few descriptive dimensions. The dimensions are 
termed principal components (PC), and they represent the main variation in the data. 
Each PC may be displayed graphically and analysed separately, and its meaning may 
often be interpreted according to simple fundamental biological characteristics, such as 
lipophilicity.
The PCA loading matrix (P) contains information about the variables. It contains 
a few vectors (PCs), which are obtained as linear combinations of the original X- 
variables. The score matrix (T), contains information about the objects and each object is 
described in terms of their projections onto the PCs, instead of the original variables.
X = TP’ + E
Information absent from these matrices is the "unexplained X-variance" in a 
residual matrix (E), which has just the same dimensionality as the original X-matrix. PCs 
are extracted in decreasing order according to how much of the variance they explain. 
Furthermore, as each PC is orthogonal to each other, there is no correlation between the 
information contained in different PCs. The dimensionality of the model, i.e. how many
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PCs should be extracted, is decided according to how much information is explained by 
each PC. Usually the first four of five PCs explain more than 90% of the X-variance. 
Further information is obtained from comparative analysis of the plotted matrices.
The scores plot represents the relative position of the objects in the two- 
dimensional (2D) or three-dimensional (3-D) space of the principal components. They are 
useful to identify clusters of objects and single objects that behave in a peculiar way 
(outliers). The position of the objects in the scores plot relative to the loadings plot may 
serve to explain the clusters. The first PCs try to explain the maximum amount of 
variation and to distinguish between clusters of objects. In essence they are a composite 
of the distinctive features of the objects in these clusters.
The loadings plot represents the original variables in the 2D or 3-D space of the 
PCs, which originally are obtained as linear combinations of the original X-variables. In 
this plot one can see which variables are influential, and how the variables are correlated. 
The loading of a single variable indicates how much this variable participates in 
defining the PC (the squares of the loadings indicate their percentage in the PC). 
Variables contributing very little to the PCs have small loading values and are plotted in 
the centre of the plot; the variables contributing the most are plotted around the borders 
of the plot. Negatively correlated variables are positioned on opposite sides of the plot 
origin, in diagonally opposed quadrants. The distance to the origin indicates the stronger 
impact that a variable has on the model. Loading plots are a test of the "homogeneity" of 
the contributions of the X-variables to the model. When there are more than one single 
field group of variables, the loadings can be plotted to highlight the variables belonging 
to one of them, to show how each field contributes to the whole description of the 
objects, as seen in chapter 2.4.
5.2.4.2. Partial Least Squares regression techniques (PLS)
Partial Least Squares (PLS) is the regression method than can deal with the kind 
of X-matrices used in 3-D-QSAR, by decomposing the X-matrix as the product of two 
smaller matrices, much like PCA does. The PLS algorithm originally proposed by Wold 
is well documented in the literature, so this is not presented in detail here (Eriksson et al., 
2001a; Wold and Ericksson, 1995). However, an overview is given to show how the PLS 
techniques were used and how the models were validated in this chapter.
PLS assumes that there are a few ‘prineipal properties’ of the molecule whieh are 
directly related to the Y response, which here is the receptor-specific biological response
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data. Different linear combinations of all the descriptors, called ‘components’, are made, 
in turn, to describe each principal property. By evaluating the regression coefficients of 
the PLS model in conjunction with the variable influence on the prediction, the relative 
importance of each descriptor can be identified. The loading matrix (P) contains 
information about the variables. It contains a few vectors (termed Latent Variables, LVs) 
which are obtained as linear combinations of the original X-variables. LVs are 
constructed in an analogous way to PCs in PCA, but differ in that PCA obtains the PCs 
that represent at best the structure of the X-matrix, while PLS obtains the LVs under two 
constraints, they have to represent the structure of the X-matrix and Y-matrix and they 
have to maximize the covariance between the X's and the Y's. The score matrix (T) 
contains information about the objects. Each object is described in terms of the LVs, 
instead of the original variables. The X-loadings (P) are calculated at the end of each 
iteration, to best approximate the X-matrix. They update the X-matrix, but are not 
directly involved in the model building. Both the LVs and PCs share some important 
properties as they are both extracted in decreasing order according to how much of the 
variance is explained. The first LV always contains more information than the second, 
the second more than the third and so on. Also each LV is orthogonal to each other, and 
there is no correlation between the information contained in different LVs. As with PCA, 
the scores represents objects in the space of X-scores (T) against the Y-scores (U), 
showing the correlation between the X's and the Y's obtained in the model for each one of 
the LVs. The plot of the first LV contains the main relationship between activities and 
structural descriptors. As for PCA, the best way to understand and diagnose the 
information from PLS is to plot the matrices obtained and examine all of the available 
plots with care and in conjunction with each other.
Variable influence on the projections (VIP)
An independent measure of the relative importance of the x  variables is 
calculated as the VIP. They are derived from the PLS weights and take into account the 
fraction of variance explained in each model dimension. When examined in conjunction 
with the coefficients plot, information about the major contributing descriptors to the 
model is discernable.
5.2.4.3. Model Validity
The conceptual model underlying 3-D-QSAR is that the large numbers of 
variables included in the X-matrix encapsulate the dominating effects due to changes in
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structure over the actual molecules. Model validation is a crucial step in the development 
of QSARs. However when attempting to define the relationship between X and Y, a 
large number of variables in the X-matrix have no relationship with the activity and 
introduce only noise in the description of the molecules. Like any other experimental 
variable, the Y variables eontain error. The models will try to fit the Y ’s as much as 
possible, but if the fitting is overworked, the model will also explain the noise. Overfitted 
models seem to work well on trainig data, but they often prove to be less useful to predict 
the Y’s of objects not included in the available data set (training set).
In PLS, selecting the correct dimensionality is critical to the validity of the 
model, if too many LVs are included, the model will be over-fitted. To prevent this, 
without destroying the structure of the X variables, a conservative variable selection is 
undertaken. If there are too many variables, the models are more weighted to explaining 
the X-structure, and the Y's do not fit well. Sufficient variables are needed to give the X- 
structure, with too few variables the models are not stabilized. The Y's may fit well, but 
their predictive ability is doubtful, even if the internal validation indicates otherwise and 
shows promising results. The models presented here were therefore tested for predictive 
ability, taking into account how many LVs to include.
There are four tools for model validation as follows:
5.2.4.3.1.External validation using a designed validation set
Validating a QSAR with external data, while the most demanding, is considered 
the best method of validation. The validation should be performed by interpolation and 
the training set should be diverse, while the test set should ideally be representative of the 
training set, so that the predicted values can be compared to the actual observed values to 
give a reliable estimate of the predictive variance (Q^).
5.2.4.3.2. Splitting of parent data set into training and validation sets
Producing large experimental data sets generated via in vitro test systems can be 
both time consuming and costly, and relatively large NR data sets that can be split into 
training and validation sets are not common in the literature. However it was possible to 
conduct this evaluation for the E R a QSAR, section 5.3, as this is arguably the most 
studied SHR receptor published. With the external prediction approach, the objects in the 
original data set are split up into two groups from the very beginning of the analysis. The 
first one, the learning set, will be used to build the PLS model. The other, the prediction
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set, will be used to compare their experimental Y-values with the predictions made by the 
PLS model. This technique tests the predictive ability, but the results depend critically 
upon how many and which objects are assigned to each group. Also, the data sets in 
QSARs often contain too few objects and it is not possible to remove objects from the 
analysis without a loss of information. This form of validation, requiring large amounts 
of relevant biological data, was implemented for the ER a QSAR based on a large 
literature data set, with random selection between the test set and training set of 
compounds within representative structural classes (section 5.3).
5.2A.3.3. The randomization test
For smaller biological experimental data sets it is not always possible to validate 
with another data set, because of lack of availability of further data. In this case, with 
PLS it is possible and preferable to internally validate the model.
Repetitive randomizations of the response data (Y) of N  compounds in the 
training set into an array of reordered variables is the basis of a probabilistic approach. In 
each cycle the resulting arrangement of random integers is used to reorder the Y data, 
with the X data intact, and then a data analysis is executed on the scrambled data to 
produce R“ and Q^ estimates. If these values are lower than for the original data, one can 
be confident in the relevance of the original QSAR model. Precise estimates can be 
produced from comparisons of the histograms of R^ and Q^ values derived from hundreds 
of cycles, but this can be very time consuming to conduct. Wold and Ericksson, 1995, 
consider that around ten trials can be sufficient for identifying the key features of the R" 
and Q^ histograms. The randomization test is an internal validation tool that is built into 
the multivariate software package used for these studies (SIMCA v 10. Umetrics AB, 
Sweden), and was conducted for the PXR QSAR model, section 5.4.
5.2.4.3.4. Cross validation
Cross-validation (CV) differs from the previous method as it has a predictive 
basis, and is considered a reliable way to test the predictive significance (Wold and 
Eriksson., 2001). CV entails dividing the data into a certain number of groups, then 
constructing a number of parallel models from reduced data (with one of the groups 
deleted). The differences between the predictive Y values and the model Y values are 
calculated for the deleted data. This process is repeated until each group has been omitted 
once. The sum of the squares of these differences is computed and collected from all the
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models to form the predictive residual sum of squares (PRESS), which estimates the 
predictive ability o f the model (Wold and Eriksson. 2001). The PRESS is also expressed 
as (the cross validated R^), which is (1-PRESS/SS) where SS is the sum o f the 
squares o f Y corrected for the mean.
SDEP: Standard Deviation of Errors of Prediction.
P R B S S
Çf: Predictive correlation coefficient
S  "
I j y - r f
' H X - 7 Ÿ
Y  : Experimental value 
Y' : Predicted value 
y  : Average value 
N  : Number o f objects
The CV technique performs an "internal validation" o f the model and obtains an 
estimation of the predictive ability without the help o f external data sets. This is 
particularly important in QSAR studies, where the number o f objects available is usually 
small, and one cannot afford to remove objects from the learning data set. This method 
was therefore utilised for the PXR QSAR, section 5.4.
There is no agreed method on how to build the reduced groups and on the 
criterion to decide how many objects to keep for CV, although the objects should be 
deleted once only. The appropriate approaches used depend upon the peculiarities o f the 
QSAR data sets and the ways in which the objects are clustered. The approaches can 
include leaving one or several out, where models are built keeping one (or several) 
object(s) at a time out o f the analysis, and repeating the procedure until all the objects are 
kept out once. Leaving several out is considered preferable both on a theoretical and 
practical basis (Wold and Eriksson., 1995), as it is less likely to over-predict the model, 
thus giving a much better, but more conservative estimation o f the real predictive ability; 
the uncertainty o f future predictions may be numerically worse but the model is more 
reliable. To obtain stable results, the procedure is repeated many times, and the Standard 
Deviation Error o f Prediction (SDEP) is computed to give an estimate o f the dispersion o f 
the SDEP values obtained from different runs, and thus the reproducibility between the 
reduced models (Eriksson et al., 2001a). This internal validation approach was used for
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the PXR QSAR. Later, test sets of in-house proprietary data were also used to explore the 
predictive nature of the PXR model, but the test sets were not representative of the 
training set, as they consisted of drugs and NCEs, most of which did not belong to the 
structure classes in the training set, which was dominated by dietary compounds, 
hormones and drugs.
The number of principal components is determined with cross-validation. R^X, is 
used to assess which variables are well explained, and those which are not. R^X, is the 
fraction of the sum of the squares (SS) of all the X’s explained by the current component. 
R^ increases with increased number of principal components. However, if the model 
increases too much in complexity, the validity can be reduced. To determine the 
appropriate number of principal components to include in a model, a cross-validation 
(CV) method is used to simulate the predictive power of a PC model. QSAR models are 
conventionally evaluated by considering the R^, the ‘explained variance’ or ‘goodness of 
fit’ and s, the residual standard deviation (RSD). The predictive residual SD’s are termed 
the standard error of prediction (SDEP). R^ can range between 0 and 1, where 1 is 
perfection, with 100% of the response (Y) data explained, and 0 indicating no 
explanatory power. A high R^ and low RSD are among the requirements for valid 
models, together with a reliable estimate of Q^, the ‘predicted variance’ or ‘goodness of 
prediction’.
With the models shown in this chapter, it is preferable for Q^ to be greater than 
0.5, and a very good score is greater than 0.9. While R^ must always be larger than Q^, 
and a high R^ value and high Q^ value is good, the difference between R^ and Q^ should 
not be too large (Wold and Ericksson, 1995).
5. 2.4.4. Predictive models
A good model is able to calculate Y values that correspond to the experimental 
ones, even for molecules not included in building the model. These models can be used to 
calculate reliable estimations of Y values for new molecules, prior to their availability, 
and so be predictive. The predictive ability of a model is attributed to the existence of a 
"true" relationship between the measured X properties (physico-chemical and field 
interaction energies) and the Y (biological response) property measurements.
Three practical examples using these techniques are shown in the following 
sections. The interpretation of VolSurf parameters will be explained and the 
pharmacokinetic relevance of these descriptors will be shown together with correlations
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with biological activity parameters. In every model described below, values of R and Q 
from CV are quoted. Section 5.4, ‘Building a QSAR for PXR’, is explored further with 
two GSK proprietary data sets. An additional computational programme, Spotfire 
(www.spotfire.com) was utilised to obtain further graphical information on the outlier 
descriptor activity observed when two external proprietary training sets were tested in the 
PXR model.
In the end, as with all regression models, even the best constructed 3-D-QSAR 
model is limited by the series it was obtained from. However even if the models are 
rough and are not able to explain to a full extent the activity values, they are extremely 
valuable to identify the structural features that contribute most to the activity. These are 
important in the context of the ligand-receptor mechanisms of interaction, and suggest 
how new chemical entities (NCEs) might be designed to stimulate or remove binding 
potential, and how a test compound might be predicted to behave at the molecular 
ligand-LBD interface. As the same VolSurf parameters are used in the QSARs (sections
5.3, 5.4 and 5.5), the models can be compared with each other more easily than with 
those in the scientific literature, so giving a new perspective in receptor signaling 
behaviour.
5.2.5. Molecular modelling
These models are also compared to the ligands visualized in silico in the crystal 
structures and homology models of the respective receptors. The E R a crystal structure, 
the PXR crystal structure and the AhR homology model as described in chapter 3 were 
refined using molecular mechanics to perform energy minimization of the entire 3-D 
structure, to achieve a low energy, stable optimized geometry. Each structure was 
minimized to produce a minimum energy geometry for each molecule (test compound) 
docked in the respective NR LBDs. The 3-D structures of compounds of interest were 
produced for docking into the relevant receptor using the build and edit/sketch option in 
Sybyl (Tripos Associates, St Louis, MO). The putative binding site of each receptor was 
located and the endogenous ligand or high potency ligands were fitted into the 
respective sites and became the template to position other compounds. Hydrogen bonds 
were displayed to ensure the binding orientation was consistent with their formation, and 
modes of binding were examined.
While one cannot (as yet) visualize the dynamic activity of NRs and ligand 
binding in real time, these models are a close approximation tool. The techniques used
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can be applied to many available data sets for different NR biological data to generate 
structure activity information and to predict a chemical’s potency as a ligand for a given 
hierarchy of receptors, as well as for the individual receptor.
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5.3. Investigation of structure-activity relationships using PLS regression and 
VoiSurf descriptors for a large diverse set of natural, synthetic and environmental
compounds in Estrogen receptor a.
5.3.1. Abstract
Relative binding affinity (RBA) data for a large and diverse set of oestrogenic 
compounds were obtained from the literature and utilised to build a semi-quantitative 
partial least squares (PLS) regression model for the ligand binding properties of estrogen 
receptor a  (ERa) ligands. The biological data ranged over 7 orders of magnitudes (Fang 
et al., 2001).
VolSurf descriptors were generated for each of the compound structures and 
subsequently used to develop a PLS regression based model (n=30, RMSEE = 1.3) for 
Log RBA. Two subsequent validation sets with a similar range of compounds 
demonstrated the applicability and generalisability of the model (n=30, n=60, RMSEP = 
1.6) to allow reliable classification of new compounds into low/medium/high 
compartments for prescreening purposes. Further analyses of VolSurf variable 
contributions (particularly hydrogen bonding, capacity factors, hydrophilic-lipophilic 
balance, hydrophobic regions at eight energy levels, globularity, rugosity, and 
amphiphilic and integy moments) will allow additional insights into ER ligand activation 
on a compound specific basis which could be of relevance to drug design in the 
treatment of E R a dependent cancers.
5.3.2. Introduction
The physiological roles of endogenous oestrogen (17|3 oestradiol) are of critical 
importance in regulating development, growth and maintenance of reproductive tissues as 
well as in normal processes of numerous tissues including: cardiovascular, neural and 
skeletal cell functions (reviewed in chapter 1). Oestrogens are involved with many 
signaling pathways, but the major receptor mediated pathway is through the Estrogen 
Receptors (ERs). The ERs are ligand regulated transcription factors whose activity as 
activators or repressors of gene transcription depends on the availability and nature of the 
ligand with which they are bound, as well as the nature of the coregulator proteins and 
receptors.
As the ERs play a role in bone density maintenance, regulation of blood-lipid 
profiles and brain function, understanding structural features necessary for a chemical to
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bind to the E R a is a target for the discovery of new drugs for treating or regulating a 
variety of hormone-related conditions. It is also essential for understanding oestrogenic 
endocrine disrupting effects. Many natural and synthetic chemicals have been shown to 
be capable of eliciting or antagonising oestrogenic responses in various species, through 
similar mechanisms, although the physiological outcomes can differ.
Fang and co-workers (Fang et al., 2001; Blair et al., 2000) recently reported 
satisfactory sized data sets of experimental binding data for ERa, and the latter report 
was utilised for the present PLS study. There is a number of other data sets of 
appropriate size in the literature for conducting similar QSARs (e.g. Miller et al., 2001), 
and future studies would consider these also, particularly with respect to tier testing and 
assay assessment for chemical risk assessment and relevance to human health. Recently a 
number of other E R a QSAR studies based on small (Jacobs and Lewis, 1999), medium 
(Sadler et al., 1998) and large data sets, such as those generated by high throughput 
screening (HTS) (Gao et al., 1999; Hong et al., 2002), have been published. The model 
presented here supports the information generated by other studies, and also adds to the 
understanding of E R a ligands in relation to the AhR and PXR (section 5.4), which can be 
used to explore further cross-talk relationships with other receptors.
5.3.3. Methods
5.33.1. Source o f  biological data
RBA data, conducted in the same laboratory and obtained from the scientific 
literature (Fang et al., 2001), was split into three data sets, the training set and two 
validation sets, each containing a representative spread of hormones, phytochemieals, 
pharmaceutical compounds and environmental compounds.
5.3.3.2. Generation o f  VolSurf descriptors.
As for section 5.2.2.2. The VolSurf descriptors generated are shown for the 
QSAR data test set 2, in Appendix 3.Table ii.
5.3.3.3. Statistical tools
PLS was utilised and it was assumed that there are a few ‘principal properties’ of 
the molecule which are directly related to the Y response, which in this model are the 
RBAs reported by Fang et al., (2001). The basic physico-chemical features of the 
molecule such as acidity, basicity, lipophilicity, size, polarity, etc. are the principle
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properties. Different linear combinations of all the descriptors called ‘components’ were 
made, in turn, to describe each principal property. The contribution that a descriptor 
makes to each component will vary depending on how relevant that particular descriptor 
is to the principal property. By evaluating the regression coefficients of the PLS model in 
conjunction with the variable influence on the prediction, the relative importance of each 
descriptor was identified.
5.3.3.4. Molecular modelling
The E R a crystal structure as described in chapter 3 was refined using molecular 
mechanics to perform energy minimization of the entire 3-D structure, to achieve a low 
energy, stable optimized geometry. Each minimization took 100 iterations to produce a 
minimum energy geometry for each molecule (test compound) docked in the LBD. The 
3-D structures of each compound were produced using the build and edit/sketch option in 
Sybyl (Tripos Associates, St Louis, MO). The putative binding site of the hER a was 
located and ivpoestradiol was fitted into the site. This ligand binding pocket is well 
defined within a loop of peptide containing complementary amino acids for binding 
interaction, as with agonists and antagonists. Combined with a predominance of leucine 
residues, the site is in an optimum position for dimerization leading to DNA interaction 
(Jacobs and Lewis, 1999). Hydrogen bonds were displayed to ensure the binding 
orientation was consistent with their formation. The fitted l?Poestradiol molecule 
became the template to position other compounds.
5.3.4. Results and Discussion
The PLS regression based model (n=30, RMSEE = 1.3, R^ = 0.62) for the Log 
RBA training set is shown in figure 5.1. Two subsequent validation sets with a similar 
range of compounds demonstrated the applicability and generalisability of the model 
(n=30, n=57, RMSEP = 1.6). The test plots are shown in figures 5.2 and 5.3.
Whilst the R^ value is not significant, this model demonstrates a clear trend and 
the compounds may be classified into suggested low and high compartments as indicated 
by the dashed (green) lines.
Figures 5.2 and 5.3 show the test sets, and indicates selected chalconids, 
polychlorinated biphenyls, triphenylethylenes, and diphenolalkanes to be outliers. Figures 
5.4 and 5.5 show the standardized coefficients plot and the variable importance plot for 
the ER a model.
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Selected compounds were modelled in the ER a crystal structure, as shown in 
figures 1.5, 5.6, 7.7 and 5,8.
Figure 5.1. Training set for ERa VolSurf model
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Figure 5.2. Test set 1 for ER a VolSurf model
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Figure 5.3. Test set 2 for ERa VolSurf model
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5.3.4.I. Key VolSuif variables
The key variables were:
Ratio Volume/Surface (R), a measure of molecular wrinkled surface or rugosity; 
Hydrophobic regions (D1 - D8); Hydrogen Bonding (HE 1-8); Integy Moments (Iwl-IwS) 
which measure the imbalance between the centre of mass of a molecules and the position 
of the hydrophilic regions around them; Polarizability (POL) (Miller, 1990); Amphiphilic 
Moment (A), which is a vector pointing from the centre of the hydrophobic domain to the 
centre of the hydrophilic domain. The vector length is proportional to the strength of the 
amphiphilic moment, and it may determine the ability of a compound to penetrate a 
membrane; Hydrophilic-Lipophilic balance (HLl, HL2), the ratio between the 
hydrophilic regions measured at -3 and -4 kcal/mol and the hydrophobic regions 
measured at -0.6 and -0.8 kcal/mol. The balance towards HLl indicates that 
hydrophilicity dominates in the molecule; Capacity factors (Cwl-Cw8) which represent 
the ratio between the hydrophilic regions and the molecular surface; Molecular 
Globularity (G) which is 1.0 for perfectly spherical molecules. It assumes values greater 
than 1.0 for spheroidal molecules and is also related to molecular flexibility.
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Figure 5.4
Standardised Coefficients Plot for Model ER -alpha
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S.3.4.2. M olecular modelling: Comparison with selected compounds docked in the E R a  
crystal structure
npoestradiol and selected test compounds, representing the different 
classes of ligands in the QSAR, formed three hydrogen bonds with Glu 353, His 524 and 
Arg 394 in agreement with other studies (Waller et a l , 1996; Métivier et al., 2002). The 
compounds modeled included hydroxylated PCB 153, hydroxylated PCB 118, 
coumestrol, daidzein, genistein, 4-hydroxytamoxifen, ICI 182780, PBDE 47 
(2,2’,4,4’PBDE) and 17P oestradiol, using the template provided by the crystal structure 
complex of E2 bound in the hER a (Jacobs, 1998). Key binding interaction is observed, 
the A-ring phenolic hydroxyl makes direct hydrogen bonds to the carboxylate of Glu 353, 
the guanidinium group of Arg 394 and a water molecule. The D-ring’s 17P hydroxyl 
makes a single hydrogen bond with His 524. The A-ring is sandwiched between the side- 
chains of hydrophobic residues on its a  and p-faces, and the D-ring has non-polar contact 
with hydrophobic residues. Where bonding occurs, OH charges on the phenyl ring may 
be significant. The critical presence of an unhindered phenolic OH group in a para 
position for ER binding has been noted in other ER models (Métivier et al., 2002) and 
for other ER bioassays such as the yeast oestrogen screening assay (Miller et al., 2001).
The other main interactions are believed to be non-polar. Analogues of 
oestradiol with a 3-position moiety that is only capable of acting as a hydrogen bond 
acceptor, and not a donor, have poor binding affinities. This may be due to electrostatic 
repulsion between the 3-position heteroatom of the ligand and the carboxylate of the Glu 
353. The hydrogen bond accepting feature of His 524 appears to be quite flexible when 
comparing agonist and antagonist structures, whereas Glu 353 forms a salt bridge with 
Arg 394, defining its location (Gillner et al., 1998). A key structural difference between 
phytoestrogens and oestrogens is that the 6 Â biophore (a distance descriptor) present in 
endogenous oestrogens and xenoestrogens (related to the A ring region in 17poestradiol) 
is not present in phytoestrogens. They appear to be less conformationally flexible due to a 
planar aromatic structure, unlike many of the other ligand classes included in the ER 
QSAR study (Jacobs, 1998; Jacobs and Lewis, 1999), as one can see when comparing the 
anti-oestrogens: tamoxifen and ICI182780, shown in figures 5.6 and 5.7, compared with 
figure 5.8, showing coumestrol in the ER a LBD. This may increase the likelihood of 
phytoestrogens being outliers in this model.
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The distances for binding with the amino acid residues in the binding site 
were within the range expected for the formation of the hydrogen bonds (2 to 3Â). 
Receptor flexibility or the presence of a bridging water molecule might account for the 
ability of the ER to accommodate ligands with a variation in the D-ring and differing 
oxygen-oxygen distances, as observed previously and discussed in Chapter 1 (shown in 
figures 1.5, 1.6 and 1.7), further illustrations are given in figures 5.6, 5.7 and 5.8. 
Ligand binding modulates the hydrogen bonding networkwhich provides the interpeptide 
communication in the hER between ligand binding and DNA activation. When an agonist 
molecule completes the electron transport ‘circuit’, the resulting effect may disrupt the 
existing framework of hydrogen bonds to free the DNA zinc finger DNA binding 
domain. In the crystal structure complex, a number of ligand classes have been observed 
to bind, including anti-oestrogens tamoxifen and ICI 182780 (figures 5.6, 5.7), and 
phytoestrogens coumestrol (figure 5.8), daidzein and genistein (figures 1.5, 1.6), together 
with PCBs and PBDEs, as shown in figure 1.7 (Jacobs, 1998).
The anti-oestrogens tamoxifen and ICI 182780 bind with additional 
amino acids outside the core LBD, as identified for the endogenous ligand 17|3 oestradiol 
see (figure 1.3), and discussed in Chapter 3 (see figure 3.7 ) and (Jacobs, 1998).
Chlorinated compounds, such as the PCBs, which were also outliers in 
this model, may have an H bonding capacity in a similar manner to that reported for 
chlorinated pesticides such as hexachlorohexanes (HCH), and p ,p ’ DDT, they contribute 
to the overall H bond basicity (Abraham et al., 2002a) and are also known to be weakly 
oestrogenic.
Figure 5. 6. Tamoxifen docked in the ERa LBD
As with the previous model and crystal structure NR figures, the ribbon denotes 
the protein backbone of the receptor, key amino acids required for binding are indicated 
in blue and red, and hydrogen bonding is indicated by dashed yellow lines.
1
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Figure 5.7. ICI 182780 docked in the ERa LBD
Figure 5.8. Coumestrol docked in the ERa LBD
5.3.5. Discussion
In combination with molecular structural data, this study has generated 
theoretical data for the production of relationships (QSARs) which examine and estimate 
potency differences between these compounds from a large and varied data set. 
Molecular dynamics simulation is a useful tool to investigate the mechanism behind the 
conformational energy changes following ligand binding which lead to hER activation, 
particularly when compared to in vitro estimations of the ligand binding affinity.
The results of this investigation support and expand homology modelling and 
structure activity relationship (SAR) studies for oestrogenic compounds available in the 
literature (Hong et al., 2002), which utilize Insight software packages (Molecular 
Simulations Inc) and the Sybyl software package (Tripos Associates Inc) with MLR,
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respectively. A previous E R a QSAR study with a small relative binding data set utilised 
quantum mechanical computer calculations obtained by docking ligands in the LBD of 
the E R a crystal structure. In this study the key parameters were hydrogen bonding, 
ionization potential, AE (where AE is the E l u m o - E h o m o , for E h o m o  the relevant xenobiotic 
characteristics include ionization potential, ease of oxidation and nucleophilic reactivity, 
for E  l u m o  these are reduction potential, ease of reduction and electrophilic activity) and 
minimized free energy. (Jacobs, 1998; Jacobs and Lewis, 1999; Soffer et al., 2001). 
There are several QSAR and structure-binding affinity studies of the ER in the literature 
utilising different 2D and 3-D descriptors (Suzuki et al., 2001; Gillner et al., 1998; Sadler 
et al., 1998), as in vitro ligand binding data, using different test systems, has been 
generated in many different laboratories for some years (Waller et al., 1996; Fang et al., 
2001; Miller et al 2001; Suzuki et al., 2001; Hong et al., 2002). As it becomes available, 
biologically derived data on novel E R a selective ligands can be evaluated further using 
such QSAR models, particularly when investigating the molecular mechanism of 
activation in E R a compared to ER(3, as observed for the furans, also a known AhR ligand 
class (Mortensen et al., 2001). The key Volsurf descriptors generated for this QSAR 
support the descriptor information reported for other ER QSAR studies, and are also 
compared with the VolSurf descriptors generated in the PXR QSAR (section 5.4) and the 
AhR QSAR (section 5.5) in Table 5.3 and section 5.6.
In the context of whole biological systems, E R a QSARs need to consider self 
regulation of the ER family between ERa, ERp, ERy and mutant ERs, and associated 
proteins, together with exposure, half-lives and body burdens, metabolism and excretion 
of different classes of compounds, on a gender specific basis. Further development of 
such models, based upon sequence homology, site-directed mutagenesis and 
crystallographic data, in combination with multivariate data handling techniques and 
descriptor tools (e.g. VolSurf), in relation to experimental and observed data, can provide 
a useful tool in an area of considerable public concern. It could be invaluable for 
providing a scientifically sound perspective on the potential risk to human health from 
environmental and dietary exposure to oestrogenic compounds and other endocrine 
disrupters, and be of potential relevance in the design of novel therapeutic anti- 
oestrogens for oestrogen related cancer treatments. These results are being utilised further 
in ongoing comparative QSAR receptor studies examining crosstalk and ligand 
promiscuity.
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5 .4 . Building a QSAR for the Pregnane-X-Receptor (PXR)
5.4.1. Abstract
There is increasing evidence that potent inducers of CYP3A can be 
present in the human diet, from food constituents, food contaminants and over-the- 
counter herbal remedies and vitamin supplements. These can be as potent as 
pharmaceutical compounds, as demonstrated by the effect of hyperforin (St John’s Wort), 
which is ten-fold more potent than the prototypical pregnane X receptor (PXR) ligand, 
rifampicin.
PXR transient transfection assays are utilised by the pharmaceutical industry for 
the prediction of the CYP3A induction potential of drug candidates. These assays also 
have applications for the analysis and risk assessment of dietary and endocrine disrupting 
compounds.
Data for a diverse set of 33 compounds and metabolites, including drugs 
(tamoxifen), bile acids (lithocholic acid), hormones (progesterone), phytochemicals 
(silybin), lignans (enterolactone), bacteriocides (triclosan), and persistent organic 
pollutants (polychlorinated biphenyls) were derived experimentally. The PXR activation 
ranged from 1.3 % (trans resveratrol) to 152 % (ICI 182780) and 184 % (GSK SR 
analogue) when compared to lOuM rifampicin. VolSurf descriptors were generated for 
each of the compound structures and subsequently used to develop a PLS regression 
based model (n=33, RMSEE = 22.37, R2 = 0.83) for % maximum induction relative to 
rifampicin. This model was successfully validated internally using the randomization test.
5.4.2. Introduction
An important requirement for homeostasis is the detoxication and 
removal of endogenous hormones and xenobiotic compounds with biological activity. 
The Pregnane X Receptor (PXR) is involved in activating the expression of several P450 
heme containing enzymes, including CYP3A4 in the adult and CYP3A7 in the foetus, in 
response to xenobiotics and steroids. While this provides a route for excess steroids to be 
eliminated from the body, it also means that drug-drug-xenobiotic-phytochemical 
interactions are likely, as CYP3A4 is the major human hepatic P450 responsible for the 
oxidative metabolism of over 60% of drugs in clinical use. Chapter 4 and figure 4.1, 
summarize the literature on the mode of PXR activation. In this study the in vitro data 
generated in chapter 3 were developed to generate PXR QSAR models using VolSurf 
descriptors, which was then supported and illustrated by docking ligands in the PXR
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crystal structure, in various orientations as indicated by the orientations of SR12813 in 
the crystal structure (Watkins et al., 2001). This approach has allowed a better 
understanding of PXR ligands.
5.4.3. Methods
Biological data were generated to yield a spread of activity for hormones, 
phytochemicals, pharmaceutical compounds and environmental compounds.
5.43.1. Generation and collation o f  biological data using an in vitro transient 
transfection assay
The transient transfection assay, developed in the GSK Nuclear Hormone 
Receptor Group at RTP (Moore et al., 2000b), was the in vitro procedure used to 
generate the biological data in the form of the % maximum induction in relation to the 
positive control Rifampicin (Rif) (lOuM). The generation of these data and typical dose- 
response curves are described in Chapter 4. The data set for building the VolSurf Model 
is shown in table 5.1. Only reproducible data were used, the number of experiments, 
mean values and standard errors are indicated. Where only one experiment is indicated, 
these data were supported by similar values observed using CV-1 cells for the same PXR 
transient transfection assay, or reported by another operator using HuH7 cells.
Two further data sets generated from the same assay, using the same HuH7 cells, 
meeting all the control criteria identified in chapter 3 (i.e. acceptable fold induction, 
positive control Rif values within the 80-120% range for % mean induction, relative to 
Rif), and conducted within the last two years, were mined and collated from GSK in- 
house data banks, for later exploration as test sets. These data included GSK validation 
sets, e.g. table 5.2, and data on a large number of proprietary experimental compounds. 
For proprietary reasons the structure and identities of these compounds cannot be 
reproduced here, however. Selection was based only on the reliability of each 
experiment, and availability of data. Selection was not based on structure or exposure as 
with the original data set. Test set one was generated principally by Gail Nolan at the 
GSK site in Ware, UK (n= 67). Test set two was generated under the supervision of 
Linda Moore at the GSK site in Research Triangle Park, North Carolina, US (n= 149). 
The test set data (selected data shown overleaf) was collated similarly to that for the 
training set, as shown in figures 5.1 and 5.2, with mean values taken where several
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experimental data sets were available for certain compounds, particularly those that 
constituted validation sets.
5.4.3.2. Generation o f descriptors
Physico-chemical and VolSurf descriptors were generated as described in section
5.2.2.2.
Table 5.1. Summary of the biological data for PXR QSAR model
Primary m ax
ID N am e induction SE Top d o s e  N
1 5 b eta  p reg n a n e  3 ,2 0  d io n e 42 .88 3 .06  lOuM 4
2 17 a lp h a  eth inyl o estra d io l 30 .95 0 .55 lOuM 2
3 17b eta  o estra d io l 24 .49 3 .66  lOuM 5
4 4hyd roxytam oxifen 84.17 12.66 lOuM 4
5 C lotrim azole 96.17 2.54  lOuM 3
6 c o u m estro l 7.49 2 .99  lOuM 4
7 daidzein 14.48 2.52  lOuM 2
8 d e x a m e th a so n e 24.21 7.44  lOuM 4
9 e n tero la c to n e 35.61 17.09 lOuM 2
10 eq u o l 9 .95 4.44  lOuM 2
11 g e n iste in 8.09 2.83  lOuM 3
12 hyperforin 112.78 22.1 luM 4
13 101182780 152.05 19.44 lOuM 3
14 lith o ch o lic  acid 11.07 lOuM 1
15 hydroxyvitam inD 3 55.90 5 .75 lOuM 4
16 PC B 118 26.63 2 .07  lOuM 2
17 PCB 153 16.93 2 .07  lOuM 2
18 p r e g n e n o lo n e  16 a lp h a  carbonitrile 7.45 7 .45 lOuM 2
19 P r o g e ste r o n e 15.73 2 .14  lOuM 4
20 q u ercetin 11.78 0.7  lOuM 2
21 ro s ig lita zo n e 37.00 lOuM 1
22 se c o iso la r ic ir e s in o l 20.03 1 lOuM 2
23 silyb in 41.30 36 .04  lOuM 2
24 S R 12813 136.32 9 .6  lOuM 5
25 tam oxifen 74.60 21.7  lOuM 2
26 tran s-resveratro l 1.34 1.34 lOuM 3
27 tran s-n o n a ch lo r 53.82 5.47 lOuM 8
28 tric lo san 46.18 4 .45 lOuM 5
29 vitam in D3 1.61 1.61 lOuM 3
30 GSK SR a n a lo g u e l 137.40 lOuM 1
31 GSK SR a n a lo g u e2 184.30 lOuM 1
32 GSK SR a n a lo g u e3 130.10 lOuM 1
33 GSK SR a n a lo g u e4 122.70 lOuM 1
5.4.3.3. Statistical tools
Partial Least Squares Regression (PLS) analytical techniques were used as 
described in section 5.2.2.3. PLS assumes that there are a few ‘principal properties’ of the 
molecule which are directly related to the biological (Y) response, which in this model is 
the % mean induction relative to the positive control, Rif. Different linear combinations 
of all the descriptors called ‘components’ are made, in turn, to describe each principal
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property. As with the E R a QSAR study, by evaluating the regression coefficients of the 
PLS model in conjunction with the variable influence on the prediction, the relative 
importance of each descriptor can be identified.
Table 5.2. Summary of selected biological data used as part of a later test set 
(set 1) for the PXR QSAR model
Compound %MAX SE N
O m eprazole 45 .14 3 .02 5
Troieandomycin 82 .42 4.63 6
D exam ethasone 21 .96 13.98 3
Phenytoin 19.50 3 .50 2
S R 12813 145.70 18.90 4
Troglitazone 111.75 10.50 5
Troglltazone m etabolite 74 .65 5 .35 2
Phénobarbital 9.90 9.90 2
T estosterone 0.00 0.00 2
Estradiol 38 .60 19.20 2
P rogesterone 15.45 8 .25 2
Clofibrate 14.31 10.01 2
PON 8.64 1.04 2
RU486 80 .00 13.80 4
Mevinolin 230 .63 41.25 5
Primidone 7.62 2 .62 2
Felbam ate 2 .10 2 .10 2
C arbam azepine 12.96 5 .26 2
Clotrimazole 67.72 13.92 2
Taxol 49.61 12.68 4
Hydrocortisone 6.10 3 .66 4
Prednisone 0.00 0 .00 2
Lansoprazole 27 .25 9 .22 4
Cyclosporine 0.00 0 .00 2
5.43.4. Molecular modelling: in silico investigations o f  ligand binding in PXR.
Ligands of interest were selected as described in section 4.3 and were initially 
investigated in the homology model of PXR as described in Chapter 3, and then the PXR 
crystal structure when it became available (I gratefully acknowledge the help of Sandeep 
Modi, GSK in obtaining the PXR crystal structure coordinates). Examples of the 
compounds, first built in Sybyl (see Chapter 3) are shown, docked in the ligand binding 
domain (LBD) of the PXR crystal structure below (Figures 5.9, 5.10) using SYBYL 
biopolymer software from (Tripos associates, St Louis, Missouri) on a Silicon Graphics 
Indigo2 IMPACT 10000 Unix workstation. Compounds were docked in the PXR LBD 
using SR12813 as the template in the orientation shown in figure 5.14.
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5.4.4. Results
The models and validation sets are shown in figures 5.9 to 5.12, overleaf.
The physico-chemical and Volsurf models compared well (figures 5.9a and
5.10), but with a better value, of 0.8, the Volsurf model was validated and tested with 
further GSK proprietary data sets. However, the coefficients and variable importance 
plots for the physico-chemical model are given (see figures 5. 9b and 5.9c), showing that 
the key positively correlated descriptors were MW, the number of heavy non-H atoms in 
the molecule, CMR (a function related to size), and Vx, relating to McGowan 
characteristic volume. As VolSurf was not able to generate descriptors for the larger 
compounds in the test sets, but physico-chemical descriptors could be generated, this 
allowed a direct physico-chemical descriptor comparison with the model generated for 
the outliers (figure 5. 26), and this is further elaborated on in the discussion in section
5.4.5.
The VolSurf PXR model demonstrates a clear trend and the compounds may be 
classified into low, medium and high affinity ligands. As highlighted by the red arrows, 
vitamin D3 (29) was an outlier, but the hydroxylated form was a medium affinity ligand 
(Figure 5.10). Figure 5.11 shows the successful 3-component internal validation via the 
randomization test.
Figures 5.14 to 5.21 are examples of high, medium and low affinity ligands 
docked in the LBD of PXR. Differences in binding with key amino acids are apparent for 
the larger high affinity compounds. Figure 5.14, shows SR12813 docked in the PXR 
crystal structure in one of the crystallization orientations a) docked in the LBD, showing 
the whole protein ribbon backbone of the PXR crystal structure and b) close up view of 
the LBD showing hydrogen bonding with key amino acids. Figures 5.15 to 5.21 show 
rifampicin, hyperforin, RU486, ICI 182780, enterolactone, PCB 153, and triclosan, 
docked in the LBD of the PXR crystal structure.
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Figure 5.9a Physico-chemical PXR model
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Figure 5.9b Physico-chemical coefficients plot PXR model
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Figure 5.9c Physico-chemical variable importance plot PXR model
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Figure 5.10 V olsurf PX R m odel
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Figure 5.11 Internai validation: R andom isation test for V olsurf PX R  m odel
Internal validation of the VolSurf PXR model provides an estimation of the predictive 
ability without the help of external data sets, as described in the Cross Validation section
5.2.4.3.4. Here the approach taken involved building models where several objects at a 
time were kept out of the analysis, and the procedure was repeated until all the objects 
were kept out once to yield a conservative estimation of the real predictive ability. 25 
permutations were conducted. To obtain stable results, the procedure was repeated many 
times, and the Standard Deviation Error of Prediction (SDEP) was computed to give an 
estimate of the dispersion of the SDEP values obtained from different runs, and thus the 
reproducibility between the reduced models. The intercepts of R“ and shown below 
indicate successful cross validation of the PXR VolSurf model.
Randomisation test
Intercepts: R2 = (0.0, 0,1 95), Q2 = (0,0, -0.330)
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Q 2
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Figures 5,12 and 5.13 below show the variable importance plot and the standardised 
coefficients plot for the PXR model.
Fig 5.12
PXR Variable Importance Plot
Fig 5.13
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Figure 5.14. The PXR crystal s tructu re  with a) SR12813 docked in the LBD, 
showing the whole protein ribbon backbone of the PXR crystal structu re  and  b) a 
close up of the LBD showing hydrogen bonding (dashed yellow lines) with key 
amino acids. (lOuM SR I2813 % max induction 136% relative to lOuM rifampicin). 
a)
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Figure 5.15. The PXR crystal structure  with a) pregnane dione docked in the LBD 
and b) rifam picin docked in the LBD. (% max induction 98,8%) 
a) b)
Figure 5.16. The PXR crystal structure  with hyperforin docked in the LBD. (luM  
hyperforin % max induction 152% relative to lOuM rifampicin).
'4W
Figure 5.17. The PXR crystal structure with a) 4-hydroxytamoxifen docked in the
LBD. (% max induction 84% relative to rifampicin) b) RU846 docked in the LBD. 
a) b)
217
Figure 5.18. The PXR crystal structure with phénobarbital docked in the LBD.
Figure 5.19. The PXR crystal structure with a) secoisoresorciresinol (% max
induction 20% relative to rifampicin) and b) enterolactone docked in the LBD. (% max 
induction 36 % relative to rifampicin) 
a)
Figure 5.20. The PXR crystal structure with a) PCB 153 and PCB 118 docked in the 
LBD. (% max induction 16% relative to rifampicin) and b) PCB 153 in a different 
orientation, in the LBD
a) b)
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Figure 5.21, The PXR crystal structure with dexamethasone docked in the LBD.
(% max induction 24% relative to rifampicin)
1
Figure 5.22. The PXR crystal structure with triclosan docked in the LBD. (%
max induction 46% relative to rifampicin)
Figure 5.23. The PXR crystal structure  with RU 486, SR12813, rifam picin and 
the other compounds all docked in the LBD, showing the structu ral space in the 
LBD cavity of PXR, and hydrogen bonding with key amino acids.
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R esults o f training sets with G SK  com pounds
Figures 5.24 and 5.25 show the test set plots. Both sets had a large number of 
outliers in the lower sections of the plots (e.g. approximate outliers within the red 
triangles).
A blue line is inserted through both plots to give a visual indication of the optimum 
regression line one would expect to see in a robust test set, as seen for the PXR Volsurf 
model and internal validation (Figures 5.10 and 5.11), and as shown in figure 5.26, 
where the outliers from test set 1 (below) are remodelled. As shown, the model could 
account for approximately 50% of the compounds in the test sets collated from RTP and 
Ware, but could not account for the subsets.
These outliers were removed and modelled separately, and although the R“ was low at
0.4, a trend in the remodelled test set 1 outlier data was apparent, as shown in figure 5. 
26.
Figure 5.24. Physico-chemical model: test set 1 (data collated from RTP)
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Figure 5.25. Physico-chemical PXR model: Test set 2 (general outliers indicated 
within the red triangles) (W are data  set)
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Figure 5.27. Variable importance plot for the Physico-chemical PXR outliers from 
test set 1
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5.4.5. D iscussion
The key variables for the original PXR QSAR model were:
Amide responsive regions (WAM8 and W AM l): the molecular 
envelope accessible by an amide probe. The volume of this envelope varies with the level 
of interaction energies between the amide (NH) probe and the solute molecule. Due to the 
lone pair of electrons on the nitrogen, the amide probe provides specific information that 
good acceptor abilities increase the potency of a high affinity PXR ligands. WAM8 
accounts for hydrogen bond acceptor regions, WAMl for dispersion forces. These 
descriptors are closely related to W1-W8 (resulting from a water probe), where W1 
accounts for polarisability and dispersion forces, and W8 for polar and hydrogen bond 
donor-acceptor regions.
Local Interaction Energy Minima Distance (D23): the distances 
between the best three local minima of interaction energies between a water probe and 
the target molecule, as figuratively illustrated in figure 5.28. Figure 5. 14b, showing 
SR I2813 docked in the PXR LBD, illustrates the optimum triangulation shape for 
hydrogen bonding with three amino acids in the PXR LBD.
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Figure 5.28. Simple representation of the Local Interaction Energy Minima 
Distance (D23)
molecule
Key: Each side of the 
triangle represents the 
distance between the 
three best local 
minima of interaction 
energies represented 
by the ellipses.
Hydrogen Bonding descriptors (HE 1-8): represent details about the hydrogen 
bonding capabilities of the ligands. Hydrogen (H) bonding is a common feature in NR 
studies, and also features in transporter studies, e.g. Pgp substrate studies (Penzotti et al., 
2002).
Abraham et al (2002a) have examined H bonding with respect to 
hexachlorohexanes, and suggest that for this class of compounds the hydrogen bond 
basicity of polychlorinated compounds, even those with no functional H bond group, can 
be explained by the presence of several non-interacting aliphatic chlorosubstituents that 
each contribute to the overall hydrogen bond basicity (B). While this finding can be 
applied to the ligand binding activity of such chlorinated compounds in the E R a and 
AhR binding domains, the principle is also applicable to the PXR QSAR study with 
respect to the dominance of the D23 descriptors which represent the distances between 
the best three local minima of interaction energies when a water probe interacts with a 
target molecule.
The less important, but relevant, variables included Molecular Surface (S), 
Molecular Volume (V), Polarisability (POL), Hydrophobic Integy Moments (ID 1-IDS), 
Capacity Factors (Cwl-CwS), Amphiphilic Moment (A) and Molecular Globularity (G).
This model was and is being tested further, utilising in house GSK proprietary 
% mean induction PXR data, generated from the same assay procedure and HuH7 cell 
line.
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Two test data sets were collected, one collated from data generated and posted by 
operators at the GSK RTP site in North Carolina, US; the other from validation data 
generated at the GSK Ware site in the UK. In both cases only data generated within the 
last two years was utilised, and only data from experimental runs reporting acceptable 
values for the positive control rifampicin (within 80-120%) and compound data that 
compared favourably with in house validated data sets. The compounds in these data sets 
cannot be identified by name or structure due to commercial confidentiality. The models 
generated in both cases had a large number of outliers in the lower quadrant of the model, 
see figure 5.11. These models are based on the Abraham and other physicochemical 
descriptors, as some of the compounds were too large to generate VolSurf descriptors.
A preliminary analysis showed that the compounds with relatively large MW 
(larger than rifampicin), and fatty acid-like in structure, with extended molecular shapes, 
were the outliers.
When removed from the model and remodelled separately these outliers did 
show a linear trend, but the correlation was not significant (R^=0.4), figure 5.26. This 
result could indicate that a bimodal form of ligand binding may occur in the PXR LBD, 
such that this group of structurally similar compounds binds with an amino acid in 
another part of the LBD, as opposed to the amino acids that are required for binding as 
shown in the PXR crystal structure figures (5.27). The following physicochemical 
properties dominate the outliers model (n=31, taken from the RTP test set, n=149), in 
descending order: Positive associations: Calculated log P (clogp), trifluoromethylbenzene 
descriptor (proprietary to GSK), flexibility (related to the number of rotatable bonds to 
total bonds), Andrew’s binding energy (the functional group contributions to drug- 
receptor interactions, (Andrews et al., 1984), Number of heavy atoms in the molecule, 
MW, CMR (a size descriptor), Vx (a molecular descriptor relating to McGowan 
characteristic volume), two in-house (and proprietary) Pgp descriptors, and the count of 
negatively ionisable groups in a molecule. Although not dominating the outliers 
coefficients plot, this last descriptor contrasts with the positively charged descriptors 
observed in the original PXR physico-chemical model (figure 5.9a). Negative 
associations were apparent for amine groups (figure 5.27). The descriptors identified 
differed to those identified for the physicochemical model for the original test. The 
differences were observed particularly for the amine descriptor and BetaH, a molecular 
descriptor relating to H-bond basicity and the count of the number of positively 
ionisable/charged groups in a molecule, which all held a positive association in the PXR
224
physicochemical model (figure 5.9c); while phenolic OH groups and Alpha, a molecular 
descriptor relating to H-bond acidity were both negatively associated. Similar descriptors 
were also observed and are shown in both plots (figure 5.9c) and figure 5.27, 
respectively. Other possibilities may be the involvement of transporters, e.g. Pgp as 
discussed in chapter 4, or something else.
If transporters are part of this interaction, the compound would be more likely to 
have organic acid functions (A. Ayrton pers comm.), but this was not observed when the 
test set 1 model was screened using Spotfire (v 5.1. www.spotfire.com). the outliers 
tended to be more basic as identified by the pale blue boxes in figure 5.29.
Figure 5.29. Spotfire plot, PXR test set 2: acid-base class
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5.4.6. Conclusions
This investigation has allowed a better understanding of PXR ligands and the 
following may be concluded:
1. Compounds with high affinity for PXR are likely to have increased hydrogen 
bond acceptor and donor abilities, have an optimum distance between the three local 
minima of the interaction energies to fit within the main LBD pocket (e.g. SR 12813 and 
SR analogues) and may accept binding with additional amino acids in the LBD, with
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increased surface and volume (e.g. hyperforin, 40H  tamoxifen) and/or enlarge the 
binding pocket further to accommodate (e.g. rifampicin and large fatty acid-like 
structures). Furthermore, the hydroxylated forms of compounds are likely to be more 
potent than the parent compound (e.g. enterolactone, OH vitamin D 3 ,4 OH tamoxifen).
Lignans present in the human diets can be metabolised to weak-medium affinity 
ligands for PXR. Common food sources such as rye, whole grains, flaxseed and berries 
provide the parent lignans from which enterolactone is fermented by colonic bacteria. 
Relatively high intestinal levels of enterolactone are likely to be present in populations 
with high dietary intakes of these foods (Heinonen et al., 2001), for example Northern 
and Eastern European populations.
2. Persistent organic pollutants, such as PCB118 and PCB158 are weak ligands, 
but may well become more potent when hydroxylated as observed in the ER. The 
pesticide trans-nonachlor is a medium affinity ligand, as is triclosan, a commonly used 
bacteriocide.
From the test set studies conducted with in-house GSK NCEs, it is apparent that 
there may be another form of binding occurring in PXR for compounds with long 
expanded side-chains. This was observed particularly for NCEs designed to be PPAR 
ligands, and therefore fatty acid like in structure. The possibility of a bimodal form of 
ligand binding in PXR is supported by the compound docking studies reported here and 
PXR crystal structure studies, upon which they are based, both indicate an expandable 
LBD. While descriptors relating to ClogP, MW, and others, featured in both the original 
physicochemical coefficients plot and the later outliers plot, certain physicochemical 
descriptors differed between the PXR model and outliers trend model, particularly the 
amine descriptor, and positively and negative charged groups. Being mainly fatty acid 
like in structure, these outliers also have a greater amount of hydrophilic regions per 
surface unit. That different classes of compounds bind differently within the same 
receptor is known for other NRs, such as the ER for instance.
These results are being utilised in ongoing comparative QSAR receptor studies 
examining crosstalk and ligand promiscuity. With sufficient resources, future QSAR 
studies of PXR could ideally use statistical experimental design to generate well balanced 
training and validation data sets of representative PXR ligands.
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5.5. Multivariate (QSAR) Modelling Of Polybrominated Diphenyl Ethers 
Activity In Different Species Cell Lines And Their Capacity To Induce CYPIA By 
The Ah Receptor Mediated Pathway
5.5 .1 . Introduction
The widely used flame retardants polybrominated diphenyl ethers (PBDEs) are 
persistent and ubiquitous organic pollutants (POPs) that biomagnify and may have 
endocrine disrupting effects similar those observed for other halogenated compounds, 
such as polychlorinated and polybrominated biphenyls (PCBs and PBBs), 
polychlorinated dibenzo-p-dioxins (PCDDs) and polychlorinated dibenzofurans (PCDFs). 
Concern with the risks to human health, particularly among infants, is increasing due to 
observations of increasing PBDE concentrations in human breast milk (Meironyté 
Guvenius et al., 2003), although available data suggest that current levels of PBDEs are 
an order of magnitude lower than those of PCBs (Meironyté Guvenius et al., 2003). 
Levels are reported to be lower in European populations (Meironyté Guvenius et al., 
2001), compared to those reported for California, where body burdens of BDE 47 were 
3-10 times higher, ranging between 5 and 510 ng/g lipid (Petreas et al., 2003). Exposure 
occurs occupationally (Eriksson et al., 2001b; Rahman et al., 2003), environmentally 
(Boon et al., 2002) and in the diet (Bocio et al., 2003; Damerud et al., 2001), as 
elaborated upon in section 2.2. While PBDEs are in extensive production and use, 
existing data on the receptor mediated toxicology of PBDEs are very limited, but there 
are indications of toxicity via the estrogen, thyroid and Ah receptors (AhR) and oestrogen 
sulphotransferase inhibition (Bergman, 2000). In vivo evidence suggests that PBDEs 
interfere with the thyroid hormone system, via upregulation of uridinediphosphate- 
glucuronosyltransferase (UDPGT) by 3 to 4 fold. The acute toxicity of mixtures appears 
to induce porphyrinicity, and increase hepatic enzymes such as ethoxy- and pentoxy- 
resorufm-D-deethylase (EROD and PROD) levels between 10-40 fold (Zhou et al., 
2001). BDE 47 and BDE 99 are reported to cause learning and memory developmental 
defects, as observed with PCBs (Eriksson et al. 2001b), and so PBDEs are considered a 
potential risk for neurobehavioural development in humans (Branchi et al., 2003). In cell 
signaling, an in vitro mechanism of toxicity has been observed by way of increasing 
Ca^^ oscillations stimulating greater release of arachidonic acid (AA), (Branchi et al., 
2003). As AA is a ligand for the PPARs, and is implicated in autoimmune dysfunction.
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the health impacts of PBDE exposure could be further implicated in the destabilizing of 
NR and PPAR molecular pathways, through multiple mechanisms.
Multivariate techniques are useful for data analyses of selected compounds, 
tested in a broad battery of test systems where there is a large variation within some of 
the variables. Here the AhR QSAR data are suitable for activity estimation, and they can 
provide warnings/alerts about possible toxic properties of the test compounds. QSARs 
can be used, therefore, for decision support in early phases of product development to 
regulatory decision-making such as in risk assessment and risk classification.
This study generates a principal component analysis (PCA) and quantitative 
structural activity relationship (QSAR) for the AhR, using multivariate techniques, 
specific descriptors, and biological data sets. This QSAR utilized experimentally 
generated PBDE data sets (Chen et al., 2001), together with an unpublished data set from 
the same laboratory, for twelve PBDEs capacities to bind and activate the AhR in rat and 
human hepatocytes, human intestinal cells and to induce CYPIA, which here was 
assayed as 7-ethoxyresorufin-O-deethylase (EROD) activity in cells from rainbow trout, 
chick, rat and human.
VolSurf and physico-chemical descriptors were generated for each of the 
compound structures for which biological data were available and subsequently used to 
develop a partial least squares regression based model. 2,3,7,8-TCDD was an outlier 
compared to the PBDEs, and major differences were apparent between the different cell 
line ECso’s (n=7) reflecting PBDE ligand potencies in AhR, and cell line EROD % values 
(n=7) reflecting CYPIA induction.
These multivariate analyses are supported by utilising a homology model of AhR 
(based on the E R a crystal structure), see chapter 3, to examine the mode of binding of 
representative compounds in the ligand-binding domain (LBD) of the receptor model. 
Key commonalities and differences between the ligands when bound in the LBD have 
been observed and are discussed in chapter 3.
5.5.2. M ethods
5.5.2.7. Generation o f  PBDE biological data using in vitro assays.
The following PBDEs (lUPAC No’s 28, 47, 66, 77, 85, 99, 100,119, 126, 153, 
154, 183) were tested relative to 2,3,7,8 TCDD in the following cell lines: RTL-W l: 
rainbow trout hepatoma; CEH: primary chick embryo hepatocytes; PRH: primary rat 
hepatocytes; H41IE; rat hepatoma; Caco-2; human adenocarcinoma; Hep G2; human
228
hepatoma, from which EC50’s and EROD%, representing the highest EROD activities 
from individual congeners compared with the activity of the positive control InM 
TCDD. Methodologies are described in Chen et al. (2001b).
5 .5 2 2 . Statistical analysis fo r  the evaluation and interpretation o f  the data
To enable the evaluation and interpretation of these multivariate data PCA and 
PLS multivariate techniques (Umetrics, SIMCA-P v.10.0) and VolSurf descriptors were 
used, as described in section 5. 2.
5.5.2.3. Utilization o f  a homology model o f  AhR based on the E R a  crystal structure
The homology model of AhR based on the E R a crystal structure was used for 
docking studies of PBDE, TCDD and PCB ligands in the hAhR model, using SYBYL 
biopolymer software and visualised on a Silicon graphics Indigo^ IMPACT 10000 Unix 
work station (Tripos Assocs. St Louis, MO), see Chapter 3.
5.5.3. Results and Discussion
The data sets were analyzed using PCA and PLS techniques. Initial analysis 
suggested the presence of an outlier, (2,3,7,8-TCDD), which was subsequently excluded 
in the 3-component model shown. In this way the PLS model R2X value improved from 
0.4 to 0.77 (n=12, RMSEE=15.71), with a good fit (R2Y=0.71) but poor predictability 
(Q2=0.16) as seen in the PLS primary variables plot (fig 5.30). The summary plot of the 
model fit, (fig 5.31) and the loadings plot (fig 5.32) show the success of the model fit for 
each of the Y responses. Specific descriptors were positively correlated with the 
biological responses in the top left box, and negatively correlated with the bottom right 
box.
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Taking the best-predicted biological parameter, the human hepatocyte cell line 
Hep G2 EC50, the following Volsurf variable importance (fig 3) and coefficients (fig 4) 
plots were derived.
Figure 5.32. Variable Importance plot
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Figure 5.33. Coefficients plot: Hep G2 EC50
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The key variable was the local interaction energy minima (Emin3) which 
had a large negative correlation. This represents the energy of interaction in kcal/mol of 
the best three local minima of interaction energies between a water probe and the target 
molecule. Positive correlations were observed for: Local interaction energy minima 
distances (D12), these are shape descriptors for the distances between the best three local 
minima of interaction energies when a water probe interacts with a target molecule; 
Hydrophobic integy moments (ID7 and IDS) which measure the imbalance between the 
centre of mass of a molecule and the position of the hydrophobic regions around them, 
and hydrogen bonding (HB7) capabilities of the ligands.
Less important negatively correlated variables were; capacity factors 
(Cw5 and Cw6), which represent the amount of hydrophilic regions per surface unit, and 
amide responsive regions (WAM7), suggesting that good acceptor abilities may not 
increase the potency of high affinity AhR ligands. WAM7 accounts for hydrogen bond 
acceptor regions, W AMl for dispersion forces. These descriptors are closely related to 
the hydrophilic regions (W5 and W6) where, in the Volsurf hydrophilic scale, W1 
accounts for polarisability and dispersion forces, and W8 for polar and hydrogen bond 
donor-acceptor regions.
Both in vitro and in silico docking studies suggest different modes of 
binding in the AhR for the planar TCDD compared to other ligands, and this is reflected 
in the key VolSurf variables observed from the QSAR exercise. 2,3,7,8-TCDD appears 
to bind in the AhR more potently by hydrogen bonding (Chapter 3, section 3.4 and figure
3.11), while other less potent ligands such as PCBs might ligand bind through n-n  
stacking (figure 3.12) or just one hydrogen bond with an arginine residue, as suggested 
from docking PBDE 47, a non-planar compound in the LBD (figure 5.34). Both possible 
modes of binding with specific key amino acid residues triggering different 
conformational shapes of the receptor-ligand binding sites and energies to that of 2,3,7,8- 
TCDD (Jacobs et al., 2003), that have also been termed electronic elasticity-toxicity 
relationships for the PCDD congeners (Asatryan et al., 2002). The importance of the 
electrostatic effects at some substituent positions of halogenated PCDD and PCB 
congeners has been shown in other QSAR studies using MLR (Lewis and Jacobs, 1999) 
and PLS (Oprea et al., 2001).
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Figure 5.34. 2,2’4,4’ TBDE (PBDE 47) shown in two different perspectives, docked 
in the LBD of the AhR in silico model based upon the ERa crystal structure.
Hydrogen bonding with the oxygen (in red) is indicated by the dashed orange line.
In this study, the only outlier was 2,3,7,8, TCDD, which does exhibit different 
structural characteristics from the rest of the PBDE series. In PLS models it has been 
often observed that the outlier molecule has different vertex occupancy compared to the 
remaining majority. These structural differences are of real importance for ligand- 
receptor interactions, so such outliers have been termed ‘artificial’, since they are likely 
to have similar and additional binding mechanisms, but are detected as belonging to a 
different cluster (Oprea et al., 2001).
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5.5.4. Conclusions
There are many considerations for cell lines of choice when conducting in vitro 
assay screening, including tissue, ease of maintenance and use, receptor and transporters 
expression. In this study, the human Hep G2 cell line was the best for predicting receptor 
binding and C Y PlA l induction for PBDEs. Analyses of the Volsurf variable 
contributions together with observed in silico modes of ligand binding in the AhR model 
allow additional insights into receptor activation on a compound and chemical family 
specific basis, as well as ligand promiscuity and ligand-receptor cross talk when 
compared to other receptor QSAR studies. This is of relevance in the consideration of 
AhR and CYPIA mediated xenobiotic species-specific interactions, and a better 
understanding of the molecular mechanisms of AhR mediated PBDE pollutant toxicity 
and endocrine disruption.
It would also be useful to conduct similar QSARs with the PBDE data generated 
from, for example, ER activation assays (Meerts et al., 2001), particularly in view of the 
known cross talk between the ER and AhR (Chapters 1 and 3).
5.6. Overall discussion and conclusions
QSARs are used extensively by the pharmaceutical industry, for prediction of 
drug metabolism, but for many applications the rules are not very well informed by the 
biology of the processes involved, and it is not possible to make effective literature 
comparisons between studies of receptors for example, because diffferent drug properties 
(descriptors) are used from one study to another. Apart from the basic physico-chemical 
descriptors, this makes it hard to directly compare the results for different processes and 
thus uncover possible models for biological processes, such as NR cross talk. Here 1 have 
made a start at examining NR metabolism by attempting a thorough review of the 
molecular to epidemiological biology of the processes involved, and then utilized the 
same body of descriptors, VolSurf descriptors, to compare a number of biological and 
physicochemical processes. The methodology was successfully validated using data from 
the literature, in house, and by conducting internal validations.
There are key differences in descriptors for the different receptors, with respect 
to different ligands. Sometimes the compound combinations might have additive effects 
(Silva et al., 2002) in defined NR systems and sometimes they might negate each other 
in a specific NR system, but have effects on other receptors, that are part of the 
communication system. A good example of this can be seen in the varied literature
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reports of ligand interactions between the ER and AhR, the steering role of PXR and 
CAR (Honkakoski et al., 2003) and other interactions discussed in chapters 1 and 3.
The key Volsurf descriptors for each receptor study in this chapter are 
summarized in descending order of significance, in Table 5.3. The Volsurf chemical 
information is distributed differently for each receptor studied, and key differences 
between receptor-ligand activation demonstrate the complexity and concerted defense 
mechanisms available at the molecular level. The varieties of receptor-ligand binding 
interaction clearance strategies provide an intricate back-up homeostatic system to clear 
tissues of xenobiotics that disturb the homeostatic equilibrium.
Similar studies in the same and other NRs, including AhR, are currently 
underway, which can add to this information, and so give indications of which 
compounds activate which receptors, and so inform as to which receptor-mediated 
pathways are likely to be stimulated by a compound or given class of compounds.
For all the receptors studied, positive correlations were observed for hydrogen 
bonding (HBl-8), and negative correlations were observed for capacity factors (Cwl-8), 
which describe the amount of hydrophilic regions per surface unit. Apart from these 
commonalities, the QSARs presented here suggest that for the ERa, rugosity (R), 
hydrophobic regions (D1-D8), polarisability (POL), amphilic moment (A) and 
globularity (G) were positively correlated with ligand binding, while this was not the case 
for PXR, where the most important descriptor was WAM8.
There are many other QSAR analytical rule-based techniques that these studies 
could be incorporated into, such as feature trees (Rarey and Dixon, 1998), decision trees 
(Bursi et al., 2001) hierarchical cluster analysis (Suzuki et al., 2001), chemical global 
positioning mapping devices (Oprea et al., 2002) and neural networks (Bayada et al., 
1999; Vendrame et al., 1999; Huuskonen, 2003). Ideally one should also incorporate the 
water molecules present in the LBD when conducting 3-D QSARs, as water present in 
the LBD has been recognized to play a major role in ligand-protein interactions (Pastor et 
al., 1997).
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Table 5.3. Summary of VolSurf descriptor data generated from the NR QSAR 
studies described in this chapter.
Key VolSurf Other key Typical Biological Cell line Test Biological da
d Descriptors* known LBD parameter ligands Reference1 NR Correlation descriptors features of
1 +ve -ve ligands
5.2 ERa R, D1-D8, wl-8, H bonding 6Â Uterine ER Rat uterine Broad Fang et al., 2001
HBl-8, Cwl-Cw8, biopbore/pbeno ligand binding cytosol ER range of
POL, A, HLLHL2 lie A ring competitive chemical
G structure binding
assay
classes
5.3 PXR WAM8- IDl-8, H bonding 1 .H bond % maximum HUH7 Broad Chapter 3
WAMl, HB7, HBl- acceptors induction transient range of
D23, S, G, 2, Cwl- 2. an optimum relative to transfection chemical
V,POL Cw8,
A
distance 
between 3 local 
minima of 
interaction 
energies
rifampicin classes
5.4 AhR D12, ID8, Emin3, H bonding 1. Planar PAH AbR ligand HepG2 PBDEs Chen et al., 20011
HB7 Cwl-8, 
HB6, HBl, 
WAM7
K-n stacking structure 
2. Non-planar 
PAH
binding and Chen, 
unpublished data
* Symbols are explained in the text and in Appendix 3 Table I: Summary of 
VolSurf descriptors
There are also many other descriptor methods available that relate well with the 
Volsurf and physico-chemical descriptors used here, such as the minimum topological 
difference method (MTD), which also aims at describing steric, hydrophobic, 
electrostatic and hydrogen bonding characteristics of the binding site regions in the 
vicinity of the ligand atom positions (Kurunczi et a l, 2002), and molecular fingerprinting 
descriptors (Bayada et al., 1999).
By looking at NR QSARs comparatively, together with homology modelling, 
crystal structures and multiple molecular dynamics simulations for different NRs as 
described in this thesis and other related NRs as reported in the literature, e.g. the AR 
(Marhefka et al., 2001) further insights and greater interpretability into receptor-ligand 
dynamics can be achieved.
236
C hapter 6
N uclear R eceptors and Ligand-G ene Interactions 
Im plications For H um an H ealth
237
Chapter 6
N uclear R eceptors and L igand-G ene Interactions 
Implications For Human Health
‘The flaw s o f  nature may turn out to be as significant as the laws o f  nature fo r  our
understanding o f  true realityd 
John Barrow (2003)
6.1. Nuclear receptors and human health
6.1.1. Summary
The studies presented in the preceding chapters examine molecular gene-ligand 
interactions with some of the many receptors involved with development and xenobiotic 
metabolism. The activation of nuclear receptors by metabolites underlies most of the 
genetic responses controlling fat, glucose, cholesterol, bile acid and xenobiotic/endobiotic 
metabolism. Steroid, heme, and xenobiotic metabolism are controlled by a network of 
interrelated but unique nuclear receptors. The ER, AhR, PXR and CAR receptors, (Figure
6.1. gives an overview) mediate the steroidogenic pathway shown in figure 6.2. PFARa 
regulates the catabolism of fatty acids and impacts upon several steps of the reverse 
cholesterol pathway, and several more receptors, such as LXR, FXR and HNF-4, are 
part of the endobiotic bile regulatory pathways. The combined effects of the ligands for 
the nuclear receptors are vast, influencing virtually every fundamental biological process, 
from development and homeostasis, to proliferation and differentiation. The supply of 
ligands is a further regulatory route for the receptors. The cognate ligand for each 
receptor is usually dependent on the supply of a specific dietary component for its 
synthesis, e.g. iodine and tyrosine for thyroid hormone, cholesterol for the VDR, GR and 
receptor mediated steroidogenic pathway, fatty acids for the PPARs, and vitamin A, as 
the ligand for all the trans-VQtinoic acid receptors (including the receptor 
heterodimerization partner RXRa).
The receptors studied in this thesis all have diverse modes of binding and 
activation mechanisms, but are part of an integrated, highly elaborate and complex 
system that has adaptively evolved in response to challenges to the endocrine system, 
breakdown of heme metabolites and exposure to xenobiotics and foods. Figure 6.3 gives 
an indication of the complexity of the communication web between the receptors studied 
here and selected cofactors reviewed from the literature. The adaptive nature of this 
system allows for flexibility and has given rise to the ‘evolution of novelty’ in hormone-
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receptor systems (Thornton, 2001), to ensure optimum endobiotic management and 
xenobiotic response.
Figure 6.1 An overview of xenobiotics as m odulators of nuclear receptor function
(Adapted from Carpenter et al., 2002)
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Figure 6.2. The key known receptors and P450s involved in the steroidogenic 
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Figure 6.3. Functionally significant cross-talk pathways between nuclear receptors 
and selected cofactors (Adapted from Carpenter et al., 2002)
Abbreviations not included in the text: Glut-1, glucose transporter 1; HIFa, Hypoxia Inducible 
Factora;Nrf2, nuclear factor drythrod 2-related factor 2; RB, retinoblastoma protein; VEGF, 
vascular endothelial growth factor
6.1.2. The development of steroid receptors, an evolutionary perspective
The oestrogen receptor (ER) was the starting point for this study as not only was 
the crystal structure available for homology modelling purposes, but it was also one of 
the most studied of all the NRs. Indeed, Joseph Thornton (2001) has argued convincingly 
that all the steroid receptors have evolved in vertebrates from an ancestral ER. Based on 
phylogenetic analyses, sequence reconstruction and knowledge of functional attributes of 
ancestral proteins, he has shown that the first steroid receptor was an oestrogen receptor, 
followed by a progesterone receptor. He suggests that NRs have developed through 
ligand exploitation and serial genome expansions. The full complement of present day 
mammalian steroid receptors evolved from these ancient receptors by two large-scale 
genomic expansions, before and after the advent of jawed vertebrates about 450 million 
years ago (Sharman and Holland 1998, cited in Thornton, 2001). Specific regulation of 
physiological processes by androgens and corticoids emerged after these events. 
Thornton suggests that the terminal ligand is the first for which a receptor evolves;
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selection for this hormone also selects for the synthesis of intermediates despite the 
absence of receptors, and duplicated receptors then evolve affinity for these substances. 
This might even be a pre-emptive strategy for vertebrates in combating plant defenses 
(Wynne-Edwards, 2001). Whilst originally developing to facilitate an increasing complex 
endocrine system in vertebrates, nuclear receptors have also been required to respond to a 
wide variety of xenobiotic challenges. They have a well developed role as the sensory 
component of the defense system that includes regulation of Phase I and Phase II 
enzymes and transporter proteins in response to xenobiotics. While exposure to the 
newer pollutants is discussed in this thesis, polyaromatic hydrocarbons (PAHs) exposure 
has always occurred, as PAHs are the most abundant form of carbon known (Mautner et 
al., 1997; Hecht, 2002). With UV irradiation, PAHs in ice have been shown to produce 
ketones, alcohols and quinone- or squalene-like structures (Bernstein et al., 1999). The 
Ah receptor, a member of a different family to that of the ER, has developmental and 
adaptive functions, it has similarly undergone duplication and diversification in 
vertebrates, resulting in three, possibly more, members of an AhR gene family, namely 
AhRl, AhR2 and AhR repressor (Karchner et al., 2002). The adaptation to binding 
dioxins and related chemicals was probably a vertebrate innovation (Hahn, 2002a), that 
may have been part of the response to PAH exposure, co-evolving with the ER, such that 
ER signaling can be modulated by association with activated AhR (Ohtake et al., 2003), 
but also ER and other NRs (Jana et al., 1999) may display activation by AhR ligands.
Hydrogen bonding properties of the ligands have been a key part of the 
evolutionary development of NRs. Hydrogen bonding has long been recognized as an 
important type of molecular interaction that is ubiquitous in nature, being found in 
systems ranging from water to cellular proteins and DNA (Pimentel and McClellan, 
1960; Del Bene, 1998). The variability in forms of hydrogen bonding (Abraham et al., 
2002a; 2002b) give rise to an even more elaborate communication system, where it may 
only be a difference between a few key residues in the ligand binding domain (LBD) that 
produces species variability and within-species receptor differences in response.
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6.1.3. Receptor-ligand interactions
Receptor-ligand interactions have been examined for selected receptors in 
Chapters 3 and 5. This work adds to and supports the literature on ligand-NR interactions. 
Ligands bind with, activate, or suppress receptors in a wide variety of ways, but 
conformational change that leads to DNA interaction is not always induced. For instance, 
recent work by Henry and Gasiewicz (Henry and Gasiewicz, 2003) shows that agonists, 
but not antagonists (such as dietary and synthetic flavones), cause a conformational 
change to the DRE-binding conformation in vitro. As mentioned in Chapters 3 and 4, the 
mutation of one key residue in the AR LBD ablates the ligand binding of testosterone 
(Rabenoelina et al., 2002), while the mutation of four specific LBD residues (or two 
different residues in mouse and human each) causes a species specificity change in PXR 
(Watkins et al., 2001; Ôstberg et al., 2002).
6.1.4. Role of Protein and Enzyme Coregulators
Molecular mechanisms of ligand-receptor binding and gene activation include a 
large number of modulatory protein transcription factors and transporters as part of the 
receptor activation process. There is an intricate network of these cofactors embedded 
into the NR communication web, each one having functionally significant inter-related 
roles with specific receptors, sometimes several receptors, and other proteins. Many 
cofactors act in concert with each receptor, to facilitate transport, activation or repression, 
and understanding of the significance of cofactors has increased dramatically in the last 
two or three years. Common intermediaries are shared in receptor and other signaling 
pathways. Some of the cofactors known to have functionally significant roles for the 
receptors, particularly for PXR, have been identified in Chapters 3 to 5. Receptors are 
also known to regulate cofactors, thus PXR and CAR not only co-regulate xenobiotic 
metabolism, but also drug transport (Staudinger et al., 2003). As previously discussed, 
the key cofactors that are part of the cross-talk pathways between the AhR, ERs, PXR, 
CAR and PPARs, shown in figure 6.3, emphasizes the influence that cofactors and 
receptors exert upon each other to maintain equilibrium. Although not discussed further 
in the context of this thesis, as with the cofactors mentioned below, repressor proteins are 
also likely to be important cofactors in receptor mediated steroid and xenobiotic 
metabolism.
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6.1.4.1. Receptor-receptor and receptor-enzyme interactions
Receptor-receptor and receptor-enzyme interactions constitute a very large field 
of study, and this thesis has attempted to describe some of the interactions between the 
ERs, AhR, PXR, CAR, the PPARs (to a lesser degree) and the P450’s these receptors 
induce. Here three further examples are given of the many varied signaling pathways 
between related NRs.
The AhR and ER have a well established intricate relationship that may be 
further modulated or regulated by COUP-TFl. COUP-TF, known to be part of the 
CYP3A signaling pathway (Swales, 2002), has been shown by Klinge and colleagues to 
regulate AhR action in vitro by direct competitive DNA binding and protein-protein 
interactions (Klinge et al., 2000).
Also part of the CYP3A signaling pathway, Drocourt et al (2002) have recently 
shown in primary human hepatocytes that, together with PXR and CAR, the VDR has a 
regulatory (but not primary) role, controlling the basal and inducible expression of 
CYP3A4, CYP2B6 and CYP2C9 (which is primarily a GR responsive gene). In doing so, 
Drocourt and co-workers suggest that the expression of VDR controlled genes might be 
affected by xenobiotics, such as rifampicin, through the PXR and CAR pathway.
In vivo studies in an immature gonadotrophin-primed female rat model have 
shown that in ovaries (an oestrogen responsive tissue), COX-2 is induced the morning 
after ovulation, but greatly inhibited by TCDD via AhR signaling (Mizuyachi et al.,
2002). GR was also observed to be down-regulated. Blockage or reduction of COX-2 
expression is known to impair ovulation, and there appears to be a feedback loop in the 
ovary between AhR signaling and reduced COX-2 expression that may depend upon a 
reduced Leutinising Hormone (LH) surge due to the stimulation of corticoids, via GR 
autoregulation, and the inhibition of gonadotrophin surges (Mizuyachi et al., 2002).
6.1.4.2. Heterodimerization Partner: R X R a
Belonging to the steroid hormone nuclear receptor superfamily, ubiquitous 
RXRa is the necessary heterodimerization partner for many receptors in order to bind to 
DNA, including the thyroid hormone receptor, ERs, PXR, CAR (Kakizaki et al., 2002), 
LXR, FXR, PPA Ra (Cai et al., 2002) and PPARy (Dubuquoy et al., 2002). The crystal 
structure data of the PPARy/RXRa heterodimer show the asymmetric conserved 
heterodimerization interfaces of both receptors (Gampe Jr et al., 2000). RX Ra dimerizes 
through a 40 amino acid sub-region within the LBD known as the identity box. Mutation
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of two important determinants (Alanine 416 and Arginine 421) within this box has been 
shown to impair the actions of receptor dimerization partners (Lee et ah, 2000). RX Ra is 
established as a heterodimeric integrator of multiple physiological processes in the liver 
and is a regulatory component of cholesterol (Edwards and Ericsson, 1999; Russell, 
1999; Song and Liao, 2000), fatty acid (Edwards et al., 2002), bile acid (Wang et al., 
1999; Makishima et al., 1999), steroid and xenobiotic metabolism and homeostasis (Wan 
et al., 2000).
Suppression of RX Ra has a concomitant effect upon the heterodimerization 
partner. For example, LXR is reported to inhibit PPARa signaling in this way, in the 
nutritional regulation of fatty acid metabolism and PPARa has a counter inhibitory 
action repressing LXR/RXR binding through the sterol regulatory element binding 
protein - I c  (SREBP-lc) (Ide et al., 2003; Yoshikawa et al., 2003).
RX Ra also has cofactors in common with the NRs, for instance Weibel et al 
(1999), have shown a competitive element between RIP 140 and SRC-1 in binding to 
heterodimers of a novel orphan receptor, OR-1 with RXR. RIP 140 is also implicated in 
the potentiation of EDCs in yeast ER in vitro studies (Sheeler et al., 2000). SRC-1 RXR 
phosphorylation can also be induced through stress pathway activation (Lee et al., 2000), 
which would reduce RXR heterodimerization availability for other receptor partners.
6.1.4.3. Heterodimerization Partner: A R N T
The heterodimerization partner of the AhR is ARNT (Elbi et al., 2002) and has 
been described in Chapter 3. However ARNT is also a potent coactivator of ER 
dependent transcription that requires the oestradiol activated LBD of E R a or ER(3 
(Brunnberg et al., 2003), but unlike the AhR does not also interact directly with orphan 
receptor COUP-TF (Klinge et al., 2000).
6.1.4.4. Chaperone proteins
Heat shock proteins such as hsp90, discussed in Chapter 1, can be shared as a 
chaperone factor, as seen with the ER and AhR but AhR activation is possible without 
the presence of hsp90 (Phelan et al., 1998).
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6.I.4.5. Selected examples o f  other activators and cellular responses
Chromatin remodelling complexes have been noted to be coactivators of 
receptors, thus Brahma/SWI2-related Gene 1 Protein (BRG-1) is part of the functional 
signaling pathway of the AhR/ARNT complex that mediates C Y PlA l transcription 
(Wang and Hankinson, 2002).
GR associated proteins are known to interact with PXR and CAR. Glucocorticoid 
receptor interacting protein-1 (GRIPl), for instance mediates ligand -independent nuclear 
translocation and activation of CAR in a mouse model (Min et al., 2002).
A CAR and PXR response element has been identified in the promoter of the 
human inducible nitric oxide synthase gene (iNOS). Since iNOS-induced production of 
nitric oxide is known to influence inflammation and apopotosis, CAR and PXR 
regulation of iNOS activity is probably part of the modulation effect of steroids and 
xenobiotics on these cellular processes (Toell et al., 2002).
Cross-talk involving stress signals and AhR mediated gene transcription may determine 
physiologic responses to xenobiotics via C Y PlA l or CYP1A2 induction. Oxidative 
stress is known to cause a down regulation of the AhR-regulated P450’s C Y PlA l and 
1A2 (Carpenter et al 2002), but whilst associated with a function of the AhR, 
mitochondrial reactive oxygen production can also produce these effects independently of 
CYP lA l and 1A2 (Senft et al., 2002).
One of the key sources of oxidative stress is the P450 system, which itself is regulated by 
these receptors.
6.1.4.6. CYP17A1/CYP19A1 (Aromatase) and cofactors
Aromatase (highlighted in Chapter 1) is part of the steroidogenic P450 signaling 
pathway and is expressed to high degree in or near ER positive breast cancer tumour 
sites (Brodie et al., 1999; Liao and Dickson, 2002). Aromatase is also stimulated through 
other biological pathways. For instance elevated levels of the cyclooxygenases COX-1 
and COX-2 appear to increase aromatase activity, and thereby increase oestradiol 
biosynthesis (Richards et al., 2002), as well as increasing prostaglandin secretion, which, 
by providing an appropriate supply of ligands, may increase activation of PPARs in 
local tissues.
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6.1.5. Considerations and conclusions
NRs are dynamic protein structures and will adapt in different ways to given 
situations. Thus the in silico models, the in vitro host cell systems and even the receptor 
null in vivo studies cannot give precise information on the real life situation: At best, they 
can only suggest possible molecular mechanisms of activation, predict cellular 
mechanisms in vitro and indicate the possible physiological pathways, in vivo. Other 
receptors, signaling proteins and transporters will expand their metabolic activities to 
fulfill the role required of the missing receptor, to adapt and optimize the receptor 
signaling pathways in living systems. However, as described in this thesis, the utilisation 
of in silico and in vitro tools can help tease out our understanding of how the receptors 
function as part of hormone dynamics and xenobiotic metabolism. Applying these 
techniques to an extended range of receptors, and new crystal structures as they become 
available is a primary avenue of future research.
There are three key strands running through this thesis that such work can be 
applied to. These include applications for the pharmaceutical industry, applications for 
environmental health and dietary exposure to chemical contaminants, and screening for 
potential EDCs.
A brief overview of possible applications and further research arising from this 
thesis follows.
6.2. Future work
6.2.1. Future research with respect to contaminants in the aquatic food chain
As discussed in Chapter 2, high persistent organic pollutants (POPs) levels are 
known to occur in fish, when compared to other food groups. The difference in these 
levels is species and fat content dependent. Therefore, certain oily fish are known to be a 
potential health risk, and dietary restrictions and maximum limits have been introduced in 
the European Union (EU). In recent years, farmed fish products have become 
increasingly available to the European consumer, and the farmed fish industry, 
particularly salmonid, has grown significantly in Europe.
While there is extensive research documenting the bioaccumulation of POPs in 
the marine environment, relatively little data have been available on contamination 
pathways in aquaculture systems, especially for farmed salmon. Raw aquaculture feed 
materials can greatly influence the fish body burden of POPs, and be significant sources
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of POPs in the feed. High POP levels may cause negative health effects in consumers of 
such fish, as well as in the fish. The Baltic sea fish caught in Finland and Sweden have 
specific EU market exceptions, which are due to be revised by the EU at the end of 2006. 
However, with reports in 2003 that there are no spawning cod in the Baltic (only fish less 
than two years old), together with a similar situation for the cod in the Atlantic, the 
consumption of salmonids from the Baltic (which remain relatively plentiful), for 
communities bordering the Baltic, is likely to increase. Due to the combination of the 
contamination situation in the Baltic Sea and a greater fat content than non-oily fish, 
Baltic salmonids have high reported levels of dioxins and PCBs. Ideally, the reduction of 
contaminant body burdens in Baltic fish need to be assessed and developed (as described 
in Gobas et al., 1999, for example).
The data available on POPs and other contaminants in oily fish and fish products 
entering the European markets need to be improved. Risk assessment-based new methods 
for pre-screening important POP chemicals can be developed, based on in silico 
modelling techniques combining NR crystal structures and compound QSARs.
This information could then be part of consumer information strategies with 
respect to the risks and benefits associated with eating (oily) farmed or wild fish.
6.2.1.1. Future research: A  European Union policy perspective
Due to the concern of human health risks, the EU has introduced maximum limits 
(MLs) for dioxins. The Baltic region is of special concern; Sweden and Finland have 
obtained exceptions from the ML on Baltic fish intended for consumption within 
respective countries until 2006. A condition for this exception is that these countries 
effectively inform the consumers about the possible risk, and give recommendations for 
restrictions on intake. Other Baltic countries are likely to apply for similar exceptions 
once they become members of the EU (in 2004). Information on consumers’ eating habits 
(with particular reference to girls and women of child bearing ages), and risk attitudes 
regarding oily fish, could also provide a base for information strategies.
Modelling techniques for dietary intake (including probabilistic modelling) and 
multivariate techniques for contaminant analysis can be applied to the analysis of the 
biomagnification of chemical contaminants between fish feed and fish as food.
The collection of epidemiological data collected for POPs breast milk studies, 
and meta-analyses of data from the literature, would address vulnerable population 
groups.
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Further studies could include selective contaminant assessment of convenience 
and processed fish products, compared with non-processed raw materials, to provide the 
means to assess contamination pathways in convenience foods and catering systems with 
respect to changing lifestyles. Such data would contribute to the EU overview of the 
maximum permitted levels of specific food contaminants. Multivariate analyses of time- 
related differences, as shown in the fish oil study in Chapter 2, section 2.5, would be 
appropriate monitoring and evaluation tools. This would indicate whether the overall 
reduction of at least 25% in dietary intake of POPs by 2006, in the EU, is likely to be 
achieved with current measures. The Commission has a written opinion in Council 
directive 2375/2001 that an overall reduction of at least 25% should be achieved by 2006.
The further development of relatively inexpensive pre-screening computer 
techniques for determining receptor mediated endocrine disruption can provide a means 
to reduce animal usage in chemical screening.
Such further research would offer a balanced methodological approach to 
assessing undesirable POPs components arising in the food chain that pose a continuous 
evolving challenge to food chain safety, by providing evidence from dietary intervention, 
epidemiological and toxicological studies concerning the benefits and risks of seafood for 
human health and well being.
6.2.1.2. Potential Impact
Public health policy and the risk assessment of chemicals can only effectively 
deal with the issue of POPs and endocrine disruption in humans and wildlife by 
considering the whole endocrine system and not limit consideration to the oestrogenic, 
androgenic and thyroid systems, since regulation of these substances may not address 
issues related to effects on the function of other endocrine hormone and xenobiotic 
clearance systems at the molecular level, such as the AhR, PXR and CAR and enzyme 
mediated processes such as steroidogenesis.
A more integrated systemic approach in future research, rather than only a single 
receptor focus, will give a more accurate picture of real-life mechanisms of action of 
EDC and NCE toxicity. This is more likely to satisfy future research needs as identified 
in the Community Strategy for Endocrine Disrupters which states that
“7n order to support a rapid development o f test methods, a focused research 
effort is required into the mechanisms o f  action o f  the endocrine system and the range o f  
effects, including the role o f  hormones at key stages in life cycles. This should also
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facilitate the development o f useful models both fo r  estimation o f  exposures and fo r  
biological testing strategies. ”
The POPs of primary concern discussed here include PCBs, organochlorine pesticides, 
PBDEs, dioxins and furans, but this list is by no means exclusive.
POPs and endocrine disruption are issues of global importance. The major source 
for human POPs exposure is dietary, particularly via oily fish, so an international 
assessment of POPs concentrations in the farmed salmonid food chain, and the 
development of both broad mechanistic and biomagnification toxicity assessment using 
in silico tools, would facilitate EU Public Health Policy aimed at improving the quality of 
life of the European consumer and protecting future generations.
6.2.2. In  silico molecular modelling and QSARs: Further research
Further research in the area of EDCs could also utilize the in silico models and 
crystal structures, and in silico modelling techniques in the development of predictive 
screening tool for improving the human risk assessment of POPs in the diet, as currently 
undertaken in drug discovery and development. Further development of the in silico 
receptors modelling would provide an effective pre-screening tool for the chemicals of 
concern. The multivariate analytical techniques described here are being increasing used 
to model biological systems. They are being developed and applied further from the field 
of chemistry, where PLS and chemical descriptors are now standard NCE discovery 
tools, to model cellular processes. QSARs such as those described in Chapter 5 show how 
chemical data can be generated in vitro (Chapter 4), or efficiently captured from the 
literature or in-house data sets to aid chemical screening.
In the field of pharmaceutical research, human pharmacokinetic factors are 
modeled in various ways, including the symCYP software program. The information 
from NR QSARs could be added to these models to improve predictability.
The models and crystal structures provide a very useful prescreening prediction 
tool; the information generated can flag potential unwanted interactions that can be 
explored further in biological systems. For instance, examination of a PBDE molecule in 
the E R a crystal structure LBD (Fig 1.7) suggested weak oestrogenicity, as indicated by 
weak hydrogen bonding in the LBD, which was later observed from in vitro studies 
conducted by Meerts et al., 2001.
As more and more biological pathways are mapped out, in silico models will be 
increasingly applied. The value of in silico modelling is well known in drug development
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and advances in this area can be effectively and usefully applied to improve our 
understanding of the molecular mechanisms of action in the biosynthetic pathways. This 
information contributes to improved holistic models for our understanding of nutrient- 
xenobiotic-hormone-receptor gene interactions. In relation to common human 
multifactoral diseases, such as cardiovascular disease and hormone-related cancers, these 
interactions have strong links with both nutrient, anti-nutrient and food contaminant 
intake, in addition to genetic predispositions. There are also very serious concerns 
surrounding foetal, infant and child development with respect to the interactions between 
POPs and various receptors. Under such circumstances, this information can be used to 
better inform public health and environmental policy, to better protect public health.
6.2.3. Applications: Tier testing
Various endocrine disruptor screening programmes are currently being instigated 
in response to public concern on the effects of endocrine disrupters on animal and human 
health (Ashby, 2001; Baker, 2001; Cooper and Kavlock, 1997) and a tiered approach is 
being recommended and debated in the literature. Thresholds of toxicological concern 
(Schmidt, 1999; Cheeseman et al., 1999; Kroes et al., 2000) such as dioxin (Mackie et al.,
2003), together with mixtures (Payne et al., 2001; Carpenter et al., 2002; Silva et al.,
2002) and low dose assessment concerns (Mauras et al., 1989; Brucker-Davis et al., 
2001; Welshons et al., 2003) particularly during foetal and childhood development 
(Bigsby et al., 1999; Straessen et al., 2001; Jacobson et al., 2002; Jacobson and Jacobson, 
2002; ten Tusscher and Koppe, 2003) are all issues of concern.
The QSAR methods presented in chapter 5 can be utilised for assessing the 
relative merits of receptor screening assays, as conducted for the AhR and flame 
retardants in section 5.4. They are also being used for integrating testing of receptor- 
specific activation in vitro assays for endocrine disruption, such as those for the TR 
(DeVito et al., 1999), the AhR (Hahn, 2002b), the ER (e.g. Yamasaki et al., 2003). They 
are also being used in mixture effects (Escher and Hermens, 2002), biotransformation 
and toxicity studies (Soffer et al., 2001), particularly in environmental toxicity studies. 
In addition to the AhR (Schneder et al., 1995; Chen, 2001b; Denison et al., 2002; Hahn, 
2002b; Nagy et al., 2002), the ER, AR and TR (Bigsby et al., 1999), further receptors, 
including orphan receptors, also need to be part of a comprehensive screening process. 
Thus the most biologically relevant GR (Wang et al., 2003; El-Sankary et al., 2000), 
PXR, CAR activation (Moore et al., 2000b) and CYP3A4 induction assays (Pascussi et
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al., 2000a; El-Sankary et al., 2001; Drocourt et al., 2002; Gibson et al., 2002; Plant and 
Gibson, 2003) could be part of a comprehensive assessment in a receptor/enzyme 
induction tier-testing scheme, in addition to those currently in use.
6.3. Conclusion
The nuclear receptors discussed in this thesis act as steroid, metabolic and 
toxicological sensors that have evolved to provide a fast, highly adaptive, response 
system to environmental changes by inducing the appropriate metabolic pathways that 
will provide the optimum protection from overexposure. For the xenobiotic receptor 
sensors, these compounds can be present at high concentrations (|iM range), unlike the 
classical SHRs (e.g. ERs), where the endocrine signaling molecules are generated in 
minute quantities (nM range). Xenobiotic NRs have generally evolved in response to 
intermediates from metabolic pathways, phytochemicals and metabolites from dietary 
origin. Now, however, humans are chronically exposed to higher levels of ligands for 
these receptors, due to a westernized lifestyle characterized by high fat and processed 
food intakes and exposure to drugs and xenobiotics.
Multiple contaminant or POPs exposure is also evolutionarily a relatively recent 
phenomenon. In response, the altered signaling by the nuclear receptors contributes to the 
pathogenesis of many common metabolic and hormone dependent diseases, such as 
obesity, insulin resistance, type 2 diabetes, hyperlipidemia, athersclerosis, gall bladder 
and liver disease, endometriosis and hormone dependent cancers. The role of these 
receptors in mediating these diseases provides a potential therapeutic target for their 
management (e.g. the statin and glitazone drugs for PPAR mediation and antioestrogens 
such as tamoxifen to inhibit ER+ breast cancers). Perturbing the receptor network can 
also result in developmental dysfunction consequences for the foetus and young child that 
may be irreversible.
The nuclear receptors studied here appear to underpin the high incidence of many 
diseases to differing degrees, and receptor perturbation can have serious implications for 
human health which cannot be explained by genetic factors and the ‘rules of nature’ 
alone. Environmental and dietary factors together with the ‘flaws of nature’ (Barrow,
2003), are integral to the multidimensional puzzle, and there is much to be learned.
Further research, particularly in the pharmaceutical industry, is developing and 
expanding NR and P450 based therapeutic treatment strategies. With improved 
understanding of the signaling pathways of receptor-ligand-gene interactions, public
251
health policy decisions can also be better informed. This work has demonstrated the 
importance of NRs to human health, and the application of this understanding to drug 
discovery and public health policy that benefits future generations.
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Appendix 1. Table i) Batch sample details for omega 3 rich dietary supplement 
samples, Chapter 2
Original 
Sample code
Description Prep date Purchase date Batch no. Brand
MJl Extra high 
strength pure 
code liver oil
4. 03.02 28.12.01 311833 Seven Seas
MJ2 Pure Cod liver 
oil
4. 03.02 28.12.01 301952 Seven Seas
MJ3 Efanatal 4. 03.02 28.12.01 15322 Nutricia
MJ4 EYEQ 4. 03.02 28.12.01 50555 Equazen
MJ5 Omega 3 ‘700’ 4. 03.02 28.12.01 18294 Solgar
MJ6 Cod liver oil 4. 03.02 31.12.01 02401 Cytoplan
MJ7 EPA 300 
marine lipid 
concentrate
4. 03.02 18.12.01 00201 Cytoplan
MJ8 Linseed oil 4. 03.02 18.12.01 050701 Cytoplan
MJ9 Fish oil 
supplement
4. 03.02 18.12.01 8281 Cytoplan
MJIO Organic flax 
seed oil
4. 03.02 18.12.01 8248 Cytoplan
M Jll High potency 
fish oil
4. 03.02 28.12.01 48609 Lamberts
MJ12 Super strength 
concentrated 
fish oils 
lOOOmg
14.03.02 8.03.02 BA55 Boots
MJ13 Mobility cod 
liver oil 200ml
14.03.02 8.03.02 IJJ Boots
MJ14 Mobility cod 
liver oil one a 
day
14.03.02 8.03.02 14673M Boots
MJ15 Mobility high 
strength cod 
liver oil 
lOOOmg one a 
day
14.03.02 8.03.02 14945M Boots
MJ16 Cardioace 14.03.02 8.03.02 93876 Vitabiotics
MJ17 Efamarine
500mg
14.03.02 8.03.02 800951 Efamarine
MJl 8 PULSE pure 
fish oils 500mg
14.03.02 8.03.02 312517 Seven Seas
MJ19 Neutrataste 
taste-free cod 
liver oil 500mg
14.03.02 8.03.02 312105 Seven Seas
MJ20 Linseed oil 
organic
14.03.02 7.03.02 L140HC2 Biona
MJ21 Ultimate 
omega 3 
vegetable oil 
blend
14.03.02 7.03.02 020115A Udo’s choice
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Appendix 3. Chapter 5.
Table 1: Descriptions of the principle VolSurf descriptors used for the NR QSAR studies
VoISurf
descriptor
Symbol Description
Molecular Volume V Represents the water solvent excluded volume (in Â^ ), or the volume contained within the water 
accessible surface computed at 0.20 kcal/mol, as determined with the water probe interaction with a 
target molecule.
Molecular Surface S Represents the accessible surface (in Â^ ) traced out by a water probe interacting at 0.20 kcal/mol 
when it rolls over the target molecule.
Ratio
Volume/Surface
R A measure of molecular wrinkled surface (rugosity). The smaller the ratio, the larger is the rugosity.
Molecular
Globularity
G Represented by S/Scquiv., in which Sequiv. is the surface area of a sphere of volume V. Globularity is 
1.0 for perfect spherical molecules, and assumes values greater than 1.0 for real spheroidal 
molecules. It is also related to molecular flexibility.
Hydrophilic 
regions at eight 
energy levels
Wl-
W8
Represent the molecular envelope accessible by solvent water molecules. The volume of this 
envelope varies with the level of interaction energies between water and the solute molecule. In 
general, W 1-4 account for polarisability and dispersion forces, while W 5-8 account for polar and 
hydrogen bond donor-acceptor regions.
Amide responsive 
regions at eight 
energy levels
WAMl-
WAM8
Represent the molecular envelope accessible by the amide probe. The volume of this envelope 
varies with the level of interaction energies between the amide (NH) probe and the molecule. Due to 
the lone pair of electrons on the nitrogen, the amide probe provides specific information about good 
acceptor abilities. In general, WAM 1-4 account for dispersion forces, while WAM 5-8 account for 
hydrogen bond acceptor regions. These descriptors are closely related to W1-W8.
Integy Moments Iwl-
Iw8
INTEraction enerGY (integy) moments express the imbalance between the centre of mass of a 
molecule and the position of the hydrophilic regions around them. Integy moments calculated at 
eight different energy levels (-0.2 -0.5 -1.0 -2.0 -3.0 -4.0 -5.0 -6.0 kcal/mol) and are vectors pointing 
from the centre of mass to the centre of W1-W8 respectively. If the integy moment is high, there is 
a clear concentration of hydrated regions in only one part of the molecular surface. If the integy 
moment is small, the polar moieties are either close to the centre of mass or they are at opposite 
ends of the molecule and the resulting barycentre is close to the centre of the molecule.
Capacity factors Cwl-
Cw8
Represent the ratio between the hydrophilic regions and the molecular surface, that is the amount of 
hydrophilic regions per surface unit. Tliey are calculated at eight different energy levels (-0.2 -0.5 - 
1.0 -2.0 -3.0 -4.0 -5.0 -6.0 kcal/mol).
Hydrophobic 
regions at eight 
energy levels
D1-D8 Hydrophobic regions indicate interactions with the hydrophobic probe at 8 different energy levels, 
which have been adapted to the energy range of the DRY probe (-0.2 -0.4 -0.6 -0.8 -1.0 -1.2 -1.4 - 
1.6). They are defined when a DRY probe is interacting with a target molecule.
Hydrophobic 
Integy moments
IDl-
ID8
Similar to the Integy moments, but calculated from DRY probe 3D interaction maps. They measure 
the imbalance between the centre of mass of a molecule and the position of the hydrophobic regions 
around them.
Local Interaction 
Energy minima
Eminl
Emin3
Represent the energy of interaction in kcal/mol of the best three local minima of interaction energies 
between the water probe and the target molecule.
Local interaction 
Energy minima 
distances
dl2 dl3 
d23
Represent the distances between the best three local minima of interaction energies when a water 
probe interacts with a target molecule.
Hydrophilic- 
Lipophilic balance
HLl-
HL2
The ratio between the hydrophilic regions measured at -3 and -4 kcal/mol and the hydrophobic 
regions measured at -0.6 and -0.8 kcal/mol. The balance describes which effect dominates in the 
molecule, or if they are roughly equally balanced.
Amphiphilic
Moment
A This is a vector pointing from the centre of the hydrophobic domain to the centre of the hydrophilic 
domain. The vector length is proportional to the strength of the amphiphilic moment, and it may 
determine the ability of a compound to penetrate a membrane.
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Critical Packing 
parameter
CP Describes a ratio between the hydrophobic and lipophilic part of a molecules. Conversely to HLb, 
CP refers just to the molecular shape: CP = Volume(hydrophobic part)/[(Surface(hydrophilic 
part)*(length of the hydrophobic part)]. The hydrophobic calculation is made at -0.6 kcal, the 
hydrophilic calculation at -3.0 kcal. CP is a good parameter to predict molecular packing, as with 
micelle formation.
Polarizability POL An estimation of the average molecular polarisability, calculated following the additive method 
reported by K.J. Miller (Miller 1990), which uses the structure of the conpounds (extracted from 
the GRID files) outside any molecular field to compute the values such that it is independent of the 
number and type of probe used.
Hydrogen Bonding HBl-8 Represent details about the H bonding capabilities of the targets, which can be different depending 
upon the nature of the polar probe used. The water probe presents the optimal ability to establish H 
bonds with the target, either donating or accepting one or more Hs. If a different polar probe is used, 
the interaction may be less favorable, as this probe is unable to accept or donate Hs. This variable is 
obtained as the differences between the hydrophilic negative volumes (Wl-8) between the water 
and any other polar probe included for each negative energy level considered.
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